,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
0,1,NCT04684602,Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions,,Recruiting,No Results Available,Autoimmune Diseases|Cardiovascular Disorders|Diabetes Complications|Integumentary Disease|Musculoskeletal Disorders|Neurodegenerative Disorders|Neurologic Disorders|Pulmonary Disorders|Sexual Dysfunction|Urologic Disorders|Viral Illness,Biological: PrimePro™/ PrimeMSK™,"Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.",Thomas Advanced Medical LLC|HeartStem Institute|NuStem,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5000,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICSS-2020-032,"July 9, 2020","July 9, 2030","December 9, 2030","December 24, 2020",,"April 29, 2022","Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City, California, United States",,https://ClinicalTrials.gov/show/NCT04684602
1,89,NCT05080465,Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis,,"Active, not recruiting",No Results Available,Liver Cirrhosis,Biological: Autologous BM MSC,MR Elastography|The level of serum alanine aminotransferase (ALT)|Clinical Examination|The level of glomerular filtration rate (GFR)|The level of serum albumin (ALB)|The level of serum total bilirubin (TB),Ukraine Association of Biobank,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 3,700,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,UAB00240818-1,"December 2, 2018","October 7, 2021","December 31, 2022","October 15, 2021",,"May 18, 2022","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,https://ClinicalTrials.gov/show/NCT05080465
2,615,NCT04492501,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,,Completed,No Results Available,Covid19|Cytokine Release Syndrome|Critical Illness|ARDS,Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy,survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications,UNICEF|Pak Emirates Military Hospital Rawalpindi,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sultan Mehmood Kamran 3,"April 1, 2020","July 20, 2020","July 20, 2020","July 30, 2020",,"July 30, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04492501
3,39,NCT02032004,Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.,DREAM HF-1,Completed,No Results Available,Chronic Heart Failure,Biological: Allogeneic Mesenchymal Precursor Cells (MPCs)|Other: Sham Comparator,"Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by left ventricular ejection fraction (LVEF [radionuclide ventriculography {RVG} or echocardiogram])|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - European Quality of Life (EuroQoL) 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBCs, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic blood pressure [BP], diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QT interval with Fridericia's correction (QTcF), heart rate-corrected QT interval (QTcB), QT, Q wave, R wave and S wave (QRS) complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data","Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,566,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSB-MPC-CHF001,"February 14, 2014","May 29, 2020","May 29, 2020","January 9, 2014",,"January 10, 2022","Mesoblast Investigational Site 10757 - Cardiology, P.C., Birmingham, Alabama, United States|Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Mesoblast Investigational Site 10756 - Mayo Clinic, Phoenix, Arizona, United States|Mesoblast Investigational Site 13023 - University of Arizona Medical Center, Tucson, Arizona, United States|Mesoblast Investigational Site 10754 - University of California, San Diego, La Jolla, California, United States|Mesoblast Investigational Site 10759 - Scripps Clinic, La Jolla, California, United States|Mesoblast Investigational Site 13265 - University of California, Los Angeles, Los Angeles, California, United States|Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States|Mesoblast Investigational Site 10778 - Orange County Cardiology, Orange, California, United States|Mesoblast Investigational Site 13031 - St. John's Regional Medical Center, Oxnard, California, United States|Mesoblast Investigational Site 13275 - Stanford University Hospital, Stanford, California, United States|Mesoblast Investigational Site 13267 - Bethesda Heart Hospital, Boynton Beach, Florida, United States|Mesoblast Investigational Site 10780 - Morton Plant Hospital, Clearwater, Florida, United States|Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida, Gainesville, Florida, United States|Mesoblast Investigational Site 13273 - University of Florida Health, Jacksonville, Florida, United States|Mesoblast Investigational Site 10768 - University of Miami, Miami, Florida, United States|Mesoblast Investigational Site 13280, Orlando, Florida, United States|Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute, Tampa, Florida, United States|Mesoblast Investigational Site 13027 - Emory University School of Medicine, Atlanta, Georgia, United States|Mesoblast Investigational Site 10765 - Georgia Regents University, Augusta, Georgia, United States|Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center, Chicago, Illinois, United States|Mesoblast Investigational Site 13030 - University of Iowa, Iowa City, Iowa, United States|Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky, Lexington, Kentucky, United States|Mesoblast Investigational Site 13022 - University of Louisville, Louisville, Kentucky, United States|Mesoblast Investigational Site 13266, New Orleans, Louisiana, United States|Mesoblast Investigational Site 10782, Boston, Massachusetts, United States|Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Mesoblast Investigational Site 10762 - Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Mesoblast Investigational Site 10761 - Mayo Clinic, Rochester, Minnesota, United States|Mesoblast Investigational Site 13281, Las Vegas, Nevada, United States|Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center, Newark, New Jersey, United States|Mesoblast Investigational Site 10776 - Columbia University Medical Center, New York, New York, United States|Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Mesoblast Investigational Site 10781 - Duke University, Durham, North Carolina, United States|Mesoblast Investigational Site 10758 - The Christ Hospital, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10770 - University of Cincinnati, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10773, Cleveland, Ohio, United States|Mesoblast Investigational Site 13278 - OhioHealth Research Institute, Columbus, Ohio, United States|Mesoblast Investigational Site 10785 - Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Mesoblast Investigational Site 13261 - University of Pennsylvania, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10767 - Temple University Hospital, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 13277, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10774 - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Mesoblast Investigational Site 13024 - Austin Heart, PLLC, Austin, Texas, United States|Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas, United States|Mesoblast Investigational Site 10755 - Texas Heart Institute, Houston, Texas, United States|Mesoblast Investigational Site 13268 - Houston Methodist Hospital, Houston, Texas, United States|Mesoblast Investigational Site 10763 - University Hospital, Salt Lake City, Utah, United States|Mesoblast Investigational Site 10771 - Heart & Vascular Research, Swedish Medical Center, Seattle, Washington, United States|Mesoblast Investigational Site 10764 - University of Wisconsin, Madison, Wisconsin, United States|Mesoblast Investigational Site 10769 - Aurora Healthcare, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 13279, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 10789 - Aspirus Research Institute, Wausau, Wisconsin, United States|Mesoblast Investigational Site 11027, Edmonton, Alberta, Canada|Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Mesoblast Investigational Site 11025 - St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02032004
4,755,NCT03011541,Stem Cell Ophthalmology Treatment Study II,SCOTS2,Recruiting,No Results Available,"Retinal Disease|Age-Related Macular Degeneration|Retinitis Pigmentosa|Stargardt Disease|Optic Neuropathy|Nonarteritic Ischemic Optic Neuropathy|Optic Atrophy|Optic Nerve Disease|Glaucoma|Leber Hereditary Optic Neuropathy|Blindness|Vision Loss Night|Vision Loss Partial|Vision, Low|Retinopathy|Maculopathy|Macular Degeneration|Retina Atrophy",Procedure: Arm 1,Visual Acuity|Visual Fields|Optical Coherence Tomography (OCT),MD Stem Cells,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCOTS2,January 2016,July 2023,July 2024,"January 5, 2017",,"August 3, 2022","MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States|Medcare Orthopaedics & Spine Hospital, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT03011541
5,214,NCT03818737,Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES),MILES,Completed,No Results Available,Osteoarthritis,Biological: Bone Marrow Derived MSCs|Biological: Adipose-derived MSCs|Biological: Umbilical Cord Tissue (UCT) MSCs|Drug: Corticosteroid injection,Change in Visual Analog Pain Scale (VAS-pain) Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Symptoms Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activities of Daily Living (ADL) Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sports and Recreation Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of Life (QoL) Subscale Score|Change in EuroQuality of Life (EQ-5D-3L) Index Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) Score,Emory University|The Marcus Foundation,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 3,480,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB00108046,"March 28, 2019","May 31, 2022","May 31, 2022","January 28, 2019",,"July 8, 2022","Andrews Institute, Gulf Breeze, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT03818737
6,6,NCT05354141,Bone Marrow Mesenchymal Stem Cell Derived EVs for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS): A Phase III Clinical Trial,,Recruiting,No Results Available,COVID-19 Acute Respiratory Distress Syndrome,Drug: EXOFLO,The primary efficacy endpoint is overall 60-day mortality (due to any cause).,"Direct Biologics, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,400,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DB-EF-PHASEIII-0001,"July 1, 2022","April 3, 2023","July 3, 2023","April 29, 2022",,"August 30, 2022","PRX Research, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT05354141
7,4,NCT00482092,Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease,,Completed,No Results Available,Crohn's Disease,Drug: Prochymal®|Drug: Placebo,Disease remission (CDAI at or below 150)|Disease improvement (Reduction by at least 100 points in CDAI)|Improvement in quality of life (IBDQ)|Reduction in number of draining fistulas,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,330,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRD 603,"September 17, 2007","September 15, 2014","September 15, 2014","June 4, 2007",,"January 13, 2022","University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",,https://ClinicalTrials.gov/show/NCT00482092
8,228,NCT01768702,Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.,CHART-1,Completed,No Results Available,Heart Failure,"Biological: Injection of C3BS-CQR-1|Biological: Sham, no injection",Efficacy between groups post-index procedure|Efficacy and safety between groups post-index procedure,Celyad Oncology SA,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,315,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",C3BS-C-11-01|2011-001117-13,November 2012,August 2017,August 2017,"January 15, 2013",,"June 1, 2018","OLV Ziekenhuis Aalst, Aalst, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hopital Civil Marie Curie, Lodelinsart, Belgium|AZ Glorieux, Ronse, Belgium|CHU Mont-Godinne, Yvoir, Belgium|City Clinic Cardiology Center Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia', Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment 'Alexandrovska' EAD, Sofia, Bulgaria|Gottsegen György Országos Kardiológiai Intézet - Felnőtt Kardiológiai Osztály, Budapest, Hungary|Semmelweis Egyetem - Városmajori Szív- és Érgyógyászati Klinika, Budapest, Hungary|MH Egészségügyi Központ Kardiológiai Osztály, Budapest, Hungary|Debreceni Egyetem Orvos - és Egészségtudomanyi Centrum, Debrecen, Hungary|Pécsi Tudományegyetem Klinikai Központ - Szívgyógyászati Klinika, Pécs, Hungary|Barzilai Medical Center - Cardiology Unit, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Western Galilee Hospital, Nahariya, Israel|Nazareth Hospital EMMS, Nazareth, Israel|Ziv Medical Center - Heart Institute, Safed, Israel|A.O. Spedali Civili di Brescia, Brescia, Italy|AOUI Verona - Borgo Trento Hospital, Verona, Italy|Uniwersyteckie Centrum Kliniczne, KliniczneCentrum Kardiologii, Gdansk, Poland|Górnośląskie Centrum Medyczne Śląskiej Akademii Medycznej, Katowice, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Kraków, Poland|Biegański Hospital, Łódź, Poland|Clinic of Emergency Internal Medicinne Military Medical Academy, Belgrade, Serbia|Clinical Center of Serbia - Cardiology Clinic, Belgrade, Serbia|Clinical Centre of Serbia, Cardiology Clinic, Belgrade, Serbia|Clinical Hospital Center Zvezdara - Cardiology Clinic, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Cardiology Dept., Belgrade, Serbia|Clinical Center of Kragujevac,, Kragujevac, Serbia|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria - Campus de Teatinos s/n, Malaga, Spain|Cardiocentro Ticino, Lugano, Switzerland",,https://ClinicalTrials.gov/show/NCT01768702
9,704,NCT01929434,Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis,CP,Completed,No Results Available,Cerebral Palsy,Other: rehabilitation|Biological: stem cell injection,Gross Motor Function Measure Score|Routine Blood Test and Biochemical Test,General Hospital of Chinese Armed Police Forces,All,1 Year to 14 Years   (Child),Phase 3,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2013-05-13 CP III,October 2013,December 2015,December 2016,"August 28, 2013",,"December 27, 2017","General Hospital of Chinese People's Armed Police Forces, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01929434
10,87,NCT04448106,Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis,AdMSCs,Not yet recruiting,No Results Available,"Osteoarthritis, Knee|Osteoarthritis, Hip|Osteoarthritis Shoulder",Biological: Celltex- AdMSCs,"the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.|Any organ damage or safety concerns determined by SMAC 20 blood test.|Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|changes in joint images (X-ray or MRI) from the baseline",Celltex Therapeutics Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CTX0020-002,"September 25, 2022","August 1, 2023","August 15, 2025","June 25, 2020",,"May 6, 2022","Stanley C Jones, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04448106
11,273,NCT05497401,A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With COVID-related Pneumonia,,Not yet recruiting,No Results Available,Covid-related Pneumonia,Biological: MesenCure|Other: Placebo,Mortality|CRP reduction|Invasive ventilation,BonusBio Group Ltd,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCS-03,October 2022,"December 31, 2023",July 2024,"August 11, 2022",,"August 11, 2022",,,https://ClinicalTrials.gov/show/NCT05497401
12,560,NCT01873547,Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China,SCI-III,Completed,No Results Available,Spinal Cord Injury,Biological: cell therapy|Other: rehabilitation,Assessment of changes in International Standards for Neurological Classification of Spinal Cord Injury according to American Spine Injury Association|Assessment of changes in score of pain index using Short-form McGill Pain Questionnaire|Assessment of changes in score of activity of daily living|Assessment of changes in sensory evoked potentials and motor evoked potentials,General Hospital of Chinese Armed Police Forces,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2013-03-04SCI-III,June 2012,October 2014,December 2015,"June 10, 2013",,"May 25, 2018","General Hospital of Chinese People's Armed Police Forces, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01873547
13,242,NCT04551456,WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease,WANICHD,Not yet recruiting,No Results Available,Coronary Artery Disease,Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS,"The primary end point was checking incidence of adverse events (AEs) within 12 months,|The secondary end point was measuring low attenuation plaque volume LAPV|The secondary end point was efficacy 2","Navy General Hospital, Beijing|Chinese PLA General Hospital|Peking University Third Hospital|Peking Union Medical College Hospital|Xijing Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NavyGHB-007,"November 30, 2020","December 30, 2021","December 30, 2022","September 16, 2020",,"September 16, 2020",,,https://ClinicalTrials.gov/show/NCT04551456
14,126,NCT03909139,Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear,,Recruiting,No Results Available,Acetabular Labrum Tear|Femoro Acetabular Impingement|Chondral Defect|Bone Marrow Aspirate Concentrate|Mesenchymal Stromal Cell,Biological: BMAC,Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Change mHHS Surveys from preoperative to various postoperative timepoints|Change RAND-36 Surveys from preoperative to various postoperative timepoints|Degree of Improvement on Hip VAS Pain Score|Patient Satisfaction Questionnaires,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2019P002191,"September 6, 2019","June 30, 2023","June 30, 2025","April 9, 2019",,"May 6, 2022","MGH, Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03909139
15,251,NCT01541579,Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease,ADMIRE-CD,Completed,No Results Available,Crohn's Disease,Other: Cx601|Other: Saline solution,Combine remission of perianal fistulising Crohn's|Efficacy Assessment by week 24|Efficacy Assessment by week 52|Efficacy Assessment by week 104|Safety analysis throughout the study:,Tigenix S.A.U.|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,278,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Cx601-0302,July 2012,July 2015,November 2016,"March 1, 2012",,"November 29, 2019","Univ.-Klinik Innsbruck, Innsbruck, Austria|Krankenhaus, St. Veit/Glan, Austria|Medizinische Universität, Wien, Austria|Hospital Oost-Limburg, Genk, Belgium|Gent University Hospital, Gent, Belgium|Leuven University Hospital, Leuven, Belgium|Hospital Hartziekenhuis, Roeselare, Belgium|CHU d'Amiens, Amiens, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Hôpital Beaujon, Clichy, France|CHRU de Lille, Lille, France|CHU de Marseille, Marseille, France|CHU de Nice, Nice, France|Hôpital Saint-Louis, Paris, France|Charite, Berlin, Germany|Krakenhaus Walfriede, Berlin, Germany|Klinikum Braunscheweig, Braunschweig, Germany|Klinikum Frankfurt, Frankfurt/Main, Germany|Evangelisches Krankenhaus Kalk, Köln, Germany|Klinikum Lüneburg, Lüneburg, Germany|Rambam MC, Haifa, Israel|Sharee Zedek MC, Jerusalem, Israel|Rabin MC, Petah Tikva, Israel|Tel Aviv Sourasky MC, Tel Aviv, Israel|Sheba MC, Tel Hashomer, Israel|Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Instituto Clinico Humanitas IRCCS, Milano, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|AMC, Amsterdam, Netherlands|VUMC, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|UMCU, Utrecht, Netherlands|Hospital de Manises, Manises, Valencia, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Juan Ramon Jimenez, Huelva, Spain|Hospital Ramón y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Son Espases, Palma de Mallorca, Spain|Hospital de Montecelo, Pontevedra, Spain|Hospital Virgen del Rocio, Seville, Spain|Hospital de Sagunto, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01541579
16,551,NCT01220492,Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis,,Completed,No Results Available,Liver Cirrhosis,Drug: conventional plus MSC treatment|Drug: conventional plus placebo treatment,survival time|incidence of HCC events|The levels of serum albumin|The levels of serum total bilirubin|The levels of serum prothrombin activity|the levels of serum cholinesterase|complications,Beijing 302 Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,266,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,beijing302-002,May 2009,April 2016,April 2016,"October 14, 2010",,"August 8, 2018","Beijing 302 Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01220492
17,196,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,18 Years to 60 Years   (Adult),Phase 3,263,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","October 30, 2020","October 30, 2020","September 12, 2017",,"October 6, 2021","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03280056
18,189,NCT03990805,A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis,,Completed,No Results Available,Degenerative Arthritis|Knee Osteoarthritis,Biological: JOINTSTEM|Drug: saline,Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|Change of Visual Analog Scale (VAS) scores from baseline|WOMAC 3 subscale score|VAS score|KOOS|SF-36|IKDC|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan|Use of rescue medication,R-Bio,All,"20 Years to 100 Years   (Adult, Older Adult)",Phase 3,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BSR-CTph3-JS1,"June 11, 2019","December 15, 2020","December 15, 2020","June 19, 2019",,"September 28, 2022","Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Health System, Seoul, Korea, Republic of|KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Chunang University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03990805
19,3,NCT00366145,Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD),,Completed,No Results Available,Graft Versus Host Disease,Biological: Prochymal®|Drug: Placebo|Drug: Standard of Care for GVHD,Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration|Overall Survival at 180 days Post First Infusion,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"6 Months to 70 Years   (Child, Adult, Older Adult)",Phase 3,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",280,"August 17, 2006","December 26, 2008","May 28, 2009","August 21, 2006",,"February 10, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Univeristy of California San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Center for Clinical Research, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois - Chicago, Chicago, Illinois, United States|Indiana Blood and Bone Marrow Transplant Center, Beech Grove, Indiana, United States|Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland/Greenbaum, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos/Wayne State University, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Univeristy of Mississippi Medical Center, Jackson, Mississippi, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park, Buffalo, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University/New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest Univeristy School of Medicine, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Baylor University, Dallas, Texas, United States|Univeristy of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Research Center, San Antonio, Texas, United States|Virginia Commonwealth/Massey Cancer Center, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane Hospital, Herston, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Co-Medica Research Network, Calgary, Alberta, Canada|British Columbia's Children's Hospital, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|London Health Sciences Centre- Westminster Campus, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Hopital Enfant-Jesus, Quebec, Canada|Hopital du Saint-Sacrement, Quebec, Canada|Universia degli Studi di Pesaro, Pesaro, PU, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Kantonsspital Basel, Basel, Switzerland|Barts & London School of Medicine, London, England, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom|Bristol Royal Hospital for Children, Bristol, UK, United Kingdom|Glasgow Royal Infirmary, Glasgow, UK, United Kingdom|Leeds General Infirmary, Leeds, UK, United Kingdom",,https://ClinicalTrials.gov/show/NCT00366145
20,129,NCT04953572,Treatment of Cartilage Defects With Peripheral Blood Stem Cells,,Not yet recruiting,No Results Available,Cartilage Injury,Genetic: autologous peripheral blood mesenchymal stem cell|Procedure: Microfracture|Combination Product: Microfracture + collagen membrane|Procedure: Autologous osteochondral transplantation,Magnetic Resonance Imaging in the 6th month after surgery|Magnetic Resonance Imaging in the 12th month after surgery|Magnetic Resonance Imaging in the 24th month after surgery|The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index|International knee documentation committee (IKDC) Knee Joint Score Sheet,Peking University Third Hospital|Inner Mongolia People's Hospital|Hebei Medical University Third Hospital|Tianjin Hospital,All,18 Years to 60 Years   (Adult),Phase 1,252,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PekingUTH001,"August 1, 2021","December 31, 2023","December 31, 2023","July 8, 2021",,"July 8, 2021","Institute of Sports Medicine, Peking University Third Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04953572
21,40,NCT04104412,The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain,,Recruiting,No Results Available,Lumbar Discogenic Pain,Biological: human umbilical cord mesenchymal stem cell,Validity evaluation by detection the change of the VAS pain score relief rate for Lumbar disc pain of participants in different time point and compare with the VAS pain score before treatment|Observe treatment|Safety evaluation by detecting adverse events and serious adverse events|Safety evaluation by detecting Activated partial thromboplastin time (APTT)|Safety evaluation by detecting Prothrombin time (PT)|Safety evaluation by detecting Fibrinogen|Safety evaluation by detecting Thrombin time (TT),"Sclnow Biotechnology Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,242,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XW-01,"August 15, 2019","December 31, 2022","December 31, 2024","September 26, 2019",,"February 14, 2022","Xuanwu Hospital Capital Medical University, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04104412
22,297,NCT05224960,Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2),,Not yet recruiting,No Results Available,Decompensated Cirrhosis,Biological: UC-MSCs|Biological: Placebo(solution without UC-MSCs),Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 96 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|plasma prealbumin (PALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events,"Beijing 302 Hospital|Chinese PLA General Hospital|Shanghai Changzheng Hospital|LanZhou University|Renmin Hospital of Wuhan University|Jin Yin-tan Hospital|Hainan Hospital of Chinese PLA General Hospital|VCANBIO Cell & Gene Engineering Corporation, Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,240,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSC-DLC-2,"April 1, 2022","December 31, 2023","December 31, 2025","February 4, 2022",,"February 4, 2022","The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Hainan hospital of Chinese PLA General Hospital, Sanya, Hainan, China|Jin Yin-tan hospital, Wuhan, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Beijing 302 Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT05224960
23,298,NCT05121870,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis,,Recruiting,No Results Available,Decompensated Cirrhosis,Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）,Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 48 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events,"Beijing 302 Hospital|Shanghai Changzheng Hospital|LanZhou University|Renmin Hospital of Wuhan University|Chinese PLA General Hospital|VCANBIO Cell & Gene Engineering Corporation, Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,240,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NCRC-ID202105,"September 1, 2021","June 30, 2023","December 31, 2023","November 16, 2021",,"November 16, 2021","The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Hainan hospital of Chinese PLA General Hospital, Sanya, Hainan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Beijing 302 Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT05121870
24,289,NCT05043610,MSCs for Prevention of MI-induced HF,PREVENT-TAHA,Recruiting,No Results Available,"Myocardial Infarction, Acute|Myocardial Infarction First|Myocardial Infarction, Anterior Wall|Cardiac Remodeling, Ventricular|STEMI|Regenerative Medicine|Heart Failure",Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|Other: Conventional Treatment,Incidence of Heart Failure|Change in Left Ventricular Function from base line|Cardiovascular Death|Composite outcome of cardiovascular death and heart failure incidence,"Shiraz University of Medical Sciences|National Institute of Medical Research Development (NIMAD), Iran|Cell Tech Pharmed Company, Iran",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IR.SUMS.REC.1400.409,"January 1, 2021","November 1, 2025","November 1, 2025","September 14, 2021",,"September 14, 2021","Al-Zahra Heart Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of|Faghihi Hospital, Shiraz, Fars, Iran, Islamic Republic of|Namazee Hospital, Shiraz, Fars, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT05043610
25,6,NCT00877903,Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI),,Completed,No Results Available,Myocardial Infarction,Drug: Prochymal®|Drug: Placebo,Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3|Left Ventricular End Systolic Volume|Infarct Size|Left Ventricular Ejection Fraction|Left Ventricular End Diastolic Volume|Number of Participants with Ventricular Arrhythmias|Duke Activity Status Index (DASI) Assessment|New York Heart Association (NYHA) Congestive Heart Failure Classification Status|Maximal Symptom-limited Exercise Test (Treadmill)|Number of Participants with Major Adverse Cardiac Events (MACE)|Overall Survival|Number of Participants with Adverse Events,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 2,220,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",403,"March 30, 2009","May 18, 2011","March 14, 2016","April 8, 2009",,"January 13, 2022","Mercy Gilbert Medical Center / Catholic Health Care West, Gilbert, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|University of California - San Diego (UCSD), San Diego, California, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo - Buffalo General Hospital, Buffalo, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Lindner Research Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State University - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Austin Heart P.A., Austin, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Wisconsin School of Medicine, Madison, Wisconsin, United States|McGill University Health Centre, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00877903
26,238,NCT04629833,Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy,IDUNN,Recruiting,No Results Available,Steroid-refractory Acute Graft-versus-host Disease,Biological: MC0518|Biological: BAT,Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score,medac GmbH,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,210,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC-MSC.1/aGvHD,"August 16, 2021","January 28, 2024","December 31, 2025","November 16, 2020",,"June 8, 2022","CHU de Grenoble Hopital Albert Michallon, Grenoble, France|CHRU Lille- Hopital Claude Huriez, Lille, France|CHU de Nice Hopital Archet 1, Nice, France|Centre Hospitalier Lyon Sud Pavillon Marcel Berard 1G, Pierre Benite Cedex, France|Rennes, Rennes, France|Centre Hospitalier Universitaire CHU de Toulouse, Toulouse, France|Hopitaux De Brabois, Vandoeuvre les Nancy, France|Klinikum rechts der Isar, Munich, Bavaria, Germany|Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II - Zentrum fuer Allogene Blutstammzelltransplantation, Würzburg, Bavaria, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet - Frankfurt am Main, Frankfurt am Main, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitatsklinikum Muenster, Münster, Nordrhein-Westfalen, Germany|Universitaet Duisburg-Essen - Universitaetsklinikum Essen - Klinik fuer Knochenmarktransplantation (KMT), Essen, North Rhine-Westphalia, Germany|Uniklinik Koeln, Koeln, North Rhine-Westphalia, Germany|Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Selbststandige Abteilung fur Hamatologie und Internistische Onkologie, Leipzig, Saxony, Germany|Universitaetsklinikum Jena, Jena, Thüringen, Germany|Universitatsklinikum Jena, Jena, Thüringen, Germany|Charit Universitaetsmedizin Berlin, Berlin, Germany|University Hospital Bonn, Medizinische Klinik III, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe, Frankfurt, Germany|Universitatklinikum Freiburg, Freiburg, Germany|University Medical Center Mainz, Mainz, Germany|UniversitÃ¤tsklinikum Mannheim, Mannheim, Germany|University Hospital Tuebingen Medical Center, Tuebingen, Germany|Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wrocław, Dolnoslaskie, Poland|Hospital Universitario Vall dHebron, Barcelona, Spain|Barcelona, Barcelona, Spain|Institut Catal dOncologia, Barcelona, Spain|Barcelona, Barcelona, Spain|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Puerta De Hierro, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Center for Allogeneic Stem Cell Transplantation and Cell Therapy (CAST), Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT04629833
27,731,NCT01366911,Stem Cells Predicting Orthopedic Outcomes,,Completed,No Results Available,Hip Arthroplasty,,Can Stem Cells Predict Orthopaedic Outcomes?,University of Nebraska,All,"Child, Adult, Older Adult",,203,Other,Observational,Observational Model: Other|Time Perspective: Prospective,168-11-FB,April 2011,"January 10, 2014","January 10, 2014","June 6, 2011",,"September 14, 2017","Dept of Orthopaedic Surgery at University of Nebraska Medical Center, Omaha, Nebraska, United States|Dept. of Orthopaedic Surgery, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT01366911
28,192,NCT03945487,Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis,,Recruiting,No Results Available,Decompensated Liver Cirrhosis,Biological: umbilical cord-derived mesenchymal stem cell|Other: Comprehensive treatment,Liver function|The incidence of serious complications|The incidence of adverse events|Disease-free survival time|Incidence of hepatocellular carcinoma (HCC) events,Beijing 302 Hospital,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Beijing302-011,"May 20, 2019","December 30, 2021","December 30, 2023","May 10, 2019",,"May 10, 2019","Beijing 302 Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03945487
29,552,NCT04551443,WJMSCs Anti-inflammatory Therapy in Acute Myocardial Infarction,WAIAMI,Not yet recruiting,No Results Available,Acute Myocardial Infarction,Biological: Intravenous infusion placebo|Biological: Intravenous infusion WJMSCs,Any composite of major adverse cardiovascular events|Checking patient LVEF|Checking patient infarct size|checking patient perfusion defect.|Coronary disease|Coronary congestive heart failure|Coronary changes in hsCRP,"Navy General Hospital, Beijing|Peking University Third Hospital|Peking Union Medical College Hospital|Xijing Hospital|Chinese PLA General Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PLAG6C,"November 1, 2020","December 30, 2021","December 30, 2022","September 16, 2020",,"September 16, 2020",,,https://ClinicalTrials.gov/show/NCT04551443
30,685,NCT05081921,Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases,BioMiStem-CT,Recruiting,No Results Available,Osteoarthritis of Knee,Drug: MesoCellA-Ortho administration|Drug: HA administration,"Nature, incidence and severity of adverse events (AEs)|Change in Numerical Rating Scale (NRS)|Change in joint swelling|Change in the 36-Item Short Form Survey (SF-36)|Change in Knee injury and Osteoarthritis Outcome Score (KOOS)|Change in the International Knee Documentation Committee (IKDC 2000)|Change in cartilage morphology|Change in cartilage T2 relaxation time mapping in MRI|Changes in bone marrow edema-like lesions (BMLs)|Change in weight distribution on stable platform|Change in Range of motion (ROM)|Change in ultrasonographic findings in knee joint","Jagiellonian University|National Center for Research and Development, Poland|KCRI",All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JU-BioMiStem-01|2019-005000-17,"January 5, 2022",June 2023,December 2023,"October 18, 2021",,"March 31, 2022","Galen - Ortopedia Sp. Z O.O., Bieruń, Silesia, Poland",,https://ClinicalTrials.gov/show/NCT05081921
31,510,NCT03562715,microRNAs Role in Pre-eclampsia Diagnosis,,Completed,No Results Available,Preeclampsia,,"The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media",Cairo University,Female,23 Years to 35 Years   (Adult),,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,BC (1870),"November 28, 2016","June 15, 2017","December 25, 2017","June 19, 2018",,"June 19, 2018",,,https://ClinicalTrials.gov/show/NCT03562715
32,287,NCT05187936,Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy,,Recruiting,No Results Available,Hemophilia A|Hemophilia B|Arthropathy,,"Evaluation of surviva|Evaluation of proliferation|Evaluation of apoptosis, phenotype, function of cells|Evaluation of phenotype","University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Other|Time Perspective: Prospective,RECHMPL21_0640,"October 1, 2021","July 1, 2022","December 31, 2022","January 12, 2022",,"January 12, 2022","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT05187936
33,143,NCT04689152,Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis,Cellgram-LC,Recruiting,No Results Available,Alcoholic Cirrhosis,Biological: Cellgram-LC,Transplant free survival (TFS)|Survival rate|Change amount of Child-Pugh score|Change amount of MELD score|Change amount of Liver function test|Change amount of Fibrosis-4|Change amount of FibroScanⓇ|Change amount of EQ-5D|Change amount of EQ-VAS,"Pharmicell Co., Ltd.",All,"20 Years to 71 Years   (Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-P-07,"March 2, 2021","March 2, 2026","March 2, 2026","December 30, 2020",,"August 24, 2021","Soonchunhyang University Hospital, Bucheon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Gangwon National University Hospital, ChunCheon, Korea, Republic of|Hallym Univ. Medical Center, ChunCheon, Korea, Republic of|Gangneung Asan Hospital, Gangneung-si, Korea, Republic of|Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of|Yongin Severance Hospital, Yongin, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04689152
34,138,NCT04811651,Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke,UMSIS,Recruiting,No Results Available,Ischemic Stroke,Biological: Umbilical Cord-derived Mesenchymal Stem Cells|Drug: Placebo,Proportion of modified Rankin Scale (mRS) 0-2|changes in Fugl-Meyer scale|changes in Purdue hand function test|changes in box and block test|Proportion of modified Rankin Scale (mRS) 0-1|changes in the national institutes of health stroke scale (NIHSS)|changes in Mini-mental State Examination (MMSE) score|changes in Montreal Cognitive Assessment (MoCA) score|The changes of head images|changes in some serum biomarkers,General Hospital of Shenyang Military Region,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",k（2019）46,"March 15, 2021","February 1, 2023","October 1, 2023","March 23, 2021",,"May 25, 2022","Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China",,https://ClinicalTrials.gov/show/NCT04811651
35,184,NCT04971161,Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb),,Recruiting,No Results Available,Skin Ulcer Venous Stasis Chronic,Biological: allo-APZ2-CVU|Drug: Placebo,"Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14",RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",allo-APZ2-CVU-IIb,"August 18, 2021",August 2023,August 2023,"July 21, 2021",,"September 21, 2022","Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany|Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany|Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie, Berlin, Germany|Helios Klinikum Berlin-Buch, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Helios Klinikum Emil von Behring, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus, Bochum, Germany|Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken für Dermatologie und Gefäßchirurgie der Ruhr-Universität Bochum, Bochum, Germany|Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis, Braunschweig, Germany|Klinikum Bremerhaven Reinkenheide gGmbH, Klinik für Dermatologie, Allergologie und Phlebologie, Wundzentrum, Bremerhaven, Germany|Klinische Forschung Dresden GmbH, Dresden, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum, Dresden, Germany|Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie, Düsseldorf, Germany|Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie, Erlangen, Germany|Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany|Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie, Freiburg, Germany|Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie), Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien, Gera, Germany|Praxis Dr. med. Abdou Zarzour, Halle, Germany|Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Hamburg, Germany|MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH, Hanau, Germany|SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin, Karlsbad, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH, Kiel, Germany|Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie, Krefeld, Germany|Hautarztpraxis Langenau, Studienzentrum, Langenau, Germany|Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig, Germany|Studienambulanz Dr. Schubert Leipzig, Leipzig, Germany|Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz, Ludwigshafen, Germany|Beldio Research GmbH, Memmingen, Germany|Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Dermazentrum München, Standort Neuhausen, Studienzentrum, München, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinikum Nürnberg Nord, Klinik für Dermatologie, Nürnberg, Germany|Hautarztpraxis Prof. Dr. med. Khusru Asadullah, Potsdam, Germany|Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie, Regensburg, Germany|Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie, Rostock, Germany|Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie, Schwerin, Germany|Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen, Stuttgart, Germany|Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen, Tübingen, Germany|Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie, Wuppertal, Germany|Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT04971161
36,84,NCT04428801,Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19,,Not yet recruiting,No Results Available,COVID-19,Biological: autologous adipose-derived stem cells,"Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.",Celltex Therapeutics Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CTX0020-003,September 2022,September 2023,September 2025,"June 11, 2020",,"May 5, 2022",,,https://ClinicalTrials.gov/show/NCT04428801
37,14,NCT00562497,Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD),,Completed,No Results Available,Graft Versus Host Disease,Drug: Prochymal®|Other: Placebo|Other: Corticosteroid,Percentage of Participants with Treatment Success|Percentage of Participants with Overall Response|Percentage of Participants with Induction of a 2-grade decrease in (Graft Versus Host Disease) GVHD by Study Day 28 with maintenance of a 2-grade decrease in GVHD through Study Day 56|Percentage of Participants with Induction of CR lasting for greater than or equal to 14 Days|Percentage of Participants with Induction of a CR after Study Day 28 and clinically managed with steroids with second line/escalation therapy through Study Day 56|Percentage of Participants with Induction of PR during the first 28 days|Time to achieve CR|Number of CR per organ|Total corticosteroid dose administered|Number of corticosteroid-related complications|Number of Infectious complications|Number of Days of Hospitalization|Average Daily Corticosteroid Dose,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,192,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",265,"January 31, 2008","July 14, 2009","May 20, 2010","November 22, 2007",,"January 19, 2022","University of Alabama Birmingham (UAB) Hospital, Birmingham, Alabama, United States|UCLA Medical Center, Los Angeles, California, United States|University of California Medical Center, San Francisco, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Center for Clinical Research, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Hospitals, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Francis Cancer Center, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Tufts New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Medical Center, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Kansas City Cancer Center, Lee's Summit, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Jewish Hospital, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Oncology Hematology Association, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Centers, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina(MUSC), Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St. Vincent's Hospital, Darlinghurst, Australia|Royal Brisbane Hospital, Herston, Australia|Peter Lougheed Centre, Calgary, Alberta, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00562497
38,294,NCT05531266,Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease,,Recruiting,No Results Available,aGVHD,Other: hUC-MSCs|Other: glucocorticoids,Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy|Cumulative relapse incidence|cumulative incidence of chronic GVHD at one year|Cumulative Incidence of Infectious Complications|Cumulative Incidence of lymphoproliferative disease,Institute of Hematology & Blood Diseases Hospital,All,"Child, Adult, Older Adult",Not Applicable,182,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20220831,"September 1, 2022","March 1, 2024","March 1, 2025","September 7, 2022",,"September 7, 2022","Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT05531266
39,749,NCT01270139,Plasmonic Nanophotothermal Therapy of Atherosclerosis,NANOM-FIM,Completed,Has Results,Stable Angina|Heart Failure|Atherosclerosis|Multivessel Coronary Artery Disease,Procedure: Transplantation of nanoparticles|Procedure: Transplantation of iron-bearing nanoparticles|Device: Stenting,Total Atheroma Volume|MACE (Major Adverse Cardiovascular Events)-Free Survival|Per Cent of Fibro-fatty Component|Event Free Survival|Restenosis Rate|Late Definite Thrombosis|Coronary Vasomotion - Mean Lumen Diameter After Infusion of Acetylcholine 10-6 M|Per Cent Atheroma Volume|Target Lesion Revascularization|Per Cent of Fibrous Component|Per Cent of Necrotic Core|Per Cent of Calcium|Minimal Lumen Diameter|MACE|Cardiac Death|TLR (Target Lesion Revascularization)|TVR (Target Vessel Revascularization)|Mean Number of Membrane Defects on Membrane of Red Blood Cells,Ural State Medical University|Ural Institute of Cardiology|De Haar Research Task Force|Ural Federal University|Transfiguration Clinic,All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,180,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NANOM-FIM,"April 1, 2007","April 1, 2009","August 1, 2016","January 5, 2011","August 30, 2012","March 17, 2021","De Haar Research Task Force, Amsterdam, North Holland, Netherlands|Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Transfiguration Clinic, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Ural Institute of Cardiology, Yekaterinburg, Sverdlovsk Oblast, Russian Federation",,https://ClinicalTrials.gov/show/NCT01270139
40,25,NCT03645525,Intratracheal Umbilical Cord-derived Mesenchymal Stem Cell for the Treatment of Bronchopulmonary Dysplasia (BPD),IUMTB,Recruiting,No Results Available,Bronchopulmonary Dysplasia,Drug: Human Umbilical Cord-derived Mesenchymal stem cell|Drug: placebo,Oxygen requirement 3 days after transplantation|Oxygen requirement 7 days after transplantation|Duration of ventilator dependence|Incidence of severe BPD|Survival rate|Temperature|Heart rate|Respiratory rate|Duration of CPAP treatment|Percentage of participants treated with steroids for weaning from ventilator|Growth velocity (Z-score)|bronohoalveolar lavage (BAL) cytokine level|The severity of BPD in X-ray patterns,Children's Hospital of Fudan University,All,2 Weeks to 3 Weeks   (Child),Phase 1|Phase 2,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EKYYIUMTB,"December 1, 2019","October 30, 2022","April 1, 2023","August 24, 2018",,"September 9, 2021","Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China|Children's Hospital of Fudan University, Shanghai, Shanghai, China|Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03645525
41,222,NCT04602104,A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome,Biological: low dose hMSC-Exos|Biological: medium dose hMSC-Exos|Biological: high dose hMSC-Exos|Biological: Dosage 1of hMSC-Exos|Biological: Dosage 2 of hMSC-Exos|Biological: No hMSC-derived exosomes,Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU,Ruijin Hospital|Cellular Biomedicine Group Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,169,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MEXARDS,"November 30, 2020",June 2022,September 2022,"October 26, 2020",,"November 2, 2021","Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04602104
42,3,NCT00658073,Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts,,Completed,No Results Available,Renal Transplant Rejection,Procedure: Kidney transplantation with MSCs infusion|Procedure: kidney transplantation without MSC infusion,Incidence rate of biopsy-proven acute rejection and early renal function recovery|Patient and graft survival and prevalence of adverse events,Fuzhou General Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,165,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-K-2,March 2008,September 2010,October 2010,"April 14, 2008",,"March 8, 2011","Stem cell therapy center,Fuzhou General Hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT00658073
43,261,NCT04089579,hCT-MSC in Children With Autism Spectrum Disorder,IMPACT,Recruiting,No Results Available,Autism|Autism Spectrum Disorder,Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion,Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,4 Years to 11 Years   (Child),Phase 2,164,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00102894,"October 12, 2020","February 1, 2023","August 1, 2023","September 13, 2019",,"February 18, 2022","Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04089579
44,8,NCT03370874,Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.,,"Active, not recruiting",No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU|Procedure: Vehicle sheet,Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure between the two groups|Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups|Change rates in wound size and depth compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations,"Anterogen Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,164,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALLO-ASC-DFU-301,"July 4, 2018","June 30, 2021","June 30, 2021","December 13, 2017",,"January 22, 2021","Korea University Kuro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03370874
45,353,NCT01291329,Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI),WJ-MSC-AMI,Completed,No Results Available,ST-Elevation Myocardial Infarction,Genetic: intracoronary human umbilical WJ-MSC transfer,"Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography.|Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE).","Navy General Hospital, Beijing|Chinese PLA General Hospital|General Hospital of Chinese Armed Police Forces|First People's Hospital of Foshan",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006AA02Z469,February 2011,February 2012,July 2012,"February 8, 2011",,"February 13, 2015","Fu Cheng Lu 6, Beijing, China",,https://ClinicalTrials.gov/show/NCT01291329
46,39,NCT05345418,Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency,,Recruiting,No Results Available,Sexual Dysfunction Male,Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency,The safety of allogenic umbilical cord-derived mesenchymal stem cell administration for the treatment of hormone deficiency in male|Testosterone levels|Changes in sexual life quality using Aging Men Symptom (AMS)|Changes in sexual life quality through quantification of International Index of Erectile Function (IIEF)|Changes in sexual life quality through quantification of Sexual Quality of Life Questionnaire (SQoL-M),Vinmec Research Institute of Stem Cell and Gene Technology,Male,"50 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,158,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,ISC.21.08,"June 1, 2022","June 1, 2022","June 30, 2024","April 25, 2022",,"August 24, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT05345418
47,195,NCT00956891,Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation,,Completed,No Results Available,Liver Failure|Mesenchymal Stem Cells,,Short-term therapeutic effects of transplantation.|Long-term outcomes of transplantation.,Sun Yat-sen University,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",,158,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,SunYat-senU 5010 hepatitisB,May 2005,June 2009,July 2010,"August 11, 2009",,"December 7, 2010","The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT00956891
48,230,NCT04692376,MSC for Treatment of cGVHD After Allo-HSCT,,Recruiting,No Results Available,Chronic Graft-versus-host Disease,Biological: Mesenchymal stem cells|Drug: Glucocorticoids|Drug: cyclosporine,ORR|OS|DFS|Response rate|EBV DNA-emia|CMV DNA-emia|PGF,"Nanfang Hospital of Southern Medical University|Sun Yat-sen University|Xinqiao Hospital, Army Medical University|Peking University People's Hospital",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-cGVHD-2020,"January 10, 2021","December 31, 2022","June 30, 2023","December 31, 2020",,"December 31, 2020","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04692376
49,77,NCT03233074,Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors,COSMOS,Recruiting,No Results Available,Myelodysplastic Syndromes|Acute Myeloid Leukemia|Cardio-vascular Surgery,Other: Bone marrow analyses,Changes in cellular properties of mesenchymal stromal cells|Number of differential biomarkers in mesenchymal stromal cells,Centre Hospitalier Universitaire de Saint Etienne|Institut de Cancérologie de la Loire,All,"50 Years to 80 Years   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2017-0701|2017-A02088-45,"November 17, 2017","September 30, 2022","September 30, 2022","July 28, 2017",,"February 8, 2022","CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|CHU de Saint-Etienne, Saint-Étienne, France",,https://ClinicalTrials.gov/show/NCT03233074
50,182,NCT03169231,Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty,,Completed,No Results Available,Aging Frailty,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo,Longeveron Inc.,All,70 Years to 85 Years   (Older Adult),Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",001-03,"July 6, 2017","September 30, 2021","September 30, 2021","May 30, 2017",,"March 7, 2022","Soffer Health Institute, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States",,https://ClinicalTrials.gov/show/NCT03169231
51,435,NCT05210309,National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study),PRIME,Recruiting,No Results Available,"Safety|Efficacy, Self",Procedure: Stem Cell Therapy,Therapeutic Efficacy of Darvadstrocel-Clinical|Therapeutic Efficacy of Darvadstrocel-MRI|Quality of Life (QoL)|PATIENT REPORTED OUTCOMES (PROs)|Efficiency,Universidad de Zaragoza|Hospital Universitario Fundación Jiménez Díaz,All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,UZaragoza-1,"January 1, 2020","July 31, 2022","December 31, 2022","January 27, 2022",,"January 27, 2022","Hospital de Elche, Elche, Alicante, Spain|HOSPITAL Meixoeiro Vigo, Vigo, Pontevedra, Spain|Hospital Vall D´Hebron, Barcelona, Spain|Hospital La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT05210309
52,147,NCT04297813,Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting,Maxibone,Recruiting,No Results Available,Alveolar Bone Atrophy,Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)|Procedure: Autologous bone graft,Change in bone width|Pain postoperatively in the two different treatments|Radiological examination of bone volume,University of Bergen|Université de Nantes|University of Ulm|Universidad Complutense de Madrid|University of Aarhus|Universitat Internacional de Catalunya|Assistance Publique - Hôpitaux de Paris|European Commission,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-001227-39,March 2020,August 2022,September 2024,"March 6, 2020",,"March 12, 2020","Syddansk Universitet SDU (University Hospital of Southern Denmark), Odense, Denmark|Assistance Publique - Hôpitaux De Paris, Créteil, France|CHU Nantes, Centre de Soins Dentaires, Nantes, France|University of Bergen, Institute of Clonical Dentistry, Bergen, Hordaland, Norway|Universidad Complutense De Madrid, Madrid, Calle Fernando De Castro Rodriguez,, Spain|Universitat Internacional De Catalunya, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04297813
53,212,NCT05484856,Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA),,Completed,No Results Available,"Osteoarthritis, Knee",Biological: Autologous adipose tissue derived stromal cells,changes in womac score|changes in cartilage thickness as assessed on 1.5 T MRI|changes in joint space width,Dr. Himanshu Bansal Foundation,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,140,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAH/CLINICALTRIAL/01/2016,"May 16, 2016","June 27, 2020","February 25, 2021","August 2, 2022",,"August 2, 2022","Anupam Hospital, Rudrapur, Uttarakhand, India",,https://ClinicalTrials.gov/show/NCT05484856
54,225,NCT01413061,Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft,,Completed,No Results Available,Degenerative Osteoarthritis|Post-traumatic; Arthrosis|Rheumatoid Arthritis & Other Inflammatory Polyarthropathies|Rheumatoid Arthritis of Subtalar Joint,Procedure: Subtalar Arthrodesis,Fusion Rate (%)(as determined by CT assessment)|Radiographic outcome assessments|Functional outcome measurements,AlloSource,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,140,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AlloSource Subtalar Fusion RCT,June 2010,February 2017,March 2018,"August 10, 2011",,"April 13, 2018","Institute for Foot and Ankle Reconstruction at Mercy, Baltimore, Maryland, United States|Orthopaedic Associates of Michigan, Grand Rapids, Michigan, United States|Minnesota Orthopedic Sports Medicine Institute (MOSMI), Edina, Minnesota, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Campbell Clinic, Germantown, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01413061
55,166,NCT04368806,A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis,,Recruiting,No Results Available,"Osteoarthritis, Knee",Drug: JointStem|Other: Placebo Control,Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score|Visual Analog Scale (VAS) score|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)|Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|International Knee Documentation Committee (IKDC) score|36-Item Short Form health survey questionnaires (SF-36) score|Structural changes in knee joint|Kellgren-Lawrence grade|Number and amount of rescue medication use,Nature Cell Co. Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JS-OAP3-US01,"May 26, 2021","June 30, 2023","December 30, 2023","April 30, 2020",,"September 23, 2022","TriWest Research Associates, El Cajon, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Neurovations Research, Napa, California, United States|Source Healthcare, Santa Monica, California, United States|International Spine Pain, and Performance Center, Washington, District of Columbia, United States|Rothman Orthopaedic Institute, Egg Harbor Township, New Jersey, United States|Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04368806
56,7,NCT04476901,Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy,DCMII,Recruiting,No Results Available,Non-ischemic Dilated Cardiomyopathy,Biological: allogeneic human mesenchymal stem cells (hMSCs)|Other: Placebo,Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs,"Joshua M Hare|United States Department of Defense|The University of Texas Health Science Center, Houston|University of Miami",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,136,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20200566|CDMRP-PR191597|20-02-134,"May 7, 2021",December 2024,December 2024,"July 20, 2020",,"March 25, 2022","Stanford University, Stanford, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Texas Heart Institute, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04476901
57,182,NCT05413148,The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa,,Recruiting,No Results Available,Retinitis Pigmentosa,Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells|Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Other: Placebo,Evaluation of best corrected visual acuity change|Evaluation of visual field change|Evaluation of multifocal ERG changes|Evaluation of ERG changes|Evaluation of optical coherence tomography changes|Evaluation of optical coherence tomography angiography changes,TC Erciyes University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TSG-2021-11599.,"August 5, 2022","July 1, 2023","December 15, 2023","June 9, 2022",,"September 7, 2022","Erciyes University, Faculty of Medicine, Kayseri, Turkey",,https://ClinicalTrials.gov/show/NCT05413148
58,597,NCT04738981,Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT,,Not yet recruiting,No Results Available,Graft Vs Host Disease,Drug: UC-MSC|Drug: Anti-CD25 mAb,Rate of complete remission|Overall survival|Rate of partial remission|Infusion toxicity,"Peking University People's Hospital|Southern Medical University, China|Third Military Medical University|Sun Yat-sen University",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GVHD-PKU2021,February 2021,December 2021,December 2021,"February 4, 2021",,"February 4, 2021","Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04738981
59,38,NCT05329662,Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female,,Not yet recruiting,No Results Available,Sexual Dysfunction Female,Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency,Change of Follicle-stimulating hormone (FSH) hormone level|Change of Estradiol (E2) hormone level|Change in Quality of life using Female Sexual Function Index - FSFI questionaires|Change in Quality of life using The Utian Quality of life Scale|The safety of AD MSC therapy in the treatment of sexual function impairment in female,Vinmec Research Institute of Stem Cell and Gene Technology,Female,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,130,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISC.21.73,"November 1, 2022","November 1, 2022","June 30, 2024","April 15, 2022",,"August 24, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT05329662
60,714,NCT03042143,Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST),REALIST,Recruiting,No Results Available,Acute Respiratory Distress Syndrome,Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148),Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality,"Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,129,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16154DMcA-AS,"January 7, 2019",March 2023,June 2025,"February 3, 2017",,"May 25, 2022","Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom",,https://ClinicalTrials.gov/show/NCT03042143
61,220,NCT04427930,Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial,,"Active, not recruiting",No Results Available,Knee Osteoarthritis,Biological: JOINTSTEM,Adverse Events|Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|WOMAC 3 subscale score|SF-36|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan,R-Bio,All,"20 Years and older   (Adult, Older Adult)",Phase 3,129,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BSR-CTph3-JS1_FU,"April 13, 2020","December 23, 2026","December 30, 2027","June 11, 2020",,"September 28, 2022","Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04427930
62,181,NCT02501811,Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure,CONCERT-HF,Completed,Has Results,Ischemic Cardiomyopathy,Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A),Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Scar Size Percent (DEMRI)|Change From Baseline in Scar Tissue Mass (DEMRI)|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Scar Size Percent (DEMRI)-Trajectory|Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Participants With Major Adverse Cardiac Events (MACE)|Participants Experiencing Other Significant Clinical Events|Cumulative Days Alive and Out of Hospital for Heart Failure,"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 79 Years   (Adult, Older Adult)",Phase 2,125,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-SPH-15-0413|5UM1HL087318,October 2015,"June 25, 2020","July 22, 2020","July 17, 2015","April 26, 2021","April 26, 2021","Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdisciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02501811
63,8,NCT04493242,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,EXIT-COVID19,Completed,No Results Available,"Covid19|ARDS|Pneumonia, Viral",Biological: DB-001|Other: Intravenous normal saline,7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality,"Direct Biologics, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DB-EF-PHASEII-001,"September 24, 2020","May 1, 2021","May 22, 2021","July 30, 2020",,"January 14, 2022","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04493242
64,225,NCT04776538,Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients,MESRIX-III,Recruiting,No Results Available,Xerostomia Following Radiotherapy,Biological: Stem cells|Biological: Placebo,Salivary gland function|Incidence of treatment-emergent adverse events|Patient-Reported Outcome of xerostomia|Salivary composition,"Rigshospitalet, Denmark|Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet|The Cell Therapy Facility, The Blood bank, Dept. of Clinical Immunology, 2034, Rigshospitalet, Denmark|Department of Oncology, 3994, Rigshospitalet, Denmark|Department of Oncology Herlev Hospital, Denmark|Department of Dentistry and Oral Health, Aarhus, Denmark",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CVB2018-1,"February 9, 2021","October 1, 2023","October 1, 2023","March 1, 2021",,"March 1, 2021","Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04776538
65,365,NCT02968459,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars,,Recruiting,No Results Available,Uterine Scar,Other: Umbilical cord MSCs|Other: 0.9% Saline,Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence,Maternal and Child Health Hospital of Foshan,Female,21 Years to 35 Years   (Adult),Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCHHFoshan-1603,October 2021,December 2021,April 2022,"November 18, 2016",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02968459
66,201,NCT05288725,Mesenchymal Stem Cell Therapy for Knee Osteoarthritis,,Not yet recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Bone Marrow Derived MSCs|Drug: Corticosteroid|Device: Bone Marrow Aspirate,Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 3 months|Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 6 months|Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 12 months|Change from Baseline Visual Analog Score (VAS) at 3 months|Change from Baseline Visual Analog Score (VAS) at 6 months|Change from Baseline Visual Analog Score (VAS) at 12 months|Magnetic Resonance Imaging (MRI) Evaluation|Change from baseline measure of Fall Risk Functional Testing at 3 months|Change from baseline measure of Fall Risk Functional Testing at 6 months|Change from baseline measure of Fall Risk Functional Testing at 12 months|Change from baseline measure of Frailty Functional Testing at 3 months|Change from baseline measure of Frailty Functional Testing at 6 months|Change from baseline measure of Frailty Functional Testing at 12 months|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 3 months.|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 6 months.|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 12 months.|Change from baseline measure of Obesity Functional Testing at 3 months|Change from baseline measure of Obesity Functional Testing at 6 months|Change from baseline measure of Obesity Functional Testing at 12 months,Next Generation Regenerative Medicine LLC,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NGRM-001,August 2022,June 2024,December 2024,"March 21, 2022",,"March 21, 2022","Bluetail Medical Group, Chesterfield, Missouri, United States|Scarpone Sports Regenerative, Steubenville, Ohio, United States|Albano Clinic, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT05288725
67,247,NCT04247945,Co-transplantation of MSC in the Setting of Allo-HSCT,,Recruiting,No Results Available,Allogeneic Hematopoietic Stem Cell Transplantation,Biological: Cotransplant with MSCs,Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse,Fujian Medical University,All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MSC-SCT-03,"February 1, 2020","December 1, 2023","December 1, 2025","January 30, 2020",,"January 30, 2020","Union Hospital,Fujian Medical University, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT04247945
68,21,NCT05086939,Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis.,ARTROCELL,Recruiting,No Results Available,Knee Osteoarthritis,Drug: Autologous MSCs|Drug: Allogenic MSCs|Drug: Hyaluronic Acid,Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).,Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Instituto de Investigación Biomédica de Salamanca|Spanish Clinical Research Network - SCReN|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Hospital Universitari de Bellvitge,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARTROCELL|2019-002446-21,"May 26, 2021",December 2025,December 2025,"October 21, 2021",,"June 2, 2022","Hospital Clinic, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT05086939
69,147,NCT03818854,Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome,STAT,Recruiting,No Results Available,"Respiratory Distress Syndrome, Adult",Biological: Human Mesenchymal Stromal Cells|Biological: Cell Reconstitution Media,Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events,"Michael A. Matthay|United States Department of Defense|Harborview Injury Prevention and Research Center|Oregon Health and Science University|Vanderbilt University Medical Center|The University of Texas Health Science Center, Houston|University of Minnesota|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",UCSF-hMSC-ARDS-P1P2-12,"November 26, 2019","July 1, 2023","July 1, 2024","January 28, 2019",,"September 14, 2022","University of California Davis Medical Center, Sacramento, California, United States|Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03818854
70,194,NCT04093336,Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients,,Recruiting,No Results Available,"Infarction, Middle Cerebral Artery|Infarction, Anterior Cerebral Artery|Cerebral Infarction|Stroke, Ischemic|Acute Stroke|Brain Infarction|Infarction, PCA|Infarction, Posterior Circulation, Brain",Biological: human umbilical cord mesenchymal stem cells|Biological: Placebo|Other: standardized treatment,adverse events|the National Institutes of Health Stroke Scale (NIHSS) of 3 months|the Barthel index (BI) of 3 months,Shanghai East Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2018-DFSC-002（V3）,"January 13, 2019","April 30, 2024","August 31, 2024","September 18, 2019",,"October 28, 2021","Gang Li, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04093336
71,650,NCT01709656,A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis,,Completed,No Results Available,Ankylosing Spondylitis,"Biological: MSC|Drug: ""celecoxib"", ""Celebrex®""",the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria|BASDAI score comparing to baseline|BASFI score comparing to baseline,Sun Yat-sen University,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),[2012]2-31,March 2012,December 2014,December 2014,"October 18, 2012",,"February 11, 2015","Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01709656
72,762,NCT04137562,Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis,,Recruiting,No Results Available,Atopic Dermatitis,Biological: ADSTEM Inj.|Other: Placebo,EASI-50|EASI-75|EASI score|SCORAD-50|SCORAD-75|SCORAD score|SCORAD subgroup|Severity|IGA grade|IGA -1 or more grade|IGA -2 or more grade|Total IgE|PGE2 and ECP|Immune cytokine|Remedy used days and frequency|Remedy used subjects,"EHL Bio Co., Ltd.",All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 2,118,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AD-CP-18-1|30902,"December 11, 2019","February 14, 2025","May 31, 2027","October 24, 2019",,"January 12, 2022","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of|Korea University AnSan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Chung-Ang University Hospital, Seoul, Seoulteukbyeolsi, Korea, Republic of|Kyunghee University Medical Center, Seoul, Seoulteukbyeolsi, Korea, Republic of|Seoul National University Hospital, Seoul, Seoulteukbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Seoulteukbyeolsi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04137562
73,2,NCT03418233,Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF),,Completed,No Results Available,Heart Failure,Drug: CardioCell|Drug: Placebos,Left ventricle ejection fraction (LVEF) increase|An increase the result of 6 minute walk test|Myocardial perfusion improvement|An improvement the result of spiroergometric test|Left ventricle ejection fraction (LVEF) change against baseline|Left ventricle end-systolic volume (ESV) change against baseline|Left ventricle end-diastolic volume (EDV) change against baseline|NT pro-BNP level|The occurrence of major adverse cardiovascular events|Quality of life improvement,"John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,115,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CardioCell in CIHF,"April 19, 2018","January 27, 2021","March 31, 2021","February 1, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|The University Hospital in Cracow, Cracovia, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Katowice, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT03418233
74,669,NCT04745299,Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS,ALSummit,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Lenzumestrocel|Drug: Riluzole|Drug: Placebo Comparator,"Joint rank scores (CAFS, Combined Assessment of Functional and Survival)|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score|Time to event","Corestem, Inc.",All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,115,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NEURONATA-R_ALS301,"March 23, 2021","October 30, 2023","May 3, 2026","February 9, 2021",,"March 9, 2022","Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Hanyang university hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04745299
75,230,NCT03276312,Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot,,Completed,No Results Available,Diabetic Foot,Device: Lipogems,Healing time|Safety: All types of adverse events will be collected|Incidence of relapse|Pain assessed using the Visual Analogue Scale (VAS) for pain|Total time of hospitalization|Total time of immobility|Quality of Life using the Short Form 36 (SF-36) questionnaire,University of Modena and Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADF01,April 2015,March 2018,March 2018,"September 8, 2017",,"June 8, 2018","University of Modena and Reggio Emilia, Modena, Italy",,https://ClinicalTrials.gov/show/NCT03276312
76,218,NCT04219657,Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application,,Completed,No Results Available,Accidental Wound|Heel Injury|Stem Cell Transplant,Biological: mesenchymal stem cell application,Ranges of Movement of ankle joint|duration of hospital stay|Weight bearing capacity of patients,King Edward Medical University,All,8 Years to 12 Years   (Child),Phase 1,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Sushil_Rijal,"October 29, 2016","December 20, 2019","December 22, 2019","January 7, 2020",,"February 17, 2020","Pediatric Surgery Department, King Edward Medical University, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04219657
77,48,NCT04208646,Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis,,Recruiting,No Results Available,Knee Osteoarthritis,Biological: Mesenchymal progenitor cells|Biological: No mesenchymal progenitor cells,WOMAC Score|MRI quantitative analysis of articular cartilage|VAS Score|SF-36|Adverse Events and Serious Adverse Events|Changes of laboratory test indexes and vital signs,"Cellular Biomedicine Group Ltd.|RenJi Hospital|Shanghai 6th People's Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Second Affiliated Hospital, School of Medicine, Zhejiang University|China-Japan Friendship Hospital|Huashan Hospital|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2,108,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBM-ALAM.1-01,"May 16, 2020",December 2021,January 2022,"December 23, 2019",,"November 4, 2020","China-Japan Friendship Hospital, Beijing, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, China|Huashan Hospital Affiliated to Fudan University, Shanghai, China|Shanghai General Hospital, Shanghai, China|Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04208646
78,416,NCT05131412,Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation,MSCTPHSCT,Completed,No Results Available,Pneumonia|Hematopoietic Stem Cell Transplantation,,overall cure rate|time to cure,Guangzhou Women and Children's Medical Center,All,1 Year to 17 Years   (Child),,107,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,GWCMC_HJ_XY_001,"August 8, 2018","January 1, 2021","October 31, 2021","November 23, 2021",,"December 3, 2021","Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT05131412
79,231,NCT00988338,Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion,TAF,Completed,No Results Available,"Tibiotalar Arthrodesis|Subtalar Arthrodesis|Calcaneocuboid Arthrodesis|Talonavicular Arthrodesis|Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular)|Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)",Biological: Trinity Evolution,"Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2).",Orthofix Inc.,All,"18 Years and older   (Adult, Older Adult)",,106,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,TY01AF,September 2009,January 2013,January 2013,"October 2, 2009",,"October 28, 2021","Orthopaedic Associates of South Broward, PA, Hollywood, Florida, United States|Sinai Hospital of Baltimore / Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States|New Mexico Orthopedics, Albuquerque, New Mexico, United States|OrthoCarolina Research Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio Orthopedic Center of Excellence, Upper Arlington, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Central Tennessee Foot and Ankle Center, Sparta, Tennessee, United States|Franciscan Foot and Ankle Specialists, Burien, Washington, United States",,https://ClinicalTrials.gov/show/NCT00988338
80,185,NCT01781390,Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction,AMICI,Completed,Has Results,Acute Myocardial Infarction,Other: Placebo|Biological: Mesenchymal Precursor Cells (MPC) 12.5 M|Biological: Mesenchymal Precursor Cells (MPC) 25 M,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,106,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANG.AMI-IC001|2010-020497-41,"March 11, 2013","April 6, 2021","April 6, 2021","February 1, 2013","January 18, 2022","June 23, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01781390/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01781390
81,1,NCT03404063,Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI),,Completed,No Results Available,Myocardial Infarction,Drug: Cardiac Drug|Drug: Placebos,Reduction of infarct size|Infarct size reduction|Myocardial perfusion improvement|Increase of left ventricle ejection fraction (LVEF)|Left ventricle ejection fraction (LVEF) change against baseline.|Left ventricle end-systolic volume (ESV) change against baseline.|Left ventricle end-diastolic volume (EDV) change against baseline.|The occurrence of major adverse cardiovascular events|Quality of life improvement,"John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,105,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CardioCell evaluation in AMI,"October 20, 2017","July 2, 2020","March 31, 2021","January 19, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT03404063
82,285,NCT01041001,Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury,,Completed,No Results Available,Cartilage Injury|Osteoarthritis,Biological: Cartistem|Procedure: Microfracture treatment,ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores,Medipost Co Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,104,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-CRP-005,February 2009,December 2010,January 2011,"December 30, 2009",,"April 20, 2017","Gachon University Gil Hospital, Incheon, Gyunggido, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01041001
83,133,NCT02302599,Mesenchymal Stem Cells to Treat Type 2 Diabetes,UC-MSCs,Completed,No Results Available,Type 2 Diabetes|Mesenchymal Stem Cells,Biological: Umbilical cord mesenchymal stem cells|Biological: Controlled suspension liquid,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D|Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D|safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,Chinese PLA General Hospital,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 2,103,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHIN-PLAGH-ST-003,January 2013,December 2020,December 2020,"November 27, 2014",,"February 3, 2021","Chinese PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02302599
84,5,NCT01626677,Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect,,Completed,No Results Available,Degenerative Osteoarthritis|Defect of Articular Cartilage,Biological: CARTISTEM|Procedure: Microfracture,Degree of improvement in knee assessments compared to the active control (microfracture)|Number of subjects with adverse events,"Medipost Co Ltd.|Dong-A Pharmaceutical Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,103,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CARTISTEM_CR_F/U,June 2012,May 2015,May 2015,"June 25, 2012",,"April 20, 2017","Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01626677
85,62,NCT02481440,Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI,,Completed,Has Results,Spinal Cord Injuries,Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs),American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up|American Spinal Injury Association (ASIA) Total Score|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score|International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score|Penn Scale|Modified Ashworth Scale|Geffner Scale|Neurogenic Bowel Dysfunction (NBD) Scale|Residual Urine Volume,"Limin Rong|Third Affiliated Hospital, Sun Yat-Sen University",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,102,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,hUC-MSC-SCI,"March 30, 2018","March 31, 2020","March 31, 2020","June 25, 2015","June 30, 2020","June 30, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02481440/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02481440
86,4,NCT04310215,Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus,,Completed,No Results Available,Chondral or Osteochondral Lesion of Talus,Biological: CARTISTEM®|Procedure: Microfracture,ICRS-Cartilage Repair Assessment Total Score|ICRS-Cartilage Repair Assessment Overall Grade|Improvement degree of Cartilage Repair by MRI|Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)|Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)|Degree of Functional improvement in Tegner activity score|Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)|Degree of pain improvement in 100 mm VAS(Visual Analogue Scale),"Hyundai Bioland Co., Ltd.|Medipost Co Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,102,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CARTISTEM_2019_01,"March 3, 2020","June 13, 2022","June 13, 2022","March 17, 2020",,"August 3, 2022","Kyunghee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Gangnam-gu, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of|Inha University Hospital, Incheon, Jung-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04310215
87,648,NCT04074408,Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration,,Recruiting,No Results Available,Basal Ganglia Hematoma,Procedure: stereotactic surgery|Biological: hUMSCs|Biological: placebo,"Frequency of dose limiting adverse events|Modified Rankin Scale (mRS) to measure the prognosis|National institute of Health Stroke Scale (NIHSS) to measure stroke recovery|Barthel Index (BI) to evaluate the self-care ability|Rate of muscle strength level of the hemiplegic limb|Mortality rate|Change in Glasgow coma scale (GCS) score|Change in Glasgow outcome scale (GOS) score|MRI (T1, T2, Flair, DWI) scanning","Second Affiliated Hospital, School of Medicine, Zhejiang University|The First Affiliated Hospital, University of Science and Technology of China|Huzhou Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Fujian Medical University|Jinhua Hospital, School of Medicine, Zhejiang University|Taizhou Hospital",All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SAHZJU-hUMSCs,May 2020,November 2022,November 2023,"August 30, 2019",,"May 26, 2020","Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04074408
88,59,NCT04675359,Adipose-derived MSCs After Enzymatic Digestion vs. Mechanically Fragmented Fat Transfer in Knee Osteoarthritis Treatment,,Not yet recruiting,No Results Available,Knee Osteoarthritis|Chondropathy,Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint,Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage,Medical University of Warsaw,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MSC,"July 1, 2021","June 30, 2023","December 1, 2023","December 19, 2020",,"January 8, 2021",,,https://ClinicalTrials.gov/show/NCT04675359
89,128,NCT03887208,Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells,2ABC,Completed,No Results Available,Skin|Scar|Cutis Laxa|Keloid|Cicatrix,Procedure: Laser therapy|Biological: Autologous ADSC injection|Procedure: Normal saline injection,Change in patient's skin condition|Evaluation of skin problems. Assessment of skin related complaints since the last visit.|The assessment of the scar by the patient.|Changes in volume of the skin (USG)|Changes in skin surface morphology (digital imagining)|Record of adverse events,Medical University of Warsaw|Timeless Chirurgia Plastyczna-Janusz Jaworowski|Melitus sp. z o.o.|Polish Stem Cells Bank S.A.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2ABC Therapy|2016-004110-10|267976/13/NCBR/2015|PL008125|Z4217,"January 31, 2018","January 31, 2019","January 31, 2019","March 22, 2019",,"January 28, 2020","Laboratory for Cell Research and Application, Medical University of Warsaw, Warsaw, Poland|Melitus sp. z o.o., Warsaw, Poland|Timeless Chirurgia Plastyczna Sp. z o. o., Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT03887208
90,398,NCT04520945,Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis,,Not yet recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Chondrogen|Biological: Placebo,VAS score|WOMAC score|IKDC score|KOOS score|PROMIS29 score|Kellegren-Lawrence grading|Interleukins,Meluha Life Sciences SDN BHD,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Chondrogen,"October 31, 2020","September 30, 2021","September 30, 2022","August 20, 2020",,"August 20, 2020","Department of Orthopedic & Traumatology, Faculty of Medicine, Hospital Canselor Tuanku Mukhriz, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur., Cheras, Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT04520945
91,72,NCT02484950,Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair,,Recruiting,No Results Available,Full Thickness Rotator Cuff Tear,Biological: Mesenchymal stem cell augmentation in rotator cuff repair|Procedure: Standard arthroscopic rotator cuff repair,American Shoulder and Elbow Surgeons (ASES) Score|Magnetic Resonance Imaging (MRI) Scan|Functional Outcomes - Shoulder Exam|Patient Centered Outcomes - Shoulder Survey,Rush University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15042702,November 2015,November 2022,March 2023,"June 30, 2015",,"June 27, 2022","Rush University Medical Center, Chicago, Illinois, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02484950/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02484950
92,9,NCT04650568,Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction,BMAC,Enrolling by invitation,No Results Available,Anterior Cruciate Ligament Injury|Anterior Cruciate Ligament Rupture,Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells|Other: Sham incision,Signal to Noise Quotient|Side to side difference in anterior tibial translation|Patient reported outcomes- Tegner Score|Patient reported outcomes- Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)|Patient reported outcomes- International Knee Documentation Committee (IKDC) Score,Rush University Medical Center,All,18 Years to 60 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",17082504,"November 3, 2017","December 3, 2022","December 31, 2022","December 2, 2020",,"January 5, 2022","Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04650568
93,243,NCT03378063,Stem Cells for Bronchopulmonary Dysplasia,,Recruiting,No Results Available,Bronchopulmonary Dysplasia,Drug: transplantation of mesenchymal stem cell|Drug: no transplantation of mesenchymal stem cell,death|Bayley Scales of Infant Development,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Children's Hospital of Chongqing Medical University|Chongqing Maternal and Child Health Hospital,All,1 Month to 3 Months   (Child),Early Phase 1,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,stem cell for BPD,"November 1, 2017","December 30, 2022","December 30, 2022","December 19, 2017",,"February 16, 2021","Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT03378063
94,211,NCT02582489,Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy,,Recruiting,No Results Available,Osteoarthritis Post-meniscectomy,Biological: Bone Marrow Aspirate Concentrate|Procedure: Standard Meniscectomy,International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis,Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",15090903,"December 22, 2017","November 30, 2022","December 31, 2022","October 21, 2015",,"January 5, 2022","Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02582489
95,139,NCT02838069,A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis,ADIPOA-2,"Active, not recruiting",No Results Available,Osteoarthritis,Biological: Injection (2x106 ASC/5ml).|Biological: Injection (10x106 ASC/5ml).|Other: Placebo,Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI),"University Hospital, Montpellier|University Hospital, Toulouse|Assistance Publique - Hôpitaux de Paris|NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)|ISTITUTO ORTOPEDICO RIZZOLI (IOR)|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)|HUMAN MED AG (HM)|Stichting Katholieke Universiteit|SPORTS SURGERY CLINIC LIMITED|UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)|EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)|PINTAIL LTD (PT)|Centre National de la Recherche Scientifique, France|UNIVERSITAET ULM (UULM)|Cambridge University Hospitals NHS Foundation Trust|Aries srl (ARIES)",All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UF 9494,"September 20, 2016",March 2023,March 2024,"July 20, 2016",,"July 11, 2022","UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02838069
96,265,NCT00603330,Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function,,Recruiting,No Results Available,Graft-versus-host Disease|Poor Graft Function|Low Donor T-cell Chimerism,Biological: Mesenchymal stem cells,Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.|Arm 2. Efficacy of MSC infusion as treatment for poor graft function|Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT|Toxicity of MSC infusion,"University of Liege|KU Leuven|Maastricht University Medical Center|Ziekenhuis Netwerk Antwerpen (ZNA)|University Hospital, Antwerp|University Hospital, Ghent|AZ-VUB|AZ Sint-Jan AV|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|University Hospital of Mont-Godinne|Jolimont Hospital Haine Saint Paul|Queen Fabiola Children's University Hospital",All,"Child, Adult, Older Adult",Phase 2,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TJB0703P1,January 2008,August 2024,August 2024,"January 29, 2008",,"September 21, 2022","UZA, Edeghem, Antwerpen, Belgium|Hôpital des enfants Reine Fabiola, Brussels, Brabant, Belgium|AZ VUB Jette, Brussels, Brabant, Belgium|Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Brussels, Brabant, Belgium|AZ Gasthuisberg Leuven, Leuven, Flamish Brabant, Belgium|UZ Gent, Gent, Flanders Ost, Belgium|Hôpital de Jolimont, Haine St Paul, Hainaut, Belgium|Cliniques Universitaires Mont-Godinne, Yvoir, Namur, Belgium|AZ St Jan, Brugge, West Flanders, Belgium|Hôpital Stuyvenberg, Antwerpen, Belgium|CHU Sart Tilman, Liege, Belgium|University Hospital Maastricht, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT00603330
97,314,NCT04288102,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),,Completed,No Results Available,Corona Virus Disease 2019(COVID-19),Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）,"Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) × voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|The General Hospital of Central Theater Command|VCANBIO Cell & Gene Engineering Corporation, Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-013-D,"March 5, 2020","May 12, 2020","July 9, 2020","February 28, 2020",,"August 19, 2020","General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04288102
98,229,NCT04903327,Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress,,Recruiting,No Results Available,Covid19,Biological: COVI-MSC|Drug: Placebo,All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation,"Sorrento Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSC-COV-201BR,"November 16, 2021",November 2022,March 2023,"May 26, 2021",,"March 16, 2022","Hospital São Rafael S.A. - Instituto D'Or de Pesquisa e Ensino, Salvador, BA, Brazil|Santa Casa de Misericórdia da Bahia (Hospital Santa Izabel), Salvador, BA, Brazil|Saraiva & Berlinger Ltda. - EPP (IPECC), Campinas, SP, Brazil|CECIP JAU - Centro de Estudos Clínicos do Interior Paulista Ltda., Jaú, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos Ltda. - EPP, São Bernardo Do Campo, SP, Brazil|Impar Serviços Hospitalares S/A (Hospital Nove de Julho), São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT04903327
99,206,NCT04482413,Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,,Not yet recruiting,No Results Available,Alzheimer Disease,Drug: AstroStem|Drug: Placebo,SUVR (Standard Uptake Value Ratio)|CDR-SB score (Clinical Dementia Rating Sum of Boxes)|ADAS-Cog-11 score (Alzheimer's Disease assessment Scale-Cognitive Subscale (11 items))|MMSE (Mini-mental status examination)|ADCS-ADL-MCI (Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|Treatment related Adverse Events,Nature Cell Co. Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AST-ADP2-US02,"February 1, 2023","May 30, 2024","December 20, 2024","July 22, 2020",,"September 28, 2022",,,https://ClinicalTrials.gov/show/NCT04482413
100,780,NCT01290367,Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain,,Completed,No Results Available,Degenerative Disc Disease,Biological: Single Dose MPCs Injection|Procedure: Single injection of saline solution|Procedure: Single injection of hyaluronic acid,"To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.|To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).","Mesoblast, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",MSB-DR001,August 2011,July 2013,July 2015,"February 7, 2011",,"June 26, 2020","Arizona Pain Specialists, Scottsdale, Arizona, United States|UC Davis Spine Center, Sacramento, California, United States|The Spine Institute, Santa Monica, California, United States|IPM Medical Group, Inc., Walnut Creek, California, United States|Denver Spine, Denver, Colorado, United States|Rocky Mountain Associates in Orthopedic Medicine, P.C., Loveland, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States|Central Texas Spine Institute, Austin, Texas, United States|Richmond Bone and Joint Clinic, Memorial Hermann Medical Group, Richmond, Texas, United States|Virginia Spine Research Institute, Inc., Richmond, Virginia, United States|Washington Center for Pain Management, Edmonds, Washington, United States|The Center for Pain Relief, Inc., Charleston, West Virginia, United States|Monash Medical Center, Clayton, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01290367
101,229,NCT04042844,A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD),,Recruiting,No Results Available,Lumbar Disc Disease,Biological: BRTX-100|Drug: Saline,Number of study participants with treatment related adverse events (TEAES) and serious adverse events (SAEs) from baseline through Week 104.|Visual Analogue Scale for Pain Assessment - Changes from Baseline in pain as assessed with the VAS score through Week 52|Oswestry Disability Index for Functional Assessment -- Changes from Baseline in function as assessed with the Oswestry Disability Index through Week 52.,BioRestorative Therapies,All,18 Years to 60 Years   (Adult),Phase 2,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLDD-001,"June 30, 2022","August 31, 2024","August 31, 2025","August 2, 2019",,"August 12, 2022","Biosolutions Clinical Research Center, La Mesa, California, United States|010 : Triwest Research Associates : USA : Levy, Louis J. Levy, Louis J. Principal Investigator llevy@triwestresearch.com 619-589-6888 San Diego, CA, 92108, United States, San Diego, California, United States|Denver Back Pain Specialists, LLC, Greenwood Village, Colorado, United States|Georgetown Washington University, Washington, District of Columbia, United States|Pain Relief Centers, Saint Petersburg, Florida, United States|Tampa Pain Relief Center, Tampa, Florida, United States|Long Island Spine Rehabilitation Medicine, East Meadow, New York, United States|Mount Sinai, New York, New York, United States|The Center of Clinical Research, LLC, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Coastal Carolina Research Center, North Charleston, South Carolina, United States|Premier Pain Centers, Richardson, Texas, United States|Precision Spine Care, Tyler, Texas, United States|Virginia iSpine Physicians, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04042844
102,9,NCT00543374,Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease,,Completed,No Results Available,Crohn's Disease,Drug: Placebo|Drug: PROCHYMAL adult human mesenchymal stem cells,Duration of clinical benefit (Crohn's disease activity index)|Re-induction of clinical benefit (Crohn's disease activity index)|Improvement in quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ] instrument),"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,98,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRD 610,"September 17, 2007",July 2009,"April 28, 2011","October 15, 2007",,"December 28, 2021","Advanced Clinical Research Institute, Anaheim, California, United States|Veteran's Administration Medical Center (does not require vet status), Long Beach, California, United States|University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Gastroenterology Center of Connecticut, Hamden, Connecticut, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Venture Research Institute, Miami, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|National Institutes of Health, Bethesda, Maryland, United States|Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Gastroenterology Research Associates, Cedar Knolls, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Dayton Science Institute, Dayton, Ohio, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann Hospital, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00543374
103,411,NCT00498316,Cord Blood Expansion on Mesenchymal Stem Cells,,Completed,No Results Available,Myelodysplastic Syndrome|Leukemia,Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Rituximab|Other: ATG|Drug: Cyclophosphamide|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)|Drug: Melphalan|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF,Engraftment and Time to Engraftment,M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI),All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1,98,Other|Industry|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0781|NCI-2011-02823|RP100469 02|1P01CA148600-01A1|5R01CA061508-20,"July 3, 2007",October 2016,October 2016,"July 10, 2007",,"February 28, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00498316
104,781,NCT03381326,"CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.",IRSTB030,"Active, not recruiting",No Results Available,Prostate Cancer|Metastatic Cancer|Castration-resistant Prostate Cancer|Circulating Tumor Cells,Procedure: blood and FFPE sample collection,Progression free survival (PFS)|Overall survival (OS),Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,Male,"18 Years and older   (Adult, Older Adult)",,94,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRSTB030,"December 15, 2014",October 2019,June 2021,"December 22, 2017",,"February 26, 2021","Ospedali Riuniti Umberto I, Ancona, AN, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy|IRCCS AOU San martino IST, Genova, GE, Italy|Ospedale Civile degli Infermi, Rimini, RN, Italy|Azienda Ospedaliera Cannizzaro, Catania, Italy|Ospedale Maggiore della Carità, Novara, Italy|Istituto Oncologico del Veneto (IOV) - Università di Padova, Padova, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Ospedale Sacro Cuore Don Calabria (Negrar), Verona, Italy",,https://ClinicalTrials.gov/show/NCT03381326
105,595,NCT02789995,Dysfunctions of Human Muscle Stem Cells in Sepsis,DISCUSS,Completed,No Results Available,Sepsis,Procedure: Human biological samples,Muscle regenerative capacities|Satellite cell dysfunction after sepsis|Regenerative capacities of Human satellite cells in presence of mesenchymal stem cells,Institut Pasteur,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,93,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-015|ID-RCB number : 2015-A01022-47,"June 23, 2016","June 28, 2018","June 28, 2018","June 3, 2016",,"November 1, 2019","Hopital Henri Mondor, Service de Réanimation chirurgicale polyvalente, Créteil, France|Hôpital Pitié Salpétrière, Salle de surveillance post-interventionnelle, Accueil des Polytraumatisés, Paris, France|Hôpital Pitié Salpêtrière, Anesthésie et Réanimation, Institut de Cardiologie, Paris, France|Hôpital Pitié Salpêtrière, Service de Chirurgie Générale, Viscérale et Endocrinienne, Paris, France|Hôpital Pitié Salpêtrière, Service de Chirurgie Hépatobiliaire et de Transplantation Hépatique, Paris, France|Hôpital Pitié Salpêtrière, Service de réanimation chirurgicale polyvalente, Paris, France|Hôpital Saint-Antoine, Département d'Anesthésie-réanimation, Paris, France",,https://ClinicalTrials.gov/show/NCT02789995
106,718,NCT04179760,Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis,,Recruiting,No Results Available,"Dermatitis, Atopic",Biological: SCM-AGH|Other: Placebo,over 50% reduction ratio of Eczema Area and Severity Index (EASI) as contrasted with baseline value (EASI-50)|Score change from Baseline in Eczema Area and Severity Index(EASI) score|Percentage of subjects who have EASI-75 (improvement of ≥75% in EASI score from Baseline)|Percentage of subjects who have EASI-90 (improvement of ≥90% in EASI score from Baseline)|Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1|Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more|Score change from Baseline on Pruritus Numerical Rating Scale (NRS)|Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more|Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)|Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index|Score change from Baseline in the Dermatology Life Quality Index (DLQI)|Score change from Baseline the Patient-Oriented Eczema Measure (POEM)|Change from Baseline in biomarker (Immunoglobulin E [IgE])|Change from Baseline in biomarker (eosinophil count)|Change from Baseline in biomarker (interleukin [IL]-13)|Change from Baseline in biomarker (interleukin [IL]-17)|Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])|Change from Baseline in biomarker (interleukin [IL]-22),"SCM Lifescience Co., LTD.",All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,92,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADT2002,"March 24, 2020","June 30, 2022","December 30, 2022","November 27, 2019",,"November 19, 2021","Inha University Hospital, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04179760
107,150,NCT03473301,A Study of UCB and MSCs in Children With CP: ACCeNT-CP,ACCeNT-CP,Completed,Has Results,Cerebral Palsy,Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs,Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,24 Months to 60 Months   (Child),Phase 1|Phase 2,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00089362,"April 10, 2018","February 26, 2020","May 31, 2021","March 22, 2018","February 17, 2021","August 19, 2021","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03473301/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03473301
108,222,NCT04642911,Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy,AUB001,"Active, not recruiting",No Results Available,Diabete Type 2|Mesenchymal Stem Cell,Other: Long term follow up,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study,Ukraine Association of Biobank,All,"Child, Adult, Older Adult",,91,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UAB00171120-1,"October 15, 2020","September 1, 2021","October 10, 2030","November 24, 2020",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,https://ClinicalTrials.gov/show/NCT04642911
109,137,NCT01652209,To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.,,Recruiting,No Results Available,Acute Myocardial Infarction,Biological: Hearticellgram-AMI,LVEF amount of change|Infarct size amount of change|Left ventricle end systolic size change|Left ventricular end-diastolic size change|Incidence of critical heart events|Heart rate variability change amount|Left ventricular local wall movement disorder index change|N-terminal pro-brain natriuretic peptide (NT-proBNP) change,"Pharmicell Co., Ltd.",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 3,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-BD-CT-P-003,"September 1, 2013","August 31, 2022","December 31, 2023","July 27, 2012",,"October 22, 2021","Kangwon National University Hospital, Chuncheon, Korea, Republic of|Chungnam National University Hospital, Chungnam, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Yongin Severance Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic University of Korea, Seoul ST. Mary's Hospital., Seoul, Korea, Republic of|Korea University Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01652209
110,271,NCT04281797,Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients,,Enrolling by invitation,No Results Available,Transplantation Infection|Kidney Transplant; Complications|Stem Cell Transplant Complications|Liver Transplant; Complications|Microbial Colonization,Diagnostic Test: Intestinal microbiome new generation sequencing,Gut microbiome composition|Infectious complications after transplantation|Organ or tissue rejection,"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology",All,"Child, Adult, Older Adult",,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Microbiome Minsk_1,"January 1, 2020","December 31, 2022","June 30, 2023","February 24, 2020",,"August 31, 2022","Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04281797
111,101,NCT02462330,Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2),MESAMI2,Recruiting,No Results Available,Chronic Myocardial Ischemia,Drug: Autologous MSC from bone marrow|Drug: Placebo comparator,Change in VO2max|Left ventricular viability|NYHA/CCS class|Quality of life (Minnesota questionnaire)|VO2 max|6'walking-test|Echocardiography|Myocardial perfusion imaging|BNP blood test,"University Hospital, Toulouse",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",10 142 01,"February 19, 2016",December 2022,December 2022,"June 4, 2015",,"October 28, 2021","University hospital of Henri Mondor, Créteil, France|University hospital of Grenoble, Grenoble, France|University hospital of Lille, Lille, France|University hospital of Nantes, Nantes, France|University hospital of Pitié-Salpêtrière, Paris, France|Cardiology Department of Rangueil Hospital - Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02462330
112,49,NCT04466007,Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia,,Recruiting,No Results Available,Limb Ischemia|Diabetic Foot,Drug: High dose allogeneic mesenchymal stromal cells|Drug: Low dose allogeneic mesenchymal stromal cells|Drug: Placebos,Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations,"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario La Paz|Gregorio Marañón Hospital|Hospital Clínico Universitario de Valladolid|Hospital Universitario Virgen de la Arrixaca|University of Salamanca|Hospital General Universitario de Alicante|Hospital Universitario La Fe|Hospital Victoria Eugenia Cruz Roja Española",All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NOMA (No More Amputations),"January 11, 2021",September 2022,September 2022,"July 10, 2020",,"August 30, 2022","Hospital General de Alicante, Alicante, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|La Paz University Hospital, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia Cruz Roja Española, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT04466007
113,214,NCT05182034,Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis,,Recruiting,No Results Available,Knee Osteoarthritis,Biological: SMUP-IA-01(low dose)|Biological: SMUP-IA-01(mid dose)|Drug: Active Control Group Sodium chloride,"Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline|Change amount of WOMAC total score at post-dose 24 weeks from the baseline|Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline|Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline|Change in T2 mapping at post-dose 52 weeks from the baseline|Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline|Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.|Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks",Medipost Co Ltd.,All,"19 Years and older   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MP-SMUP-IA-01-P02,"February 24, 2022","August 30, 2023","August 30, 2023","January 10, 2022",,"September 1, 2022","Seoul Nation University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Anam Hospita, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05182034
114,587,NCT04034615,The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars,,Recruiting,No Results Available,Cicatrix,Biological: Mesenchyme Stem Cells low-dose group|Biological: Mesenchyme Stem Cells high-dose group|Biological: Placebo,Vancouver Scar Scale score|Erythema|Pigmentation|Scar Thickness and Uniformity|Subject's satisfaction,Maternal and Child Health Hospital of Foshan,Female,21 Years to 35 Years   (Adult),Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MCHHFoshan-1902,"May 20, 2021","December 1, 2021","June 1, 2022","July 26, 2019",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04034615
115,78,NCT01484574,A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease,,Completed,No Results Available,Critical Limb Ischemia|Buerger's Disease,Biological: Allogeneic Mesenchymal Stem Cells,"Relief of the rest pain|Healing of ulcerations or reduction of ulcer area in the target limb|Pain free walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Increase in transcutaneous partial oxygen pressure (TcPO2)|Quality of life by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)|The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).|Assessment of clinical laboratory parameters|Physical examination findings and assessment of vital signs|Assessment of electrocardiogram (ECG) parameters",Stempeutics Research Pvt Ltd,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRPL/CLI/10-11/001,January 2012,February 2014,March 2016,"December 2, 2011",,"September 13, 2016","Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, Delhi, India|Division of Peripheral Vascular and Endovascular Sciences, Medanta - The Medicity, Gurgaon, Haryana, India|Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Peripheral Vascular Surgery, Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore, Karnataka, India|Department of Surgery, KMC, Mangalore, Mangalore, Karnataka, India|Department of Vascular Surgery, Madras Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Sri Ramchandra Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Stanley Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, AMRI Hospital, Kolkata, West Bengal, India|Nightingale Hospital, Kolkata, West Bengal, India",,https://ClinicalTrials.gov/show/NCT01484574
116,588,NCT02772289,Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars,,Completed,No Results Available,Cicatrix,Biological: Mesenchyme Stem Cells low-dose group|Biological: Mesenchyme Stem Cells high-dose group|Biological: Placebo,Change of Vancouver Scar Scale (VSS)|Wound healing status|Erythema measured by reflectance|Pigmentation measured by reflectance|Scar Thickness and Uniformity|Change of scar area|Immunoglobulin concentrations in breast milk|Subject's satisfaction|Adverse events occurrence,Maternal and Child Health Hospital of Foshan,Female,21 Years to 35 Years   (Adult),Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCHHFoshan-1602,November 2016,September 2018,March 2019,"May 13, 2016",,"May 7, 2019","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02772289
117,226,NCT04675970,Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy,UB-OVF,"Active, not recruiting",No Results Available,Primary Ovarian Insufficiency|Premature Ovarian Failure,Other: Observational,Antral follicular count (AFC) serum levels|anti-Müllerian hormone (AMH) serum levels|Regular menstruation and/or pregnancy,Ukraine Association of Biobank,Female,18 Years to 40 Years   (Adult),,86,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UAB1220-2,"September 1, 2020","September 30, 2022","September 30, 2022","December 19, 2020",,"May 18, 2022","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,https://ClinicalTrials.gov/show/NCT04675970
118,764,NCT00512434,Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture,IMOCA,Completed,No Results Available,"Tibial Fractures|Fractures, Open",Procedure: Osteosynthesis,Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture.|Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union.|Comparison of the rate of complications between the 2 groups.|Economic impact study.,"University Hospital, Tours",All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,85,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRN/06/PR/IMOCA|ID RCB 2007 - A00032 - 51,September 2007,September 2012,September 2013,"August 7, 2007",,"October 22, 2018","UH Angers, Angers, France|UH Besançon Jean Minjoz, Besancon, France|UH Brest Cavale Blanche, Brest, France|UH Clermont Ferrand Gabriel Montpied, Clermont Ferrand, France|UH Grenoble Michallon Hospital, Grenoble, France|UH Grenoble South Hospital, Grenoble, France|UH Nancy Central Hospital, Nancy, France|UH Nantes Hôtel Dieu, Nantes, France|UH Pitié Salpétrière AH HP, Paris, France|UH Tours CHRU Trousseau, Tours, France|UHTOURS, Tours, France",,https://ClinicalTrials.gov/show/NCT00512434
119,670,NCT03676400,Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia,,Completed,No Results Available,Androgenic Alopecia,Other: conditioned media of umbilical cord blood-derived stem cells|Other: Placebo,Change in mean total hair density (hair/cm2)|Compare visual assessment before and after cosmetic treatment|Change in mean Telogen hair density|Change in mean Anagen hair density|Change in hair growth speed|Change in hair diameter,Medipost Co Ltd.,All,18 Years to 60 Years   (Adult),Not Applicable,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",MP-CM-001,"October 2, 2018","July 22, 2019","July 24, 2019","September 18, 2018",,"August 12, 2019","Dankook University Hospital, Cheonan, Chung Nam, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03676400
120,267,NCT02582775,MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs,,Recruiting,No Results Available,Epidermolysis Bullosa,Drug: Thymoglobulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Bone marrow infusion|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Biological: Donor mesenchymal stem cell infusions|Drug: Busulfan,Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism,"Masonic Cancer Center, University of Minnesota",All,"up to 25 Years   (Child, Adult)",Phase 2,84,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015LS076,March 2016,December 2024,December 2024,"October 21, 2015",,"January 24, 2022","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02582775
121,439,NCT02445547,Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease,,Completed,No Results Available,Crohn Disease,Other: UC-MSCs by peripheral intravenous infusion|Drug: received hormone maintenance therapy,Crohn's disease activity index|Harvey-Bradshaw index|Corticosteroid dosage,Fuzhou General Hospital|Shaanxi Provincial People's Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,82,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCMSC-CD,June 2012,June 2015,,"May 15, 2015",,"January 18, 2017","Shaanxi Provincial People's Hospital, Xi Ail, Shaanxi, China",,https://ClinicalTrials.gov/show/NCT02445547
122,213,NCT02709343,Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction,ASSIST-CLAD,"Active, not recruiting",No Results Available,Chronic Lung Allograft Dysfunction (CLAD),Drug: Bone-marrow derived MSCs|Drug: Placebo,Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days,The University of Queensland|Isopogen|Cell and Tissue Therapies,All,"18 Years and older   (Adult, Older Adult)",Phase 2,82,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ASSIST-CLAD,"April 21, 2017",July 2023,July 2023,"March 16, 2016",,"August 24, 2022","St Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT02709343
123,1,NCT05127122,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS,EXIT-ARDS,Not yet recruiting,No Results Available,"ARDS, Human",Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline,The incidence of serious adverse events.|Number to patients with All-Cause Mortality at 28 days|Ventilator-free days at 28days|Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.,"Direct Biologics, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,81,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DB-EF-EXITARDS-0003,January 2023,January 2023,January 2023,"November 19, 2021",,"September 10, 2022",,,https://ClinicalTrials.gov/show/NCT05127122
124,195,NCT02633163,Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE),,Recruiting,No Results Available,Systemic Lupus Erythematosus,Drug: Low Dose Mesenchymal Stem Cells (MSCs)|Drug: High Dose Mesenchymal Stem Cells (MSCs)|Drug: Placebo Infusion,Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:,Medical University of South Carolina,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,81,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MUSC-UCMSC-001,"October 26, 2018",December 2022,June 2023,"December 17, 2015",,"September 7, 2022","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|The Feinstein Institute for Medical Research, Manhasset, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02633163
125,7,NCT01603836,Study Confirms or Refutes the Hypothesis That the Autologous Bone Marrow Concentrate Together With the Allograft is a Better Alternative for the Posterolateral Fusion in Spine Surgery Than the Allograft Alone,,Completed,No Results Available,"Spondyloarthrosis, Spondylosis",Biological: bone allogaft with bone marrow concentrate,The improvement of the fusion of the posterolateral fusion measured on X-rays|The improvement of the fusion of the posterolateral fusion measured on X-rays and CT scans.,Hospital Znojmo,All,"45 Years to 89 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PLFBMC,February 2009,March 2010,March 2012,"May 23, 2012",,"May 23, 2012",,,https://ClinicalTrials.gov/show/NCT01603836
126,237,NCT04194671,Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury,,Not yet recruiting,No Results Available,Acute Kidney Injury|Mesenchymal Stem Cells,Biological: Mesenchymal stem cells|Other: Saline,The difference in the renal function between the two groups (MSC treatment group vs placebo control group) within 28 days after receiving MSC/ placebo treatment|Overall survival within 28 days after receiving MSC/ placebo treatment|Overall survival within 3 months after receiving MSC/ placebo treatment|Renal replacement therapy (RRT) dependent within 3 months after receiving MSC/ placebo treatment|Complete renal recovery within 3 months after receiving MSC/ placebo treatment|Partial renal recovery within 3 months after receiving MSC/ placebo treatment|ICU and hospitalization duration of stay among all AKI patients within 3 months after receiving MSC/ placebo treatment|Adverse events within 3 months after receiving MSC/ placebo treatment,Chinese PLA General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,MSC-001,"December 31, 2021","October 31, 2022","December 31, 2022","December 11, 2019",,"October 25, 2021","Chinese PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04194671
127,156,NCT02668068,A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells,,Completed,No Results Available,Pneumoconiosis,Procedure: large volume whole-lung lavage (WLL)|Biological: clinical grade umbilical cord mesenchymal stem cells,"Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)|Imaging indicator: Quantitative analysis of CT density histograms|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in MRC chronic dyspnea scale|Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|self-evaluation","Jianwu Dai|Southwest Hospital, China|Nanjing Chest Hospital|Chinese Academy of Sciences",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CAS-XDA-SH/NCH/IGDB,January 2016,March 2019,March 2019,"January 29, 2016",,"July 24, 2019","First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital), Chongqing, Chongqing, China|Nanjing Chest Hosptial, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02668068
128,216,NCT01392105,Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction,SEED-MSC,Completed,No Results Available,Acute Myocardial Infarction,Drug: Mesenchymal stem cell|Drug: Control group,Absolute changes in global LVEF by SPECT|Changes in left ventricular end-diastolic volume (LVEDV)|Changes in left ventricular end-systolic volume (LVESV)|Changes in regional wall motion score index (WMSI) by Echocardiography|Major adverse cardiac event (MACE),Yonsei University|FCB-Pharmicell Co Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC2-Version 6.0,March 2007,May 2010,May 2010,"July 12, 2011",,"July 12, 2011","Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of|Inha University Hospital, Inchon, Korea, Republic of|Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01392105
129,236,NCT01803347,Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells,FISPAC,Completed,No Results Available,Anal Fistula,Drug: ◦Drug: ASCs. + fibrin glue|Drug: fibrin glue,Safety/efficacy,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,All,"18 Years and older   (Adult, Older Adult)",Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2012-001178-28,February 2013,October 2017,October 2017,"March 4, 2013",,"April 19, 2018","Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Clínico Universitario, Salamanca, Castilla-Leon, Spain|Hospital General Universitario, Valencia, Comunidad Valenciana, Spain|Hospital Universitario La Paz, Madrid, Spain|Clínica Universitaria de Navarra, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT01803347
130,5,NCT05402748,Safety and Efficacy of Injection of Human Placenta Mesenchymal Stem Cells Derived Exosomes for Treatment of Complex Anal Fistula,,Recruiting,No Results Available,Fistula Perianal,Other: placenta-MSCs derived exosomes,Safety of injected exosomes|clinical Efficacy of injected exosomes|inflammatory markers,Tehran University of Medical Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRCT20211212053361N1,"December 22, 2021","July 22, 2022","August 22, 2022","June 2, 2022",,"June 2, 2022","Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT05402748
131,159,NCT05126563,Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome,HBPCOVID02,Recruiting,No Results Available,Post COVID-19 Syndrome,Biological: HB-adMSCs (allogeneic)|Other: Placebo,Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue|Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog|Changes in Visual Analog Scale of Neurological Symptoms. - Headache|Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities.|AEs of special interest (serious or non-serious) - infections.|AEs of special interest (serious or non-serious) - hypersensitivities.|Changes in Laboratory values. - CBC.|Changes in Laboratory values. - CMP.|Changes in Laboratory values. - Coagulation Panel.|Changes in Vital Signs. - Respiratory Rate (breaths per minute)|Changes in Vital Signs. - Heart Rate (beats per minute)|Changes in Vital Signs. - Body Temperature (Fahrenheit )|Changes in Vital Signs. - Blood Pressure (mmHg)|Changes in Weight in lb.|Changes in Physical examination results. - General|Changes in Physical examination results. - Body Systems|Changes in Subject's energy - Fatigue Assessment form.|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity|Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough|Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches|Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain|Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire|Changes in Subject's level of depression - PHQ 9 scale.,Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HBPCOVID02,"January 6, 2022","December 20, 2023","December 20, 2025","November 19, 2021",,"February 3, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT05126563
132,6,NCT05499156,Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients,,"Active, not recruiting",No Results Available,Perianal Fistula in Patients With Crohn's Disease,Other: placenal MSC derived exosomes,Safety of injected exosomes|clinical Efficacy of injected exosomes|inflammatory markers,Tehran University of Medical Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",IRCT20200413047063N3,"January 20, 2022",August 2022,September 2022,"August 12, 2022",,"August 12, 2022","Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT05499156
133,100,NCT04314687,Stem Cell and Conditioned Medium for Cerebral Palsy,,Recruiting,No Results Available,Cerebral Palsy,Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: Conditioned Medium|Other: Standard Therapy,Gross Motor Function|Cognitive Function|Chemical Marker,PT. Prodia Stem Cell Indonesia,All,6 Months to 3 Years   (Child),Phase 1|Phase 2,78,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CT/CP/02/2020,"October 13, 2021","September 25, 2023","December 25, 2023","March 19, 2020",,"June 14, 2022","Indonesian National Brain Center, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04314687
134,716,NCT04189432,Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease,,Recruiting,No Results Available,Chronic Graft-versus-host-disease,Biological: SCM-CGH|Other: Placebo,Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])|Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR]).|Organ-specific Assessments|Patient-Reported Outcomes|Clinician-Assessed Global Rating/Scale|Failure-free Survival,"SCM Lifescience Co., LTD.",All,"19 Years and older   (Adult, Older Adult)",Phase 2,77,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SCM-CGH2001,"September 28, 2016","March 31, 2022","December 31, 2022","December 6, 2019",,"September 28, 2021","National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Seoul, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04189432
135,24,NCT05167721,Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy,,Recruiting,No Results Available,Multiple System Atrophy,Biological: Autologous Mesenchymal Stem Cells|Other: Placebo,Change in UMSARS total (= UMSARS I + UMSARS II) score|Change in UMSARS I score|Change in UMSARS II score|Change in modified UMSARS score|Change in COMPASS select score|Rate of atrophy of selected brain regions,Mayo Clinic,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",21-005569|FD-R-07290-01,"December 15, 2021","December 15, 2025","December 30, 2025","December 22, 2021",,"January 21, 2022","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT05167721
136,269,NCT05319106,Phase Ⅱ Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Venous Leg,,Recruiting,No Results Available,Venous Leg Ulcer,Other: stem cell preparation combined with silver ion dressing|Procedure: silver ion dressing,Healing time|Wound shrinkage rate,"ShiCang Yu|Southwest Hospital, China",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,zsyx1,"April 1, 2022","June 30, 2026","March 31, 2027","April 8, 2022",,"April 8, 2022","Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT05319106
137,740,NCT03379168,Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.,,"Active, not recruiting",No Results Available,Knee Osteoarthritis,Device: Microfragmented Adipose Tissue (Lipogems)|Drug: Corticosteroid injection|Drug: Saline,Change in Visual Analog Pain Scale (VAS) Over Time|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Over Time|Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Over Time,"Dustin L. Richter, MD|University of New Mexico",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-146,"April 1, 2018","June 15, 2022",July 2022,"December 20, 2017",,"May 24, 2022","UNM Hospital, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT03379168
138,72,NCT05501418,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19,UMSC01,"Active, not recruiting",No Results Available,COVID-19 Infection,Biological: Allogeneic umbilical cord mesenchymal stem cells|Biological: Controlled normal saline,Two Co-Primary Efficacy Endpoints|Secondary Efficacy Endpoints|Secondary Safety Endpoints,"Ever Supreme Bio Technology Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ES-CMSC01-C1101,"August 5, 2020","December 31, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,https://ClinicalTrials.gov/show/NCT05501418
139,487,NCT02286128,Effect of NF-кB Dependent Proinflammation on Osteogenic Differentiation of the Mesenchymal Stem Cells in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and apoptotic marker expression in the MSC to measure effects of NF-кB dependent-proinflammation on cellular apoptosis in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.,Chiang Mai University,All,"18 Years and older   (Adult, Older Adult)",,75,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,ChiangMaiU,November 2014,"May 3, 2018","May 3, 2018","November 7, 2014",,"July 12, 2018","Mattabhorn Phornputkul, Chiang Mai, Thailand",,https://ClinicalTrials.gov/show/NCT02286128
140,180,NCT05464381,"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)",,Not yet recruiting,No Results Available,Epidermolysis Bullosa,Drug: allo-APZ2-OTS|Drug: Placebo,Proportion of subjects with complete target wound closure,RHEACELL GmbH & Co. KG,All,"Child, Adult, Older Adult",Phase 3,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",allo-APZ2-EB-III,December 2022,December 2024,December 2025,"July 19, 2022",,"July 19, 2022",,,https://ClinicalTrials.gov/show/NCT05464381
141,96,NCT02808208,Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure,,Enrolling by invitation,No Results Available,End Stage Renal Disease (ESRD)|Vascular Access Complication,Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|Drug: Placebo|Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC),Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow,Mayo Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,74,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,15-009053,"June 7, 2017",December 2022,December 2022,"June 21, 2016",,"January 20, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02808208
142,8,NCT01233960,Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease,,Completed,No Results Available,Crohn's Disease,Drug: adult human mesenchymal stem cells,Disease remission|Disease Improvement|Improvement in Quality of Life (IBDQ)|Number of Adverse events as a measure of safety|Infusional toxicity as a measure of safety and tolerability,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,73,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRD 611,"November 29, 2010","September 15, 2014","September 15, 2014","November 3, 2010",,"December 8, 2021","University of California, San Francisco, San Francisco, California, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|University of Chicago, Chicago, Illinois, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Saint Louis Center for Clinical Research, Saint Louis, Missouri, United States|St. Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth HItchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Gastroenterology Center of the Midsouth, PC, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|McGuire Research Institute, Richmond, Virginia, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",,https://ClinicalTrials.gov/show/NCT01233960
143,224,NCT02962661,Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines,,Recruiting,No Results Available,Cardiomyopathy|Heart Failure|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Best Practice|Other: Laboratory Biomarker Analysis|Drug: Mesenchymal Stem Cell Transplantation,Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,72,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0835|NCI-2016-01921,"July 18, 2020","July 30, 2023","July 30, 2023","November 11, 2016",,"September 2, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02962661
144,124,NCT01875081,REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient),,Completed,No Results Available,Alcoholic Liver Cirrhosis,Biological: Livercellgram,"Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)|Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)|MELD Score|Child-Pugh grade|Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)|Visual Inspection (Liver volume, Fibroscan)","Pharmicell Co., Ltd.",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-BD-CT-P-002,November 2012,March 2016,March 2016,"June 11, 2013",,"March 17, 2016","Pharmicell Co., Ltd., Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01875081
145,82,NCT01448434,Allogeneic Mesenchymal Stem Cells for Osteoarthritis,,Completed,No Results Available,Osteoarthritis of Knee Joint,Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline,Stempeutics Research Pvt Ltd|Stempeutics Research Malaysia SDN BHD,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,72,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SRM/OA/10-11/001,September 2011,September 2013,September 2013,"October 7, 2011",,"May 12, 2016","Pantai Cheras Medical Centre, Kuala Lumpur, Federal territory, Malaysia|Serdang Hospital, Kuala Lumpur, Selangor, Malaysia|KPJ Ampang Puteri Specialist Hospital, Kuala Lumpur, Selangor, Malaysia|Selayang Hospital, Kuala Lumpur, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT01448434
146,4,NCT04629105,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER),RECOVER,Recruiting,No Results Available,"ARDS, Human|Covid19",Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography,Longeveron Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-006,"July 24, 2020",August 2023,July 2025,"November 16, 2020",,"September 30, 2021","Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04629105
147,154,NCT04565665,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,,Recruiting,No Results Available,COVID-19 Infection|COVID-19-Associated Acute Respiratory Distress Syndrome|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed,Other: Best Practice|Biological: Mesenchymal Stem Cell,"Incidence of composite serious adverse events (Phase I)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Overall survival rate (Phase I)|Survival rate in patients who present intubated on ventilator support (Phase I)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Clinical parameters (Phase I)|Oxygenation parameters (Phase I)|Respiratory parameters (Phase I)|Laboratory markers (Phase I)|Hospitalization stay (Phase I)|Intensive care unit stay (Phase I)|Incidence of infusion-related adverse events (Phase I)",M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0365|NCI-2020-06741,"July 29, 2020","April 30, 2023","April 30, 2023","September 25, 2020",,"July 12, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04565665
148,1,NCT05027581,Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA),,Recruiting,No Results Available,"Osteoarthritis, Knee",Drug: Bone marrow mesenchymal stem cells|Drug: hyaluronic acid,Efficacy-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessment|Efficacy-Visual Analogue Scale (VAS) assessment|Efficacy-SF-36 Quality of Life (QoL) health survey questionnaire|Efficacy-Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Efficacy-knee joint space width (JSW)|Efficacy-synovial fluid|Efficacy-rescue medication|Safety-AE/SAE based on NCI-CTCAE v5.0|Safety-vital signs|Safety-laboratory examination|Safety-physical examination,"Taiwan Bio Therapeutics Co., Ltd.|A2 Healthcare Taiwan Corporation",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Chondrochymal-01,"September 15, 2021","September 10, 2023","September 10, 2024","August 30, 2021",,"September 24, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT05027581
149,63,NCT03905824,The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus,OLT,Recruiting,No Results Available,Osteochondral Fracture of Talus,Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord|Procedure: Debridement and microfracture,Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis,University of Chile,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",OLT Protocol,"January 15, 2019","December 31, 2020","December 31, 2024","April 5, 2019",,"April 9, 2019","Universidad de Chile Clinical Hospital, Santiago, Independencia, Chile",,https://ClinicalTrials.gov/show/NCT03905824
150,496,NCT01828957,Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants,,Completed,No Results Available,Bronchopulmonary Dysplasia,Biological: Pneumostem®|Other: Normal Saline,Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA|Intubation duration|Incidence of BPD|Survival rate|Duration of ventilator dependence|Duration of CPAP treatment|Postnatal steroid use (%) for the purpose of ventilator weaning|Cumulative duration of oxygen use|Incidence of Retinopathy of Prematurity (ROP) of Grade III or more|Retinopathy of Prematurity (ROP) that require treatment with avastin or laser|Growth velocity (Z-score)|Length of stay prior to the first discharge from the hospital|Incidence of adverse events|Clinically significant laboratory findings|Incidence of pneumothorax that require intubation|Incidence of moderate to severe pulmonary hemorrhage|Incidence of intraventricular hemorrhage of grade 3 or more,Medipost Co Ltd.,All,5 Days to 14 Days   (Child),Phase 2,69,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-009,April 2013,May 2015,August 2015,"April 11, 2013",,"September 6, 2019","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01828957
151,99,NCT01552707,Safety Study of Mesenchymal Stem Cells and Spinal Fusion,,Completed,No Results Available,"Lumbar Spondylolisthesis Involving L4-L5, and/or|Degenerative Discopathy Involving L4-L5",Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment,"safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)","Banc de Sang i Teixits|TFS Trial Form Support|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,69,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XCEL-MT-10-02,"July 19, 2012","May 3, 2018","October 21, 2019","March 13, 2012",,"January 21, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Universitari Dexeus (ICATME), Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01552707
152,703,NCT04345601,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),,Recruiting,No Results Available,Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19,Biological: Mesenchymal Stromal Cells|Other: Supportive Care,Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-47561 MSC for COVID-19,"February 12, 2021",October 2022,October 2022,"April 14, 2020",,"October 6, 2021","Houston Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04345601
153,732,NCT04749758,Assessment of the Efficacy of Stromal Vascular Fraction Treatment for Knee Osteoarthritis,,"Active, not recruiting",No Results Available,Knee Osteoarthritis,Biological: SVF treatment,Change from baseline knee pain measured with a Visual Analogue Scale (VAS) at 1 year|Change from baseline functionality measured with Knee Injury and Osteoarthritis Outcome Score (KOOS) at 1 year|Change from baseline quality of life measured with SF-36 questionnaire at 1 year.|Change from baseline disability measured with WHODAS 2.0 questionnaire at 1 year.|Change from baseline joint cartilage characteristics measured with Magnetic Resonance Imaging at 1 year.,University of Andorra,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UA003GRCSSS,"September 20, 2018","December 1, 2022",December 2022,"February 11, 2021",,"May 18, 2022","CelularClinic, Escaldes-Engordany, Andorra",,https://ClinicalTrials.gov/show/NCT04749758
154,210,NCT05061030,Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents,,Recruiting,No Results Available,Type1diabetes,Biological: the ATMP Protrans,Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide,Uppsala University Hospital,All,"7 Years to 21 Years   (Child, Adult)",Phase 1|Phase 2,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WJMSC-P01,"January 14, 2022",September 2028,December 2028,"September 29, 2021",,"May 23, 2022","Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT05061030
155,143,NCT02883803,Treatment of Severe Infections With Mesenchymal Stem Cells,CHOCMSC,Not yet recruiting,No Results Available,Septic Shock,Biological: Injection of mesenchymal stem cells|Biological: Injection of albumin alone,"SOFA score|Number of living days without catecholamines|Number of living days without mechanical ventilation|Number of living days without dialysis|Duration of residence time in recovery unit|Mortality, across all causes|Administration safety (i.e. side effects)","Central Hospital, Nancy, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PHRCI 2012/CHOCMSC-GIBOT/SKJ,December 2019,November 2021,November 2022,"August 30, 2016",,"October 25, 2019","Service de Réanimation Médicale, Hôpital Bocage, Dijon, France|Service de Réanimation Médicale, Hôpital Central, Nancy, France|Hôpital Hautepierre, Service de réanimation médicale, Strasbourg, France|UTCT, Hôpital Brabois, Vandoeuvre-les-Nancy, France",,https://ClinicalTrials.gov/show/NCT02883803
156,361,NCT05308342,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency,,Recruiting,No Results Available,Premature Ovarian Insufficiency,Procedure: transplantation of human UC-MSCs into ovaries of POI patients|Drug: hormone replacement treatment,Follicular development rate|Changes in blood flow index in the ovary|Clinical pregnancy rate,Li-jun Ding|Nanjing University,Female,20 Years to 39 Years   (Adult),Not Applicable,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SZ-POF-2019-4,"November 20, 2019","July 31, 2023","December 1, 2023","April 4, 2022",,"April 4, 2022","Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT05308342
157,743,NCT01071577,Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products,,Completed,No Results Available,Bone Marrow Stromal Cells,,Tissue Collection,National Institutes of Health Clinical Center (CC),All,"18 Years to 100 Years   (Adult, Older Adult)",,65,NIH,Observational,Observational Model: Other|Time Perspective: Prospective,100053|10-CC-0053,"March 17, 2010",,,"February 19, 2010",,"September 8, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01071577
158,3,NCT02065245,AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery,CRATUS,Completed,Has Results,Frailty,Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo|Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs),Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels,"Longeveron Inc.|The Emmes Company, LLC",All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,65,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20130646,"March 3, 2014","October 2, 2019","October 2, 2020","February 17, 2014","April 27, 2021","July 14, 2021","ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02065245/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02065245
159,102,NCT00768066,The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT),TAC-HFT,Completed,Has Results,"Stem Cell Transplantation|Ventricular Dysfunction, Left",Biological: Autologous human mesenchymal cells (hMSCs)|Biological: Autologous human bone marrow cells (hBMCs)|Biological: Placebo,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT.","University of Miami|The Emmes Company, LLC",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,65,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20070443,August 2008,August 2012,September 2013,"October 7, 2008","December 14, 2015","December 14, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00768066
160,4,NCT04497805,Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers,,Recruiting,No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-SHEET,Proportions of subjects who achieved complete wound closure.|Time to initial complete wound closure between the 2 groups.|Changes in wound size compared to baseline between the 2 groups.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.|Durability of complete wound closure for the additional 24 weeks.,"Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,64,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALLO-ASC-SHEET,"August 1, 2020",June 2022,December 2022,"August 4, 2020",,"January 22, 2021","University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT04497805
161,2,NCT00690066,PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM),,Completed,No Results Available,"Type 1 Diabetes Mellitus|Type 1 Diabetes|Diabetes Mellitus, Insulin-Dependent|Juvenile Diabetes",Drug: PROCHYMAL®|Drug: Placebo,C-peptide area under the concentration curve (AUC) response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies,"Mesoblast, Inc.|Juvenile Diabetes Research Foundation|Mesoblast, Ltd.",All,"12 Years to 35 Years   (Child, Adult)",Phase 2,63,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",901,"June 11, 2008","December 12, 2010","December 19, 2011","June 4, 2008",,"December 23, 2021","University of Alabama, Division of Endocrinology & Metabolism, Birmingham, Alabama, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Desert Endocrinology CRC, Henderson, Nevada, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina, United States|American Health Research, Inc., Charlotte, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Research, Dayton, Ohio, United States|Cumberland Valley Endocrinology, Carlisle, Pennsylvania, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|The Strelitz Diabetes Center, Eastern VA Medical School, Norfolk, Virginia, United States|University of Wisconsin Health- West Clinic, Madison, Wisconsin, United States|Clinical and Transitional Science Institute, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00690066
162,13,NCT00683722,PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),,Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive|Pulmonary Emphysema|Chronic Bronchitis",Drug: Prochymal™|Drug: Placebo,Number of Participants with Adverse Events (AEs)|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume to Forced Vital Capacity Ratio (FEV1/FVC) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) %predicted at Year 1 and Year 2|Change from Baseline in Alveolar Volume (VA) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide to Alveolar Volume ratio (DLCO/VA)at Year 1 and Year 2|Change from Baseline in Functional residual capacity (FRC) at Month 6|Change from Baseline in Total Lung Capacity (TLC) at Month 6|Change from Baseline in Residual Volume (RV) at Month 6|Change from Baseline in Airway Resistance (RAW) at Month 6|Change from Baseline in 6-Minute Walk Test at Year 1 and Year 2|Change from Baseline in Borg Dyspnea Scale at Year 2|Change from Baseline in Health-related quality of life: St George's Respiratory Questionnaire (SGRQ) at Year 1 and Year 2|Change from Baseline in Physician Global Assessment Scale at Year 1 and Year 2|Time to COPD Exacerbation|Number of COPD Exacerbations|Change from Baseline in Pulmonary Hypertension at Month 6|Change from Baseline in Systemic Inflammation at Year 1 and Year 2,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",801,"March 20, 2008","March 9, 2009","August 24, 2010","May 23, 2008",,"December 23, 2021","David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States|American Health Research, Charlotte, North Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Vermont Lung Center, University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00683722
163,199,NCT02982915,Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty,HERA,Completed,No Results Available,Aging Frailty,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Biological: Fluzone High Dose Vaccine,"The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause|Falls Efficacy Scale-International (FES-I)|Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:|Rate of decline in Aging Frailty status as assessed by the 6 minute walk test|Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)|Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test|Rate of decline in Aging Frailty status as assessed by the Weight Loss|Rate of decline in Aging Frailty status as assessed by the Handgrip Test",Longeveron Inc.,All,65 Years to 90 Years   (Older Adult),Phase 1|Phase 2,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-0000-03,November 2016,June 2021,June 2022,"December 6, 2016",,"August 17, 2022","Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Miami, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Optimal Research LLC, Rockville, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02982915
164,257,NCT03766217,Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair,CLOSE,Completed,No Results Available,Cleft Lip and Palate,Combination Product: Mesenchymal stem cells associated with biomaterials|Combination Product: Iliac crest autogenous bone graft,"Alveolar bone filling rate|Serious adverse events|Non serious adverse events|Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair|Position of the canine tooth and formation of dental root|Patient-reported outcome (PRO, including appearance, fuction and quality of life)","Hospital Sirio-Libanes|Ministry of Health, Brazil",All,7 Years to 12 Years   (Child),Phase 3,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CAAE47719215.5.0000.5461,"April 5, 2019","December 6, 2019","December 15, 2019","December 6, 2018",,"May 13, 2020","Hospital Sírio-Libanes, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03766217
165,495,NCT01897987,Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial,,Completed,No Results Available,Bronchopulmonary Dysplasia,Biological: Pneumostem®|Biological: normal saline,"Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infection|Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)|Number of admissions to Emergency Room|Survival|Growth measured by Z-score|Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy|Deafness or Blindness|Number of adverse events|Significant changes in vital signs|Significant changes in physical exam",Medipost Co Ltd.,All,7 Months to 7 Months   (Child),Not Applicable,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-009-FU,January 2014,March 2020,March 2020,"July 12, 2013",,"August 7, 2020","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01897987
166,212,NCT01576328,Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Drug: Mesenchymal Precursor Cells (MPCs),Primary objective of the study is to assess the safety and tolerability of MPC therapy,"Mesoblast, Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,61,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,MSB-DM003,April 2012,October 2013,October 2015,"April 12, 2012",,"June 2, 2020","SC Clinical Research, Garden Grove, California, United States|Diabetes Research Institute, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Big Sky Clinical Research, Butte, Montana, United States|Desert Endocrinology Clinical Research Center-Henderson, Henderson, Nevada, United States|Alliance Against Diabetes/AAD Clinical Research, Las Vegas, Nevada, United States|Active Practices and Research, Newington, New Hampshire, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Reseach, Dayton, Ohio, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|West Houston Clinical Research Services, Houston, Texas, United States|Paragon Research Center, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Norfolk, Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT01576328
167,8,NCT03268603,Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS),,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Autologous Adipose-derived Mesenchymal Stromal Cells,Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R),Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-008008|UL1TR000135,"October 10, 2017",December 2022,December 2022,"August 31, 2017",,"February 16, 2022","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03268603
168,227,NCT04371601,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells,"Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin",Fuzhou General Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-CoViD-2020,"March 1, 2020","December 31, 2021","December 31, 2022","May 1, 2020",,"May 1, 2020","Fuzhou General Hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT04371601
169,209,NCT04494386,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,ULSC,Recruiting,No Results Available,Covid19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus,Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control),"Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline","Restem, LLC.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ULSC-CV-01,"July 23, 2020","October 30, 2021","December 30, 2021","July 31, 2020",,"March 9, 2021","Miami Baptist Hospital, Miami, Florida, United States|Sanford Research, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT04494386
170,154,NCT03337243,Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis,,Completed,No Results Available,Knee Osteoarthritis|Knee Pain Chronic|Joint Disease|Arthritis|Osteo Arthritis Knee|Musculoskeletal Disease,Procedure: HAM and HUMCWJ Injections,Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months,Sport and Spine Rehab Clinical Research Foundation,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,StemCell,"November 9, 2017","April 26, 2019","April 26, 2019","November 8, 2017",,"May 6, 2020","Scott Medical Health Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03337243
171,354,NCT02941666,Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip,,Recruiting,No Results Available,Osteonecrosis,,The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.,Mayo Clinic,All,"18 Years to 90 Years   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16-002241,September 2016,November 2022,November 2022,"October 21, 2016",,"April 21, 2022","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02941666
172,223,NCT01873625,Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis,,Completed,No Results Available,Rheumatoid Arthritis,Biological: mesenchymal cell transplantation|Biological: placebo,pain|physical activity|walking distance|Imaging,Royan Institute,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-RA-001,October 2009,March 2011,December 2011,"June 10, 2013",,"June 10, 2013","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01873625
173,7,NCT05116761,ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome,,Not yet recruiting,No Results Available,Covid19|Postviral Syndrome|Dyspnea,Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline,Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale,"Direct Biologics, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DB-EF-POSTCOVID-0002,February 2023,February 2023,February 2023,"November 11, 2021",,"September 8, 2022",,,https://ClinicalTrials.gov/show/NCT05116761
174,136,NCT04992247,"Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",BR,Not yet recruiting,No Results Available,Covid19,Biological: COVI-MSC|Biological: Placebo,Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels,"Sorrento Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSC-PLH-201BR,November 2022,July 2023,September 2023,"August 5, 2021",,"August 8, 2022",,,https://ClinicalTrials.gov/show/NCT04992247
175,20,NCT02497443,Safety of Autologous MSC Infusion to Treat Epilepsy,AMSCDRSE,Completed,No Results Available,Epilepsy,Biological: Autologous mesenchymal stem cells,Safety of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy|Efficacy of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy,"Ministry of Public Health, Republic of Belarus",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,Minsk-MH001,April 2011,December 2017,December 2019,"July 14, 2015",,"April 5, 2022",,,https://ClinicalTrials.gov/show/NCT02497443
176,489,NCT04003857,Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial,,Recruiting,No Results Available,Bronchopulmonary Dysplasia,Biological: PNEUMOSTEM®|Biological: normal saline,Respiratory outcome: Number of hospitalizations|Mortality|Growth measured by Z-score|Neurological developmental status: Korean Developmental Screening Test for infants and children(K-DST)|Deafness or Blindness|Bayley Scales of Infant and Toddler Development (Third Edition)|Gross Motor Function Classification System for Cerebral Palsy|Number of adverse events|Number of admissions to Emergency Room (ER)|Medical treatment records,Medipost Co Ltd.,All,6 Months to 60 Months   (Child),Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-012-F/U,"July 5, 2019","June 30, 2027","June 30, 2027","July 1, 2019",,"August 28, 2020","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04003857
177,618,NCT03901235,MSC Intratissular Injection in Crohn Disease Patients,MSC,Recruiting,No Results Available,Efficacy and Safety,Biological: Mesenchymal Stromal Cells,"Proportion of patients with deep ulcer healing|Proportion of patients with stricture healing|Proportion of patients with complex perianal fistula healing|Safety assessed by the incidence of treatment-emergent adverse events during the study period|Evolution of clinical disease activity index|Evolution of Short health scale (quality of life)|Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)|Evolution of the "" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube"" obstructive score for Crohn Disease strictures",University of Liege|Centre Hospitalier Universitaire de Liege,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TJT1707P1,"January 15, 2018","December 31, 2022","December 31, 2023","April 3, 2019",,"November 26, 2021","CHU de Liège, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT03901235
178,406,NCT05433298,Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.,,Recruiting,No Results Available,COVID-19 Pneumonia|COVID-19,Biological: Mesenchymal stem cell|Other: Placebo,Safety of intravenously infused UCT-MSC suspension|Pulmonary function test to evaluate the improvement of respiratory function|Radiography to evaluate the improvement of respiratory function|6-minute walk to evaluate the improvement of respiratory function|Decrease on days of non-invasive mechanical ventilation|Biochemical tests to evaluate the improvement of laboratory parameters|Blood count to evaluate the improvement of laboratory parameters|Viral load to evaluate the improvement of laboratory parameters|Cytokine dosage to evaluate inflammatory parameters|Decrease in hospital stay|Computed tomography score to evaluate the improvement of pulmonary function|Reduction in the percentage of intubated patients|Decrease in mortality,Paulo Brofman|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Pontifícia Universidade Católica do Paraná,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MSC SARS-CoV-2|U1111-1267-1200|31935420.7.1001.0020,"May 1, 2022","November 26, 2022","December 31, 2022","June 27, 2022",,"June 27, 2022","Paulo Roberto Slud Brofman, Curitiba, Paraná, Brazil",,https://ClinicalTrials.gov/show/NCT05433298
179,198,NCT04061746,Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells,,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Biological: Mesenchymal Stem Cells (MSCs)|Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin),12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 30 Years   (Adult),Phase 1,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00085542|R01DK118529-01A1,"February 13, 2020","March 31, 2025","March 31, 2026","August 20, 2019",,"March 31, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04061746
180,163,NCT05167552,Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells,,Not yet recruiting,No Results Available,Allergic Rhinitis|Rhinosinusitis Chronic,Biological: Olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment of type Allergic Rhinitis according to the clinical protocols|Other: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols,The relapse-free period|The need for surgical intervention|The need for the use of basic drug therapy|Adverse effects associated with the therapy,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The Republican Center for Research and Practice in Otolaryngology,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_AllRhin,"March 1, 2022","December 31, 2023","December 31, 2023","December 22, 2021",,"January 19, 2022",,,https://ClinicalTrials.gov/show/NCT05167552
181,479,NCT00225095,A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy,,Completed,No Results Available,Recovery Following Partial Medial Meniscectomy,Drug: Mesenchymal Stem Cells|Drug: Hyaluronan,Meniscal Volume|Quality of Life Questionnaire|Visual Analog Scale (VAS)|Lysholm Knee Scale|Safety Assessment Adverse Event|Safety Assessment Immunological|Safety Assessment Laboratory|Safety Assessment Physical Exam|Safety Assessment Magnetic Resonance Imaging (MRI),"Mesoblast International Sàrl|University of Southern California|Midwest Orthopedics at Rush - Chicago, IL|Unlimited Research - San Antonio, TX|Triangle Orthopaedic Associates, P.A.|Orthopedic Center of Vero Beach - Vero Beach, FL|OrthoIndy|TRIA Orthopaedic Center|Greater Chesapeake Orthopaedic Associates, LLC|Mesoblast, Ltd.",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Osiris 550,September 2005,April 2008,April 2008,"September 23, 2005",,"December 27, 2021","University of Southern California, Los Angeles, California, United States|Orthopedic Center of Vero Beach, Vero Beach, Florida, United States|Midwest Orthopaedics at Rush, Chicago, Illinois, United States|Ortholndy, Indianapolis, Indiana, United States|Greater Chesapeake Associates, Baltimore, Maryland, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Triangle Orthopaedics Associates, P.A., Durham, North Carolina, United States|Unlimited Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00225095
182,451,NCT04356300,Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection,,Not yet recruiting,No Results Available,Multiple Organ Failure,Biological: Exosome of MSC,survival after intervention|sequential organ failure assessment score|interleukin-6|The number of allergic reactions|The number of people who get cancer|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system,Fujian Medical University,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2020005,"September 1, 2020","September 1, 2021","September 1, 2030","April 22, 2020",,"May 6, 2020",,,https://ClinicalTrials.gov/show/NCT04356300
183,753,NCT04847739,Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II),,Recruiting,No Results Available,Perianal Fistula|Crohn's Disease,Procedure: Seton Placement|Drug: AVB-114,"Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups.|Change in the means of durability of clinical remission between the AVB-114 and standard of care groups.|Change in means of time to clinical remission between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups.|Change in means of time to fistula relapse between the AVB-114 and standard of care groups.|Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups.|Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups.|Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups.|Change in number of adverse events between the AVB-114 and standard of care groups.|Change in number of serious adverse events between the AVB-114 and standard of care groups.","Avobis Bio, LLC|Alimentiv Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STOMP-II,"September 13, 2021",August 2023,January 2025,"April 19, 2021",,"August 9, 2022","Mayo Clinic, Scottsdale, Arizona, United States|Office of Phillip Fleshner, MD, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Vanderbuilt University Medical Center Diagnostic Laboratory, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04847739
184,260,NCT04590118,Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST),,Recruiting,No Results Available,Ischemic Stroke,Drug: it-hMSC|Drug: Placebo,Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.|Modified Rankin Scale|National Institute of Health stroke scale|Mini-mental State Examination|Barthel Index|Geriatric Depression Scale,"Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.|Beijing Tiantan Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STCMSC-CT-001,"April 26, 2021","April 1, 2023","August 1, 2023","October 19, 2020",,"March 31, 2022","Beijing Tiantan Hospital, Capital Medical University, Beijing, China",,https://ClinicalTrials.gov/show/NCT04590118
185,65,NCT01453738,Allogeneic Mesenchymal Stem Cells in Osteoarthritis,,Completed,No Results Available,Osteoarthritis of Knee,Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline,Stempeutics Research Pvt Ltd,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SRPL/OA/09-10/001,November 2011,November 2014,November 2014,"October 18, 2011",,"May 12, 2016","Department of Orthopedics, M. S. Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Department of Orthopedics, Kasturba Medical College, Manipal, Karnataka, India|Seth G. S. Medical College and KEM Hospital, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,https://ClinicalTrials.gov/show/NCT01453738
186,146,NCT00721045,A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure,,Completed,No Results Available,Heart Failure,Biological: Mesenchymal Precursor Cells (MPCs)|Procedure: standard-of-care treatment with mock mapping and injection procedures.,"The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.|The secondary objectives are to explore functional efficacy for subsequent study design.","Mesoblast, Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HF-AB002,August 2008,June 2011,July 2013,"July 23, 2008",,"March 11, 2020","Mercy Gilbert Medical Center, Gilbert, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Minneapolis Heart Institute 920 East 28th St, Suite 300, Minneapolis, Minnesota, United States|UPMC, Pittsburgh, Pennsylvania, United States|Texas Heart Institue, Houston, Texas, United States|Swedish Heart and Vascular Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00721045
187,207,NCT05193877,Autologous Bone Marrow Aspirate Concentrate Injection for the Treatment of Early Osteoarthritis:Baghdad 2022,,Recruiting,No Results Available,Treatment Complication,Procedure: autologous bone marrow aspirate concentrate by centrifugation,clinical|radiological proof,"zaid husein ali|Global Stem Cell Center, Baghdad",All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Ibn-sina protocol,"February 8, 2022",September 2022,November 2022,"January 18, 2022",,"March 21, 2022","Ibn Sina, Baghdad, Iraq",,https://ClinicalTrials.gov/show/NCT05193877
188,329,NCT00114452,Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction,,Completed,No Results Available,Myocardial Infarction,Biological: Provacel|Biological: Placebo,"Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.","Mesoblast, Inc.|Mesoblast, Ltd.",All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 1,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",401-402,"March 22, 2005","October 4, 2006","April 24, 2008","June 15, 2005",,"March 10, 2020","Arizona Heart Institute, Phoenix, Arizona, United States|University of California - San Diego; Thornton, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|Jewish Hospital, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington Adventist, Takoma Park, Maryland, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Columbia Presbyterian Hospital, New York, New York, United States|University of Rochester - Strong Memorial, Rochester, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Austin Heart Institute, Austin, Texas, United States|Texas Medical School, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00114452
189,13,NCT03326505,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,,Completed,No Results Available,Multiple Sclerosis,Biological: Umbilical cord derived Mesenchymal Stem Cells|Other: Supervised physical therapy,Isolation and Expansion of Mesenchymal Stem Cells|Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments,University of Jordan,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,ALLOMSUJCTC,"September 25, 2017","January 25, 2020","February 20, 2020","October 31, 2017",,"March 4, 2020","Cell Therapy Center, University of Jordan, Amman, Jordan|Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT03326505
190,37,NCT02097641,Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START),START,Completed,Has Results,"Respiratory Distress Syndrome, Adult",Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Biological: Plasma-Lyte A,Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h,"Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|Ohio State University|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",UCSF-hMSC-ARDS-P2|1U01HL108713-01,"March 15, 2014","March 9, 2017","February 9, 2018","March 27, 2014","April 10, 2019","April 10, 2019","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Saint Paul, Minnesota, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02097641/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02097641
191,280,NCT04953663,Clinical Plan of Ischemic Stroke,,Recruiting,No Results Available,Stroke,Biological: it-hMSC,Adverse events and serious adverse events rate|Rate of clinical significant changes in laboratory|Rate of abnormal neurological physical examination results|Rate of imaging changes|Change of NIHSS scores|Change of BI scores|Change of mRS scores|Change of MMSE scores|Change of GDS scores,Peking University Third Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D2020093,"January 1, 2021","January 1, 2022","January 1, 2023","July 8, 2021",,"July 8, 2021","Peking University Third Hospital, Beijin, China",,https://ClinicalTrials.gov/show/NCT04953663
192,632,NCT05216562,Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients,EXOMSC-COV19,Recruiting,No Results Available,SARS-CoV2 Infection,Drug: Exosome-MSC Intravenous injection|Drug: Placebo Intravenous Injection|Drug: COVID-19 Standard Treatment,Time to clinical improvement (days)|Increase in Lymphocytes counts|Decrease in D-dimer|Decrease in LDH level|Decrease in Ferritin concentration|Decrease in C-reactive protein|Adverse events,"Dermama Bioteknologi Laboratorium|Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DBL-EXO-MSC-COV-19-CT-01|PPUK-RG.01.06.1.2.03.21.29,"July 1, 2021","June 30, 2022","December 30, 2022","January 31, 2022",,"February 18, 2022","RSPAD Gatot Soebroto, Jakarta, DKI Jakarta, Indonesia|RSUP Dr. M. Jamil, Padang, West Sumatra, Indonesia|RSUP Dr. Sardjito, Yogyakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT05216562
193,137,NCT04905836,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress,,Recruiting,No Results Available,Covid19,Biological: COVI-MSC|Drug: Placebo,All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation,"Sorrento Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSC-COV-202,"November 16, 2021",December 2022,March 2023,"May 28, 2021",,"April 11, 2022","Teradan Clinical Trials LLC, Brandon, Florida, United States|Sarasota Memorial Health Care System (SMH), Sarasota, Florida, United States|St Luke's Research, Boise, Idaho, United States|St. Luke's Boise, Boise, Idaho, United States|Ascension St. John, Tulsa, Oklahoma, United States|PRX Research/Dallas Regional Medical Center, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04905836
194,642,NCT01449032,MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial),MyStromalCell,Completed,No Results Available,Chronic Ischemic Heart Disease,Biological: MSC|Biological: Saline,Exercise test|Clinical evaluation,"Rigshospitalet, Denmark",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MyStromalCell,April 2010,January 2014,January 2014,"October 7, 2011",,"June 10, 2014","Rigshospitalet University Hospital Copenhagen, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT01449032
195,76,NCT04212728,Treatment of Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells,,Recruiting,No Results Available,Knee Osteoarthritis,Biological: Auotologous AMSCs plus autologous PRP|Biological: Auotologous PRP,Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS),Yantai Yuhuangding Hospital,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2019-003,"December 29, 2019",December 2022,December 2023,"December 27, 2019",,"February 24, 2022","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,https://ClinicalTrials.gov/show/NCT04212728
196,93,NCT03969680,Mesenchymal Stem Cell Transplantation for Osteoarthritis,,Recruiting,No Results Available,Knee Osteoarthritis,Biological: Auotologous BMSCs plus autologous PRP|Biological: Auotologous PRP,Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS),Yantai Yuhuangding Hospital,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2019-002,"July 8, 2019","June 30, 2023","December 31, 2023","May 31, 2019",,"August 4, 2022","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,https://ClinicalTrials.gov/show/NCT03969680
197,223,NCT04544215,A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection,,Recruiting,No Results Available,Drug-resistant,Biological: Dosage 1 of MPCs-derived exosomes|Biological: Dosage 2 of MPCs-derived exosomes|Biological: No MPCs-derived exosomes,Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.,Ruijin Hospital|Cellular Biomedicine Group Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MEXDR,"July 1, 2020",May 2023,July 2023,"September 10, 2020",,"September 10, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04544215
198,649,NCT01409954,Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells,,Enrolling by invitation,No Results Available,Pseudarthrosis After Fusion or Arthrodesis,,Osteogenic Potential of Mesenchymal Stem Cells,University of Utah,All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,46970,October 2011,January 2024,January 2024,"August 4, 2011",,"May 9, 2022","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01409954
199,721,NCT04557514,Comparative Study Between Fat Injection And Platelet Rich Plasma In Post Burn Facial Scar,,Not yet recruiting,No Results Available,Burn Scar,Procedure: platelet rich plasma injection in post burn facial scar|Procedure: fat injection in post burn facial scar,vancouver scale,Assiut University,All,"15 Years to 60 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,facial burn scar,"October 1, 2020","October 1, 2023","December 1, 2023","September 21, 2020",,"September 21, 2020",,,https://ClinicalTrials.gov/show/NCT04557514
200,95,NCT04995081,Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD).,,Recruiting,No Results Available,Parkinson Disease,Biological: Biological/Vaccine: Allogeneic HB-adMSCs|Other: Placebo,"1. Changes in the total score MDS-UPDRS Part II.|2. Incidence of treatment-emergent Adverse Event (TEAEs).|3. Incidence of treatment-emergent Serious Adverse Events (SAEs).|4. AEs of special interest (serious or non-serious) - thromboembolic events.|5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities|6. AEs of special interest (serious or non-serious) - infections|7. AEs of special interest (serious or non-serious) - hypersensitivities.|8. Laboratory value Complete Blood Count (CBC)|9. Laboratory values Chemistry Metabolic Panel (CMP)|10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern|11. Vital signs. - Respiratory Rate (breaths per minute)|12. Vital signs. - Heart Rate (beats per minute)|13. Vital signs. - Body Temperature (Fahrenheit )|14. Vital signs. - Blood Pressure (mmHg)|15. Weight in lb.|16. Physical examination results. General|17. Physical examination results. Body Systems.|18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.|19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.|20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.|21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.|22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).|23. Changes in Parkinson's disease fatigue scale (PFS-16)|24. Changes in Parkinson's disease Questionnaire (PDQ-39).|25. Changes in Visual Analog Scale for Pain.|26. Changes in Visual Analog Scale for Muscle spasms.|27. Changes in Dosage of medications taken to treat Parkinson's disease.",Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HBPD04,"July 16, 2021","July 20, 2023","July 20, 2023","August 6, 2021",,"September 21, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04995081
201,38,NCT03383081,The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis,,Recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Low dose mesenchymal stem cells|Biological: High dose mesenchymal stem cells|Procedure: Intraarticular injection,Kellgren-Lawrence Grading Scale|Assessment of Preoperative Cartilage Defect Severity (AMADEUS)|Lysholm scoring|The international knee documentation committee (IKDC) knee evaluation form|Visual Analogue Scale/Score（VAS）,"Sclnow Biotechnology Co., Ltd.",All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XY-02,"October 1, 2018",December 2022,June 2023,"December 26, 2017",,"July 22, 2022","Xiangya Hospital Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03383081
202,159,NCT00644410,Autologous Mesenchymal Stromal Cell Therapy in Heart Failure,,Completed,No Results Available,Congestive Heart Failure,Biological: Mesenchymal stromal cell|Biological: Saline,Improvements in left ventricular function|Clinical improvements,"Rigshospitalet, Denmark",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,59,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSC heart failure,September 2008,March 2015,March 2015,"March 26, 2008",,"March 17, 2015","The Heart Centre, Rigshospitalet University Hospital Copenhagen,, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00644410
203,9,NCT02619877,Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers,,Completed,No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU|Other: Standard therapy,Proportion of re-epithelialization|Time to re-epithelialization|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,59,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ALLO-ASC-DFU-201,October 2015,September 2016,October 2016,"December 2, 2015",,"September 1, 2017","Korea University Guro Hospital, Guro-gu, Seoul, Korea, Republic of|Eulji General Hospital, Nowon-Gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-Gu, Seoul, Korea, Republic of|Asan medical center, Songpa-Gu, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02619877
204,720,NCT03197623,Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids,,Completed,No Results Available,Osteopenia|Osteoporosis|Osteonecrosis,Drug: LLP2A-ALENDRONATE|Drug: Placebo,Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine,"Nancy E. Lane, MD|California Institute for Regenerative Medicine (CIRM)|University of California, Davis",All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20161825|LLP2A-001,"October 14, 2016","March 15, 2021","March 31, 2021","June 23, 2017",,"August 6, 2021","West Coast Clinical Trials (WCCT), Cypress, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03197623
205,205,NCT02068794,"MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",,Recruiting,No Results Available,Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Other: Laboratory Biomarker Analysis|Procedure: Mesenchymal Stem Cell Transplantation|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter,Maximum tolerated dose (MTD) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Toxicity profiles by dose level and patient (Phase I)|Proportion of patients alive at 12 months (Phase II)|Tumor response (Phase II)|Rate of progression free survival (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Maximum grade for each type of toxicity (Phase II),Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,57,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC1266|NCI-2014-00016|P30CA015083|P50CA136393|P50CA083639,"March 31, 2014","December 31, 2023","December 31, 2023","February 21, 2014",,"March 15, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02068794
206,6,NCT03754465,Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers,,Recruiting,No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU|Procedure: Hydrogel SHEET(Vehicle control),"Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure","Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALLO-ASC-SHEET-102,"January 2, 2019","December 30, 2022","December 30, 2022","November 27, 2018",,"May 3, 2022","University of Southern California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03754465
207,1,NCT04349631,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,,Completed,No Results Available,COVID-19,Biological: HB-adMSCs,Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9,Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"Child, Adult, Older Adult",Phase 2,56,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HBCOV01,"April 22, 2020","November 24, 2020","May 1, 2021","April 16, 2020",,"July 7, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04349631
208,149,NCT04348435,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,Completed,No Results Available,COVID-19,Biological: HB-adMSCs|Other: Placebos,Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9,Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"Child, Adult, Older Adult",Phase 2,55,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",HBCOV02,"May 14, 2020","July 9, 2021","July 30, 2021","April 16, 2020",,"August 20, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04348435
209,691,NCT00702741,Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy,,Completed,No Results Available,Recovery Following Partial Medial Meniscectomy,Drug: Chondrogen|Drug: Placebo,Comparison of treatment adverse event rates|Concomitant Medications|Visual Analog Scale,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,55,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",551,June 2008,September 2011,September 2011,"June 20, 2008",,"January 11, 2022","University of Southern California Keck School of Medicine, Los Angeles, California, United States|OrthoIndy, Indianapolis, Indiana, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Unlimited Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00702741
210,7,NCT04652908,Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial,CuRe,Recruiting,No Results Available,Myelomeningocele,Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|Other: Untreated contemporaneous cohort,Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product|Efficacy of the PMSC-ECM Product,"Diana Lee Farmer|California Institute for Regenerative Medicine (CIRM)|University of California, Davis",All,19 Weeks to 25 Weeks   (Child),Phase 1|Phase 2,55,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1617774,"June 21, 2021",March 2024,March 2024,"December 3, 2020",,"September 6, 2022","UC Davis Health, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT04652908
211,5,NCT02336230,"A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)",,Completed,Has Results,Grade B aGVHD|Grade C aGVHD|Grade D aGVHD,Drug: remestemcel-L,"Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy|Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement|OR Rate at Day 56 and 100 Post Initiation of Therapy","Mesoblast, Inc.|Quintiles, Inc.|Mesoblast, Ltd.",All,2 Months to 17 Years   (Child),Phase 3,55,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSB-GVHD001,"June 4, 2015","April 9, 2018","April 9, 2018","January 12, 2015","March 17, 2022","March 17, 2022","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|Miami Children's Research Institute, Miami, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Albert Einstein College of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02336230/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02336230
212,187,NCT02525432,Autologous Stem Cell Study for Adult TBI (Phase 2b),,Enrolling by invitation,No Results Available,"Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)",Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion,Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.,"The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Development Command",All,18 Years to 55 Years   (Adult),Phase 2,55,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-16-0283,"November 21, 2016",August 2023,December 2023,"August 17, 2015",,"August 2, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02525432
213,619,NCT04798716,The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19,ARDOXSO,Not yet recruiting,No Results Available,Covid19|Novel Coronavirus Pneumonia|Acute Respiratory Distress Syndrome,Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Drug: MSC-exosomes delivered intravenously every other day (8:8:8),"Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime.",AVEM HealthCare,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,55,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",020582,September 2023,September 2024,December 2024,"March 15, 2021",,"March 11, 2022","Mission Community Hospital, Panorama City, California, United States",,https://ClinicalTrials.gov/show/NCT04798716
214,46,NCT04594850,Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously,Cellgram-ED,Recruiting,No Results Available,Erectile Dysfunction,Biological: Cellgram-ED,The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline,"Pharmicell Co., Ltd.",Male,"19 Years to 79 Years   (Adult, Older Adult)",Phase 2,54,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PMC-P-10,"October 19, 2020","October 31, 2023","October 31, 2023","October 20, 2020",,"October 26, 2020","Asan medical center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul ST. Mary's hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04594850
215,125,NCT04170426,Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis,,Not yet recruiting,No Results Available,Rheumatoid Arthritis,Biological: autologous adipose derived stem cells,Adverse Events and Sever Adverse Events|Efficacy of Celltex AdMSCs,Celltex Therapeutics Corporation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTX0019-001,December 2022,December 2023,December 2025,"November 20, 2019",,"May 5, 2022",,,https://ClinicalTrials.gov/show/NCT04170426
216,220,NCT05344157,A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis,,Recruiting,No Results Available,"Osteoarthritis, Knee",Biological: XSTEM-OA,"Safety and tolerability: Adverse events (AEs)|Safety and tolerability: 12-lead electrocardiogram (ECG)|Safety and tolerability: Laboratory examinations|Safety and tolerability: Physical examinations|Safety and tolerability: Vital signs|Preliminary efficacy: Changes in Visual Analogue Scale (VAS) for pain compared to baseline|Preliminary efficacy: Changes in Knee injury and Osteoarthritis Outcome Score (KOOS) compared to baseline|Preliminary efficacy: Change in EuroQoL 5 Dimension 5 Level test (EQ-5D-5L) compared to baseline|Preliminary efficacy: Change in 40 m fast paced walk test compared to baseline|Preliminary efficacy: Change in cartilage structure compared to baseline, based on MRI assessment of cartilage volume and composition|Preliminary efficacy: Change in whole knee health compared to baseline, based on MRI assessment by the MRI Osteoarthritis Knee Score (MOAKS)|Preliminary efficacy: Change in inflammatory activity compared to baseline, based on MRI assessment of synovial thickness and synovial blood flow|Preliminary efficacy: Changes in joint space narrowing based on x-ray compared to baseline",Xindu Pty Ltd|Xintela AB,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,54,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XIN-XSTEM-101,"June 22, 2022",December 2024,December 2024,"April 25, 2022",,"July 13, 2022","Emeritus Research, Camberwell, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT05344157
217,99,NCT02162693,Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis,,Completed,No Results Available,Knee Osteoarthritis,Biological: Mesenchymal progenitor cells|Biological: Sodium Hyaluronate,WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Recording of Adverse Events and Serious Adverse Events,Cellular Biomedicine Group Ltd.|RenJi Hospital|General Hospital of Chinese Armed Police Force,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,53,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CBMG-KOA-Ⅱb,November 2013,May 2016,November 2016,"June 13, 2014",,"November 17, 2017","General Hospital of Chinese Armed Police Force, Beijing, China|Shanghai Renji Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02162693
218,254,NCT01663116,"Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients",,Completed,No Results Available,Rheumatoid Arthritis Aggravated,Genetic: Stem cells|Genetic: Placebo,"Number of Adverse Events and Severe Adverse Events|Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)",Tigenix S.A.U.|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,53,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Cx611-0101,March 2011,January 2013,January 2013,"August 13, 2012",,"April 12, 2019","Hospital U. Central de Asturias, Oviedo, Asturias, Spain|Hospital General de Mérida, Mérida, Badajoz, Spain|Hospital U. de Canarias, La Laguna, Tenerife, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Complejo Hospitalario U. A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. de Guadalajara, Guadalajara, Spain|Hospital de La Princesa, Madrid, Spain|Hospital U. Gregorio Marañon, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital U. La Paz, Madrid, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital U. Marques de Valdecilla, Santander, Spain|Hospital Ntra. Sª de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital La Fe, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01663116
219,112,NCT05066334,Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD,DREAM,Recruiting,No Results Available,Intervertebral Disc Degeneration|Chronic Low-back Pain,Drug: Autologous BM-MSC|Procedure: Sham,Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation,"Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",DREAM (GR - 2018-12367168)|2019-002749-40,"March 22, 2021","May 31, 2022","June 9, 2023","October 4, 2021",,"October 4, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,https://ClinicalTrials.gov/show/NCT05066334
220,104,NCT04759105,Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD,ACTIVE,Recruiting,No Results Available,Intervertebral Disc Degeneration|Chronic Low-back Pain,Drug: Autologous BM-MSC|Other: Sham Procedure,Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration,"Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",ACTIVE trial_(BRIC2018-ID03)|2019-004476-19,"November 17, 2020","July 31, 2021","June 30, 2022","February 18, 2021",,"February 18, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04759105
221,11,NCT04210440,The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression,NEC15,Completed,No Results Available,Hip Necrosis|Hip Injuries,Procedure: Core decompression procedure,Avoiding arthroplasty|Harris Hip Score,"Dante Dallari, MD|Istituto Ortopedico Rizzoli",All,18 Years to 50 Years   (Adult),Not Applicable,52,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0029170,"March 1, 2003","March 1, 2011","March 1, 2012","December 24, 2019",,"December 24, 2019","Istituto Ortopedico Rizzli, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT04210440
222,613,NCT02290886,A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CeTMAd/ELA/2011,July 2014,"March 2, 2022","March 2, 2022","November 14, 2014",,"April 6, 2022","Hospital Regional Universitario Reina Sofía, Cordoba, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Servicio de Neurología, Seville, Spain|Hospital Universitario Virgen del Rocío, Seville, Spain",,https://ClinicalTrials.gov/show/NCT02290886
223,18,NCT03726255,Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula,RESCeCUF,Completed,No Results Available,Perianal Fistula,Procedure: Mesenchymal Stem Cell injection,Number of patients with fistula healed|Number of adversus events,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,All,"24 Years to 70 Years   (Adult, Older Adult)",,52,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,EO166-18_FJD,"April 1, 2014","January 26, 2018","July 26, 2018","October 31, 2018",,"November 13, 2018","Instituto Investigación Sanitario Fundación Jiménez Díaz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03726255
224,623,NCT04763369,Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP),,Recruiting,No Results Available,Retinitis Pigmentosa (RP),Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa,Evaluation of safety related adverse ocular events including immune response|Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart|Measurement of electrical activity/function of retina using Electroretinography (ERG) test|Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test|Examination of retinal damage by Fundus Photography|Evaluation of visual field sensitivity using perimeter,"Jinnah Burn and Reconstructive Surgery Centre, Lahore|The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township Lahore.|Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JB&RSC-02,February 2021,May 2022,June 2022,"February 21, 2021",,"February 21, 2021","Stem Cell laboratory, Jinnah Burn & Reconstructive Surgery Centre, Lahore, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT04763369
225,352,NCT00827398,Treatment of Steroid Resistant GVHD by Infusion MSC,MSCforGVHD,Completed,No Results Available,Graft-versus-host-disease,Biological: MSC (hPPL),number of adverse events after infusion of MSC (hPPL)|Number of severe infections after MSC infusion|Response of acute GVHD|Determination of incidence of chronic GVHD|Survival,N.M. Wulffraat|UMC Utrecht,All,"1 Month to 68 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL13729.000.07,January 2009,July 2013,July 2013,"January 22, 2009",,"November 6, 2014","UMC Utrecht, department of pediatrics, Utrecht, Netherlands|UMCU department of Haematology, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00827398
226,118,NCT04146519,Parkinson's Disease Therapy Using Cell Technology,,Recruiting,No Results Available,Transplantation:Mesenchymal Stem Cell Transplantation,Biological: Autologous mesenchymal stem cells|Other: Placebo,motor symptoms change|non-motor symptoms change|sleep quality change|daytime sleepiness change|signs of depression change,Belarusian Medical Academy of Post-Graduate Education,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2|Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20171292,"July 1, 2017","December 1, 2021","December 31, 2021","October 31, 2019",,"March 3, 2021","the Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04146519
227,101,NCT05016011,Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury,,Recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Procedure: Marrow cellution,Recording of Adverse Events and Serious Adverse Events|International Knee Documentation Committee (IKDC) score|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Visual Analog Score (VAS)|Magnetic resonance imaging (MRI)|Immunohistochemistry (IHC),Cytopeutics Sdn. Bhd.|Universiti Kebangsaan Malaysia Medical Centre,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,POD0032/CP/R,"July 1, 2020","June 1, 2022","June 1, 2023","August 23, 2021",,"August 23, 2021","Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM), Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT05016011
228,122,NCT03355365,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,,"Active, not recruiting",No Results Available,Multiple Sclerosis,Biological: Intrathecal MSC-NP injection|Other: Intrathecal saline injection,Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function,Tisch Multiple Sclerosis Research Center of New York,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TISCHMS-MSCNP-002,"September 21, 2018",May 2022,November 2023,"November 28, 2017",,"October 6, 2021","Tisch MS Research Center of New York, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03355365
229,750,NCT01544712,Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow,,Completed,No Results Available,Non Traumatic Osteonecrosis of the Femoral Head (Hip),Procedure: core decompression with autologous bone marrow implantation|Procedure: core decompression of the femoral head,reduction of total prosthesis|Pain reduction|functional status,University of Liege,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Ref 2004/08 st 3,August 2004,September 2010,September 2010,"March 6, 2012",,"March 6, 2012","University of Liège, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT01544712
230,152,NCT02334878,Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence,,Completed,No Results Available,"Urinary Incontinence, Stress","Biological: Stem Cells,Mesenchymal|Procedure: surgery (TVT)",change in cough test & urodynamic study as a measure of efficacy of treatment|Quality of life as measured by the Incontinence Quality of Life (I-QOL) Instrument Score,Ain Shams Maternity Hospital,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMASU 3098/2014,"October 1, 2015","October 30, 2016","December 1, 2016","January 8, 2015",,"September 11, 2017","Maternity hospital, Ain Shams University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT02334878
231,3,NCT03423732,Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI),,"Active, not recruiting",No Results Available,Critical Limb Ischemia,Drug: CardioCell|Drug: Placebos,"Change in pain-free walking distance|Amputation-free survival period|Ulcer-free survival|Ulcer-extension free survival|Change in tissue oxygen/CO2 tension|An improvement of tissue perfusion|Change in transcutaneous pressure of O2|Change in ABI score|Quality of life improvement, assessed by SF-36 questionnaire","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CardioCell in N-O CLI,"April 19, 2018","May 31, 2021","September 30, 2021","February 6, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland",,https://ClinicalTrials.gov/show/NCT03423732
232,576,NCT04653077,MSCs Therapy for Cerebral Palsy,,Not yet recruiting,No Results Available,Stem Cell Transplant Complications,Other: stem cells,Changes in Motor Performance.,Aljazeera Hospital|AMR KHALIL ORTHOPEDIC SURGERY CENTER,All,2 Years to 12 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,cerebral palsy,"December 2, 2020","October 15, 2022","December 1, 2022","December 4, 2020",,"December 4, 2020","Aljazeera( Al Gazeera) hospital, Giza, Egypt",,https://ClinicalTrials.gov/show/NCT04653077
233,5,NCT05160831,Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis,,Not yet recruiting,No Results Available,Knee Osteoarthritis,Biological: Human umbilical cord mesenchymal stem cells,VAS score|Kellgren-Lawrence score,"Southwest Hospital, China",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCforKneeOA,"January 20, 2022","January 20, 2023","January 20, 2024","December 16, 2021",,"December 16, 2021",,,https://ClinicalTrials.gov/show/NCT05160831
234,272,NCT02635464,Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy,,Completed,No Results Available,Chronic Ischemic Cardiomyopathy,Biological: hUC-MSCs+Injectable collagen scaffold+CABG|Biological: hUC-MSCs+CABG|Procedure: CABG,Incidence of treatment-emergent adverse events|Myocardial blood flow|Left ventricle ejection fraction (LVEF)|Infarct size|New York Heart Association (NYHA) Functional Classification|Canadian Cardiovascular Society (CCS) Angina Grading Scale,Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CAS-XDA-CIC/IGDB,October 2015,August 2019,August 2019,"December 18, 2015",,"December 23, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02635464
235,480,NCT03592849,The Efficacy and Safety of Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchymal Stem Cells in Infertile Women With Thin Endometrium or Endometrial Scarring,,Enrolling by invitation,No Results Available,"Infertility, Female|Endometrium",Procedure: UC-MSCs therapy,endometrial thickness|ongoing pregnancy rate|live birth rate|endometrial blood flow,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Female,20 Years to 42 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC201700101,"September 10, 2018","January 31, 2021",December 2021,"July 19, 2018",,"September 1, 2021","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03592849
236,44,NCT02672267,A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction,,Completed,No Results Available,Myocardial Infarction,Biological: Stem cells|Other: Placebo,"The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint|The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration|LV end diastolic volume|LV end systolic volume|Infarct size measured by MRI, with contrast|Global Left Ventricular Ejection Fraction","Altaco XXI, LLP|Duke University",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,CARDIO 1/2,July 2014,April 2016,April 2016,"February 3, 2016",,"October 6, 2016","National Research Medical Center, Astana, Kazakhstan",,https://ClinicalTrials.gov/show/NCT02672267
237,471,NCT00361049,Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant,,Completed,No Results Available,Cancer,Biological: graft versus host disease prophylaxis/therapy|Genetic: fluorescence in situ hybridization|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: in vitro-treated bone marrow transplantation|Procedure: management of therapy complications,"Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,49,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWRU3Y03|P30CA043703|CASE-CWRU-3Y03,September 2004,June 2009,November 2010,"August 7, 2006",,"November 5, 2010","Geauga Regional Hospital, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Suburban Health Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00361049
238,377,NCT04753476,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,,Recruiting,No Results Available,Covid-19|Cytokine Storm,Biological: Injection of Secretome-MSCs|Drug: Standard treatment of Covid-19,Change in patients clinical manifestation|Need for a ventilator|Duration of using a ventilator|Length of stay|Routine blood profile|CRP|D-dimer|Blood Gas Analisis (BGA)|Photo thorax|Survival,"Stem Cell and Cancer Research Indonesia|Provincial Government of Central Java, Indonesia",All,"Child, Adult, Older Adult",Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCCR_Secretome,"June 8, 2020","February 1, 2022","March 1, 2022","February 15, 2021",,"May 24, 2021","RSUD Bantul, Bantul, Central Java, Indonesia|RS PKU Muhammadiyah Gamping, Yogyakarta, Central Java, Indonesia|RS Primaya Bekasi Timur, Bekasi, Jakarta, Indonesia|Bhayangkara Hospital, Makassar, South Celebes, Indonesia|Gatot Soebroto Army Hospital, Jakarta, Indonesia|Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04753476
239,52,NCT02166021,Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis,,Completed,No Results Available,Multiple Sclerosis (MS),Biological: Mesenchymal stem cells,Safety Assessment|Neurological efficacy|EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology,Dimitrios Karussis|Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MSC-MS-001-IL,"January 29, 2015","June 15, 2018","December 24, 2018","June 18, 2014",,"August 1, 2019","Hadassah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT02166021
240,152,NCT04869397,Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells,ProTrans19+,Recruiting,No Results Available,Covid19,Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Other: Placebo,Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay,McGill University Health Centre/Research Institute of the McGill University Health Centre,All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2021-6954,"June 14, 2021","June 30, 2022","July 30, 2022","May 3, 2021",,"June 15, 2021","McGill University Health Centre, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04869397
241,193,NCT02585622,NEPHSTROM for Diabetic Kidney Disease,NEPHSTROM,Recruiting,No Results Available,Diabetic Kidney Disease,Biological: Mesenchymal Stromal Cells|Other: Placebo,"Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy","Mario Negri Institute for Pharmacological Research|Leiden University Medical Center|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy|Belfast Health and Social Care Trust|National University of Ireland, Galway, Ireland|University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK|NHS Blood and Transplant",All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",NEPHSTROM|2016-000661-23,"December 11, 2017",December 2021,July 2022,"October 23, 2015",,"July 14, 2021","National University of ireland - Galway University Hospital -Regenerative Medicine Institute, Galway, Ireland|ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, BG, Italy|Belfast Health and Social Care Trust - Belfast City Hospital, Belfast, United Kingdom|University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre, Birmingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02585622
242,491,NCT05292625,Stem Cell Infusion in the Treatment of Patients With Neurological Complications After Ischemic Stroke,,Recruiting,No Results Available,Ischemic Stroke,Biological: UC-MSC infusion via intravenous route|Biological: UC-MSC infusion via intrathecal route|Other: standard stroke treatment and rehabilitation therapy,Adverse events and serious adverse events|National Institutes of Health Stroke Scale (NIHSS) score|Functional Independence Measure (FIM) score|Modified Ashworth Scale|Fine motor skills (FMI) score|Short Form 36 items (SF-36) score,Vinmec Research Institute of Stem Cell and Gene Technology,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,VinmecISC1809,"July 15, 2021","April 30, 2023","June 2, 2023","March 23, 2022",,"April 4, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT05292625
243,763,NCT00710411,Inflammatory Response After Muscle and Skeleton Trauma,IRAMST,Completed,No Results Available,Multiple Trauma,,"Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes|inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality",University of Ulm|German Research Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",,48,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,DFG KFO-200,April 2009,October 2015,December 2015,"July 4, 2008",,"December 17, 2015","Clinic of Anesthesiology and Clinic of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00710411
244,276,NCT02917291,Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury,SPINE,Recruiting,No Results Available,Acute Traumatic Spinal Cord Injury,Drug: FAB117-HC|Other: Control group,"Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord|Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC|Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)|Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.|Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test","Ferrer Internacional S.A.|Histocell, S.L.",All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",FAB117-CT-01,December 2016,July 2022,July 2023,"September 28, 2016",,"September 16, 2021","Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Complejo Hospitalario de Toledo (HNP y VS), Toledo, Spain|Hospital Universitari La Fe, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT02917291
245,57,NCT01851070,A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor,,Completed,No Results Available,Rheumatoid Arthritis,Drug: Allogeneic Mesenchymal Precursor Cells|Drug: Normal Saline,Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion|Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA|Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA,"Mesoblast, Ltd.|PPD",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSB-RA001,July 2013,May 2016,March 2017,"May 10, 2013",,"June 26, 2020","Pinnacle Research Group, Anniston, Alabama, United States|Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States|Triwest Research Associates, El Cajon, California, United States|UCLA, Los Angeles, California, United States|Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Arthritis Center, Palm Harbor, Florida, United States|Sarasota Arthritis Research Center, Sarasota, Florida, United States|McIlwain Medical Group, Tampa, Florida, United States|JHU Arthritis Center Baltimore, Baltimore, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Office of Ramesh C. Gupta, MD, Fair Lawn, New Jersey, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Accurate Clinical Research, Houston, Texas, United States|Texas Arthritis Research Center, San Antonio, Texas, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Southern Clinical Research Pty Ltd, Hobart, Tasmania, Australia|Emeritus Research, Malvern, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01851070
246,131,NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May 2014,March 2016,July 2016,"December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02017912
247,76,NCT04333368,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,STROMA-CoV2,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome,Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%,"Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage",Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",APHP200395|2020-001287-28,"April 6, 2020","October 26, 2021","October 26, 2021","April 3, 2020",,"February 18, 2022","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,https://ClinicalTrials.gov/show/NCT04333368
248,115,NCT03166189,Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures,,Completed,No Results Available,"Infertility, Female|Infertility of Uterine Origin|Asherman Syndrome",Biological: bone marrow-derived MSC and HRT|Other: hormonal replacement therapy,Assessment of endometrial receptivity|Clinical pregnancy rate|Treatment-Emergent Adverse Events,"D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology",Female,21 Years to 44 Years   (Adult),Phase 2,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-001,"December 20, 2017","March 16, 2019","December 28, 2019","May 25, 2017",,"January 2, 2020","D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT03166189
249,431,NCT02054208,Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL,Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers,Medipost Co Ltd.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-CR-010,March 2014,December 2019,December 2019,"February 4, 2014",,"August 28, 2020","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02054208
250,773,NCT03298763,Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer,TACTICAL,Recruiting,No Results Available,Adenocarcinoma of Lung,Genetic: MSCTRAIL|Drug: Placebo,Determination of recommended Phase II dose (RP2D) of MSCTRAIL in combination of cisplatin and pemetrexed treatment (Phase 1)|Tumour response rate (Phase 2)|Frequency of adverse events (Phase 1 & 2)|Best Overall response (Phase 1&2)|Progression free survival (Phase 1 & 2)|Overall survival (Phase 2),"University College, London",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UCL/14/0453,"March 5, 2019","September 1, 2023","September 1, 2025","October 2, 2017",,"April 28, 2021","University College London Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03298763
251,143,NCT03865394,Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells,1ABC,Completed,No Results Available,Diabetic Foot Ulcer,Biological: Application of allogeneic ADSC stem cells in fibrin gel|Procedure: Standard care in diabetic foot ulcer,Changes in wound size|Changes in wound morphology|Changes in pro-angiogenic factors expression|Changes in wound-associated pain|Changes in the quality of life|Record of adverse events,Medical University of Warsaw|Polish Stem Cells Bank S.A.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1ABC Therapy|267976/13/NCBR/2015|2016-004109-15|PL008125|Z4217,"July 1, 2019","March 31, 2021","September 30, 2021","March 6, 2019",,"October 14, 2021","Medical University of Warsaw, Department of Diabetology and Internal Diseases, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT03865394
252,56,NCT03325504,A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union,ORTHOUNION,"Active, not recruiting",No Results Available,Non Union Fracture,Biological: Cultured Mesenchymal Stem Cells|Procedure: Autologous iliac crest graft,Bone consolidation|Radiological Bone consolidation|Level of Pain|Complications|Health status,Universidad Autonoma de Madrid,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORTHOUNION|2015-000431-32|EUCTR2015-000431-32-ES,"September 5, 2017","December 30, 2022","December 31, 2023","October 30, 2017",,"June 1, 2022","CHU Clermont-Ferrand, Clermont-Ferrand, France|Department of Orthopaedic Surgery, Hospital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Nantes, Nantes, France|Department of Orthopaedic Surgery Toulouse University Hospital, Toulouse, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|Universitätsklinikum Frankfurt, Department of Trauma, Hand and Reconstructive Surgery, Frankfurt, Germany|Universitätsklinikum Freiburg, Klinik für Orthopädie und Unfallchirurgie, Freiburg, Germany|Universitätsklinikum München, Munich, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, SSD Fisiopatologia Ortopedica e Medicina Rigenerativa, Bologna, Italy|Arienda Spedali Civili di Brescia II Ortopedia e Traumatologia, Brescia, Italy|Istituto Ortopedico Galeazzi, Chirugia dell´Anca l, Milano, Italy|Hospital U. Puerta de Hierro-Majadahonda, Servicio de Cirugía Ortopédica y Traumatología, Majadahonda, Madrid, Spain|Hospital Clínica San Carlos, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. 12 de Octubre, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. Gregorio Marañon, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. La Princesa, Servicio de CirugíaOrtopédica y Traumatología, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03325504
253,155,NCT02509156,Stem Cell Injection in Cancer Survivors,SENECA,Completed,Has Results,Cardiomyopathy Due to Anthracyclines,Biological: Allo-MSCs|Biological: Placebo,Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure,"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,46,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-SPH-15-0443|5UM1HL087318,August 2016,November 2019,"April 20, 2020","July 27, 2015","November 5, 2020","November 5, 2020","Stanford University School of Medicine, Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdiciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02509156
254,131,NCT04506073,Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD,,"Active, not recruiting",No Results Available,Parkinson's Disease,Drug: MSC+placebo|Drug: MSC|Drug: Placebo,"Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale|Safety and tolerability as measured by serious adverse reactions.|Safety and tolerability as measured by immunologic responses.|Motor function as measured by the Timed-Up-and-Go (TUG) scale|Global measurement of disability as measured by the change in the screening ""Off"" modified Hoehn and Yahr (H&Y)|Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)|Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)|Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)|Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).|Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)|Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)|Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)|Measurement of putative paracrine mechanism of MSCs using neuroimaging|Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors|Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid","The University of Texas Health Science Center, Houston|Michael J. Fox Foundation for Parkinson's Research",All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HSC-MS-20-0150,"November 9, 2020","July 26, 2023","December 22, 2023","August 10, 2020",,"February 10, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04506073
255,118,NCT03378414,Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia,,Not yet recruiting,No Results Available,Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 6,Procedure: Intravenous infusion|Procedure: Intrathecal injection|Biological: umbilical cord mesenchymal stem cell,Scale for the assessment anf rating of ataxia (SARA)|Image examinations|Inventory of Non-Ataxia Symptoms (INAS) score|Cerebrospinal fluid (csf) routine,"Sclnow Biotechnology Co., Ltd.",All,"16 Years to 60 Years   (Child, Adult)",Phase 2,45,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XY-03,June 2022,December 2022,December 2023,"December 19, 2017",,"May 9, 2022",,,https://ClinicalTrials.gov/show/NCT03378414
256,96,NCT04328714,Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease,,Recruiting,No Results Available,Acute Leukemia|Myelodysplastic Syndromes,Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells,Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation,"Edwin Horwitz|Ossium Health, Inc.|Emory University",All,"1 Year and older   (Child, Adult, Older Adult)",Phase 1,45,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00105305,"December 2, 2021",August 2023,August 2023,"March 31, 2020",,"July 19, 2022","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04328714
257,2,NCT03863002,Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure,,Not yet recruiting,No Results Available,"Liver Failure, Acute on Chronic",Biological: Mesenchymal Stem Cell,survival rate|Adverse reactions|White blood cell|Platelet|Hemoglobin|Creatinine|ALT|ALB|TBil|INRs|AFP|MELD scores|Tumor formation|Liver failure-associated serious complications,"Tianjin Weikai Bioeng., Ltd.|Tianjin Nankai Hospital",All,"16 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,45,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Weikai Bioeng., Ltd","October 1, 2019","October 1, 2021","October 1, 2022","March 5, 2019",,"March 20, 2019","Tianjin Weikai Bioeng., Ltd., Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT03863002
258,593,NCT04397796,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,,"Active, not recruiting",No Results Available,COVID,Biological: BM-Allo.MSC|Biological: Placebo,Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs,"ImmunityBio, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",QUILT-COVID-19-MSC,"August 3, 2020",June 2022,June 2022,"May 21, 2020",,"February 1, 2022","St. Francis Medical Center, Lynwood, California, United States",,https://ClinicalTrials.gov/show/NCT04397796
259,124,NCT04919135,Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty,,Not yet recruiting,No Results Available,Frailty,Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: standard frailty treatment and supplementary medication,Adverse events and serious adverse events|Reduced activities|Slowing of mobility|reduction of handgrip strength|exhaustion|the level of pain in the knee|respiratory function|Quality of Life|patients' inflammation|patients' immune|immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells|Cellular senescence|metabolic profiles of CD3+ cells,Vinmec Research Institute of Stem Cell and Gene Technology,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,VinmecISC2111,"July 1, 2021","November 30, 2021","November 30, 2022","June 9, 2021",,"June 9, 2021",,,https://ClinicalTrials.gov/show/NCT04919135
260,212,NCT03437759,MSC-Exos Promote Healing of MHs,MSCs,"Active, not recruiting",No Results Available,Macular Holes,Biological: exosomes derived from mesenchymal stem cells (MSC-Exo),Macular holes closure|Best corrected visual acuity(BCVA),Tianjin Medical University,All,"up to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2015KY-05,"March 1, 2017","May 30, 2018","December 30, 2021","February 19, 2018",,"April 6, 2021","Tianjin Medical University Hospital, Tianjin, China",,https://ClinicalTrials.gov/show/NCT03437759
261,357,NCT05512988,Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 ),,Recruiting,No Results Available,Chronic Kidney Diseases,Biological: UC-MSC|Biological: Saline solution,"Change of GFR|Incidence of Treatment-Serious Adverse Events as assessed by SPSS 23.0 and Graphpad prism 6|Number of participants with treatment-related adverse events as assessed by SPSS 23.0 and Graphpad prism 6|IgA|IgG|IgM|C3|C4|CRP|IL-6|Peripheral hemolymocyte subsets|Urine protein|Urine RBC|24-hour urine protein|Urine albumin/creatinine|Electrolytes|Hemoglobin|Albumin|Heart ultrasound|Carotid ultrasound|NT-proBNP|iPTH+1,25-VitD3","Tongji Hospital|Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TongjiHospitalxugangtjh,"April 13, 2021","April 30, 2024","May 31, 2024","August 23, 2022",,"August 23, 2022","Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT05512988
262,99,NCT03362424,Mesenchymal Stem Cells in Rotator Cuff Repair,,Recruiting,No Results Available,Rotator Cuff Tear|Tendon Injuries|Mesenchymal Stem Cell,Biological: Mesenchymal stem cell|Procedure: Rotator cuff repair,MRI integrity|American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES)|University at California at Los Angeles Shouder Rating Scale (UCLA)|Visual Analog Scale for Pain (VAS),University of Sao Paulo,All,"35 Years and older   (Adult, Older Adult)",Phase 2,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2.335.243,"November 1, 2020","December 1, 2023","December 1, 2023","December 5, 2017",,"August 24, 2022","Universidade de São Paulo, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT03362424
263,3,NCT04464213,Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer,,Recruiting,No Results Available,Diabetic Foot Ulcer,Other: Single dose experiments|Other: Multi-dose experiments,Rate of adverse event|Rate of serious adverse event|Rate of cure rate,Beijing Tongren Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,43,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HS201901,"November 1, 2020","August 1, 2021","December 31, 2021","July 9, 2020",,"December 11, 2020","National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, Beiijng, China",,https://ClinicalTrials.gov/show/NCT04464213
264,183,NCT03968198,Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia,ACellDREAM2,Recruiting,No Results Available,Critical Limb Ischemia and Peripheral Artery Disease,Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell),Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang",All,"18 Years and older   (Adult, Older Adult)",Phase 2,43,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14 7441 01,"March 4, 2020",December 2022,July 2023,"May 30, 2019",,"July 30, 2020","CHU de BORDEAUX, Bordeaux, France|CHU de LIMOGES, Limoges, France|Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03968198
265,184,NCT04421274,Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction,Bmmsct,Completed,No Results Available,Myocardial Infarction,Biological: Bone marrow mesenchymal stem cells transfer|Drug: Best medical treatment|Procedure: Percutaneous coronary intervention,changes in myocardial metabolic activity|Changes in left ventricular ejection fraction (LVEF)|incidence of cardiovascular events|overall mortality|adverse events at 12 months after transplantation of autologous BM-MSCs,Afﬁliated Hospital of North Sichuan Medical College|Chinese PLA General Hospital|Peking Union Medical College Hospital|Beijing Tongren Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ScPHFPC-100306,"May 1, 2008","July 10, 2010","July 15, 2011","June 9, 2020",,"June 9, 2020","The Third Hospital of Mianyang, Mianyang, Sichuan, China",,https://ClinicalTrials.gov/show/NCT04421274
266,88,NCT05132972,Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients,UCMSC,Recruiting,No Results Available,Covid 19,Biological: Normoxic Allogenic UCMSC|Other: Normal saline solution,Duration of hospital stay|Post-administration clinical and radiological improvement|Adverse Event and Serious Adverse Event Evaluation,"Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia|Dr. Moewardi General Hospital, Surakarta, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia|Dr. Hasan Sadikin General Hospital, Bandung, Indonesia|PT Bifarma Adiluhung",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,42,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRIN20211118a,"January 17, 2021",November 2021,November 2021,"November 24, 2021",,"November 24, 2021","Dr. Moewardi General Hospital, Surakarta, Central Java, Indonesia|Dr. Hasan Sadikin, Bandung, West Java, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT05132972
267,113,NCT05095532,Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT,,Recruiting,No Results Available,Chronic Pancreatitis|Mesenchymal Stem Cells,Biological: Bone marrow-derived mesenchymal stem cells|Other: Placebo,Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score,Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 1,42,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",Pro00099487|R01DK126454,"December 1, 2021","June 30, 2026","June 30, 2026","October 27, 2021",,"March 25, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT05095532
268,35,NCT02266394,Hypoxia and Inflammatory Injury in Human Renovascular Hypertension,,Completed,No Results Available,Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease,Drug: Mesenchymal stem cell|Procedure: Mesenchymal stem cell delivery with stent placement,Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation,Mayo Clinic|University of Mississippi Medical Center|University of Alabama at Birmingham,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,42,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-002799,"October 21, 2014","September 25, 2020","September 25, 2020","October 17, 2014",,"January 27, 2021","University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT02266394
269,455,NCT05507697,Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy,,Recruiting,No Results Available,Diabetic Peripheral Neuropathy Type 2,Biological: HUC-MSCs|Biological: Lipoic Acid,Change of TCSS scale|Change of nerve conduction velocities in the lower extremity|Change of serum inflammatory factors|Change of growth factors (GF)|Change of fasting plasma glucose (FPG)|Change of glycosylated hemoglobin (HbA1c),"Wuhan Central Hospital|Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China|Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WuhanCH,"May 19, 2022","May 18, 2024","May 31, 2024","August 19, 2022",,"August 19, 2022","The Central Hospital of Wuhan, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT05507697
270,71,NCT05532943,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,UMSC01,Not yet recruiting,No Results Available,Multiple Sclerosis,Biological: Allogeneic umbilical cord mesenchymal stem cells|Biological: Control group,Primary Endpoint for Phase I portion|Primary Endpoint for Phase IIa portion|Efficacy endpoint for phase I portion|Efficacy endpoints for phase IIa portion|The safety endpoints are listed below for both phase I and IIa portions,"Ever Supreme Bio Technology Co., Ltd.",All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ES-CMSC01-D1101,"December 31, 2022","December 31, 2026","December 31, 2026","September 8, 2022",,"September 8, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,https://ClinicalTrials.gov/show/NCT05532943
271,33,NCT01504464,The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis,,Completed,No Results Available,Osteoarthritis,Biological: mesenchymal stem cell|Biological: Placebo,physical function improvement|change in pain density|joint swelling|joint erythema|deterioration of joint function|Allergic reactions,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Royan-Bone-010,October 2012,September 2015,October 2015,"January 5, 2012",,"May 17, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01504464
272,133,NCT02833792,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,,Recruiting,No Results Available,Alzheimer Dementia,Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo,Safety of aMBMC administration|Efficacy of aMBMC administration,"Stemedica Cell Technologies, Inc.|Stemedica International SA",All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STEM105-M-AD,June 2016,December 2022,June 2023,"July 14, 2016",,"October 29, 2020","John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",,https://ClinicalTrials.gov/show/NCT02833792
273,644,NCT03902067,UC-MSC Transplantation for Left Ventricular Dysfunction After AMI,,Not yet recruiting,No Results Available,Left Ventricular Dysfunction|Acute Myocardial Infarction,Biological: UC-MSC|Biological: Control Group,Safety measured as the number of Major Adverse Cardiac Events (MACE)|Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up,Shanghai Life Science & Technology|Shanghai Jiao Tong University Affiliated Sixth People's Hospital,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,40,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ShanghaiLST-ucmsc-ami01,"December 1, 2022","December 31, 2022","December 31, 2022","April 3, 2019",,"July 11, 2022","Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03902067
274,30,NCT02140528,Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures,,Completed,No Results Available,Tibial Fracture,Biological: Mesenchymal stem cell injection|Biological: Placebo,Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Royan-Bone-012,August 2013,March 2016,April 2016,"May 16, 2014",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02140528
275,477,NCT02331134,Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,,Recruiting,No Results Available,Malignant Melanoma|Head and Neck Cancer,Drug: Filgrastim,Tissue and Hematopoietic Stem Cell Collection|Identify pharmacodynamic markers,"University of Colorado, Denver|Karsh Family Research Fund",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-0842.cc,"May 13, 2015",February 2023,March 2023,"January 6, 2015",,"June 22, 2022","University of Colorado Cancer Center, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02331134
276,86,NCT04519671,Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease,PFCD,Recruiting,No Results Available,Perianal Crohn Disease|Perianal Fistula|Crohn Disease,Drug: Mesenchymal Stem Cells|Other: Placebo,Treatment related adverse events|Complete clinical healing,Amy Lightner|The Cleveland Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20-1020,"November 19, 2020",November 2022,November 2022,"August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04519671
277,2,NCT05191381,Immune Modulation by Exosomes in COVID-19,IMECOV19,Recruiting,No Results Available,COVID-19|Critical Illness|Hypercytokinemia|Lung Fibrosis,Biological: Application of exosomes in a whole blood assay,Cytokine profile in supernatants|Immune phenotyping|Genetic predisposition to hyperinflammation,University of Ulm,All,"18 Years to 90 Years   (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Lung fibrosis in COVID19,"December 22, 2021","July 31, 2022","December 31, 2022","January 13, 2022",,"February 2, 2022","Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT05191381
278,167,NCT01429038,Mesenchymal Stem Cells After Renal or Liver Transplantation,,Completed,No Results Available,Liver Failure|Kidney Failure,Biological: Mesenchymal Stem Cells,"Infusional toxicity|Incidence of infections (bacterial, viral, fungal, parasitic) and cancers|Patient and graft survivals|Effects of MSC on graft function|Biopsy-proven (Banff classification) rejection rates|Feasibility and safety of weaning or decreasing immunosuppression|Recipient's immune function|Anti-MSC donor HLA antibodies.",University of Liege,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TJT1106P1,"February 1, 2012","March 11, 2019","March 11, 2019","September 5, 2011",,"June 14, 2022","University Hospital Liege, Liege, Belgium",,https://ClinicalTrials.gov/show/NCT01429038
279,34,NCT04520373,Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients,,Recruiting,No Results Available,Spinal Cord Injuries|Paralysis,"Other: Best Medical Management: Occupational and Physical Therapy|Biological: Autologous, Adipose Derived Mesenchymal Stem Cells",•Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|change in Neurogenic Bladder Symptom Score (NBSS)|change in Neurogenic Bowel Symptom Score|Incidence of abnormal CSF composition|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Correlation of adverse events to study drug,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-011706,"June 25, 2020",June 2024,June 2024,"August 20, 2020",,"August 31, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04520373
280,683,NCT03264573,"Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars",,Completed,No Results Available,Atrophic Scar,Biological: Stem cell|Device: MSCs,Patient satisfaction (Patient Assessment Scar Scale)|Doctor satisfaction (Vancouver Scar Scale),Heba Mohamed Saad Eldien|M.A. Eloteify|Ahmed Kamal Osman|G.M. Hafsa|Assiut University,All,"10 Years to 35 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MSCs, PRP, Scar",July 2016,February 2017,July 2017,"August 29, 2017",,"August 29, 2017",,,https://ClinicalTrials.gov/show/NCT03264573
281,141,NCT00955669,Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer,,Completed,No Results Available,Autologous Transplantation|Diabetic Foot,Biological: Symptoms and Objective Examination,Magnetic resonance angiography,Third Military Medical University,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ldb2008101,August 2009,August 2010,August 2010,"August 10, 2009",,"December 1, 2010","the southwest Hospital, Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT00955669
282,85,NCT04519697,Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease,RVF,Recruiting,No Results Available,Rectovaginal Fistula|Crohn Disease|Crohn Disease of Vulva|Rectolabial; Fistula,Drug: Mesenchymal Stem Cells|Other: Placebo,Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease,Amy Lightner|The Cleveland Clinic,Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20-936,"October 28, 2020",October 2022,October 2022,"August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04519697
283,124,NCT04126603,Impact of Semaglutide on CD34+ EPC and Fat Derived MSC,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebos,CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio,Sabyasachi Sen|George Washington University,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NCR191206,"August 1, 2019","December 30, 2022","August 30, 2023","October 15, 2019",,"March 22, 2022","The GW Medical Faculty Associates, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT04126603
284,197,NCT04433104,Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease,,Recruiting,No Results Available,COPD,Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: drug therapy according to Vietnamese MOHS procedure,Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council,Vinmec Research Institute of Stem Cell and Gene Technology,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,VinmecISC1916,"June 9, 2020","July 30, 2021","December 25, 2021","June 16, 2020",,"April 21, 2021","Vinmec International Hospital Times City, Hà Nội, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT04433104
285,142,NCT04780685,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,,Recruiting,No Results Available,Covid19,Biological: hMSC,Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0,"Stemedica Cell Technologies, Inc.|bioRASI, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STEM-107-COVID-19,"March 20, 2021","September 30, 2022","December 31, 2022","March 3, 2021",,"July 8, 2022","Providence Medical Foundation, Fullerton, California, United States|Providence Saint John's Health Center - Saint John's Cancer Institute, Santa Monica, California, United States",,https://ClinicalTrials.gov/show/NCT04780685
286,94,NCT04992832,Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）,PRIME-HFrEF,Recruiting,No Results Available,"Heart Failure, Systolic",Biological: human umbilical cord mesenchymal stem cells|Other: human serum albumin,Left ventricular ejection fraction|Mortality|NT-proBNP|Left ventricular end diastolic diameter|6 minutes walking distance|Minnesota Living with Heart Failure Questionnaire（MLHFQ）|PET/CMR,Shanghai East Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DFSC-2018(CR)-08,"July 28, 2021","October 31, 2023","December 31, 2023","August 5, 2021",,"November 18, 2021","Heart Failure Department, East Hospital Affiliated to Tongji University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04992832
287,89,NCT04519684,Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease,IPAAF,Recruiting,No Results Available,Ileal Pouch|Crohn Disease,Drug: Mesenchymal stem cells|Other: Placebo,Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease,Amy Lightner|The Cleveland Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20-818,"October 28, 2020",October 2022,October 2022,"August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04519684
288,73,NCT04615455,Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome,AMASS,"Active, not recruiting",No Results Available,"Keratoconjunctivitis Sicca, in Sjogren's Syndrome",Drug: ASCs|Drug: Cryostor CS10,Ocular Surface Disease Index (OSDI)|Non-invasive keratography tear break-up time (NIKBUT)|Tear meniscus height (TMH)|Schirmer's I test|Tear osmolarity|Oxford scale|HLA anti-bodies,"Rigshospitalet, Denmark",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2020-002804-38,"November 3, 2020","December 1, 2022","January 1, 2023","November 4, 2020",,"February 15, 2022","Rigshospitalet, Copenhagen, DK, Denmark",,https://ClinicalTrials.gov/show/NCT04615455
289,1,NCT04573270,Mesenchymal Stem Cells for the Treatment of COVID-19,,Completed,No Results Available,Covid19|Prophylaxis,Biological: PrimePro|Other: Placebo,Survival Rates|Contraction Rates,Thomas Advanced Medical LLC|HeartStem Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Pro00043080,"April 24, 2020","August 20, 2020","September 1, 2020","October 5, 2020",,"October 5, 2020","Southern California Hospital at Culver City / Southern California Hospital at Hollywood, Culver City, California, United States",,https://ClinicalTrials.gov/show/NCT04573270
290,129,NCT05262829,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate and Severe Crohn's Disease,,Not yet recruiting,No Results Available,Crohn Disease,Biological: Human Umbilical Cord Mesenchymal Stem Cells,Crohn's disease activity index score|simplified endoscopic score for Crohn's disease|Inflammatory Bowel Disease Questionnaire|Albumin|Hemoglobin|Fecal calprotectin|body mass index (BMI),Shanghai East Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DFSC-2021(CR)-07,"February 28, 2022","August 31, 2024","January 31, 2025","March 2, 2022",,"March 2, 2022","Shanghai East Hospital, Shanghai, Pudong New Area, China",,https://ClinicalTrials.gov/show/NCT05262829
291,127,NCT05122234,Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19,,Completed,No Results Available,COVID-19,Biological: Injection of secretome - mesenchymal stem cell|Other: Placebo|Drug: Standard treatment of Covid-19,Assessment of inflamation marker levels|Assessment of clinical outcome|Assessment of laboratory routine|Assessment of photo thorax|Assessment of RT-PCR conversion|Mortality rate,Indonesia University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,54/FI/P-KCOVID-19.2B3/IX/2020,"August 10, 2020","July 30, 2021","November 14, 2021","November 16, 2021",,"November 16, 2021","RSUPN Dr. Cipto Mangunkusumo, Jakarta Pusat, DKI Jakarta, Indonesia|RSUP Fatmawati, Jakarta, DKI Jakarta, Indonesia|RSUP Persahabatan, Jakarta, DKI Jakarta, Indonesia|Rumah Sakit Universitas Indonesia, Depok, Jawa Barat, Indonesia",,https://ClinicalTrials.gov/show/NCT05122234
292,64,NCT04869761,Stem Cell Therapy for Chronic Kidney Disease,,Recruiting,No Results Available,"Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies",Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions,Adverse events and/or serious adverse events,LaTonya J. Hickson|Mayo Clinic,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,20-008380,"October 7, 2021",December 2026,May 2027,"May 3, 2021",,"November 4, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04869761
293,15,NCT01591200,Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis,,Completed,No Results Available,Alcoholic Liver Cirrhosis,Biological: Allogeneic Mesenchymal Stem Cells,"Safety|Liver function tests.|CT scan of abdomen.|Change in MELD score|Improvement in quality of life as assessed by SF 36 questionnaire|Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA|Change in Child-Pugh score",Stempeutics Research Pvt Ltd,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRPL/LC/09-10/001,June 2012,April 2016,April 2016,"May 3, 2012",,"September 15, 2016","Centre for Liver Research & Diagnostics, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Manipal Hospital, Bangalore, Karnataka, India|KMC Hospital, Mangalore, Karnataka, India|Institute of liver disease, HPB surgery and transplant Global Hospitals, Mumbai, Maharashtra, India|Bombay Hospital & Medical Research Center, Mumbai, Maharashtra, India|Ruby Hall clinic, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|SMS Medical college and Hospital, Jaipur, Rajasthan, India|SGPGI Lucknow, Lucknow, Uttar Pradesh, India",,https://ClinicalTrials.gov/show/NCT01591200
294,183,NCT02587572,Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial,SIRONA,Not yet recruiting,No Results Available,Metabolic Disease|Endothelial Dysfunction,Biological: Peripheral Intravenous (IV) infusion of LMSCs,Endothelial function: Changes in endothelial function as assessed by the following:|Difference in rate of change in the metabolic syndrome as defined by the following:,Longeveron Inc.,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00-0000-02,December 2022,December 2023,December 2023,"October 27, 2015",,"March 7, 2022",,,https://ClinicalTrials.gov/show/NCT02587572
295,5,NCT04739930,Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation,,Recruiting,No Results Available,Cartilage Injury,Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Procedure: Control group incision,Synovial Fluid Cytokine Measurement,Rush University Medical Center|Joint Restoration Foundation (JRF),All,18 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17121805,"March 2, 2018","December 31, 2023","March 31, 2024","February 5, 2021",,"February 9, 2022","Rush University Medical Center, Chicago, Illinois, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/Prot_001.pdf|""Informed Consent Form: HIPAA Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_000.pdf|""Informed Consent Form: Main Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04739930
296,84,NCT04390152,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome,"Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.",BioXcellerator|Clinical Somer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIOXSOMCOV001,"January 13, 2020",December 2021,April 2022,"May 15, 2020",,"January 15, 2021","BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT04390152
297,103,NCT04011059,Randomized Study of Coronary Revascularization Surgery With Injection of WJ-MSCs and Placement of an Epicardial Extracellular Matrix,scorem-cells,Not yet recruiting,No Results Available,Cardiovascular Diseases|Heart Failure|Coronary Artery Disease|Mesenchymal Stem Cell Transplantation|Regenerative Medicine,Biological: Wharton's jelly-derived mesenchymal cells,Left ventricular ejection fraction (LVEF)|Final diastolic and systolic volumes|Left ventricule viability|Ventricular arrhythmias|Estimated functional status|Change in the median score of Quality of life|Delayed enhancement of the left ventricle|Improvement in the 6-minute walk test|Mortality at 3 and 12 months due to cardiovascular causes|Mortality at 3 and 12 months due to all causes,Hospital San Vicente Fundación|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)|IPS Universitaria Servicios de Salud Universidad de Antioquia|Hospital San Vicente Fundación - Rionegro,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",001,"July 2, 2019","January 30, 2022","June 30, 2023","July 8, 2019",,"July 9, 2019","Hospital San Vicente Fundación, Medellín, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT04011059
298,264,NCT04377334,Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS),,Not yet recruiting,No Results Available,ARDS|COVID-19,Biological: MSC,lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9),University Hospital Tuebingen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RESCOVID,May 2022,November 2022,February 2023,"May 6, 2020",,"January 27, 2022","University Hospital Tuebingen, Tuebingen, Germany",,https://ClinicalTrials.gov/show/NCT04377334
299,52,NCT03917797,Mesenchymal Stromal Cells (MSC´s) in Renal Lupus,MSC-ROLE,Recruiting,No Results Available,"Lupus Erythematosus, Systemic|Lupus Glomerulonephritis",Biological: MSC treatment|Drug: Standard of Care|Drug: Placebo,Achievement of Global Renal Response (GR) at Study Endpoint|Achievement of Complete Renal Response (CR) at Study Endpoint|Achievement of Partial Renal Response (PR) at Study Endpoint|Treatment Failure|Response of SLE Responder Index (SRI).|Selena Sledai|BILAG score|Disease Flares|Biomarker Response,"Universidad de los Andes, Chile",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,39,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Phase II Lupus MSC,"April 2, 2019",December 2022,December 2022,"April 17, 2019",,"November 16, 2020","Clínica Universidad de los Andes, Santiago de Chile, Región Metropolitana, Chile|Hospital Barros Luco Trudeau, Santiago de Chile, Región Metropolitana, Chile",,https://ClinicalTrials.gov/show/NCT03917797
300,565,NCT04452097,Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS,,Not yet recruiting,No Results Available,COVID-19|ARDS|Acute Respiratory Distress Syndrome,Biological: Human umbilical cord mesenchymal stem cells + best supportive care|Other: Placebo control + best supportive care,Incidence of infusion-related adverse events|Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)|Selection of an appropriate dose of BX-U001 for the following Phase 2 study|All-cause mortality|Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.|Duration of ICU stay|Duration of hospital stay|Changes in blood cytokine levels,Baylx Inc.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,39,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BXU001-COVID19,"July 1, 2023","March 31, 2024","May 31, 2024","June 30, 2020",,"August 10, 2022",,,https://ClinicalTrials.gov/show/NCT04452097
301,28,NCT01297413,A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke,,Completed,No Results Available,Ischemic Stroke,Biological: Allogeneic adult mesenchymal bone marrow stem cells,The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.,"Stemedica Cell Technologies, Inc.|University of California, San Diego|Mercy Gilbert Medical Center at AZ|Chandler Regional Medical Center at Chandler AZ|UCI Medical Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STEM 101-M,February 2011,September 2017,"November 15, 2018","February 16, 2011",,"December 3, 2018","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|University of California Irvine Department of Neurology, Orange, California, United States|University of California San Diego Division of Neurological Surgery, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01297413
302,5,NCT01392625,PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study),PoseidonDCM,Completed,Has Results,Non-ischemic Dilated Cardiomyopathy,Biological: Autologous hMSCs|Biological: Allogeneic hMSCs,Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,37,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20100968|1R01HL110737-01,"May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT01392625
303,499,NCT01343511,Safety and Efficacy of Stem Cell Therapy in Patients With Autism,,Completed,No Results Available,Autism,Biological: human cord blood mononuclear cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells,Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event,"Shenzhen Beike Bio-Technology Co., Ltd.|Shandong Jiaotong Hospital|Association for the Handicapped Of Jinan",All,3 Years to 12 Years   (Child),Phase 1|Phase 2,37,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BKCR-AUTISM-1.0(2009),March 2009,June 2010,May 2011,"April 28, 2011",,"October 14, 2011","Shandong Jiaotong Hospital, Jinan, Shandong, China",,https://ClinicalTrials.gov/show/NCT01343511
304,293,NCT03102879,Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.,RanoKure,Completed,Has Results,Periapical Periodontitis,Procedure: Regenerative Endodontic Procedure|Procedure: Conventional Root Canal Treatment,Number of Participats Showing Efficacy (Functionality)|Change in Pulpal Response|Change in Apical Lesion Size|Pain to Percussion|Numbers of Participants With Adverse Event|Pulp Regeneration,"Universidad de los Andes, Chile|Cells for Cells, Chile",All,"16 Years to 58 Years   (Child, Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RPD-8-16,"September 23, 2016","September 30, 2018","September 30, 2018","April 6, 2017","January 21, 2020","January 21, 2020","Universidad de los Andes, Santiago, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03102879/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03102879
305,93,NCT03673748,Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells,MSV_LE,Not yet recruiting,No Results Available,Lupus Nephritis|Lupus Erythematosus,Drug: Mesenchymal stromal cells (MSC)|Drug: Placebo,Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity,Red de Terapia Celular|Hospital del Río Hortega|Hospital Clínico Universitario de Valladolid|University of Valladolid,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,36,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TerCel_006|2017-000391-28,December 2022,December 2023,June 2024,"September 17, 2018",,"June 7, 2022","University Hospital Río Hortega, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT03673748
306,279,NCT03896568,MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma,,Recruiting,No Results Available,IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma,Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery,Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies,"M.D. Anderson Cancer Center|DNAtrix, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,36,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0953|NCI-2019-01195,"February 12, 2019","September 30, 2023","September 30, 2023","April 1, 2019",,"August 15, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03896568
307,557,NCT05155657,Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells,,Recruiting,No Results Available,Alcoholic Cirrhosis,Biological: Conventional therapy plus low dose UCMSCs treatment|Biological: Conventional therapy plus medium dose UCMSCs treatment|Biological: Conventional therapy plus high dose UCMSCs treatment,Severity and incidence of adverse events (SIAE) on the 3rd day after the first administration|1 week SIAE after the first administration|3 weeks SIAE after the first administration|3 week SIAE after the the second administration|1 month SIAE after the last administration|3 months SIAE after the last administration|6 months SIAE after the last administration|12 months SIAE after the last administration|24 months SIAE after the last administration|Child-Pugh score (effectiveness evaluation index)|Survival rate (effectiveness evaluation index)|Liver function (effectiveness evaluation index)|The Model for End-Stage Liver Disease (MELD) score (effectiveness evaluation index)|KPS score (effectiveness evaluation index)|Detection of Blood Coagulation Index of PT (effectiveness evaluation index)|Detection of Blood Coagulation Index of APTT (effectiveness evaluation index)|Detection of Blood Coagulation Index of TT (effectiveness evaluation index)|Detection of Blood Coagulation Index of FIB (effectiveness evaluation index),Yantai Yuhuangding Hospital,All,18 Years to 60 Years   (Adult),Phase 1,36,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2021-001,"June 13, 2022","December 25, 2022","December 25, 2024","December 13, 2021",,"June 28, 2022","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,https://ClinicalTrials.gov/show/NCT05155657
308,717,NCT04189419,Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis,,Completed,No Results Available,"Pancreatitis, Acute",Biological: SCM-AGH|Other: Placebo,"The change from baseline in modified Marshall score on Day 7 for organ failure subject|The change from baseline in CTSI Score on Day 28|Percentage of subjects whose organ failure was resolved at 3 days, 7 days, 14 days and 28 days|The change from baseline in modified Marshall score at each assessment point up to Day 28|The change from baseline in sequential organ failure assessment (SOFA) at each assessment point up to Day 28|Duration of Systemic inflammatory response syndrome (SIRS)|Time to resolution of organ failure|The change from baseline value of C-Reactive Protein(CRP) which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of Tumor Necrosis Factor(TNF)-α which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-6 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-8 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of lymphocyte count ratio which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|Duration of intensive care unit (ICU) stay|The change from baseline in Computed Tomography Severity Index(CTSI) on Day 28|Incidence of pancreatic complication|Requirement of drainage or surgery|Rate of infection|Mortality on Day 28 and 90","SCM Lifescience Co., LTD.",All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APT2001,"August 12, 2019","January 14, 2022","March 15, 2022","December 6, 2019",,"June 1, 2022","Soonchunhyang University Hosptial Bucheon, Bucheon, Gyenggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04189419
309,126,NCT04612465,Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula,,Recruiting,No Results Available,Crohn's Fistula,Biological: ASC|Drug: Fibringlue,Proportion of subjects who are completely blocked fistula|Proportion of subjects who are more than 50% blocked fistula|Score of evaluation about Investigator satisfaction using questionnaire|Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test|Visual improvement effect of perianal fistula wound through photography of it,"Anterogen Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANTG-ASC-301,"January 9, 2020","December 31, 2021","December 31, 2021","November 3, 2020",,"January 22, 2021","Seoul Natinoal Univetsity Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04612465
310,145,NCT05284604,Mesenchymal Stem Cells for Age-Related Frailty,MESCAFY,Not yet recruiting,No Results Available,Frailty,Drug: Mesenchymal Stem Cells (MSCs),Adherence|Recruitment|Modified Physical Performance Test|6-Minute Walk Test,VA Office of Research and Development|Michael E. DeBakey VA Medical Center|Baylor College of Medicine,All,65 Years to 85 Years   (Older Adult),Phase 1|Phase 2,36,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E4096-P,"October 15, 2022","June 30, 2025","December 31, 2025","March 17, 2022",,"September 10, 2022","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT05284604
311,181,NCT04236479,Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP),,Recruiting,No Results Available,Congenital Heart Disease (CHD),Biological: BM-MSC,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery.",Catherine Bollard|Children's National Research Institute,All,up to 6 Months   (Child),Phase 1,36,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00011914,"July 29, 2020",September 2024,April 2025,"January 22, 2020",,"May 13, 2022","Children's National Health System, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT04236479
312,539,NCT04219241,Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.,ADORE-EXT,"Active, not recruiting",No Results Available,Huntington Disease,Biological: Cellavita-HD,Maintenance of effectiveness on clinical progression of the disease|Clinical neurological worsening over the treatment by UHDRS|BMI assessment|Risk of suicidal ideation and/or behavior by C-SSRS|Risk of suicidal ideation and/or behavior by HDS|CNS assessment by MRI (Magnetic Ressonance Imaging),Azidus Brasil|Cellavita Pesquisa Científica Ltda,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,35,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADORE-EXT|23917319.0.0000.5412,"February 10, 2020",January 2022,April 2022,"January 7, 2020",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04219241
313,410,NCT01879046,Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells,ARTHROSTEM,Completed,No Results Available,Knee Osteoarthritis,Procedure: arthroplasty,Increased expression of chondrogenic markers|Increasing secretion of anti-inflammatory molecules in vitro,Nantes University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC12_0394,October 2015,December 2016,December 2016,"June 17, 2013",,"February 17, 2017","Nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT01879046
314,432,NCT02557724,Mobilization of Mesenchymal Stem Cells During Liver Transplantation,,Completed,No Results Available,Liver Failure|Liver Neoplasm,Procedure: blood samples,post operative liver injury|Total Bilirubin level|(INR) International Normalized Ratio|(ALT) Alanine Aminotransferase|(AST) Aspartate Aminotransferase,"Rutgers, The State University of New Jersey",All,"18 Years to 80 Years   (Adult, Older Adult)",,35,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20140000266,September 2015,July 2017,July 2017,"September 23, 2015",,"October 16, 2018","University Hospital, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02557724
315,440,NCT03014037,Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration,,Completed,No Results Available,Osteoarthritis,Procedure: Unilateral Bone Marrow Procurement|Procedure: Bilateral Bone Marrow Procurement,Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages,Emory University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB00093044,"September 7, 2017","June 13, 2020","June 13, 2020","January 9, 2017",,"December 14, 2021","The Emory Clinic, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03014037
316,761,NCT02037204,IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.,IMPACT,Completed,Has Results,Foreign-Body Reaction|Inflammation|Effusion (L) Knee|Knee Pain Swelling,Other: Cartilage repair surgery,"Safety: Adverse Events|Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score",UMC Utrecht,All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMPACT,March 2013,April 2016,April 2016,"January 15, 2014","January 2, 2019","January 2, 2019","University Medical Center Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT02037204
317,607,NCT03252535,Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease,ADORE-DH,Completed,No Results Available,Huntington Disease,Biological: Cellavita HD lower dose|Biological: Cellavita HD higher dose|Other: Placebo,Effective Dose|Clinical neurological worsening over the treatment|BMI assessment|Risk of suicidal ideation|CNS assessment|Clinical Interview Based impression of Severity (CIBIS),Azidus Brasil|Cellavita Pesquisa Científica Ltda,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,35,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADORE-DH|52375916.1.0000.5412,"January 15, 2018","March 23, 2021","April 30, 2021","August 17, 2017",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03252535
318,336,NCT00836732,Mesenchymal Stem Cells: Alterations in Genome,MESSAGE,Completed,No Results Available,Pened Chest Surgery for Programmes Coronary Bypass,Procedure: harvest of a small bone marrow sample,Presence of small genetic alteration in mesenchymal stem cells,Nantes University Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),BRD 08/9-S,November 2008,March 2012,March 2012,"February 4, 2009",,"September 30, 2013","nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT00836732
319,3,NCT02600130,Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease,Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo,To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.,Longeveron Inc.,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00-0000-01,"October 10, 2016",September 2020,September 2021,"November 9, 2015",,"December 14, 2021","Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02600130
320,115,NCT01745744,Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.,,Completed,No Results Available,Critical Limb Ischemia,Other: Mesenchymal stem cells from adipose tissue,Number of adverse events and serious adverse events|Evolution of chronic critical ischemia,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CeTMAd/ICC/2009|2009-013554-32,February 2011,July 2018,July 2018,"December 10, 2012",,"July 9, 2018","Hospital San Lazaro, Sevilla, Spain|University Hospital Virgen Macarena, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT01745744
321,94,NCT01257776,Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients,,Completed,No Results Available,Critical Limb Ischemia (CLI)|Diabetes,Drug: Autologous adipose derived mesenchymal stem cells,"Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)|Major adverse event (death, target limb amputation)|Ankle Brachial Index|University of Texas Classification at target limb",Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CeTMAd/ICPD/2008,December 2010,February 2013,July 2015,"December 10, 2010",,"August 5, 2015","University Hospital Virgen Macarena, Seville, Spain|CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine), Seville, Spain",,https://ClinicalTrials.gov/show/NCT01257776
322,452,NCT02958267,Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee,,Completed,Has Results,Knee Osteoarthritis,Biological: BMAC injection|Biological: PRP injection|Device: Gel-One® hyaluronate injection,Knee Injury and Osteoarthritis Outcome Score|Numeric Pain Rating Scale|Patient Reported Outcome Measurement Information System Global Health Scores,OhioHealth,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 2,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OH1-16-00672,December 2016,August 2018,August 2018,"November 8, 2016","September 24, 2019","September 24, 2019","McConnell Spine, Sport, and Joint Physicians, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02958267/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02958267
323,742,NCT04980261,Freeze-dried Bovine Hydroxyapatite/Secretome Composite for Bone Defects,,Recruiting,No Results Available,Bone Loss,Procedure: ORIF + autograft|Procedure: ORIF + FD BHA/Secretome,X-ray evaluation immediately following surgery.|X-ray evaluation at 4 weeks following surgery|X-ray evaluation at 8 weeks following surgery.|X-ray evaluation at 12 weeks following surgery.|X-ray evaluation at 16 weeks following surgery.|Ultrasonography evaluation at 2 weeks|Ultrasonography evaluation at 4 weeks|Ultrasonography evaluation at 8 weeks|Ultrasonography evaluation at 12 weeks|Ultrasonography evaluation at 16 weeks|Functional evaluation at 8 weeks following surgery.|Functional evaluation at 12 weeks following surgery.|Functional evaluation at 16 weeks following surgery.,"Dr. Soetomo General Hospital|Dr. Ramelan Naval Hospital|Airlangga University Hospital|Sidoarjo General Hospital|Cell & Tissue Bank, Dr. Soetomo General Hospital",All,18 Years to 50 Years   (Adult),Not Applicable,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0045/KEPK/VIII/2020,"July 1, 2020","July 1, 2022","December 31, 2022","July 28, 2021",,"July 28, 2021","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",,https://ClinicalTrials.gov/show/NCT04980261
324,2,NCT02652130,Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD,,Completed,Has Results,Grade B Acute Graft Versus Host Disease|Grade C Acute Graft Versus Host Disease|Grade D Acute Graft Versus Host Disease,Biological: Remestemcel-L,Overall Survival Rate Through Day 180|Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001,"Mesoblast, Inc.|Quintiles, Inc.|Mesoblast, Ltd.",All,2 Months to 17 Years   (Child),Phase 3,32,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MSB-GVHD002,"October 28, 2015","June 15, 2018","June 15, 2018","January 11, 2016","March 16, 2022","March 16, 2022","Children's Hospital Los Angeles, Los Angeles, California, United States|CHOC Children's Hospital of Orange County, Orange, California, United States|UCSF Benioff Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States|Alfred I. duPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|Miami Children's Research Institute, Miami, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Children's Hospital at Montefiore, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02652130/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02652130
325,24,NCT04382547,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,,Completed,No Results Available,"COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2",Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,Number of cured patients|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC2(Covid),"May 11, 2020","June 30, 2021","June 30, 2021","May 11, 2020",,"August 23, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04382547
326,191,NCT02328612,"Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers",CELLULA,Completed,No Results Available,Sepsis,Other: Intravenous infusion of cells,Inflammatory response as measured by laboratory measurements and functional assays of innate immunology,Tigenix S.A.U.|Cellerix,Male,18 Years to 35 Years   (Adult),Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Cx611-0102,October 2014,March 2015,March 2015,"December 31, 2014",,"April 3, 2015","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02328612
327,226,NCT00136903,Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD),,Completed,No Results Available,Graft Vs Host Disease,Drug: Prochymal® - 2 Million cells/kg|Drug: Prochymal®- 8 Million cells/kg|Drug: Methylprednisolone|Drug: Prednisone|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Mycophenolate Mofetil,"Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)|Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90","Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,260-261,"April 27, 2005","July 28, 2006","July 14, 2008","August 29, 2005",,"January 31, 2022","St. Francis Hospital, Indianapolis, Indiana, United States|Kansas City Cancer Centers - BMT, Kansas City, Missouri, United States|The Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, FEC, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00136903
328,274,NCT01033552,"Biochemical Correction of Severe EB by Allo HSCT and ""Off-the-shelf"" MSCs",,"Active, not recruiting",No Results Available,Epidermolysis Bullosa,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Anti-thymocyte globulin|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Procedure: Mesenchymal stem cell transplantation|Radiation: Total body irradiation|Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation,Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Measure patients Quality of Life using a questionnaire|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Number of participants experiencing Acute GVHD,"Masonic Cancer Center, University of Minnesota",All,"up to 25 Years   (Child, Adult)",Phase 1|Phase 2,32,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT2009-09|0911M74035,January 2010,"November 12, 2022","December 12, 2022","December 16, 2009",,"September 29, 2022","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01033552
329,178,NCT04224207,Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells,WJ-MSC,Completed,No Results Available,Retinitis Pigmentosa|Inherited Retinal Dystrophy,Biological: Wharton's jelly derived mesenchymal stem cell,ETDRS visual acuity|Outer retinal thickness,Ankara Universitesi Teknokent,All,18 Years to 60 Years   (Adult),Phase 3,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01.11.2018/01,"April 1, 2019","October 30, 2019","January 1, 2020","January 13, 2020",,"January 13, 2020","Ankara University Biotechnology Institute, Ankara, Türkiye, Turkey|Umut Arslan, Ankara, Türkiye, Turkey",,https://ClinicalTrials.gov/show/NCT04224207
330,2,NCT01087996,The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study),,Completed,Has Results,Stem Cell Transplantation,Biological: Auto-hMSCs|Biological: Allo-hMSCs,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,31,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849,March 2010,April 2011,October 2012,"March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01087996
331,43,NCT02239393,Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study,MESCAMS,Completed,No Results Available,Multiple Sclerosis,Biological: Mesenchymal Stem Cells,Safety|Efficacy,Ottawa Hospital Research Institute,All,18 Years to 50 Years   (Adult),Phase 2,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20140368,June 2015,December 2019,December 2019,"September 12, 2014",,"March 4, 2020","Health Sciences Centre, Winnipeg, Manitoba, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02239393
332,111,NCT00875654,Intravenous Stem Cells After Ischemic Stroke,ISIS,Completed,No Results Available,Ischemia|Stroke,Genetic: Autologous mesenchymal stem cells,feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study,"University Hospital, Grenoble|Commissariat A L'energie Atomique|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 06 25,August 2010,"October 20, 2017","October 20, 2017","April 3, 2009",,"November 1, 2017","Neuroradiology/MRI, University Hospital of Grenoble, Grenoble, France|Stroke Unit, University Hospital of Grenoble, Grenoble, France|Tissular and cell therapy unit, UniversityHospitalof Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00875654
333,266,NCT03257098,Allogeneic ABCB5-positive Stem Cells for Treatment of CVU,,Completed,No Results Available,Skin Ulcer Venous Stasis Chronic,Biological: allo-APZ2-CVU,Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Epithelialization|Assessment of further wound healing parameters: formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs at Week 6.1 and Week 12,RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services,All,"35 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,31,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,allo-APZ2-CVU-II-01,"November 16, 2017","June 25, 2020","June 25, 2020","August 22, 2017",,"September 10, 2020","Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus, Bochum, Germany|Universitätsklinikum Erlangen, Hautklinik, Erlangen, Germany|Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald, Greifswald, Germany|Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie, Hamburg, Germany|pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung, Kiel, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT03257098
334,767,NCT00260338,Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia,,Completed,No Results Available,Myocardial Ischemia|Coronary Heart Disease,Biological: stem cell,Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status,"Rigshospitalet, Denmark",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,31,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jens Kastrup,December 2005,July 2009,July 2009,"December 1, 2005",,"May 31, 2013","Cardiovascular Lab. 2014, The Heart Centre, Rigshospitalet, Blegdamcvej 9, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00260338
335,182,NCT03939741,SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.,StemCell&CKD,Recruiting,No Results Available,Chronic Kidney Diseases,Biological: SVF Containg Autologous Non Expanded ADSC,"Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I|Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II|Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II|Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II|Change from baseline to all post-treatment visits in body weight|Change from baseline to all post-treatment visits in Blood-pressure|Change from baseline to all post-treatment visits in S.creatinine|Change from baseline to all post-treatment visits in blood urea.|Change from baseline to all post-treatment visits in Hemoglobin level|Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)|Change from baseline to all post-treatment visits in hemoglobin A1c|Change from baseline to all post-treatment visits in random blood sugar (RBS)|Change from baseline to all post-treatment visits in Anti-Hypertensive medication if there is any.|Change from baseline to all post-treatment visits in Hypoglycemic agent if there is any.|Change from baseline to post-treatment visits in urine total protein-creatinine ratio (UPCR)|Change from baseline to all post-treatment visits in urinary Protein-to-creatinine ratio PCR)|Change from baseline to post-treatment level of serum Alpha Feto Protein|Change from baseline to post-treatment level of serum CEA level|Change from baseline to post-treatment level of serum CA 19.9 level|Change from baseline to post-treatment level LDH level|Change from baseline to post-treatment level of Beta 2 Microglobulin level|Change from baseline to post-treatment level of serum CA 125 level (in case of female patients)|Change from baseline to post-treatment level of PSA level (in case of male patients)",Bangladesh Laser & Cell Surgery Institute & Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,31,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BangladeshLCS001,"April 1, 2019","March 31, 2024","March 31, 2025","May 7, 2019",,"July 15, 2020","Bangladesh Laser And Cell Surgery Institute And Hospital, Dhaka, Bangladesh","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03939741/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03939741
336,503,NCT04863183,Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis,,Not yet recruiting,No Results Available,Mesenchymal Stem Cells|Knee Osteoarthritis|Cell Therapy,Biological: CELLISTEM-OA|Drug: Triamcinolone acetonide,Decrease in joint pain|Increased joint functionality|Improvement in the quality of life|Imaging improvement of articular cartilage,Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle|Cells for Cells,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",OA-01,"June 1, 2021","December 31, 2021","June 30, 2022","April 28, 2021",,"April 28, 2021",,,https://ClinicalTrials.gov/show/NCT04863183
337,16,NCT02131077,Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis,,Completed,No Results Available,Tennis Elbow,Biological: ALLO-ASC-TI|Drug: Placebo,Efficacy|VAS pain score|Improvement rate of VAS pain score|Modified Mayo Clinic Performance Index|Ultrasonic photography|Safety,"Anterogen Co., Ltd.",All,"19 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALLO-ASC-TI-201,January 2014,October 2014,August 2015,"May 6, 2014",,"November 23, 2016","Asan Medical Center, Seoul, Korea, Republic of|Chung-Ang University Hosptal, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Nanoori hospital, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02131077
338,602,NCT05280002,Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis,,Completed,No Results Available,Osteoarthritis Knees,Biological: Adipose Tissue derived Total-Stromal-Cells (TOST),Changes in pain intensity|Changes in Physical functioning of knee joints.|Changes in femoral cartilage thickness,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Dhaka Medical College",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BSMMU/2018/25,"January 1, 2018","October 31, 2021","December 31, 2021","March 15, 2022",,"March 15, 2022","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT05280002
339,340,NCT02513238,Mesenchymal Stemcells for Radiation Induced Xerostomia,MESRIX,Completed,No Results Available,Xerostomia,Drug: Mesenchymal stem cell|Drug: Isotonic NaCl,Number of Participants with Adverse Events as a Measure of Safety|Change in whole saliva production|Subjective complaints of xerostomia|Change in volume and vascularisation - MRI of glands - composite|MRI - Change in fibrosis|histological sections - gland tissue - composite|histological sections - fibrosus|histological sections - vascularisation,"Rigshospitalet, Denmark",All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1406653,"August 8, 2015","April 6, 2017","April 6, 2017","July 31, 2015",,"August 21, 2017",,,https://ClinicalTrials.gov/show/NCT02513238
340,726,NCT03325322,Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease,,Recruiting,No Results Available,Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies,Dietary Supplement: Fisetin|Drug: Placebo oral capsule,Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16-010521,"January 2, 2018",January 2023,April 2025,"October 30, 2017",,"September 14, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03325322
341,356,NCT04951882,Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research,,Recruiting,No Results Available,Acute Lung Injury,Biological: human derived umbilical cord derived mesenchymal stem cells,PaO2/FiO2|the days of ventialtion and hospital stay,"Second Affiliated Hospital, School of Medicine, Zhejiang University",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-592,"June 9, 2021","December 31, 2022","December 31, 2022","July 7, 2021",,"July 7, 2021","SAHZU, Hanzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04951882
342,116,NCT04898088,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,REPAIR,Completed,No Results Available,COVID-19 Pneumonia,Biological: Mesenchymal Stem Cells Transplantation,"Expression of PARP1 gene as indicator of base excision repair|Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair|Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair|Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair",SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Liv Hospital (Ulus),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8860/9193,"January 1, 2020","August 30, 2020","September 30, 2020","May 24, 2021",,"May 24, 2021","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04898088
343,585,NCT05508191,Microneedle Versus Fractional CO₂ Laser for Skin Aging Treatment With Stem Cell Secretome in Indonesian Adult Women,,Not yet recruiting,No Results Available,Skin Aging|Transepidermal Water Loss,Device: Fractional CO₂ Laser|Device: Microneedle,Skin aging changes evaluated by dermoscopy photoaging scale (DPAS)|Skin aging changes evaluated by Janus-3Ⓡ skin analyzer|Skin capacitance evaluated by the CorneometerⓇ|Transepidermal water loss evaluated by the TewameterⓇ|Likert scale for the satisfaction degree|Visual analog scale (VAS) of pain for the convenience degree|Number of adverse events experienced during the clinical trial,"Shannaz Nadia Yusharyahya|PT. Kimia Farma (Persero) Tbk|Ministry of Education, Culture, Research, and Technology, Republic of Indonesia|Indonesia University",Female,35 Years to 59 Years   (Adult),Not Applicable,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,22-08-0682,"August 17, 2022","October 14, 2022","December 31, 2022","August 19, 2022",,"August 29, 2022","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT05508191
344,604,NCT04392778,Clinical Use of Stem Cells for the Treatment of Covid-19,,Completed,No Results Available,Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection,Biological: MSC Treatment|Biological: Saline Control,Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test,SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus),All,40 Years to 60 Years   (Adult),Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Bak. Sadi Konuk-Istinye Uni.,"April 1, 2020","November 1, 2020","November 30, 2020","May 19, 2020",,"May 25, 2021","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04392778
345,387,NCT05283317,Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock,,Completed,No Results Available,Sepsis|Septic Shock,Biological: Mesenchymal stem cells,Mortality|Length of stay in the hospital,TC Erciyes University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Mesenchymal Stromal Cells,"March 11, 2018","August 25, 2019","November 13, 2019","March 16, 2022",,"March 16, 2022","Erciyes University, Kayseri, Turkey",,https://ClinicalTrials.gov/show/NCT05283317
346,231,NCT03296501,Intraspinal Transplantation of Autologous ADRC in ALS Patients,ADIPOSTEM,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients,Functional progression rate|Electrophisiological progression rate,Mossakowski Medical Research Centre Polish Academy of Sciences|Medical University of Warsaw,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DPO/014/33/09/2015,"October 13, 2015","October 31, 2020","October 31, 2022","September 28, 2017",,"April 15, 2020","Medical University of Warsaw, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT03296501
347,687,NCT04956744,"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis",,Recruiting,No Results Available,Multiple Sclerosis,Biological: IMS001,Safety and tolerability,"ImStem Biotechnology|Rho, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMS001-01,"August 31, 2021",December 2027,December 2027,"July 9, 2021",,"September 21, 2021","Shepherd Center, Atlanta, Georgia, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT04956744
348,680,NCT04524962,Study of Descartes-30 in Acute Respiratory Distress Syndrome,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|Covid19,Biological: Descartes 30,To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.,Cartesian Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DC30-1A,"February 23, 2021","September 25, 2022","September 25, 2022","August 24, 2020",,"May 20, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California-Irvine, Irvine, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland Medical Center Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04524962
349,630,NCT02848131,Senescence in Chronic Kidney Disease,,Enrolling by invitation,No Results Available,Chronic Kidney Disease,Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin,Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-005843,July 2016,April 2023,April 2023,"July 28, 2016",,"May 17, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02848131
350,60,NCT01038596,Mesenchymal Stromal Cells and Osteoarthritis,,Completed,No Results Available,Osteoarthritis,,"Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors|Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation",Technische Universität Dresden|German Federal Ministry of Education and Research,All,"50 Years to 90 Years   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,HipMSC-Osteoarthritis,January 2009,June 2016,December 2016,"December 24, 2009",,"April 14, 2017","University Hospital Dresden, Orthopaedic Department, Dresden, Germany",,https://ClinicalTrials.gov/show/NCT01038596
351,149,NCT04314011,Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty,,Completed,No Results Available,Aging Frailty,Biological: Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Biological: Placebo,Safety of HUC-MSCs infusion|Difference in rate of decline of Frailty|Difference in subject quality of life assessments|Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts|Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts,Shanghai East Hospital,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EC.D (BG).020.02.0,"June 1, 2020","December 30, 2021","March 1, 2022","March 18, 2020",,"March 17, 2022","Shanghai East Hospital, Shanghai Tongji University, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04314011
352,239,NCT04625738,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,MSC-COVID19,Completed,No Results Available,COVID19 ARDS,Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Biological: Placebo,"PaO2 / FiO2 ratio|respiratory function evolution|respiratory assistance|organ failures 1|organ failures 2|organ failures 3|duration of intensive care|Cause of death|respiratory morbidity (TDM, functional respiratory measures)|viral load|Anti-HLA antibody rate|immediate hypersensitivity reactions|thromboembolic adverse events 1|thromboembolic adverse events 2|infectious adverse events","Central Hospital, Nancy, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-002772-12,"November 6, 2020","May 14, 2021","September 1, 2021","November 12, 2020",,"November 5, 2021","Nancy University Hospital, Vandœuvre-lès-Nancy, France",,https://ClinicalTrials.gov/show/NCT04625738
353,445,NCT05106972,Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis,,Recruiting,No Results Available,Liver Cirrhosis,Drug: UC-MSC infusion,Number of Participants with abnormal Total bilirubin|Number of Participants with abnormal albumin|Ishak Inflammation Rating System|Ishak Fibrosis Score|Overall survival (OS)|HBV-DNA|incidence of liver cancer|Number of Participants with abnormal immunoglobulin|portal vein flow rate|portal vein width|abdominal volume|Number of Participants with abnormal coagulation function,"Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.",All,20 Years to 60 Years   (Adult),Not Applicable,30,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCT20181032,"December 1, 2021","December 31, 2024","December 31, 2025","November 4, 2021",,"November 4, 2021","Haikou People's Hospital, Haikou, China",,https://ClinicalTrials.gov/show/NCT05106972
354,2,NCT05125562,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,,Not yet recruiting,No Results Available,COVID-19,Drug: ExoFlo,"Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29","Direct Biologics, LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DB-EF-EMOTECOVID-0006,"December 7, 2022","March 7, 2023","March 7, 2023","November 18, 2021",,"August 25, 2022","Direct Biologics, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT05125562
355,697,NCT05165628,"Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers",,Recruiting,No Results Available,Diabetic Foot Ulcer|Cutaneous Ulcer,Combination Product: CYP-006TK,"Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.|Percentage of area change of study ulcer from baseline to weeks 12 and 24|Number of days to complete ulcer healing|Number of days to 50% ulcer healing|Percentage change in ulcer volume from baseline to weeks 12 and 24|Changes from baseline in ulcer pain assessed using a Numeric Rating Scale|Number clinic/home care visits across groups|Differences across groups on ulcer dressing products used|Changes from baseline in Quality of Life assessed using the Cardiff Wound Impact Schedule|Duration of clinic/home care visits across groups",Cynata Therapeutics Limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CYP-DFU-P1-01,"January 4, 2022",December 2022,December 2022,"December 21, 2021",,"March 22, 2022","Central Adelaide Local Health Network, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT05165628
356,179,NCT04280003,Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke,AMASCIS-02,Recruiting,No Results Available,Ischemic Stroke|Adipose Tissue-derived Stem Cell|Functional Status,Other: Alogenic adipose tissue-derived stem cells|Drug: Placebo solution,Safety of administration of adipose tissue-derived mesenchymal stem cells measured as reported adverse events|Safety of administration of adipose tissue-derived mesenchymal stem cells measured as neurological o systemic complications|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the Modified Rankin Scale|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the NIHSS|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measuring blood brain repair biomarkers,Instituto de Investigación Hospital Universitario La Paz,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMASCIS - 02,"January 20, 2021","July 15, 2023","July 15, 2023","February 21, 2020",,"June 14, 2022","Hospital Universitario La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04280003
357,674,NCT01065337,Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia,,Completed,No Results Available,Diabetic Foot,Biological: tissue repair cells (TRC)|Biological: bone marrow stem cells (BMC),"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred|Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion",Ruhr University of Bochum,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HDZ-SBE-2004,August 2005,February 2009,February 2009,"February 9, 2010",,"May 25, 2012","Herz- und Diabeteszentrum Nordrhein Westfalen, Bad Oeynhausen, Germany",,https://ClinicalTrials.gov/show/NCT01065337
358,476,NCT03460795,Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease,,Not yet recruiting,No Results Available,Liver Cirrhosis,Biological: MSC and Tregs,Albumin (ALB)|Alanine aminotransferase (ALT)|Prealbumin (PA)|Total bilirubin (TB)|Direct bilirubin (DB)|Blood urea nitrogen (BUN)|Uric acid (UA)|Serum creatinine (Scr)|Child-Pugh|Model for end-stage liver disease (MELD)|Quality of life (QOL),Nanjing Medical University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NJLT005,"June 1, 2020","March 1, 2025","September 1, 2025","March 9, 2018",,"March 4, 2020","Nanjing Medical University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03460795
359,62,NCT05017298,Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells,AdMSCs,Not yet recruiting,No Results Available,Corona Virus Infection|Covid19,Biological: Allogeneic adipose-derived stem cells,Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive,Celltex Therapeutics Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTX0020-004,"November 1, 2022","November 1, 2023","November 15, 2025","August 23, 2021",,"April 29, 2022",,,https://ClinicalTrials.gov/show/NCT05017298
360,465,NCT05018637,Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture,,Enrolling by invitation,No Results Available,Vertebral Compression Fracture|Osteoporotic Fractures,Drug: WJ-MSC|Drug: Teriparatide,improvement in Visual Analogue Scale|improvement in Oswestry Disability Index|Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry|Presence of new vertebral fracture|Change in the bone mineral density (computed tomography) of fractured vertebrae,Inbo Han|CHA University,Female,"40 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-11-010,"September 1, 2020","December 31, 2022","December 31, 2022","August 24, 2021",,"August 24, 2021","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05018637
361,138,NCT05465096,Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells.,Lipo-Hip,Not yet recruiting,No Results Available,Hip Osteoarthritis|Hip Disease,Procedure: Micro-fragmented adipose tissue injection,Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Visual Analogue Scale (VAS)|Harris Hip Scale (HHS),Istituto Ortopedico Rizzoli,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Lipo-Hip,September 2022,March 2023,September 2024,"July 19, 2022",,"July 25, 2022","Istituto Ortopedico Rizzoli, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT05465096
362,462,NCT02123368,Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells,,Completed,No Results Available,Osteoarthritis,Drug: Hyaluronic acid|Biological: 10 million Bone marrow mesenchimal stem cells|Biological: 100 million Bone marrow mesenchimal stem cells,Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at on month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months|SF-36 value at 1 month|SF 36 value at 3 months|SF 36 value at 6 months|SF 36 value at 12 months|Euroquol 5D value at 1 month|Euroquol 5D value at 3 months|Euroquol 5D value at 6 months|Euroquol 5D value at 12 months|Lequesne index at 1 month|Lequesne index at 3 months|Lequesne index at 6 months|Lequesne index at 12 months|Femorotibial distance at 6 months|Femorotibial distance at 12 months|Baseline MRI WORMS protocol|MRI WORMS protocol score at 6 months|MRI WORMS protocol score at 12 months,"Clinica Universidad de Navarra, Universidad de Navarra",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMM/ART|2009-017624-72,May 2012,November 2014,February 2015,"April 25, 2014",,"October 24, 2017","Traumatology department. Complejo Hospitalario de Salamanca, Salamanca, Castilla y León, Spain|Orthopaedic and traumatology department. Clínica Universidad de Navarra, Pamplona, Navarra, Spain",,https://ClinicalTrials.gov/show/NCT02123368
363,609,NCT04390139,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,COVIDMES,"Active, not recruiting",No Results Available,COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome,Drug: XCEL-UMC-BETA|Other: Placebo,"All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin",Banc de Sang i Teixits,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BST-COVID-01,"May 13, 2020",September 2022,December 2022,"May 15, 2020",,"July 6, 2022","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04390139
364,87,NCT04441658,Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus,,Recruiting,No Results Available,Type 2 Diabetes|Mesenchymal Stem Cells,Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: saline,The changes in HbA1C level|Reduction of insulin requirement|The changes in blood glucose level,Shanghai East Hospital,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DFSC-2020(CR)-02,"April 10, 2020",July 2022,December 2022,"June 22, 2020",,"June 22, 2020","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04441658
365,105,NCT02449005,Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects,PerioRegen,Completed,No Results Available,Chronic Periodontitis,Biological: BM-MSCs/fibrin glue/collagen fleece|Other: Fibrin glue/collagen fleece|Procedure: Open flap debridement,"A reduction in the distance in mm from the bottom of the periodontal pocket to the cementoenamel junction using a manual probe (Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) with 20-25g of pressure by a single calibrated examiner.|A reduction in the distance in mm between the gingival margin and the bottom of the defect using a manual periodontal probe (Hu-Friedy XP-23/QW) by a single calibrated examiner.",Aristotle University Of Thessaloniki|University of Glasgow,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELKE-90467,March 2014,September 2016,December 2016,"May 20, 2015",,"June 3, 2022","Dental School, Aristotle University, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT02449005
366,3,NCT01586312,Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells,MSV_allo,Completed,Has Results,"Osteoarthritis, Knee|Arthritis of Knee|Knee Osteoarthritis",Other: Allogenic mesenchymal stromal cells injection|Drug: Hyaluronic Acid,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)",Red de Terapia Celular|University of Valladolid|Sanidad de Castilla y León|Centro Medico Teknon,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",TerCel004|2011-005321-51|EC11-309|MSV_allo,April 2012,December 2013,June 2014,"April 26, 2012","November 6, 2014","October 16, 2015","Centro Medico Teknon, Barcelona, Spain|Hospital Clinico Universitario, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT01586312
367,7,NCT01056471,Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis,,Completed,No Results Available,"Autoimmune Diseases|Immune System Diseases|Demyelinating Diseases|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System",Other: Autologous mesenchymal stem cells from adipose tissue.,"To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells|To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.",Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Carlos III Health Institute|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CMM/EM/2008,January 2010,June 2012,June 2015,"January 26, 2010",,"August 7, 2015","Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT01056471
368,62,NCT03840343,Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease,,Recruiting,No Results Available,"Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency",Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose,Adverse Events|Kidney Function,Mayo Clinic|Regenerative Medicine Minnesota,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-002423|RMM 091718 CT 001,"October 23, 2019",December 2024,December 2025,"February 15, 2019",,"March 15, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03840343
369,221,NCT03943576,Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis,,Recruiting,No Results Available,Knee Osteoarthritis,Drug: GXCPC1|Device: HA,WOMAC pain score|MRI|Visual Analogue Scale (VAS)|12-item Short Form (SF-12),"Gwo Xi Stem Cell Applied Technology Co., Ltd.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GXCPC1,"December 1, 2019","December 31, 2021","October 31, 2022","May 9, 2019",,"March 17, 2020","GWOXI Stem Cell Applied Technology Co., Ltd., Hsinchu, Taiwan",,https://ClinicalTrials.gov/show/NCT03943576
370,6,NCT02013674,The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study),Trident,Completed,Has Results,Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction,Biological: Allogeneic hMSCs,Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB),"Joshua M Hare|The Emmes Company, LLC|University of Miami",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20120660,"February 13, 2014","March 2, 2017","September 18, 2017","December 17, 2013","February 5, 2020","February 11, 2020","ISCI / University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02013674/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02013674
371,256,NCT02580695,A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis,,Completed,No Results Available,Osteoarthritis,Biological: umbilical-cord mesenchymal stromal cells|Drug: Hyaluronic Acid,Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI,"Francisco Espinoza, MD|Universidad de los Andes, Chile",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C4COA01,December 2015,January 2017,April 2017,"October 20, 2015",,"December 26, 2018","Clinica Universidad de los Andes, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT02580695
372,204,NCT04714801,Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation,,Recruiting,No Results Available,Lung Transplant Rejection,Drug: adipose derived mesenchymal stromal cells|Drug: Saline,Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers,"Rigshospitalet, Denmark",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ASC Lungtransplantation,"October 1, 2020","November 30, 2023","November 30, 2024","January 19, 2021",,"July 16, 2021","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04714801
373,13,NCT03343782,Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes,ASD2,Completed,No Results Available,Type 2 Diabetes Mellitus,Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell,Insulin dose|Adverse events|Hemoglobin A1c (HbA1c) level,Vinmec Research Institute of Stem Cell and Gene Technology,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VinmecRISCGT70,"November 1, 2017","August 1, 2019","August 1, 2019","November 17, 2017",,"June 18, 2021","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT03343782
374,188,NCT00504803,Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease,,Completed,No Results Available,Hematological Malignancies,Procedure: Mesenchymal stem cell infusion,Day-100 incidence of non-relapse mortality|1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution,University of Liege,All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,TJB0601,December 2006,December 2010,December 2010,"July 20, 2007",,"September 2, 2011","CHU Sart Tilman, Liege, Belgium",,https://ClinicalTrials.gov/show/NCT00504803
375,209,NCT04308213,Study on Shoulder Arthritis Treatment With Intra-articular Injections of Autologous Bone Marrow Aspirate.,Stemshoulder,Recruiting,No Results Available,Shoulder Arthritis,Device: Marrow Cellution System,"Change of the Constant-Murley score|Change of the VAS pain score|Change of range of motion (ROM)|clinical change based on the DASH scale (disability of the arm, shoulder and Hand)|clinical change based on the , American Shoulder and Elbow Surgeons (ASES) score|evaluation of shoulder MRI results|evaluation of shoulder X-ray (XR) results",Istituto Clinico Humanitas,All,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,955,"November 12, 2019","April 30, 2024","September 30, 2024","March 13, 2020",,"March 17, 2020","Humanitas Research Hospital, Rozzano, Milano, Italy",,https://ClinicalTrials.gov/show/NCT04308213
376,103,NCT04918706,Allogeneic MSC Treatment for Pulmonary Emphysema,,Recruiting,No Results Available,Pulmonary Emphysema|Mesenchymal Stromal Cells,Genetic: Allogeneic MSC|Drug: Placebo,"Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo.","Leiden University Medical Center|Erasmus Medical Center|Amsterdam UMC, location VUmc",All,"45 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HEP study,"June 25, 2019","September 1, 2021","June 1, 2022","June 9, 2021",,"June 9, 2021","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT04918706
377,45,NCT03876197,Mesenchymal Stem Cells for Radiation-induced Xerostomia,,Enrolling by invitation,No Results Available,Radiation Toxicity|Xerostomia Due to Radiotherapy|Dry Mouth|Hyposalivation|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Long Term Adverse Effects,Biological: Autologous adipose-derived mesenchymal stem/stromal cells|Other: Placebo,Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL,"Rigshospitalet, Denmark",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other",CVB2019-1|2014-004349-29,"August 1, 2020","December 1, 2022","December 1, 2023","March 15, 2019",,"October 22, 2020","Department of Otolaryngology, University Hospital of Copenhagen, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03876197
378,218,NCT05207995,The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells,,Not yet recruiting,No Results Available,Diabetes Mellitus,Biological: Autologous tolerogenic dendritic cells|Other: Standard treatment according to the clinical protocols,The glucose concentration in blood|The glycated hemoglobin concentration|The C-peptide level in blood|Autoantigen specific T cell count|Adverse effects associated with the therapy,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_DM,"March 1, 2022","December 31, 2023","December 31, 2023","January 26, 2022",,"January 26, 2022",,,https://ClinicalTrials.gov/show/NCT05207995
379,29,NCT04776239,Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD),ACESO-IHD,Recruiting,No Results Available,Diabetes Mellitus|Ischemic Heart Disease,Drug: 100 million Allogeneic Mesenchymal Human Stem Cells|Other: Placebo,Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR|Post-PCI coronary artery endothelial function as assessed via FFR|Target lesion lumen loss|Flow Mediated Diameter Percentage (FMD%)|EPC-CFUs levels|Circulating angiogenic factors marker levels|Circulating inflammatory markers|Seattle Angina Questionnaire (SAQ) Angina Frequency|EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire|EQ-5D Quality of life Questionnaire Overall Health Status Question|Short Form (SF) 36 Questionnaire Quality of Life Questionnaire|International Index of Erectile Function (IIEF) Questionnaire|Sexual Quality of Life - Females (SQOL-F) Questionnaire|Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)|Incidence of Major Adverse Cardiac Events (MACE)|Rates of Adverse Events|Number of participants with abnormal lab values|Number of participants with Target Vessel Failure,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20200874|1R01HL134558-01,"August 16, 2021","July 16, 2024","July 16, 2024","March 1, 2021",,"July 11, 2022","University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04776239
380,7,NCT03183648,A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial,,"Active, not recruiting",No Results Available,Burn,Biological: ALLO-ASC-DFU,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale,"Anterogen Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",,30,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALLO-ASC-BI-202,August 2016,December 2022,June 2023,"June 12, 2017",,"July 21, 2021","Hallym university Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03183648
381,201,NCT01739777,Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy,RIMECARD,Completed,No Results Available,Dilated Cardiomyopathy,Biological: ucMSC|Other: Controls,• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP),"Universidad de los Andes, Chile",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",UANDES-C4C|CORFO-11IEI-9766,December 2012,June 2015,June 2015,"December 3, 2012",,"June 4, 2015","Universidad de los Andes, Santiago de Chile, Chile",,https://ClinicalTrials.gov/show/NCT01739777
382,205,NCT05261360,Clinical Efficacy of Exosome in Degenerative Meniscal Injury,KNEEXO,Recruiting,No Results Available,"Knee; Injury, Meniscus (Lateral) (Medial)|Meniscus Tear|Meniscus Lesion|Meniscus; Degeneration|Meniscus; Laceration|Meniscus Injury, Tibial|Knee Injuries|Knee Pain Swelling|Arthralgia",Drug: SF-MSC-EX|Drug: SF-MSC,Evaluation of Knee Functions|Evaluation of Physical Activity|Evaluation of Pain|Evaluation of Radiological Images|Evaluation of Cytokine Levels and Cytokine Genes Analyzes|Evaluation of Edema|Evaluation of Knee Joint Range of Motion|Monitoring of treatment-related complications,Eskisehir Osmangazi University|The Scientific and Technological Research Council of Turkey,All,30 Years to 50 Years   (Adult),Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,56733164/203,March 2022,March 2024,March 2025,"March 2, 2022",,"March 4, 2022","Eskisehir Osmangazi University, Eskisehir, Turkey",,https://ClinicalTrials.gov/show/NCT05261360
383,14,NCT03449082,Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC),,"Active, not recruiting",No Results Available,Lateral Epicondylitis,Biological: High concentration of Allo-ASC|Biological: Low concentration of Allo-ASC|Drug: Fibrin glue|Drug: Normal saline,Change of pain visual analogue scale (VAS) during activity|Change of pain visual analogue scale (VAS) at rest|Change of Mayo elbow performance index (MEPI)|Ultrasonographic assessment|Shear wave elastography|Magnetic resonance image (MRI) assessment,Seoul National University Hospital|Korea Health Industry Development Institute,All,"19 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNUH-RM-SGChung-ASC-02,"May 4, 2018","April 3, 2019","December 30, 2021","February 28, 2018",,"March 26, 2021","Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03449082
384,110,NCT01842477,Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing,OrthoCT1,Completed,No Results Available,"Delayed Union After Fracture of Humerus, Tibial or Femur",Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells,Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C11-12|2011-005441-13,May 2013,"February 5, 2016","February 5, 2016","April 29, 2013",,"December 2, 2017","Depatment of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHRU Tours, Tours, France|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01842477
385,217,NCT01759823,Bone Marrow Derived Stem Cell Transplantation in T2DM,,Completed,No Results Available,Type 2 Diabetes Mellitus,Biological: mesenchymal stem cell transplantation|Other: control|Biological: MNC's TRANSPLANTATION,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,Postgraduate Institute of Medical Education and Research,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,stem cell therapy in T2DM,December 2012,December 2014,October 2015,"January 3, 2013",,"October 27, 2015","Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India",,https://ClinicalTrials.gov/show/NCT01759823
386,3,NCT02755376,Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell,,Completed,No Results Available,Deficiency of Anterior Cruciate Ligament,Biological: Cartistem(TM)|Biological: hyaluronic acid|Procedure: ACL reconstruction only,Bone formation on interface between bone tunnel and graft|Arthroscopic grading of graft|Telos stress X-ray|KT-2000|clinical knee scoring|Instability assessing with physical examination|Tunnel enlargement after anterior cruciate ligament reconstruction,Samsung Medical Center,All,20 Years to 50 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SMC 2013-07-117-002,"January 1, 2014","April 28, 2016","December 1, 2018","April 28, 2016",,"April 10, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02755376
387,203,NCT01843387,Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy,,Completed,No Results Available,Diabetic Nephropathy|Type 2 Diabetes,Biological: Mesenchymal Precursor Cells (MPCs),The primary objective of the study is to assess the safety and tolerability of MPC therapy|Exploratory assessment of the efficacy of MPC therapy,"Mesoblast, Ltd.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSB-DN001,July 2013,September 2014,September 2015,"April 30, 2013",,"October 14, 2016","Monash Universtiy, Clayton, Australia|Melbourne Renal Research Group, Melbourne, Australia",,https://ClinicalTrials.gov/show/NCT01843387
388,134,NCT02315027,Mesenchymal Stem Cell Therapy in Multiple System Atrophy,,"Active, not recruiting",No Results Available,MSA,Biological: Autologous Mesenchymal Stem Cells,"Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months.",Mayo Clinic|Food and Drug Administration (FDA)|National Institute of Neurological Disorders and Stroke (NINDS),All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other|U.S. Fed|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-005950|R01FD004789|R01NS092625,October 2012,March 2024,March 2024,"December 11, 2014",,"September 9, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02315027
389,208,NCT03920397,Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus,,Completed,No Results Available,Type 1 Diabetes Mellitus,Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation,Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation,Universidade Federal do Rio de Janeiro,All,"16 Years to 35 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Nutro_MesenchymalStemCells_DM1,"March 1, 2015","March 1, 2021","May 1, 2021","April 18, 2019",,"May 26, 2021","Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT03920397
390,177,NCT00420134,Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial,,Completed,No Results Available,Liver Failure|Cirrhosis,Procedure: injection of progenitor of hepatocyte drived from Mesenchymal stem cell,Liver function test|MELD score|Cirrhosis mortality after 6 months,Shahid Beheshti University of Medical Sciences|Tarbiat Modarres University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,348,February 2006,May 2009,June 2009,"January 9, 2007",,"September 17, 2009","Research Center for Gastroenterology and Liver Diseases, Tehran, Iran, Islamic Republic of|Research center of Gastroenterology and Liver Disease, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00420134
391,25,NCT03522545,Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression,,Recruiting,No Results Available,Treatment-resistant Bipolar Depression,Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Biological: Placebo,"Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment","The University of Texas Health Science Center, Houston",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-16-0657,"June 1, 2021","July 1, 2024","July 1, 2024","May 11, 2018",,"September 7, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03522545
392,259,NCT03706482,Boost Brittle Bones Before Birth,BOOSTB4,Recruiting,No Results Available,Osteogenesis Imperfecta,Biological: BOOST cells,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events.|Number of fractures.|Time (days) to first fracture after each stem cell administration.|Numbers of fractures at birth.|Change in bone-marrow density (g/cm2).|Growth (cm).|Growth (kg).|Change in clinical status of OI.|Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples.","Karolinska Institutet|Karolinska University Hospital|Great Ormond Street Hospital for Children NHS Foundation Trust|University College, London|Universitätsklinikum Köln|UMC Utrecht|Leiden University Medical Center|Lund University",All,up to 18 Months   (Child),Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KIBB01,"August 12, 2019","August 12, 2023","August 12, 2033","October 16, 2018",,"October 14, 2021","Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03706482
393,39,NCT03955497,Effectiveness of Autologous Adipose-derived Stem Cells in the Treatment of Knee Cartilage Injury,,Recruiting,No Results Available,Knee Osteoarthritis|Cartilage Degeneration,Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel|Drug: Sodium Hyaluronate|Procedure: Extraction of abdominal fat,Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Hospital for special surgery knee score postoperative 12 month|Hospital for special surgery knee score postoperative 24 month|Hospital for special surgery knee score postoperative 36 month|Visual Analogue Scale Postoperative Day 1|Visual Analogue Scale Postoperative Day 2|Visual Analogue Scale Postoperative Day 3|Visual Analogue Scale Postoperative Day 7|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Visual Analogue Scale Postoperative 12 month|Visual Analogue Scale Postoperative Day One|Visual Analogue Scale Postoperative 24 month|Visual Analogue Scale Postoperative 36 month|Evaluation of cartilage repair under MRI postoperative 12 month|Evaluation of cartilage repair under MRI postoperative 24 month|Evaluation of cartilage repair under MRI postoperative 36 month|Degree of meniscus injury under MRI postoperative 12 month|Degree of meniscus injury under MRI postoperative 24 month|Degree of meniscus injury under MRI postoperative 36 month|Evaluation of cartilage repair under arthroscope postoperative 12 month|Degree of meniscus injury under arthroscope postoperative 12 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Squatting to Standing Time postoperative 12 month|Squatting to Standing Time postoperative 24 month|Squatting to Standing Time postoperative 36 month,Qilu Hospital of Shandong University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2018023,"October 1, 2018","October 1, 2022","December 1, 2022","May 20, 2019",,"September 16, 2020","Qilu hospital of Shandong University, Jinan, Shandong, China",,https://ClinicalTrials.gov/show/NCT03955497
394,269,NCT05019287,Menstrual Blood Stem Cells in Severe Covid-19,,Completed,No Results Available,Covid19|Cytokine Storm,Biological: Allogeneic human menstrual blood stem cells secretome|Other: Intravenous saline injection,Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10,Avicenna Research Institute|Tehran University of Medical Sciences,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",990308-026|99/3436,"April 17, 2021","May 21, 2021","June 9, 2021","August 24, 2021",,"September 2, 2021","Avicenna Research Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT05019287
395,1,NCT03265808,Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.,Alaunus,"Active, not recruiting",No Results Available,Major Depressive Disorder|Alcohol Use Disorder,Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo,Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI,Ihsan Salloum|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,28,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20170674|1R01AA024933-01A1,"March 18, 2018","October 23, 2022",April 2025,"August 29, 2017",,"February 28, 2022","University of Texas Rio Grande Valley School of Medicine, Harlingen, Texas, United States",,https://ClinicalTrials.gov/show/NCT03265808
396,203,NCT02674399,A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis,,Completed,Has Results,"Osteoarthritis, Knee",Drug: JointStem|Drug: Synvisc-One,"Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group|Change From Baseline on Visual Analog Scale (VAS) in JointStem Group|MRI Improvement Evaluation in JointStem Group|Change From Baseline on WOMAC Between JointStem and Positive Control Groups|Change From Baseline on VAS Between JointStem and Positive Control Groups|Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups|Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups|Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups|Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups|Change From Baseline on WOMAC in JointStem Group|Change From Baseline on VAS in JointStem Group|Comparison of MRI Improvement Evaluation in JointStem Group|Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12|Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group","Nature Cell Co. Ltd.|KCRN Research, LLC",All,22 Years to 60 Years   (Adult),Phase 2,28,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JS-OAP2-US01,"February 16, 2016","March 12, 2018","December 28, 2018","February 4, 2016","July 13, 2021","August 10, 2021","Orthopedic Pain Specialists, Santa Monica, California, United States|Walnut Creek, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02674399
397,16,NCT03608631,iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation,,Recruiting,No Results Available,KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA,Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS),M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-0126|NCI-2018-01441,"January 27, 2021","March 31, 2023","March 31, 2023","August 1, 2018",,"April 26, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03608631
398,374,NCT03877471,Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency,MSCLCTWPOI,"Active, not recruiting",No Results Available,Primary Ovarian Insufficiency,Genetic: Cell therapy,Temperature|Pulse|Breaths per minute|Blood pressure|Number of antral follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Ovarian volume,Chinese Academy of Sciences|The First Affiliated Hospital of Zhengzhou University|National Natural Science Foundation of China,Female,"up to 40 Years   (Child, Adult)",Phase 1,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IOZ ChineseAS POI-2,"April 3, 2019","July 1, 2020","December 31, 2021","March 15, 2019",,"August 5, 2021","The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,https://ClinicalTrials.gov/show/NCT03877471
399,252,NCT03254758,A Study of ADR-001 in Patients With Liver Cirrhosis,,Recruiting,No Results Available,Decompensated Liver Cirrhosis,Biological: Mesenchymal stem cell,Safety profile of ADR-001 including the incidence of adverse events (Phase 1)|Improvement rate of Child-Pugh score (Phase 2)|Change of liver function evaluated by Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh grade (Phase 1)|Change of liver function evaluated by Child-Pugh score (Phase 2)|Improvement rate of Child-Pugh grade (Phase 2)|Safety profile of ADR-001 including the incidence of adverse events (Phase 2),"Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,27,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADR-001-01,"July 20, 2017",June 2022,December 2022,"August 18, 2017",,"April 27, 2022","Niigata University Medical & Dental Hospital, Niigata, Japan|Nihon University Itabashi Hospital, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT03254758
400,239,NCT03226015,Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency,,Completed,No Results Available,Limbal Stem-cell Deficiency,,change in number of acute surgeries|change in days of acute inpatient treatment|change in number of curative surgical procedures after oral mucosa transplantation|change in conjunctival inflammation,Klinikum Chemnitz gGmbH|Institute of Anatomy TU Dresden,All,"18 Years and older   (Adult, Older Adult)",,27,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,EK-BR-64/15-1,July 2015,April 2017,May 2017,"July 21, 2017",,"July 21, 2017",,,https://ClinicalTrials.gov/show/NCT03226015
401,272,NCT04213248,Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD,,Recruiting,No Results Available,Dry Eye,Drug: Umbilical Mesenchymal Stem Cells derived Exosomes,Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height,"Zhongshan Ophthalmic Center, Sun Yat-sen University",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019KYPJ048,"February 21, 2020","May 18, 2023",December 2023,"December 30, 2019",,"February 11, 2022","Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04213248
402,64,NCT04834609,Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas,,Completed,No Results Available,Perianal Fistula|Adipose Tissue|Tissue Transplantation,Procedure: Injection of autologous adipose tissue in anal fistula,Investigation of cell proliferation of AT-MSCs|Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte|Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast|Measurement of gene expression profile of AT-MSCs|Healing of anal fistula after treatment|Evaluation of fistula healing after treatment|Functional gastroenterological outcome after treatment|Defecation disorder evaluation after treatment|Functional urological outcome after treatment,University of Aarhus|University of Southern Denmark|UiT The Arctic University of Norway,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AT-MSCs_Anal fistulas,January 2015,October 2017,February 2021,"April 8, 2021",,"April 8, 2021",,,https://ClinicalTrials.gov/show/NCT04834609
403,37,NCT00911365,Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy,,Completed,No Results Available,Multiple System Atrophy,Biological: autologous mesenchymal stem cells|Biological: normal saline,Scores on unified MSA rating scale,Yonsei University,All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 2,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,4-2008-0137,May 2008,June 2011,June 2011,"June 1, 2009",,"August 4, 2011","Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00911365
404,120,NCT04434794,Treatment of Gingival Recession Using Mesenchymal Stem Cells,,Completed,No Results Available,Gingival Recession,Biological: mesenchymal stem cells|Other: standard treatment,number of patients cured,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,27,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(GR2),"January 1, 2018","December 31, 2019","December 31, 2019","June 17, 2020",,"June 17, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04434794
405,238,NCT00629096,Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy,,Completed,No Results Available,Dilated Cardiomyopathy,Procedure: Intracoronary infusion of autologous bone marrow cells,Improvement of left ventricular function|Functional status,Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,27,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCMR0007/2006|EudraCT 2007-003088-36,February 2008,August 2010,December 2010,"March 5, 2008",,"December 5, 2014","Reina Sofía University Hospital, Córdoba, Spain",,https://ClinicalTrials.gov/show/NCT00629096
406,144,NCT01562002,Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome,,Completed,No Results Available,Limbus Corneae Insufficiency Syndrome,Procedure: Stem Cell with Amniotic Membrane Transplant,Viability and safety of mesenchymal stem cell transplant|Absence of complications in pre and peri surgical implantation|Improvement of 2 lines in Best Corrected Visual Acuity,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Red de Terapia Celular,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,27,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IOBA-05-2010,March 2012,December 2014,December 2014,"March 23, 2012",,"January 8, 2015","IOBA, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT01562002
407,14,NCT01609283,A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-008415,May 2012,"January 31, 2019","January 31, 2019","May 31, 2012",,"September 3, 2019","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01609283
408,27,NCT05165017,Safety & Efficacy of AlloRx SC® in PTHS Patients,,Not yet recruiting,No Results Available,Pitt Hopkins Syndrome,Biological: AlloRx Stem Cells®|Other: Placebo control,Safety: Incidence of adverse events improvement) in one or more areas of ailments related to PTHS|Safety: Incidence of serious adverse events|Change in motor function in individuals with PTHS|Change in communication abilities in individuals with PTHS.|Change in sleep habits|Change in gastrointestinal health|Change in breath holding spells|Change in cognition|Change in adaptive function|Change in autistic features|Change in parent assessment of quality of life|Change in global clinical status,Vitro Biopharma Inc.,All,"2 Years to 45 Years   (Child, Adult)",Phase 1|Phase 2,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALLORX-PTHS,December 2021,December 2022,December 2023,"December 21, 2021",,"December 21, 2021",,,https://ClinicalTrials.gov/show/NCT05165017
409,54,NCT03828123,Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis,AMSC-ALS-001,Completed,No Results Available,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Biological: Suspension of human autologous MSC 3P in 1.5 ml,Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC),"Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,26,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMSC-ALS-001,January 2012,"August 18, 2017","August 18, 2017","February 4, 2019",,"February 12, 2019",,,https://ClinicalTrials.gov/show/NCT03828123
410,31,NCT01745783,"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",,Completed,No Results Available,Multiple Sclerosis,Other: Bone marrow mesenchymal stem cells autologous|Other: Placebo comparator,Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image|Differences the results obtained in the two groups of patients due to determined parameters.,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CeTMMo/EM/2010|2010-023368-42,January 2013,"June 30, 2020","June 30, 2020","December 10, 2012",,"April 6, 2022","University Hospital Reina Sofia, Córdoba, Spain|University Regional Hospital Carlos Haya, Málaga, Spain|University Hospital Virgen Macarena, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT01745783
411,161,NCT04289194,Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome,Drug: HCR040 (Phase 1)|Drug: Placebo (Phase 2)|Drug: HCR040 (Phase 2),"Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection|Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040|Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040|Mechanical ventilation-free days 28 days after the administration of HCR040|Percent mortality 28 days after the administration of HCR040|Daily pulmonary mechanics values (Ppl, DP, CRS)|Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040|Vasopressor-free days 28 days after the administration of HCR040|ICU-free days 28 days after the administration of HCR040","Histocell, S.L.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALICELL-CT-01|2019-002688-89,"December 10, 2019","August 15, 2021","April 16, 2022","February 28, 2020",,"May 14, 2021","Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain|Fundación Jiménez Díaz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04289194
412,643,NCT02313415,Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchyma Stem Cells,,Completed,No Results Available,Infertility|Intrauterine Adhesions,Procedure: UC-MSCs therapy,live birth rate|Reduction of intrauterine adhesion|The change of endometrial thickness|ongoing pregnant rate,"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Institute of genetic development, Chinese Academy of Sciences|Institute of zoology, Chinese Academy of Sciences",Female,20 Years to 45 Years   (Adult),Not Applicable,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20141206,"November 28, 2014","January 28, 2015","August 31, 2017","December 10, 2014",,"October 24, 2017","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02313415
413,23,NCT02065167,Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip,ORTHO-2,Completed,No Results Available,Avascular Necrosis of the Femoral Head,Biological: Cultured autologous Mesenchymal Cells,Complication rate|complication rate|Progression of disease to the next stage|Amount of necrotic bone in the femoral head in MRI|Pain (VAS)|serum levels of bone turnover markers,Universidad Autonoma de Madrid,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORTHO -2|2012-002010-39,February 2014,June 2016,December 2017,"February 17, 2014",,"October 14, 2021","Department of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|University Children's Hospital, Tübingen, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02065167
414,169,NCT03000712,Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.,,Completed,No Results Available,Degenerative Arthritis|Knee Osteoarthritis,Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml,MRI scan|WOMAC score|WOMAC sub-scale|Kellgren & Lawrence grade|EQ5D|ROM|KOOS (Knee Injury & Osteoarthritis Outcome Score)|PGIC(Patient Global Impression of Change)|PSQI(Pittsburgh Sleep Quality Index)|Biomarkers|Incidence of adverse reactions and characteristics associated with investigational product,R-Bio,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HTO-MSCs,"November 2, 2016","May 22, 2020","May 22, 2020","December 22, 2016",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03000712
415,55,NCT04366323,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,,Completed,No Results Available,Sars-CoV2,Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate,Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AdiQure/COVID-19,"April 27, 2020","December 30, 2021","December 30, 2021","April 28, 2020",,"April 6, 2022","Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT04366323
416,553,NCT05349565,Effects of Muscle Energy Technique in Knee Osteoarthritis Patients,,Recruiting,No Results Available,Knee Osteoarthritis,Other: CONVENTIONAL PHYSICAL THERAPY|Other: MUSCLE ENERGY TECHNIQUE,Numeric Pain Rating Scale (NPRS)|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Goniometer (range of motion)|SF-12 (quality of life),Riphah International University,All,"41 Years to 70 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,REC/01255 Fanila Ashraf,"September 13, 2022",May 2023,June 2023,"April 27, 2022",,"September 19, 2022","Institute of Regenerative medicine, Islamabad, Pakistan",,https://ClinicalTrials.gov/show/NCT05349565
417,202,NCT01351610,Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia,,Completed,No Results Available,Critical Limb Ischemia|Peripheral Artery Disease,Biological: PTA + Infusion of MSC_Apceth|Procedure: PTA,Collection of adverse events|Safety laboratory values|ECG findings|Analysis of inflammation markers|Comparison of course of haemodynamic and vascular processes,Apceth GmbH & Co. KG,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,25,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC_Apceth_001,March 2011,October 2014,October 2015,"May 11, 2011",,"December 15, 2015","Isar Medizin Zentrum, Munich, Bavaria, Germany",,https://ClinicalTrials.gov/show/NCT01351610
418,103,NCT04484402,Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells,,Completed,No Results Available,Corneal Ulcer|Corneal Disease|Corneal Dystrophy,Biological: mesenchymal stem cells|Biological: limbal stem cells|Other: standard treatment,Number of cured patients|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_LSC,"October 3, 2016","December 30, 2019","December 30, 2019","July 23, 2020",,"July 30, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04484402
419,2,NCT01860417,Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV),Disc_allo,Completed,No Results Available,Degenerative Disc Disease|Intervertebral Disc Disease|Low Back Pain,Biological: Allogenic Mesenchymal Stromal Cells|Drug: Mepivacaine,Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire),Red de Terapia Celular|Citospin|University of Valladolid,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,25,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",TerCel005|2012-004444-30|Disc_allo_MSV,April 2013,April 2017,April 2017,"May 22, 2013",,"April 26, 2017","Hospital Clinico Universitario, Valladolid, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT01860417
420,447,NCT05167188,Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells,,Recruiting,No Results Available,Graft Vs Host Disease,Other: no intervention,Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT,Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna,All,"6 Months to 99 Years   (Child, Adult, Older Adult)",,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GvHD damage on MSCs,"October 14, 2021",March 2025,March 2025,"December 22, 2021",,"December 22, 2021","AOU Città della Salute e della Scienza di Torino, Torino, Italy",,https://ClinicalTrials.gov/show/NCT05167188
421,244,NCT03672825,REcycled CartiLage Auto/Allo IMplantation,,Recruiting,No Results Available,Cartilage Defect,Drug: REcycled CartiLage Auto/Allo IMplantation,"Nature, incidence and severity of adverse events (AEs)",Mayo Clinic,All,18 Years to 50 Years   (Adult),Phase 1,25,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-000939,"September 13, 2018","September 13, 2022","September 13, 2022","September 17, 2018",,"December 17, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03672825
422,232,NCT04670302,Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation,,Recruiting,No Results Available,Supraspinatus Tear,Procedure: Tendon repair procedure|Procedure: Tendon repair augmented with AAdMSC-HAM composite,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Pain pre-surgery|Pain at follow-up 12 months|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months|Constant-Murley Score (CS) pre-surgery|Constant-Murley Score (CS) at follow-up 12 months|Tear recurrence (re-tear)",Dr. Soetomo General Hospital,All,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,1208/KEPK/V/2019,"October 17, 2019","December 31, 2021","December 31, 2022","December 17, 2020",,"December 17, 2020","Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,https://ClinicalTrials.gov/show/NCT04670302
423,145,NCT04823000,Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis,MSC-pMS,Completed,No Results Available,Multiple Sclerosis,Biological: Mesenchymal Stem Cells (MSC),"Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)|Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment",Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-MS-001,"January 1, 2013","December 1, 2016","April 1, 2020","March 30, 2021",,"March 30, 2021",,,https://ClinicalTrials.gov/show/NCT04823000
424,254,NCT05442437,Human Umbilical Cord Mesenchymal Stem Cells for Treating HBV Clinical Study,THSW-MSC,Recruiting,No Results Available,HBV,Biological: hUCMSCs,Serum albumin in g/L|alanine aminotransferase in U/L|aspartate aminotransferase in U/L|cholinesterase in U/L|Total bilirubin in μmol/L|Direct bilirubin in μmol/L|Serum cholesterol in mmol/L|Prothrombin activity in percentage|Antithrombin in mg/L|survival rate|Child-Pugh grade|Rate of weight change|Ascites|clinical symptoms|Th1 cells in percentage|Th2 cells in percentage|Natural killer T cells in percentage|Interleukin-1β cells in pg/mL|Interleukin-4 cells in pg/mL|Interleukin-6 cells in pg/mL|Interleukin-8 cells in pg/mL|Interleukin-12 cells in pg/mL|Interleukin-15 cells in pg/mL|Interleukin-17A cells in pg/mL|Medical images|The Medical outcomes study 36-item Short Form Health Survay scale (SF-36 scale)|MELD score,Zhongnan Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THSW MSC 2018005,"September 8, 2019","July 31, 2022","December 31, 2022","July 5, 2022",,"July 5, 2022","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT05442437
425,51,NCT02298023,Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear),,Completed,Has Results,Rotator Cuff Tear,Biological: allogenic adipose stem cell injection|Biological: fibrin glue/normal saline injection|Biological: normal saline injection,"Change of Pain During Activity From Baseline to 3 Months After Intervention|Pain During Rest|Pain During Activity|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|Disability of Arm, Shoulder and Hand (DASH) Score|University of California, Los Angeles(UCLA) Shoulder Score|Tear Size at 3 Months After Injection|Tear Size at 12 Months After Injection",Seoul National University Hospital,All,"19 Years to 90 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALLO-ASC_TR,September 2014,"July 19, 2016","April 10, 2018","November 21, 2014","June 30, 2021","October 19, 2021","Seoul National University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02298023
426,109,NCT03478215,Mesenchymal Stromal Cells in Living Donor Kidney Transplantation,,Recruiting,No Results Available,Renal Transplantation|Mesenchymal Stem Cells,Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion|Other: Normal Saline (Placebo) Infusion,"Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.","The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",Pro00012858|U1111-1169-2289,December 2016,December 2023,December 2023,"March 27, 2018",,"March 9, 2022","Houston Methodist Hospital System, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03478215
427,215,NCT04939337,A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.,,Enrolling by invitation,No Results Available,Crohn's Disease,Drug: TH-SC01,Percentage of Participants who Achieve Combined Remission|Percentage of Participants who Achieve Clinical Remission|Percentage of Participants who Achieve Clinical Response|Percentage of Participants who decrease in PDAI|Percentage of Participants who decrease in IBDQ|Percentage of Participants who decrease in VAS scale|Percentage of Participants who decrease in Wexner incontinence score,"Jinling Hospital, China|Jiangsu Topcel-KH Pharmaceutical Co., Ltd",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20181231,"November 12, 2020",January 2024,August 2024,"June 25, 2021",,"June 25, 2021","Jinling hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04939337
428,90,NCT04744116,Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease,,Recruiting,No Results Available,Hematopoietic and Lymphoid Cell Neoplasm|Steroid Refractory Graft Versus Host Disease,Other: Cellular Therapy|Drug: Ruxolitinib,Death from any cause|Response|Incidence of adverse events|Graft versus host disease status|Proportion of response|Time to complete response|Time to very good partial response|Time to partial response|Incidence of complete response for each organ|Incidence of very good partial response for each organ|Incidence of partial response for each organ|Durability of organ response|Cumulative incidence of non-relapse mortality (NRM)|Cumulative incidence of relapse/progression of the primary disease|Overall survival|Disease-free survival|Graft versus host disease-free survival|Incidence of chronic graft versus host disease|Incidence of systemic infections|Incidence of toxicities|Incidence of any grade cytokine release|Incidence of any infusional toxicity,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,24,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-1122|NCI-2020-13889|P01CA148600,"February 17, 2021","November 30, 2022","November 30, 2022","February 8, 2021",,"July 12, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04744116
429,18,NCT00813969,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,,Completed,No Results Available,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,Biological: Autologous mesenchymal stem cell transplantation,"To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months",The Cleveland Clinic|University Hospitals Cleveland Medical Center,All,18 Years to 55 Years   (Adult),Phase 1,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MS-MSC-001,March 2011,January 2014,May 2014,"December 23, 2008",,"March 30, 2016","Cleveland Clinic Mellen Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00813969
430,350,NCT04313647,A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers,,Completed,Has Results,Healthy,Biological: 1X level of MSCs-Exo|Biological: 2X level of MSCs-Exo|Biological: 4X level of MSCs-Exo|Biological: 6X level of MSCs-Exo|Biological: 8X level of MSCs-Exo,Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE),Ruijin Hospital|Cellular Biomedicine Group Ltd.,All,18 Years to 45 Years   (Adult),Phase 1,24,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEXVT,"March 12, 2020","April 30, 2020","July 31, 2020","March 18, 2020","August 4, 2021","August 4, 2021","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04313647
431,198,NCT04543994,Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC),UC,Recruiting,No Results Available,Ulcerative Colitis,Drug: Remestemcel-L|Other: Placebo,Treatment related adverse events|Clinical and endoscopic remission|Clinical and endoscopic response|Partial clinical and endoscopic response|Lack of response|Mayo clinic score,"The Cleveland Clinic|Mesoblast, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20-1005,"November 10, 2020",November 2023,November 2023,"September 10, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04543994
432,573,NCT04223622,Effects of ASC Secretome on Human Osteochondral Explants,ASC-OA,Recruiting,No Results Available,Osteoarthritis,Biological: ASC secretome,"Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers",Istituto Ortopedico Galeazzi,All,"18 Years and older   (Adult, Older Adult)",,24,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ASC-OA,"April 12, 2021",December 2022,December 2022,"January 10, 2020",,"December 3, 2021","IRCCS Istituto Ortopedico Galeazzi, Milano, MI, Italy",,https://ClinicalTrials.gov/show/NCT04223622
433,10,NCT02658344,Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis,,Completed,No Results Available,Degenerative Arthritis|Knee Osteoarthritis,Biological: JOINTSTEM|Drug: Saline solution,WOMAC score|WOMAC 3 subscale|KOOS (Knee Injury & Osteoarthritis Outcome Score)|SF(Short Form)-36 Score|Global assessment of disease activity|Overall satisfaction|X-ray|MRI scan|Arthroscopy evaluation|Histological evaluation|VAS|IKDC|ROM|Quadriceps power|effusion|Crepitus|Ligament laxity|Medial joint line tenderness|Pes tenderness,R-Bio,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Jointstem2b,July 2015,November 2016,December 2016,"January 18, 2016",,"June 5, 2019","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02658344
434,187,NCT04654286,Human Amniotic Membrane and Mesenchymal Stem Cells Composite,BPI+MSC,Recruiting,No Results Available,Brachial Plexus Neuropathies,Procedure: Nerve transfer procedure|Procedure: Nerve transfer with HAM-AdMSC composite wrapping,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Functional motor power outcome pre-surgery|Functional motor power outcome at 12 months follow-up|Initial elbow flexion MRC grade 1 (in months)|Initial elbow flexion MRC grade 3 (in months)|Pain outcome pre-surgery|Pain outcome at 12 months follow-up|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at 12 months follow-up|Short Form-36 (SF-36) score pre-surgery|Short Form-36 (SF-36) score at 12 months follow-up",Dr. Soetomo General Hospital,All,"15 Years to 55 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,647 / Panke.KKE/ XI / 2016,"November 17, 2016","July 30, 2021","July 30, 2022","December 4, 2020",,"December 7, 2020","Cell and Tissue Bank - Regenerative Medicine, Dr. Soetomo General Academic Hospital/ Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,https://ClinicalTrials.gov/show/NCT04654286
435,196,NCT04548583,Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis,,Recruiting,No Results Available,Crohn Colitis,Drug: Remestemcel-L|Other: Placebo,Treatment related adverse events|Complete clinical healing|Clinical response|Partial clinical response|Lack of response|Crohn's disease activity index|Inflammatory bowel disease questionnaire|EuroQol 5 Dimensions survey|Inflammatory bowel disease patient reported treatment impact survey|Short Form 36 health survey,"The Cleveland Clinic|Mesoblast, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20-845,"November 4, 2020",October 2023,October 2023,"September 14, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04548583
436,12,NCT00781872,Mesenchymal Stem Cells for the Treatment of MS,,Completed,No Results Available,Multiple Sclerosis,Biological: Injection of autologous bone marrow derived mesenchymal stem cells,Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS,Hadassah Medical Organization,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MS22MSC-HMO-CTIL,October 2006,December 2009,December 2009,"October 29, 2008",,"March 29, 2021",,,https://ClinicalTrials.gov/show/NCT00781872
437,656,NCT04537351,The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause,MEND,Recruiting,No Results Available,Covid19|Acute Respiratory Distress Syndrome,Biological: CYP-001,Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination,Cynata Therapeutics Limited|Cerebral Palsy Alliance,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CYP-COVID-19-01,"August 24, 2020","December 31, 2022","December 31, 2022","September 3, 2020",,"July 20, 2022","Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Footscray Hospital, Footscray, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT04537351
438,207,NCT04276987,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,,Completed,No Results Available,Coronavirus,Biological: MSCs-derived exosomes,Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality,"Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEXCOVID,"February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04276987
439,388,NCT04355728,Use of UC-MSCs for COVID-19 Patients,,Completed,Has Results,"Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19",Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,"Number of Participants With Pre-Specified Infusion Associated Adverse Events|Number of Subjects With Serious Adverse Events by 31 Days After First Infusion|Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity|Subjects With Adverse Events and Serious Adverse Events by Severity|Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment|Subjects With Adverse Events by Relatedness to Treatment|Survival at 31 Days Post First Infusion|Survival at 60 Days Post First Infusion|Time to Recovery|Ventilator-Free Days Throughout 28 Days Post Second Infusion|Ventilator-Free Days Throughout 90 Days|Respiratory Rate and Oxygenation Index (ROX Index)|Oxygenation Index (OI)|Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)|Sequential Organ Failure Assessment (SOFA) Scores|Smell Identification Test (SIT) Scores|White Blood Cell Count (WBC)|Platelets Count|Hemogoblin|Hematocrit|Neutrophils|Lymphocytes|Glomerular Filtration Rate|Total Protein|Sodium|Potassium|Creatinine|Glucose|Albumin|Alkaline Phosphatase|Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)|Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)|Total Bilirubin|Blood Urea Nitrogen (BUN)|Calcium|Chloride|Carbon Dioxide (CO2)|C-Reactive Protein Levels|Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio|D-dimer Levels|25-Hydroxy Vitamin D Levels|Tumor Necrosis Factor-alpha (TNFα)|Tumor Necrosis Factor-beta (TNFβ)|Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)|Viral Load by SARS-CoV-2 RT-PCR|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion|Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG",Camillo Ricordi|University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20200671|20200370,"April 25, 2020","October 31, 2020","October 31, 2020","April 21, 2020","December 6, 2021","December 6, 2021","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04355728/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04355728
440,8,NCT04928287,"Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)",PD,"Active, not recruiting",No Results Available,Parkinson Disease,Biological: HB-adMSCs|Other: Placebo,"Changes in MDS-UPDRS Part II.|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities|AEs of special interest (serious or non-serious) - infections|AEs of special interest (serious or non-serious) - hypersensitivities.|Laboratory values. CBC|Laboratory values. CMP|Laboratory values. Coagulation Panel|Vital signs. - Respiratory Rate (breaths per minute)|Vital signs. - Heart Rate (beats per minute)|Vital signs. - Body Temperature (Fahrenheit )|Vital signs. - Blood Pressure (mmHg)|Weight in lb.|Physical examination results. General|Physical examination results. Body Systems.|Changes in MDS-UPDS total score.|Changes in MDS-UPDRS Part I.|Changes in MDS-UPDRS Part III.|Changes in MDS-UPDRS Part IV.|Changes in Neuro-QOL. - Communication|Changes in Neuro-QOL. - Social Roles and Activities|Changes in Neuro-QOL. - Anxiety|Changes in Neuro-QOL. - Depression|Changes in Neuro-QOL. - Dyscontrol|Changes in Neuro-QOL. - Fatigue|Changes in Neuro-QOL. - Mobility|Changes in Neuro-QOL. - Well-Being|Changes in Neuro-QOL. - Sleep|Changes in Neuro-QOL. - Fine Motor|Changes in Neuro-QOL. - Stigma|Changes in Neuro-QOL. - Social Roles|Changes in Neuro-QOL. - Cognition|Changes in Parkinson's disease fatigue scale (PFS-16).|Changes in Parkinson's disease Questionnaire (PDQ-39).|Changes in Visual Analog Scale for Pain.|Changes in Dosage of medications taken to treat Parkinson's disease.|Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).|Incidence and risk of AEs of special interest (serious or non-serious),|Clinically significant changes in laboratory values. - CBC|Changes in Visual Analog Scale for muscle spasms.|Clinically significant changes in vital signs. - Respiratory Rate|Clinically significant changes in vital signs. - Heart Rate|Clinically significant changes in vital signs. - Body Temperature.|Clinically significant changes in vital signs. - Blood Pressure.|Clinically significant changes in vital signs. - Oxygen Saturation.|Clinically significant changes in physical examination results.|Clinically significant changes in weight in lb.|Clinically significant changes in laboratory values. - CMP|Clinically significant changes in laboratory values. - Coagulation Panel",Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HBPD03,"June 28, 2021","May 28, 2023","May 28, 2023","June 16, 2021",,"July 21, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT04928287
441,25,NCT02805855,Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis,,"Active, not recruiting",No Results Available,"Osteoarthritis, Knee",Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells,Number of subjects experiencing adverse events.,"Jacob L. Sellon, M.D.|Mayo Clinic",All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-008179,"October 26, 2016","April 26, 2023","April 26, 2023","June 20, 2016",,"April 6, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02805855
442,5,NCT04063215,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy,,"Active, not recruiting",No Results Available,Traumatic Brain Injury,Biological: HB-adMSCs,Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10,"Hope Biosciences|The University of Texas Health Science Center, Houston",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,24,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HBTBI01,"January 1, 2020","May 27, 2022","December 31, 2024","August 21, 2019",,"May 31, 2022","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04063215
443,132,NCT05495711,hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility,,Recruiting,No Results Available,"Infertility, Female",Biological: human umbilical cord mesenchymal stem cell complex collagen|Procedure: intrauterine injection,Irregular menstruation patients efficacy evaluation|Intrauterine adhesion patients efficacy evaluation,"Sclnow Biotechnology Co., Ltd.",Female,20 Years to 39 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XY-05,"May 1, 2020","October 1, 2022","December 31, 2022","August 10, 2022",,"August 10, 2022","Xiangya Hospital Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT05495711
444,9,NCT05116540,Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis,HBMS01,Recruiting,No Results Available,Multiple Sclerosis,Biological: HB-adMSCs|Drug: Placebo,To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index|To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test|To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)|To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events,Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HBMS01,"November 24, 2021","November 22, 2023","November 22, 2023","November 11, 2021",,"May 24, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,https://ClinicalTrials.gov/show/NCT05116540
445,47,NCT00250302,Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures,,Completed,No Results Available,Tibial Fracture,Procedure: autologous mesenchymal stem cells implantation,Safety|Number of patients reaching clinical union of fracture,"Hadassah Medical Organization|Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMSC-01-HMO-CTIL,April 2009,April 2011,April 2011,"November 8, 2005",,"April 28, 2011","Hadassah Medical Organizaton, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00250302
446,281,NCT03015623,A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy,,"Active, not recruiting",No Results Available,Acute Kidney Injury,Biological: SBI-101|Device: Sham,Safety and tolerability as measured by incidence of IP-related serious adverse events,"Sentien Biotechnologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SBI-101-01,"June 20, 2017",December 2021,December 2021,"January 10, 2017",,"March 16, 2021","Lehigh Valley Hospital, Allentown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03015623
447,91,NCT03406585,Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes,,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos,"Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",NextCell Pharma Ab,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ProTrans-T1D|2017-002766-50,"November 28, 2017","July 1, 2020","September 4, 2020","January 23, 2018",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03406585
448,44,NCT03608579,Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA,,Recruiting,No Results Available,"Osteoarthritis, Hip",Drug: Autologous Adipose Derived Mesenchymal Stromal Cells,"Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip",Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-000015,"November 5, 2018",December 2022,December 2022,"August 1, 2018",,"December 17, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03608579
449,14,NCT04361942,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),COVID_MSV,Completed,No Results Available,COVID-19 Pneumonia,Biological: Mesenchymal Stromal Cells|Other: Placebo,Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses,Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TerCel_007|2020-001682-36,"May 1, 2020","October 28, 2021","October 28, 2021","April 24, 2020",,"June 7, 2022","Hospital Universitario Rio Hortega, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT04361942
450,158,NCT01605383,Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head,,Completed,No Results Available,Avascular Necrosis of Femur Head,Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment,Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC),"Banc de Sang i Teixits|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain|European Regional Development Fund",All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,23,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XCEL-MT-10-01|2010-023998-18,"May 5, 2015","April 11, 2018","June 27, 2019","May 24, 2012",,"January 21, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01605383
451,268,NCT03267784,"Allogeneic ABCB5-positive Stem Cells for Treatment of DFU ""Malum Perforans""",,Completed,No Results Available,Diabetic Neuropathic Ulcer,Biological: allo-APZ2-DFU,"Percentage of wound surface area reduction|Assessment of adverse event (AE) occurrence|Percentage of invisible and visible wound surface area reduction|Absolute wound surface area reduction|Absolute invisible and visible wound surface area reduction|Assessment of wound infection|Time to first complete wound closure|Proportion of patients achieving complete wound closure|Time to first 30% reduction of wound surface area|Proportion of patients achieving 30% reduction of wound surface area|Assessment of wound exudation, epithelialization and formation of granulation tissue|Time to amputation at target leg until Week 12|Pain assessment as per numerical rating scale (NRS)|Assessment of Quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of Dermatology-specific QoL based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs|Time to amputation of target leg until month 12",RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,23,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,allo-APZ2-DFU-II-01,"November 21, 2017","June 29, 2020","June 29, 2020","August 30, 2017",,"September 10, 2020","Universitätsmedizin Greifswald; Klinik und Poliklinik für Hautkrankheiten, Greifswald, Germany|St. Josefskrankenhaus Heidelberg GmbH; Klinische Studienabteilung, Heidelberg, Germany|Diabetologikum Raab, Privatärztliche Facharztpraxis, Kassel, Germany|pro scientia med im Mare Klinikum, Department Klinische Forschung und Entwicklung, Kronshagen, Germany|Studienambulanz Leipzig, medamed GmbH, Leipzig, Germany|Diabetologikum Ludwigshafen, Gemeinschaftspraxis, Ludwigshafen, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT03267784
452,655,NCT02644447,Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF,,Completed,No Results Available,Premature Ovarian Failure,Biological: HUC-MSCs Transplantation|Biological: HUC-MSCs with Injectable Collagen Scaffold Transplantation,Safety and Tolerability assessed by Adverse Events|Number of Antral follicle development|Estradiol (E2) serum level|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Pregnancy rate,Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Female,20 Years to 39 Years   (Adult),Phase 1|Phase 2,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CAS-XDA-POF/IGDB,October 2015,October 2018,October 2018,"December 31, 2015",,"January 13, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02644447
453,13,NCT04614025,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,,"Active, not recruiting",No Results Available,COVID|ARDS,Biological: PLX-PAD,Number of ventilator-free days|All-cause mortality|Duration of mechanical ventilation,Pluristem Ltd.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLX-COV-03,"October 19, 2020","August 4, 2021",September 2022,"November 3, 2020",,"August 10, 2021","Charite Campus Virchow, Berlin, Germany|Campus Benjamin Franklin - CBF Charité - Universitätsmedizin, Berlin, Germany|University of hospital Bonn, Bonn, Germany|Hospital Cologne-Merheim, Köln, Germany|Emek Medical Center, Afula, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Galilee Medical Center, Nahariya, Israel|Baruch Padeh Medical Center, Poriya, Tiberias, Israel",,https://ClinicalTrials.gov/show/NCT04614025
454,79,NCT02467387,A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure,,Completed,Has Results,Non-Ischemic Heart Failure,Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution,Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.,"CardioCell LLC|Stemedica Cell Technologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,23,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STEM-104-M-CHF,"June 1, 2014","May 11, 2017","May 11, 2017","June 10, 2015","January 7, 2020","January 7, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02467387/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02467387
455,221,NCT01719640,MSC and BMMNC in Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: infusion of BMMSCs|Drug: infusion BMMNCs|Drug: insulin,HbA1c|exogenous insulin requirements|fasting hemoglucose|fasting c-peptide|The incidence and severity of adverse events related to the stem cell infusion procedure,Fuzhou General Hospital,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-BMMNC-DM,January 2011,January 2014,January 2015,"November 1, 2012",,"April 25, 2018","Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT01719640
456,778,NCT04723303,Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM),,Recruiting,No Results Available,Polymyositis|Dermatomyositis,Drug: Umbilical Cord Lining Stem Cells,Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.,"University of Florida|Restem, LLC.",All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,22,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM/PM V2.0|IRB201903442|OCR33722,"October 6, 2021","April 20, 2023","April 20, 2023","January 25, 2021",,"April 20, 2022","University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04723303
457,275,NCT04445220,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,,"Active, not recruiting",No Results Available,COVID-19|Acute Kidney Injury|Sepsis,Biological: SBI-101,Safety and tolerability as measured by incidence of IP-related serious adverse events,"Sentien Biotechnologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SBI-101-02,"November 19, 2020",March 2022,September 2022,"June 24, 2020",,"January 14, 2022","University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT04445220
458,46,NCT02641860,Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis,,Completed,No Results Available,Osteoarthritis,Biological: Mesenchymal progenitor cells,"Safety, recording of Adverse Events and Serious Adverse Events|WOMAC Score|VAS Score|SF-36|The volume of articular cartilage|WORMS Score",Cellular Biomedicine Group Ltd.|RenJi Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,22,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBMG-Allo-KOA-1.1,December 2015,March 2018,March 2018,"December 30, 2015",,"September 13, 2018","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02641860
459,13,NCT02619851,A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects,,"Active, not recruiting",No Results Available,Burn Injury,Biological: ALLO-ASC-DFU|Device: Conventional Therapy,Time of re-epithelialization|Safety (laboratory tests and adverse events)|Burn Scar Index|healing status of the wound evidenced by photography,"Anterogen Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALLO-ASC-BI-201,December 2015,December 2022,June 2023,"December 2, 2015",,"July 21, 2021","Hallym university Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02619851
460,156,NCT01377870,Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis,,Completed,No Results Available,Multiple Sclerosis,Biological: intravenous injection of mesenchymal stem cells|Biological: injection of cell free media,MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC|quality of life|RAO Test|intravenous cell transplantation,Royan Institute,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Royn-nerve-001,December 2011,March 2014,April 2014,"June 21, 2011",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01377870
461,250,NCT04961658,Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients,AMETHYST,Recruiting,No Results Available,Septic Shock,Biological: GEM00220,The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose,Northern Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-GEM-001,"August 11, 2021",September 2023,August 2024,"July 14, 2021",,"June 21, 2022","Lakeridge Health, Oshawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04961658
462,172,NCT01144962,Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease,,Completed,No Results Available,Crohn's Disease|Fistula,"Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety,Leiden University Medical Center|DigestScience,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P10.102,June 2010,September 2014,December 2014,"June 16, 2010",,"December 30, 2014","Leiden University Medical Center (LUMC), Leiden, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01144962
463,288,NCT01606215,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,STREAMS,Completed,No Results Available,Multiple Sclerosis,Drug: Mesenchymal stem cells|Drug: Placebo,"Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0|Total number of GELs at weeks 4, 12 and 24 after MSC therapy|contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.|Comparison of contrast enhancing lesions between treatment periods|Combined unique MRI activity|Relapses|Progression of disability|Disease free patients|MSFC score|peripheral immune responses|Type 4 hypersensitivity reaction",Imperial College London,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRO1959|13HH0228,January 2013,August 2019,August 2019,"May 25, 2012",,"August 9, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01606215
464,12,NCT02384499,"Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",,Completed,No Results Available,Fecal Incontinence,Biological: ALLO-ASC injection|Drug: Placebo,Clinically measured abnormality of laboratory tests and adverse events|Satisfaction as measured by Wexner Score,Yonsei University,All,"19 Years and older   (Adult, Older Adult)",Phase 1,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,3-2014-0271,December 2014,"June 30, 2017","June 30, 2017","March 10, 2015",,"August 13, 2018","Section of Colon and Rectal Surger, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02384499
465,9,NCT04821102,Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration,,Not yet recruiting,No Results Available,Degenerative Arthritis|Knee Arthritis,Biological: JOINTSTEM|Drug: Saline,Arthroscopy|WOMAC total score|WOMAC subscale score|VAS score|RAND-36|IKDC|Biopsy|Use of rescue medication|Kellgren-Lawrence grade,R-Bio,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BS-JS-IIT1,"July 1, 2023","August 1, 2024","December 31, 2024","March 29, 2021",,"September 28, 2022","Bethesda Hospital, Yangsan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04821102
466,4,NCT01090817,An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease,,Completed,No Results Available,Crohn Disease,Drug: Mesenchymal stromal cells (MSC) for infusion,Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy|Incidence of infusional toxicity|Induction of remission|Improved quality of life|Endoscopic improvement.,R.P.Herrmann|The Queen Elizabeth Hospital|Concord Hospital|Sir Charles Gairdner Hospital|The Alfred|Royal Perth Hospital,All,18 Years to 55 Years   (Adult),Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC2009/123|CTN2010/0098,January 2010,June 2014,June 2015,"March 23, 2010",,"June 9, 2015","Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT01090817
467,52,NCT04713878,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19) Pneumonia,Other: Mesenchymal stem cells,Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms,Kanuni Sultan Suleyman Training and Research Hospital,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020.05.20,"May 8, 2020","June 30, 2020","July 15, 2020","January 19, 2021",,"January 20, 2021","University of Health Sciences, Istanbul, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04713878/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04713878
468,393,NCT03472742,An Follow-Up Study of Liver Cirrhosis,,Recruiting,No Results Available,Decompensated Liver Cirrhosis,Drug: Mesenchymal Stem Cell,Number of patients with adverse events (AEs) and serious AEs (SAEs)|Change of liver function evaluated by Child-Pugh Score|Improvement rate of Child-Pugh score|Improvement rate of Child-Pugh grade|Number of patients with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) findings|Number of patients with abnormal pulse rate findings|Number of patients with abnormal body temperature findings|Number of patients with abnormal electrocardiogram (ECG) findings|Number of patients with abnormal clinical chemistry parameters|Number of patients with abnormal clinical hematology parameters|Number of patients with abnormal urinalysis parameters,"Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",,21,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ADR-001-02,"March 7, 2018","December 31, 2022","June 30, 2023","March 21, 2018",,"April 27, 2022","Niigata University Medical & Dental Hospital, Niigata, Japan",,https://ClinicalTrials.gov/show/NCT03472742
469,204,NCT03117738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,,Completed,Has Results,Alzheimer Disease,Drug: AstroStem|Other: Placebo-Control,Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale),Nature Cell Co. Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AST-ADP2-US01,"May 9, 2017","June 26, 2019","August 31, 2019","April 18, 2017","July 9, 2021","August 10, 2021","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03117738
470,582,NCT05305833,Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease,,Recruiting,No Results Available,Temporomandibular Joint Disorders|Temporomandibular Disorder|Temporomandibular Joint Osteoarthritis|Temporomandibular Joint Pain|Temporomandibular Joint Effusion,Biological: Stem Cells,Change from Baseline Pain at 15th day|Change from baseline maximum mouth opening at 15th day|Change from baseline maximum mouth opening at 1 month|Change from baseline maximum mouth opening at 3 months|Change from baseline maximum mouth opening at 6 months|Change from baseline pain at 1 month|Change from baseline pain at 3 month|Change from baseline pain at 6 month|Change from baseline 'comfort ' at 6th month,TC Erciyes University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2021/584,"October 1, 2021","December 1, 2022","December 1, 2023","March 31, 2022",,"March 31, 2022","Erciyes University, Kayseri, Turkey",,https://ClinicalTrials.gov/show/NCT05305833
471,10,NCT04414592,Human Umbilical Cord Mesenchymal Stem Cells For the Treatment of Lumbar Disc Degeneration Disease,,Recruiting,No Results Available,Lumbar Disc Degeneration|Lumbar Disc Herniation,Other: human umbilical cord mesenchymal stem cells,"Lumbar disc signaling values from magnetic resonance imaging|Visual Analogue Scale (VAS) (0-10 scores, the higher scores mean a worse outcome)|Oswestry Disability Index(ODI) (0-50 scores, the higher scores mean a worse outcome)|The Short Form (36) Health survey (SF36) (0-100 scores, the higher scores mean a better outcome)|Disc Height Index (DHI) from X ray|Size of herniated nucleus pulposus from magnetic resonance imaging|Number of participants with treatment-related adverse events by CTCAE v4.0","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",All,18 Years to 60 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QFu,August 2020,March 2022,March 2023,"June 4, 2020",,"June 4, 2020","Shanghai General Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04414592
472,441,NCT03516006,Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis,,"Active, not recruiting",No Results Available,Primary Sclerosing Cholangitis,Drug: UCMSC|Drug: UDCA,adverse effects regarding UCMSC infusion|Pathological score of liver inflammation|Changes of biliary lesions in magnetic resonance image|alanine aminotransferase,Fuzhou General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCMSC-PSC,January 2017,January 2019,January 2024,"May 4, 2018",,"May 4, 2018",,,https://ClinicalTrials.gov/show/NCT03516006
473,120,NCT05152381,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis,,Recruiting,No Results Available,Osteoporosis,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-018,January 2022,January 2026,January 2026,"December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05152381
474,170,NCT05520086,Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.,CELOPHIN,Not yet recruiting,No Results Available,Chronic Conjunctivitis|Stevens-Johnson Syndrome|Lyell Syndrome|Pemphigoid,Drug: Single Dose|Drug: Double Dose,Percentage of complications|Signs improvement|Symptom improvement|Visual acuity improvement|changes in quality of life|evolution of the conjunctival flora,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Effice Servicios Para la Investigacion S.L.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CELOPHIN,September 2022,February 2024,February 2024,"August 29, 2022",,"August 29, 2022","Instituto Oftalmológico Fernández - Vega, Oviedo, Asturias, Spain|Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain|Hospital General La Mancha Centro, Alcázar De San Juan, Ciudad Real, Spain|Hospital La Arruzafa, Córdoba, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT05520086
475,50,NCT04352803,Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease,,Not yet recruiting,No Results Available,Covid-19 Pneumonia|Cyotokine Storm,Biological: Autologous Adipose MSC's,Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate,Regeneris Medical,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-MSCIV,April 2020,April 2024,April 2026,"April 20, 2020",,"April 21, 2020",,,https://ClinicalTrials.gov/show/NCT04352803
476,26,NCT02213705,Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells,MSC,"Active, not recruiting",No Results Available,SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT,Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS,toxicity|survival|progression free survival|Rodnan score|Clinical response,Assistance Publique - Hôpitaux de Paris,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC Severe Systemic Sclerosis,"May 6, 2014","February 9, 2020","January 27, 2022","August 11, 2014",,"October 19, 2020","Saint-Louis Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02213705
477,175,NCT05152368,Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy,,Recruiting,No Results Available,Peripheral Neuropathy|Trigeminal Neuralgia,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-019,January 2022,January 2026,January 2026,"December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05152368
478,591,NCT03186417,Mesenchymal Stem Cells in Early Rheumatoid Arthritis,,Recruiting,No Results Available,Rheumatoid Arthritis,Biological: 2 million hMSC/kg|Biological: 4 million hMSC/kg|Biological: 6 million hMSC/kg|Biological: placebo,Safety assessed by dose limiting toxicity (DLT)|Safety assessed by dose limiting toxicity|Safety assessed by change in spirometry|Safety assessed by all adverse events|Change in patient reported outcomes|DAS28-CRP,MetroHealth Medical Center|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB16-00587|R21AR069226,"December 15, 2017","March 31, 2023","May 31, 2023","June 14, 2017",,"April 12, 2022","UH Hospitals Cleveland, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03186417
479,234,NCT03389919,Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT,,Recruiting,No Results Available,Mesenchymal Stem Cell Transplantation,Biological: MSC administration (intraosseal),Engraftment,"National Research Center for Hematology, Russia",All,"18 Years and older   (Adult, Older Adult)",Phase 3,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BM-MSC-01,"January 1, 2017","December 31, 2020","December 31, 2022","January 4, 2018",,"January 4, 2018","BMT department, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT03389919
480,119,NCT05003934,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA,,Recruiting,No Results Available,Rheumatoid Arthritis,Biological: AlloRx,Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-8-ATG-10-03,February 2022,September 2025,September 2025,"August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003934
481,180,NCT01468064,Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke,AMETIS,Completed,No Results Available,"Stroke|Infarction, Middle Cerebral Artery",Genetic: Autologous BMSCs transplantation|Genetic: Autologous EPCs transplantation|Genetic: IV infusion of placebo,Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).,"Southern Medical University, China|The Second People's Hospital of Nanhai District of Foshan|The First People's Hospital of Haizhu District Guangzhou|Cellonis Biotechnology Co. Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ZJH-001|2011A030400007,November 2011,December 2015,March 2017,"November 9, 2011",,"April 2, 2021","Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01468064
482,157,NCT04661644,Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia,,Recruiting,No Results Available,Critical Limb Ischemia,Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial),Changes in ischemic pain|Changes in pain-free walking distance|Changes in TBI (Toe Brachial Index)|Changes in ABI (Ankle Brachial Index)|Change in size of the Ulcer|Determination of maximum tolerable dose according to DLT occurrence|Incidence of abnormal laboratory tests results|Incidence of abnormal blood pressure|Incidence of abnormal temperature|Incidence of abnormal physical condition,"S.Biomedics Co., Ltd.|Dt&Sanomedics",All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-AC-001,"November 4, 2020",June 2022,June 2022,"December 10, 2020",,"May 5, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04661644
483,122,NCT05018845,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD,,Recruiting,No Results Available,Chronic Kidney Diseases,Biological: AlloRx,Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR,The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-20-ATG-22,February 2022,November 2025,November 2025,"August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05018845
484,8,NCT05387278,Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19),,Recruiting,No Results Available,COVID-19 Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome,Drug: EV-Pure™ and WJ-Pure™|Drug: Placebo,"To Assess the safety of EV-Pure™ and WJ-Pure™ administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.|To assess the efficacy of EV-Pure™ and WJ-Pure™ compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19|Time to clinical improvement|Overall Survival|COVID-19 polymerase chain reaction (PCR) test result as negative","Vitti Labs, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EW-01,June 2022,October 2022,December 2022,"May 24, 2022",,"June 8, 2022","Kit Bartalos, Liberty, Missouri, United States",,https://ClinicalTrials.gov/show/NCT05387278
485,132,NCT04336254,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,,Recruiting,No Results Available,COVID-19,Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo),TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L),"Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020K-G005|hDPSC-CoVID-2019-02-2020,"May 6, 2020","November 30, 2021","December 31, 2021","April 7, 2020",,"March 10, 2021","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04336254
486,121,NCT05018832,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI,,Not yet recruiting,No Results Available,Traumatic Brain Injury,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-20-ATG-12-4,December 2022,November 2025,November 2025,"August 24, 2021",,"July 22, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05018832
487,53,NCT04312113,Angiographic Delivery of AD-MSC for Ulcerative Colitis,,Recruiting,No Results Available,Ulcerative Colitis,"Drug: Adipose derived, autologous mesenchymal stem cells",Number of participants with treatment-related adverse events|Number of participants with mucosal healing|Number of participants with clinical symptom response|Number of participants with improved healing on pathology,Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-000826,"November 16, 2020","December 31, 2022","December 31, 2022","March 18, 2020",,"September 30, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT04312113
488,364,NCT04611256,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,,Recruiting,No Results Available,Covid19,Biological: MSC|Drug: Control,"Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.",Hospital Reg. Lic. Adolfo Lopez Mateos|Instituto de Terapia Celular: ITC,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,060I.2020,"August 1, 2020","November 30, 2020","December 30, 2020","November 2, 2020",,"November 12, 2020","Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico",,https://ClinicalTrials.gov/show/NCT04611256
489,114,NCT05152394,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease,,Not yet recruiting,No Results Available,Parkinson Disease,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-016,January 2022,January 2026,January 2026,"December 9, 2021",,"January 28, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05152394
490,168,NCT02192749,Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism,,Completed,No Results Available,Autism,Biological: Umbilical cord mesenchymal stem cells,Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC),Translational Biosciences,All,6 Years to 16 Years   (Child),Phase 1|Phase 2,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TBS-UCMSC-ASD001,July 2014,August 2017,August 2017,"July 17, 2014",,"October 13, 2017","Stem Cell Institute, Panama City, Panama",,https://ClinicalTrials.gov/show/NCT02192749
491,608,NCT02742857,"Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury",,Completed,No Results Available,Brain Death,Biological: BQ-A Peptide Extract|Biological: Mesenchymal Stem Cells|Device: Transcranial Laser Therapy|Device: Median Nerve Stimulator,"Reversal of brain death as noted in clinical examination or EEG|Cerebrospinal fluid (CSF) analysis of color consistency, cell counts, and microbial evaluation|MRI analysis to analyze any changes in meninges|Pulse|O2 saturation|Blood Pressure|Respiration changes",Bioquark Inc.|Revita Life Sciences|Anupam Hospital,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,BQ12016|AAH -01-2016,July 2016,August 2020,August 2020,"April 19, 2016",,"October 1, 2020","Anupam Hospital, Rudrapur, Uttaranchal, India",,https://ClinicalTrials.gov/show/NCT02742857
492,10,NCT04445454,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,,Recruiting,No Results Available,Coronavirus Infection,Biological: Mesenchymal stromal cells,To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy),University of Liege,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TJT2012,"June 12, 2020","September 30, 2024","September 30, 2024","June 24, 2020",,"September 21, 2022","CHU de Liège, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT04445454
493,106,NCT03626090,Mesenchymal Stem Cell Therapy for Liver Cirrhosis,,Recruiting,No Results Available,Liver Cirrhosis,Biological: Autologous BM MSC,Clinical Examination|MR Elastography|The level of serum alanine aminotransferase (ALT)|The level of glomerular filtration rate (GFR)|The level of serum prothrombin time (PT)|The level of serum total bilirubin (TB)|The level of serum albumin (ALB)|MELD Score,Stem Med Pte. Ltd.|Parkway Cancer Centre|Asian American Liver Centre|Desmond Wai Liver & Gastrointestinal Diseases Centre,All,"21 Years to 69 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P-SM-L0001,"August 18, 2018","October 22, 2021","October 22, 2021","August 10, 2018",,"March 17, 2021","Asian American Liver Centre - Gleneagles Hospital (Annexe Block), Singapore, Singapore|Parkway Cancer Centre - Gleneagles Hospital, Singapore, Singapore|Desmond Wai Liver & Gastrointestinal Disease Centre - Mount Elizabeth Novena Specialist Centre, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03626090
494,109,NCT05147766,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease,,Recruiting,No Results Available,Congestive Heart Failure|Angina,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-017,February 2022,February 2026,February 2026,"December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05147766
495,18,NCT02260375,MSC Therapy in Liver Transplantation,,Recruiting,No Results Available,Liver Transplant Rejection,Biological: Mesenchymal Stromal Cells,Number of adverse events|Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes|Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)|T-cell function in mixed lymphocyte reaction,Monia Lorini|Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC liver transplant tolerance|2014-001531-37,October 2014,October 2024,October 2025,"October 9, 2014",,"April 6, 2018","U.S.C Nefrologia e Dialisi, Bergamo, Italy|USC Chirurgia Generale III, Bergamo, Italy|USC Ematologia, Bergamo, Italy|USC Gastroenterologia, Bergamo, Italy|Servizio di Immunoematologia e Medicina Trasfusionale, Bologna, Italy|Unità Chirurgia Generale e Trapianti, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT02260375
496,176,NCT05147779,"Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis",,Recruiting,No Results Available,Erectile Dysfunction|Peyronie's Disease|Interstitial Cystitis,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-015,December 2021,December 2025,December 2025,"December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05147779
497,16,NCT00883870,Mesenchymal Stem Cells in Critical Limb Ischemia,,Completed,No Results Available,Critical Limb Ischemia,Drug: mesenchymal stem cells|Drug: Plasmalyte A,AE and symptomatic relief|Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler,Stempeutics Research Pvt Ltd,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SRPL/CLI/07-08/001,April 2009,February 2010,August 2012,"April 20, 2009",,"March 5, 2013","M.S.Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Sri Ganga Ram Hospital, New Delhi, India",,https://ClinicalTrials.gov/show/NCT00883870
498,11,NCT04615429,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,,Recruiting,No Results Available,Acute Respiratory Distress Syndrome|COVID-19 Pneumonia,Biological: Mesenchymal stromal cells|Other: Placebo,"Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.",Cristina Avendaño Solá|Puerta de Hierro University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",COVID-AT|2020-002193-27,"September 15, 2020",January 2022,February 2022,"November 4, 2020",,"November 10, 2021","Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04615429
499,155,NCT05520112,Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells,,Not yet recruiting,No Results Available,Recurrent Pregnancy Loss,Biological: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Other: Standard treatment according to the clinical protocols,Adverse effects associated with the therapy|Percent of patients with successful pregnancy,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,Female,18 Years to 49 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(Endometrial),"November 1, 2022","December 31, 2023","December 31, 2023","August 29, 2022",,"August 29, 2022","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT05520112
500,94,NCT04939077,Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC),,Recruiting,No Results Available,"Myocardial Ischemia|Ventricular Dysfunction, Left",Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells,Left ventricular ejection fraction|Left ventricular end diastolic volume|Left ventricular end systolic volume|Stroke volume|Left ventricular apex four-chamber end systolic diameter|6 minutes walking distance|THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF,Shanghai East Hospital,All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MR-31-20-000323,"November 27, 2019","July 31, 2022","November 30, 2022","June 25, 2021",,"June 25, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04939077
501,389,NCT05507762,Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage),,Recruiting,No Results Available,Cirrhosis Due to Hepatitis B,Biological: UC-MSCs|Biological: Saline solution,FibroScan|IV-C|HA|LN|PC-III|Hepatic histopathologic examination|IgG|IgA|IgM|IgE|C3|C4|CD3|CD4|CD8|CD19|CD16+56|ALB|ALT|AST|TBIL|DBIL|HBV-DNA|Change of ultrasound examination of liver,"Renmin Hospital of Wuhan University|VCANBIO Cell & Gene Engineering Corporation, Ltd|Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RenminHJiangYingan,"July 20, 2021","July 20, 2023","August 20, 2023","August 19, 2022",,"August 19, 2022","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT05507762
502,65,NCT01933802,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis,,Completed,No Results Available,Multiple Sclerosis,Biological: intrathecal administration of autologous MSC-NP,Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy,Tisch Multiple Sclerosis Research Center of New York,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TISCHMS-MSCNP-001|IND 13889,April 2014,December 2016,March 2017,"September 2, 2013",,"March 19, 2018","Tisch MS Research Center of New York, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01933802
503,627,NCT02685722,UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers,UC-MSCs,Completed,No Results Available,Difficult to Healing of Skin Ulcers,Biological: UC-MSCs Gel group|Other: Gel group,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 6 Week,Chinese PLA General Hospital,All,"17 Years to 78 Years   (Child, Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHIN-PLAGH-ST-008,January 2012,December 2015,December 2015,"February 19, 2016",,"February 19, 2016","Chinese PLA General Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02685722
504,176,NCT02033525,Mesenchymal Stromal Cells for Degenerative Meniscus Injury,,Completed,No Results Available,Chronic Meniscal Injury,Drug: XCEL-M-ALPHA and standard rehabilitation|Other: Rehabilitation,VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires,"Banc de Sang i Teixits|Hospital Universitari Quirón Dexeus|Ministerio de Sanidad, Servicios Sociales e Igualdad",All,40 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,XCEL-MEN-01|2011-006270-13,"January 31, 2014","May 2, 2017","May 2, 2017","January 10, 2014",,"January 9, 2018","ICATME-Hospital Quiron Dexeus, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02033525
505,154,NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,,Completed,No Results Available,"Multiple Sclerosis, Chronic Progressive",Biological: NurOwn (MSC-NTF cells),Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BCT-101-US,"March 13, 2019","March 11, 2021","March 30, 2021","January 10, 2019",,"September 1, 2021","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03799718
506,67,NCT02611167,Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease,,Completed,No Results Available,Parkinson's Disease,Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg),Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS),"The University of Texas Health Science Center, Houston",All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-MS-Schiess MSC PD,"November 1, 2017","September 18, 2019","September 18, 2019","November 20, 2015",,"September 7, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02611167
507,128,NCT05158114,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia,,Recruiting,No Results Available,Testicular Injury|Oligospermia,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-2-MSC-013,January 2022,January 2026,January 2026,"December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05158114
508,705,NCT05120726,A Novel Therapeutic Treatment of Pyoderma Gangrenosum,,Recruiting,No Results Available,Pyoderma Gangrenosum,Biological: Dehydrated human amnion/chorion membrane,Gene Measurements|Wound Size|Infection|Pain Level,Louisiana State University Health Sciences Center in New Orleans,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB: #1579,"June 2, 2021","August 1, 2022","August 1, 2022","November 15, 2021",,"November 15, 2021","LSU Healthcare Network Clinic, Metairie, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT05120726/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT05120726
509,108,NCT04744051,"ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion",,Recruiting,No Results Available,Post-Concussion Syndrome,Drug: 50 Adipose Derived Stem Cell Infusion|Drug: 150 Adipose Derived Stem Cell Infusion|Drug: 300 Adipose Derived Stem Cell Infusion|Drug: Placebo Infusion,Health Status using the 36 item Short Form Health Survey (SF-36)|Assessment of Visual Attention and Task Switching|Assessment of Contextual Verbal Learning|Assessment of Verbal Fluency|Assessment of Attention and Executive functions|Assessment of Unstructured Verbal Learning and Memory|Assessment of Visuospatial Learning and Memory|Assessment of Symptoms of Anxiety over Time|Assessment of Pain|Assessment of Sleep Quality|Assessment of Treatment by Participant|Assessment of Depression by Participant,American CryoStem Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRYO_PCS_ADSC_001|FDA File No. 019089,"February 1, 2021",June 2022,September 2022,"February 8, 2021",,"February 15, 2022","BioSolutions Clinical Research Center, La Mesa, California, United States",,https://ClinicalTrials.gov/show/NCT04744051
510,427,NCT04998058,Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting,,Not yet recruiting,No Results Available,"Bone Loss, Osteoclastic|Bone Loss, Alveolar|Alveolar Bone Loss|Alveolar Bone Atrophy|Grafting Bone",Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute.,Assessment of changes in bone density and quantity|Assessment of bone quantity|Presence of bone formation markers,"Pontificia Universidade Católica do Rio Grande do Sul|ITI International Team for Implantology, Switzerland|KU Leuven|Rio Grande do Sul Brain Institute (InsCer)",All,"35 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Bone Graft-Exosomes Project,"December 15, 2022","August 30, 2023","September 30, 2024","August 10, 2021",,"April 20, 2022","Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT04998058
511,233,NCT03060551,Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients,,Completed,Has Results,Systemic Sclerosis,Procedure: SVF injection,Raynaud's Condition Scale|Hand Visual Analogue Scale|Colchin Hand Function Scale|Kapandji Score (Ranging 0 to 10) - Dominant Hand|Kapandji Score (Non-dominant Hand)|Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO)|Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS)|Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ)|The Degree of Hand Edema (Right)|The Degree of Hand Edema (Left)|Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Hemorrhages)|Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array)|Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications),Suk-Ho Moon|Seoul St. Mary's Hospital,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SVF treatment in SSc,"July 1, 2018","December 30, 2019","December 30, 2019","February 23, 2017","October 8, 2020","October 8, 2020","Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03060551/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03060551
512,339,NCT01342250,Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis,,Completed,No Results Available,Liver Cirrhosis,Biological: conventional therapy plus low dose hUC-MSCs treatment|Biological: conventional therapy plus medium dose hUC-MSCs treatment|Biological: conventional therapy plus high dose hUC-MSCs treatment,"Overall Survival (OS)|Liver function improvement|The size of liver and the width of portal venous|Incidence of hepatocellular carcinoma within 1 year|Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)|The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )","Shenzhen Beike Bio-Technology Co., Ltd.|No.85 Hospital, Changning, Shanghai, China",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BKCR-LD-1.0(2010),October 2010,July 2011,October 2011,"April 27, 2011",,"October 14, 2011","Shanghai Liver Disease Research Center, the Nanjing Military Command (Shanghai 85 Hospital), Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01342250
513,126,NCT05016817,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF,,Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis,Biological: AlloRx,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test,The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-10-ATG-13-08,February 2022,September 2025,September 2025,"August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05016817
514,85,NCT04821479,Repeated Mesenchymal Stem Cell Injections in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Mesenchymal stem cells (MSC),Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC,Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0208-16-HMO,"January 1, 2016","June 30, 2020","December 31, 2020","March 29, 2021",,"March 29, 2021",,,https://ClinicalTrials.gov/show/NCT04821479
515,43,NCT03550183,Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease,,Enrolling by invitation,No Results Available,Parkinson's Disease,Biological: mesenchymal stem cells,Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)|Changes of in the Hoehn and Yahr staging|Changes of the Mini-Mental State Examination (MMSE)|Changes of the Hamilton depression scales 24 (HAMD 24)|Changes of the Hamilton Anxiety Scale 14 (HAMA-14)|Adverse reaction,"Hebei Newtherapy BIo-Pharma technology Co., Ltd.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18967728D,"January 10, 2018","October 10, 2022","December 30, 2022","June 8, 2018",,"December 30, 2021","Hebei Newtherapy BIo-Pharma Technology Co., Ltd, Shijiazhuang, Hebei, China",,https://ClinicalTrials.gov/show/NCT03550183
516,127,NCT05535803,Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells,,Enrolling by invitation,No Results Available,Tracheal Stenosis|Laryngeal Stenosis,Biological: Olfactory mucosa-derived mesenchymal stem cells|Other: Patients treated according to current clinical protocols,Number of patients who didn't require the repeated surgical interventions,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The Republican Center for Research and Practice in Otolaryngology,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSCStenosis,"June 1, 2021","June 30, 2023","June 30, 2023","September 10, 2022",,"September 10, 2022","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT05535803
517,646,NCT02669199,MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound,MSCs,Completed,No Results Available,MSCs,Biological: MSCs,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 12 Week,Chinese PLA General Hospital,All,18 Years to 60 Years   (Adult),Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHIN-PLAGH-ST-007,January 2012,December 2015,December 2015,"February 1, 2016",,"February 1, 2016","Chinese PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02669199
518,76,NCT05362786,Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease,,Recruiting,No Results Available,Chronic Kidney Diseases,Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC),Adverse events and/or serious adverse events|Change in eGFR Value,LaTonya J. Hickson|Mayo Clinic,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-011822,"July 1, 2022",December 2025,December 2025,"May 5, 2022",,"July 22, 2022","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT05362786
519,234,NCT01915927,Stem Cell Fistula Plug in Perianal Crohn's Disease,MSC-AFP,Completed,No Results Available,Perianal Crohn's Disease,Drug: MSC-AFP,To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC,"William A. Faubion, M.D.|Mayo Clinic",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-009716,July 2013,December 2019,December 2019,"August 5, 2013",,"January 3, 2020","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01915927
520,108,NCT05147701,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases,,Recruiting,No Results Available,Eye Diseases|Retinitis Pigmentosa|Glaucoma|Diabetic Retinopathy|Macular Degeneration|Traumatic Optic Neuropathy|Optic Atrophy,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-014,January 2022,January 2026,January 2026,"December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05147701
521,246,NCT05075811,Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease,,Recruiting,No Results Available,"Pouch, Ileal|Fistula",Drug: Ossium vBM-MSC|Other: Placebo,Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease,"Amy Lightner|Ossium Health, Inc.|The Cleveland Clinic",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,21-860,"February 1, 2022","November 15, 2024","November 15, 2024","October 13, 2021",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT05075811
522,48,NCT02804945,Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies,,Completed,No Results Available,Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome,Biological: Mesenchymal Stem Cells (MSCs),Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD),M.D. Anderson Cancer Center|Katz Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0327|NCI-2016-01184,"February 24, 2017","June 13, 2019","June 13, 2019","June 17, 2016",,"April 10, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02804945
523,106,NCT05520125,Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles,,Not yet recruiting,No Results Available,Segmental Fracture - Bone Loss,Biological: Mesenchymal stem cells enriched by extracellular vesicles|Other: Standard treatment of bone defects,Adverse effects associated with the therapy|Percent of completely recovered patients with segmental bone tissue defects,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSCVesicles,"November 1, 2022","December 31, 2023","December 31, 2023","August 29, 2022",,"August 29, 2022","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT05520125
524,93,NCT02291926,Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect,,Completed,No Results Available,Cartilage Diseases|Osteoarthritis,Biological: Human umbilical cord mesenchymal stem cells,Severity of adverse events|Magnetic resonance imaging (MRI) of the knee|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),"Shenzhen Hornetcorn Bio-technology Company, LTD|The Fifth Affiliated Hospital of Guangzhou Medical University",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HYK-Articular Cartilage Defect,December 2014,July 2016,December 2016,"November 17, 2014",,"May 10, 2017","The Fifth Affiliated Hospital Immunotherapy center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02291926
525,170,NCT01663376,Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia,,Completed,No Results Available,Critical Limb Ischemia,Procedure: Autologous Adipose Tissue derived MSCs Transplantation,Major Adverse Events Analysis (MAEs)|Ankle-Brachial Index (ABI)|Digital subtraction angiography (DSA)|Thermography|Wong-Baker FACES Pain Rating Score|Treadmill test,R-Bio|Pusan National University Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KSC-MSCs-CLI,January 2009,March 2010,April 2011,"August 13, 2012",,"June 5, 2019","Pusan National University Hospital, Pusan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01663376
526,247,NCT03826433,hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis,,Recruiting,No Results Available,Hepatitis B,Biological: Peripheral iv,Validity evaluation by detection of the Model for end-stage Liver Disease score of participants|Safety evaluation by detecting Blood routine|Validity evaluation by detection of the child-pugh of participants,"Sclnow Biotechnology Co., Ltd.",All,18 Years to 60 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XY-04,"October 1, 2018",December 2022,June 2023,"February 1, 2019",,"July 22, 2022","Xiangya Hospital Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03826433
527,122,NCT02034188,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,,Completed,No Results Available,Multiple Sclerosis,Biological: Umbilical cord mesenchymal stem cells,Number of participants with adverse events|Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)|Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale|Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT)|Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test|Number of participants with a change in mobility and leg function as measured by the 25 foot walking test|Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire|Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)|Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI),Translational Biosciences,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TBS-UCMSC-001,January 2014,March 2016,March 2016,"January 13, 2014",,"August 10, 2017","Stem Cell Institute, Panama City, Panama",,https://ClinicalTrials.gov/show/NCT02034188
528,128,NCT04651855,The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS,ALSTEM,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Mesenchymal stem cells isolated from Wharton's jelly,"The number of (S)AESI [(Serious) Adverse Event of Special Interest]|Disease progression|Pulmonary function decline|Muscle strength decline|Upper motor neuron function|Cognitive function|Quality of life changes|The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)|The change of defined cytokines, chemokines level in blood|The change of creatinine and p75ECD level in urine|Muscle function changes|The change of the brain visualization|SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI|Survival period to disease progression|Mortality rate","Polski Bank Komorek Macierzystych JSC (PBKM)|National Center for Research and Development, Poland",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALSTEM,"December 2, 2020","March 8, 2022",April 2023,"December 3, 2020",,"May 3, 2022","JST sp. z o.o., Częstochowa, Poland",,https://ClinicalTrials.gov/show/NCT04651855
529,117,NCT05003908,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes,,Recruiting,No Results Available,Diabetes,Biological: AlloRx,Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction,The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-10-ATG-11-01,February 2022,November 2025,November 2025,"August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003908
530,127,NCT05003921,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: AlloRx,Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-7-ATG-7-01,February 2022,September 2025,September 2025,"August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003921
531,6,NCT05521672,Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease,MEIC,Not yet recruiting,No Results Available,Stenosis; Bowel|Crohn Disease,Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC),Percentage of complications|Change from baseline length and diameter of the stenosis|Crohn's disease activity index (CDAI) questionnaire score|inflammatory bowel disease questionnaire (IBDQ32 )|patients with an obstructive episode who required resection surgery,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Effice Servicios Para la Investigacion S.L.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FJD-MEIC-21-01|2021-006068-26,September 2022,"June 1, 2025","June 1, 2025","August 30, 2022",,"August 30, 2022","Hospital Universitario Valle de Hebrón, Barcelona, Spain|Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT05521672
532,756,NCT01771913,Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts,,Completed,Has Results,Breast Reconstruction|Contour Irregularities|Volume Insufficiency,Genetic: centrifuged fat graft|Genetic: ADSCs enriched fat graft,Volume Maintenance|Immunophenotyping,University of Sao Paulo,Female,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",boosteredADSCs,March 2012,September 2014,May 2015,"January 18, 2013","August 24, 2015","August 24, 2015","Hospital Municipal Carmino Caricchio, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01771913
533,268,NCT04888949,A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19),,Recruiting,No Results Available,SARS-CoV-2 Infection( COVID-19 ),Biological: Mesenchymal stem cell|Biological: Placebo,Ventilator Free Days,"Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADR-001-1921,"June 15, 2021","September 30, 2022","September 30, 2022","May 17, 2021",,"September 10, 2021","Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT04888949
534,83,NCT04326985,RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee):,MSC,Completed,No Results Available,"Osteoarthritis, Knee",Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)|Drug: Hyaluronic acid (HA),Knee Society Score|Knee Society Function Score|Magnetic resonance image (MRI) and X-ray assessment|Health related quality of life score (HRQoL) - SF36|Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Visual Analogic Scale (VAS) pain evaluation,Chinese University of Hong Kong,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OA MSC Study protocol v 1.4,"January 31, 2015","January 30, 2019","February 28, 2019","March 30, 2020",,"May 18, 2020","Department of Orthopaedics & Traumatology, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04326985
535,106,NCT05152290,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI,,Recruiting,No Results Available,Spinal Cord Injuries,Biological: AlloRx,Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-012,January 2022,January 2026,January 2026,"December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05152290
536,17,NCT00883727,Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI,,Completed,No Results Available,Myocardial Infarction,Drug: Stem cell|Drug: Plasmalyte A,AE and ECG parameters|Regional myocardial perfusion and infarct size,Stempeutics Research Pvt Ltd,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",SRPL/AMI/07-08/001,April 2009,May 2010,August 2012,"April 20, 2009",,"March 5, 2013","Care Hospital, Hyderabad, Andhra Pradesh, India|SAL Hospital and Medical Institute, Ahmedabad, Gujarat, India|MS Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT00883727
537,186,NCT01844661,Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.,,Completed,No Results Available,Children|Solid Tumors|Metastases,Biological: CELYVIR,Adverse effects after intravenous infusions|Clinical outcome,"Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Instituto de Salud Carlos III",All,"6 Months to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT2008-000364-16,January 2013,December 2014,January 2016,"May 1, 2013",,"February 19, 2016","Hospital Universitario Niño Jesús, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01844661
538,63,NCT05331872,Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis,,Recruiting,No Results Available,Liver Cirrhosis,Biological: Human umbilical cord-derived mesenchymal stem cell infusion,Number of Adverse events and serious adverse events (AEs or SAEs)|Change of liver function through the Model for End Stage Liver Disease (MELD) score|Change in health-related quality of life using Chronic Liver Disease Questionnaire - (CLDQ),Vinmec Research Institute of Stem Cell and Gene Technology,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISC.19.29,"December 1, 2020","December 30, 2023","December 30, 2023","April 18, 2022",,"April 18, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT05331872
539,239,NCT03211793,Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis,MANUS,Recruiting,No Results Available,Systemic Sclerosis|Digital Ulcer,Drug: Mesenchymal stromal cells|Other: Placebo,Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations,UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MANUS|2015-000168-32,"October 6, 2021","November 1, 2023","November 1, 2023","July 7, 2017",,"March 22, 2022","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT03211793
540,125,NCT05018767,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty,,Recruiting,No Results Available,Frailty,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-11-ATG-12-01,February 2022,November 2025,November 2025,"August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05018767
541,73,NCT01068951,Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells,,Completed,No Results Available,Type 1 Diabetes,Biological: Mesenchymal stem cells,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,Uppsala University Hospital,All,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AS2010-0180,June 2010,September 2013,September 2013,"February 17, 2010",,"February 5, 2014","Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01068951
542,105,NCT05147675,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA,,Recruiting,No Results Available,Osteoarthritis|Spinal Arthritis,Biological: AlloRx,Safety (adverse events)|Efficacy: Single Assessment Numeric Evaluation Score (SANE),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-011,December 2021,December 2025,December 2025,"December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05147675
543,138,NCT02594839,Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease,,Completed,No Results Available,Idiopathic Interstitial Pneumonia|Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis,Drug: Bone marrow mesenchymal stem cells|Drug: Placebo,Safety: Number of serious adverse events|DLCO changes from baseline|FVC changes from baseline|exercise capacity changes,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILD-01,February 2013,January 2018,January 2018,"November 3, 2015",,"January 9, 2018","Federal Research Clinical Center FMBA of Russia, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT02594839
544,110,NCT05158933,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure,,Recruiting,No Results Available,Ovarian Failure,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-2-MSC-012,January 2022,January 2026,January 2026,"December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05158933
545,29,NCT02755922,Bone Regeneration With Mesenchymal Stem Cells,,Completed,No Results Available,Mandibular Fractures,Biological: Application of autologous mesenchymal stem cells,"Change of bone quality|Number of patients with infection ( increase of local temperature, tenderness, leukocyte count >10,000/ µL, confirmed by Gram stain and blood culture).|Number of patients with bleeding after surgery (Persistent bleeding, ineffectiveness stopping bleeding using dressings)|Number of patients with surgical wound dehiscence (subcutaneous tissue , bone or osteosynthesis material exposed and seen through opened skin )",Instituto Mexicano del Seguro Social,All,"17 Years to 59 Years   (Child, Adult)",Phase 3,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2010-1301-27,April 2010,September 2010,December 2010,"April 29, 2016",,"April 29, 2016",,,https://ClinicalTrials.gov/show/NCT02755922
546,124,NCT05016804,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis,,Recruiting,No Results Available,Systemic Sclerosis,Biological: AlloRx,Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-10-ATG-12-04,February 2022,November 2025,November 2025,"August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05016804
547,679,NCT05113342,Descartes-25 in Relapsed/Refractory Multiple Myeloma,,Recruiting,No Results Available,Multiple Myeloma|Relapse Multiple Myeloma,Drug: Descartes-25,Maximum tolerated dose of Descartes-25|Overall Response Rate according to the IMWG response criteria|Median Duration of Response,Cartesian Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DC25-1A,"November 25, 2021",December 2022,January 2023,"November 9, 2021",,"December 17, 2021","Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Medical College of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT05113342
548,8,NCT05215288,Intermediate Size Expanded Access for the Use of ExoFlo in the Treatment of Abdominal Solid Organ Transplant Patients Who Are at Risk of Worsening Allograft Function With Conventional Immunosuppressive Therapy Alone,,Not yet recruiting,No Results Available,Solid Organ Transplant Rejection|Organ Rejection Transplants|Organ Rejection,Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment,Number of participants with adverse/serious adverse events,"Direct Biologics, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DB-EF-TRANSPLANT-0002,October 2022,October 2022,December 2022,"January 31, 2022",,"September 10, 2022",,,https://ClinicalTrials.gov/show/NCT05215288
549,522,NCT05279768,Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.,,Not yet recruiting,No Results Available,Polycystic Ovary Syndrome,Biological: WJ-MSCs|Biological: Secretomes|Biological: WJ-MSCs and Secretomes,"Blood serum sample|Free Androgen index (FAI)|Insulin, Glucose Plasma, and Insulin Resistance|Sex Hormone Binding Globulin (SHBG) and Anti-Mullerian Hormone (AMH)|Leptin and Adiponectine Profile|TNFα, IL-1 β, IL-6, IL-10 Profile",PT. Prodia Stem Cell Indonesia,Female,20 Years to 40 Years   (Adult),Phase 1|Phase 2,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,CT/PCOS/PSI/2022,April 2022,April 2022,April 2023,"March 15, 2022",,"March 15, 2022","PT Prodia StemCell Indonesia, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT05279768
550,638,NCT02696876,Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair,AURA,Recruiting,No Results Available,"Defect of Articular Cartilage|Cartilage Injury|Osteoarthritis, Knee",Device: Arthroscopic synovial brushing|Procedure: Microfracture,"The mean change in the number of MSCs present in the knee pre- and post- microfracture/microfracture plus arthroscopic synovial brushing.|Number of patients whose clinical effusion scores improve at 3, 6 and 12 months|Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months|Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)|Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Visual Analogue Scale (VAS)",University of Leeds|The Leeds Teaching Hospitals NHS Trust,All,"16 Years to 55 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RR15/173,January 2017,December 2021,December 2021,"March 2, 2016",,"April 28, 2021","Chapel Allerton Orthopaedic Centre, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02696876
551,112,NCT05147688,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases,,Recruiting,No Results Available,Pulmonary Disease|Asthma|Chronic Obstructive Pulmonary Disease,Biological: AlloRx,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Pulmonary function test,The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-1-MSC-013,December 2021,December 2025,December 2025,"December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05147688
552,574,NCT04288934,Treatment of Spinal Cord Injuries With (AutoBM-MSCs)vs (WJ-MSCs).,,Completed,No Results Available,Spinal Cord Injuries,Biological: Collection and expansion of BM-MSC|Diagnostic Test: VI-SCI evaluation and patients' follow up,SCI evaluation and patients follow up|SCI evaluation and MSCs transplantation,University of Jordan,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCICTC,"August 15, 2017","April 15, 2020","September 20, 2020","February 28, 2020",,"August 25, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT04288934
553,379,NCT03638154,Regenerative Potential of Cultured Gingival Fibroblast- Mesenchymal Stem Cells in Treatment of Periodontitis,,Completed,No Results Available,Periodontal Intrabony Defect,Procedure: GF+GMSCs carried on β TCP|Procedure: β TCP bone substitute only,bone gain in periodontal defects(by mm)|the regenerative power of the defect was evaluated by growth factor concentration in GCF.,Ain Shams University,All,32 Years to 50 Years   (Adult),Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",PER 16-P1,"March 15, 2016","April 15, 2016","February 22, 2018","August 20, 2018",,"August 20, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03638154/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03638154
554,107,NCT05158127,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer,,Recruiting,No Results Available,Skin Ulcer,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-2-MSC-015,January 2022,January 2026,January 2026,"December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05158127
555,98,NCT03070275,Dental Implant Placement in Adjunction With Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs),Implant_bone,Completed,No Results Available,Implant Therapy,Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Procedure: Two-stage surgical implant placement,A reduction in the marginal bone levels|Radiographic changes in the marginal bone levels|Reduction in the thickness of the buccal/lingual bone|Changes in the alveolar mucosa|Changes in the width of keratised mucosa,Aristotle University Of Thessaloniki,All,20 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ELKE_91480,February 2015,June 2017,December 2017,"March 3, 2017",,"November 1, 2018",,,https://ClinicalTrials.gov/show/NCT03070275
556,46,NCT01788059,The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital,,Completed,No Results Available,Nonunion Fracture,Other: injection the mesenchymal stem cell in non union site,"clinical and radiological union at 1 month to 6 months|•Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects.|Incidence of adverse events in patients (e.g infection , malignancy , ...) Adverse events will be continuously monitored",Emdadi Kamyab Hospital,All,18 Years to 60 Years   (Adult),Phase 2,19,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,900939,January 2013,October 2013,November 2013,"February 11, 2013",,"December 30, 2013","Emdai Kamyab Hospital, Mashhad, Khorasan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01788059
557,4,NCT01678534,"Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial",AMASCIS-01,Completed,No Results Available,Ischemic Stroke,Drug: Allogenic mesenchymal stem cells from adipose tissue|Drug: Placebo,"Number of participants with Adverse events, complications.|Efficacy",Instituto de Investigación Hospital Universitario La Paz,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMASCIS-01/2011|2011-003551-18,September 2014,December 2017,December 2017,"September 5, 2012",,"February 28, 2018","University Hospital La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01678534
558,5,NCT01222039,Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.,CMM/EICH/2008,Completed,No Results Available,Graft Versus Host Disease|Chronic and Expanded Graft Versus Host Disease|Immune System Diseases,Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.,"Number of adverse events|Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment|Overall survival and disease-free survival.|Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.",Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT: 2008-004014-27,June 2010,June 2014,June 2014,"October 18, 2010",,"November 18, 2016","Hospital de Jerez de la Frontera., Jerez de la Frontera, Cádiz., Spain|Hospital Universitario Virgen de las Nieves, Granada., Spain|Hospital Universitario Virgen del Rocío de Sevilla, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01222039
559,217,NCT03079401,Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle,,"Active, not recruiting",No Results Available,Hypoplastic Left Heart Syndrome|Atrioventricular Canal,Biological: MPC; rexlemestrocel-L,Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio,Boston Children's Hospital,All,up to 5 Years   (Child),Phase 1|Phase 2,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IRB-P00020575,"November 27, 2017",January 2023,January 2024,"March 14, 2017",,"January 5, 2022","Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03079401
560,559,NCT02378974,Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Cordstem-ST in Patients With Cerebral Infarction,,Completed,No Results Available,Cerebral Infarction,Biological: Cordstem-ST|Biological: Placebo,Number of treatment related-adverse events during the study period|Improvement in clinical function as assessed by Modified Rankin Score(mRS) compared to baseline at 6 months|Improvement in clinical function as assessed by National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months|Improvement in clinical function as assessed by Barthel Index (BI) compared to baseline at 6 months|Improvement in clinical function as assessed by Brain MRI tratogram compared to baseline at 6 months,"CHABiotech CO., Ltd",All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,19,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CHA-CST-101,"February 24, 2015","April 13, 2017","April 13, 2017","March 4, 2015",,"November 15, 2019","CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02378974
561,36,NCT02181712,Mesenchymal Stem Cell Therapy for Lung Rejection,,Completed,No Results Available,Lung Transplant Reject|Bronchiolitis Obliterans,Biological: Mesenchymal stem cell 0.5|Biological: Mesenchymal stem cell 1.0,Number of Participants with serious and non-serious adverse events|Changes in pulmonary function tests,Mayo Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,19,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-000025,July 2014,"August 12, 2021","August 12, 2021","July 4, 2014",,"October 7, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02181712
562,18,NCT02492516,Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: mesenchymal stem cells,fever|Unconsciousness|The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)|FVC,Royan Institute,All,18 Years to 55 Years   (Adult),Phase 1,19,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-008,September 2014,March 2017,April 2017,"July 8, 2015",,"April 28, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02492516
563,141,NCT02230514,Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones,,Completed,No Results Available,Atrophic Nonunion of Fracture,Drug: XCEL-MT-OSTEO-ALPHA|Other: autologous iliac crest|Procedure: Surgery,Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test,Banc de Sang i Teixits|Hospital ASEPEYO Sant Cugat,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,XCEL-PSART-01|2013-005025-23,"November 20, 2014","March 5, 2019","December 20, 2019","September 3, 2014",,"April 12, 2021","Hospital ASEPEYO Sant Cugat, Sant Cugat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02230514
564,35,NCT04457037,Treatment of Patients With Trophic Ulcers Using Mesenchymal Stem Cells,,Completed,No Results Available,Trophic Ulcer,Biological: Autologous adipose-derived mesenchymal stem cells,Number of patients with tropic ulcers cured|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(TrophicUlcer),"October 1, 2009","December 31, 2013","December 31, 2013","July 7, 2020",,"July 7, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04457037
565,33,NCT04626583,Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells,,Recruiting,No Results Available,Mesenchymal Stromal Cells|Cornea|Safety|Corneal Defect,Biological: Allogeneic MSC,Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness,University of Illinois at Chicago|United States Department of Defense,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0334|W81XWH-18-1-0661,"March 5, 2021","December 30, 2023","December 30, 2023","November 12, 2020",,"April 21, 2022","University of Illinois, Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04626583
566,241,NCT04315025,Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa,RP,Completed,No Results Available,Retinitis Pigmentosa,Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Biological: Conditioned Medium (CM),Visual Acuity Test|Visual Field Test|Funduscopy|Electrorectinography|Optical Coherence Tomography (OCT)|Angiography,PT. Prodia Stem Cell Indonesia,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CT/RP/02/2018,"October 7, 2018","June 20, 2019","September 20, 2019","March 19, 2020",,"June 4, 2020","Jakarta Eye Center Hospital, Jakarta, DKI Jakarta, Indonesia|Sardjito Hospital, Yogyakarta, Special Region, Indonesia",,https://ClinicalTrials.gov/show/NCT04315025
567,570,NCT05151133,Clinical Study of Allergic Rhinitis Therapy by Stem Cells,,Recruiting,No Results Available,Allergic Rhinitis,Biological: Low dose UCMSCs|Biological: Moderate dose UCMSCs|Biological: High dose UCMSCs,Severity and incidence of adverse events (SIAE) on the day of treatment|3rd day SIAE|1 week SIAE|1 month SIAE|3 months SIAE|6 months SIAE|12 months SIAE|24 months SIAE|RQLQ score|VAS score|Nasal function test|Nasal endoscopy|U-HCG|Detection of Serum Interferon γ (IFN-γ)|Detection of Serum Interferon α (IFN-α)|Detection of Serum Interleukin 1β (IL-1β)|Detection of Serum Interleukin 2 (IL-2)|Detection of Serum Interleukin 4 (IL-4)|Detection of Serum Interleukin 5 (IL-5)|Detection of Serum Interleukin 6 (IL-6)|Detection of Serum Interleukin 8 (IL-8)|Detection of Serum Interleukin 10 (IL-10)|Detection of Serum Interleukin 12P70 (IL-12P70)|Detection of Serum Interleukin 17A (IL-17A)|Detection of Serum Tumor necrosis factor-α（TNF-α）|Detection of inflammatory factor Interferon γ (IFN-γ) in nasal secretions|Detection of inflammatory factor Interferon α (IFN-α) in nasal secretions|Detection of inflammatory factor Interleukin 1β (IL-1β) in nasal secretions|Detection of inflammatory factor Interleukin 2 (IL-2) in nasal secretions|Detection of inflammatory factor Interleukin 4 (IL-4) in nasal secretions|Detection of inflammatory factor Interleukin 5 (IL-5) in nasal secretions|Detection of inflammatory factor Interleukin 6 (IL-6) in nasal secretions|Detection of inflammatory factor Interleukin 8 (IL-8) in nasal secretions|Detection of inflammatory factor Interleukin 10 (IL-10) in nasal secretions|Detection of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions|Detection of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions|Detection of inflammatory factor Tumor necrosis factor-α（TNF-α） in nasal secretions,Yantai Yuhuangding Hospital,All,18 Years to 60 Years   (Adult),Phase 1,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2021-002,"June 13, 2022","December 15, 2022","December 15, 2024","December 9, 2021",,"June 30, 2022","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,https://ClinicalTrials.gov/show/NCT05151133
568,163,NCT05204329,Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease,MSC Secretome,Not yet recruiting,No Results Available,Mesenchymal Stromal Cells|Cornea|Corneal Defect|Corneal Epithelium Defect,Biological: MSC Secretome Eye Drops,Epithelial Status Assessment|Visual Acuity|Corneal Epithelial thickness|Corneal Scarring / Haze|Tolerability of MSC secretome drops|Durability of Corneal Epithelial Status Improvement|Time to Improvement of Corneal Epithelial Barrier,University of Illinois at Chicago|National Institutes of Health (NIH)|National Eye Institute (NEI),All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,18,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2021-0754|1UG3EY031809-01,"December 1, 2022","January 1, 2025","January 1, 2025","January 24, 2022",,"January 24, 2022",,,https://ClinicalTrials.gov/show/NCT05204329
569,29,NCT04356287,Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis,CARE-SSc,Not yet recruiting,No Results Available,"Sclerosis, Systemic|Mesenchymal Stem Cells",Biological: UCMSC|Other: Placebo,Measure of safety one month after first infusion|Change in modified Rodnan skin score (mRss) between Month 0 and Month 12,"Marie Hudson, MD|Medical University of South Carolina|McGill University Health Centre/Research Institute of the McGill University Health Centre|Université de Montréal|Assistance Publique - Hôpitaux de Paris|Centre hospitalier de l'Université de Montréal (CHUM)|University Paris 7 - Denis Diderot|Sir Mortimer B. Davis - Jewish General Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP-05-2020-2251,May 2022,April 2024,April 2025,"April 22, 2020",,"April 1, 2022",,,https://ClinicalTrials.gov/show/NCT04356287
570,88,NCT02474342,Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease,,Completed,No Results Available,Rotator Cuff Disease,Biological: Autologous Adipose Tissue Derived MSCs Transplantation,SPADI(Shoulder pain and disability index)Score|Constant-Murley score|Visual Analog Scale_pain in motion|Changes in the size of rotator cuff tears determined by MRI|Changes in the size of rotator cuff tears determined by arthroscopy|Adverse event,Seoul National University Hospital,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRM-15-01,"July 7, 2015",November 2016,"November 7, 2016","June 17, 2015",,"March 7, 2017","Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02474342
571,677,NCT05348772,A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19,,Not yet recruiting,No Results Available,COVID-19,Drug: AmnioPul-02,Dose-limiting adverse events/toxicities (DLTs)|OS|Event-free survival|Ventilator-free days|Time to clinical response|Time to hospital discharge,Amniotics AB,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AmnioPul-02-001,"June 30, 2022","June 30, 2023","June 30, 2024","April 27, 2022",,"April 27, 2022",,,https://ClinicalTrials.gov/show/NCT05348772
572,197,NCT01585857,ADIPOA - Clinical Study,,Completed,No Results Available,Osteoarthritis,Biological: Autologous adipose derived stem cells administrated for intra-articular use,Recording of Serious Adverse Events|Functional status of the knee|Quality of life,"University Hospital, Montpellier",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8606,April 2012,December 2014,December 2014,"April 26, 2012",,"December 4, 2014","UH Montpellier, Montpellier, France|Orthopädische Klinik, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT01585857
573,80,NCT01809769,Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis,,Completed,No Results Available,Knee Osteoarthritis,Biological: Mesenchymal stem cells low-dose group|Biological: Mesenchymal stem cells mid-dose group|Biological: Mesenchymal stem cells high-dose group,Recording of Adverse Events and Serious Adverse Events|Electrocardiogram|Vital signs|Physical examination|WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Laboratory tests|SF-36|NRS-11|The volume of articular cartilage,Cellular Biomedicine Group Ltd.|RenJi Hospital,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBMG-KOA-1.1,March 2013,March 2015,July 2015,"March 13, 2013",,"April 4, 2016","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01809769
574,138,NCT05054803,Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury,,"Active, not recruiting",No Results Available,Spinal Cord Injury Cervical,Drug: WJ-MSC (XCEL-UMC-BETA)|Drug: Placebo,Incidence of adverse events|American Spinal Injury Association (ASIA) impairment scale|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walking index for spinal cord injury (WISCI II)|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|Spinal Cord Independence Measure III (SCIM III)|World Health Organization Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF,Banc de Sang i Teixits|Institut Guttmann|Academic Research Organization (ARO) - VHIR|Complexo Hospitalario Universitario de A Coruña,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BST-SCI-02,"October 13, 2021",October 2023,October 2025,"September 23, 2021",,"July 8, 2022","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain",,https://ClinicalTrials.gov/show/NCT05054803
575,72,NCT01300598,Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis,,Completed,No Results Available,Degenerative Arthritis,Procedure: Autologous Adipose Tissue derived MSCs Transplantation,Safety evaluation|WOMAC(Western Ontario and McMaster Universities) Index|Magnetic Resonance Imaging|KSCRS(Knee Society Clinical rating System)|VAS(11-point box visual analogue scale)|Histological evaluates,R-Bio,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jointstem,December 2008,September 2011,March 2012,"February 21, 2011",,"June 5, 2019","SMG-SNU Boramae Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01300598
576,629,NCT02468492,Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation,,Completed,No Results Available,Knee Osteoarthritis,Biological: Platelet Rich Plasma|Other: Normal Saline,Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes,Hunter Holmes Mcguire Veteran Affairs Medical Center|Foundation for Physical Medicine and Rehabilitation,All,"40 Years and older   (Adult, Older Adult)",Early Phase 1,18,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,IRB #01979/FDA IDE#15944,September 2014,November 2015,November 2015,"June 10, 2015",,"August 16, 2017","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02468492
577,92,NCT05468502,Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF),,Not yet recruiting,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: Human umbilical cord mesenchymal stem cell injection,Tolerance of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection|Dose exploration of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection|Preliminary efficacy evaluation,Shanghai Life Science & Technology,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHLF-MSC-101,August 2022,August 2023,August 2025,"July 21, 2022",,"August 1, 2022","Shanghai Sixth People's Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT05468502
578,639,NCT03747913,Oxidative Stress as an Acute Exercise-induced Mechanism of Stem and Progenitor Cell Mobilization,EISMO,Completed,No Results Available,Healthy,Dietary Supplement: Antioxidative supplementation,Changes in exercise-dependently mobilized stem and progenitor cell numbers in the peripheral blood with antioxidative supplementation|Changes in numbers of exercise-induced apoptotic cells and oxidative stress markers in the peripheral blood with antioxidative supplementation,Swiss Federal Institute of Technology,Male,18 Years to 35 Years   (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,EISMO,"May 2, 2019","October 21, 2019","October 31, 2019","November 20, 2018",,"December 16, 2019","Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich, Zürich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT03747913
579,148,NCT03589287,Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis,,Completed,No Results Available,Knee Osteoarthritis,Biological: Chondrochymal®,Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment,"Taipei Veterans General Hospital, Taiwan|Virginia Contract Research Organization Co., Ltd.",All,"40 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-11-006C,"May 2, 2018","May 3, 2019","April 30, 2020","July 17, 2018",,"August 19, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03589287
580,277,NCT04976140,Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis,,Enrolling by invitation,No Results Available,Polymyositis|Dermatomyositis,Biological: PN-101,Dose Limiting Toxicity(DLT)|International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)|Response rate of IMACS-TIS|Changes of Core Set Activity Measures(CSAM)|Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Changes of Peak Pruritus Numeral Rating Scale(PPNRS),Paean Biotechnology Inc.,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PN-101-101,"December 15, 2021",April 2023,April 2023,"July 26, 2021",,"June 13, 2022","Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04976140
581,474,NCT04877067,Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation,Magnovision,Completed,No Results Available,Methanol Poisoning|Toxic Optic Neuropathy|Stem Cell Tyrosine Kinase 1 Y842X|Magnetic Field Exposure,Biological: Wharton jelly derived mesenchymal stem cell|Device: Repetitive electromagnetic stimulation,"ETDRS visual acuity:|Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)|Ganglion cell complex thickness (GCC thickness, µm):|Pattern visual evoked potential (pVEP)",Ankara Universitesi Teknokent|International Olympic Committee,All,"18 Years and older   (Adult, Older Adult)",Phase 3,18,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,56733164/203 E.1925,"April 1, 2019","April 30, 2021","April 30, 2021","May 7, 2021",,"May 10, 2021","Ankara University Biotechnology Institute, Ankara, Türkiye, Turkey|Umut Arslan, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT04877067
582,22,NCT02336646,Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease,,Completed,No Results Available,Critical Limb Ischemia,Drug: Allogenic MSC|Drug: Normal saline,Adverse events|Efficacy-The Wong Baker FACES® pain rating scale|Efficacy-Transcutaneous oxygen pressure(TcPO2)|Efficacy-walking distance (TWD)|Efficacy-Ankle Brachial Pressure Index (ABPI),"Taiwan Bio Therapeutics Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012-02-070B,"May 1, 2015","April 27, 2018","December 20, 2018","January 13, 2015",,"August 25, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02336646
583,229,NCT03724617,Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium,,Completed,No Results Available,Thin Endometrium|Intrauterine Adhesion,Drug: umbilical cord mesenchymal stem cells combined with collagen scaffold,the change of endometrial thickness|pregnancy rate|live birth rate|abortion rate,Sir Run Run Shaw Hospital,Female,20 Years to 40 Years   (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRRSHRMC20180924,"October 29, 2018","June 30, 2020","December 31, 2020","October 30, 2018",,"April 13, 2021","Sir Run Run Shaw hopital,School of medicine,Zhejiang University, Hangzhou, China",,https://ClinicalTrials.gov/show/NCT03724617
584,1,NCT04749667,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,SMART-MS,Recruiting,No Results Available,Multiple Sclerosis|Progressive Multiple Sclerosis,Other: MSCs|Drug: Saline,Neurophysiological parameters - Combined evoked potentials|Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events,"Haukeland University Hospital|University of Bergen|University Hospital Ulm|University Hospital, Akershus|St. Olavs Hospital|University Hospital of North Norway",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",159326,"August 9, 2021","October 4, 2024","January 4, 2025","February 11, 2021",,"July 29, 2022","University hospital of North Norway, Tromsø, Troms Og Finnmark, Norway|St.Olav university hospital, Trondheim, Trøndelag, Norway|Haukeland University Hospital, Bergen, Vestland, Norway|Akershus university hospital, Lørenskog, Viken, Norway",,https://ClinicalTrials.gov/show/NCT04749667
585,511,NCT04347967,Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS),,Not yet recruiting,No Results Available,Acute Respiratory Distress Syndrome,Biological: UMC119-06,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in mortality status|Ventilator Free Days (VFD)|Change in Oxygenation Index (OI)|Change in Lung Injury Score (LIS)|Change in positive end-expiratory pressure (PEEP)|Change in Lung Static Compliance|Change in acute physiology and chronic health evaluation score (APACHE II),"Meridigen Biotech Co., Ltd.",All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMC119-06-ARDS-01,September 2021,December 2022,December 2023,"April 15, 2020",,"May 18, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04347967
586,116,NCT05491135,Hepatocyte Microbeads for Acute Liver Failure,HELP,Not yet recruiting,No Results Available,Acute Liver Failure,Biological: HMB002,"Safety: Moderate to severe (including life threatening and death) adverse event occurrences due to product in 1st 52 weeks post procedure|Tolerability: assessed by the proportion of initiated infusion where >80% of the infusion is received by the patient.|Biological activity: Survival with native liver at 24 weeks post treatment.|Change in blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment.|Change in Quality of life measures from baseline to week 52|Patient survival with native liver at 52 weeks post treatment|Patient survival with transplanted or native liver at 24 and 52 weeks post treatment.",King's College Hospital NHS Trust|Medical Research Council,All,up to 16 Years   (Child),Phase 1|Phase 2,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3571|2019-000316-29,September 2022,November 2025,May 2026,"August 8, 2022",,"August 8, 2022",,,https://ClinicalTrials.gov/show/NCT05491135
587,79,NCT01919827,Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis,CMM/FPI,Completed,No Results Available,Idiopathic Pulmonary Fibrosis,Biological: Endobronchial infusion of adult mesenchymal stem cells|Biological: Autologous mesenchymal stem cells derived from bone marrow,Number of participants with adverse side effects.|Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF,"Clinica Universidad de Navarra, Universidad de Navarra",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMM/FPI,March 2013,"May 1, 2018","May 1, 2018","August 9, 2013",,"May 3, 2018","Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Servicio de Neumología. Hospital Universitario de Salamanaca, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT01919827
588,252,NCT02923375,A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease,,Completed,No Results Available,Graft vs Host Disease,Biological: Mesenchymoangioblast-derived mesenchymal stem cells,Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100,Cynata Therapeutics Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CYP-GvHD-P1-01|2016-000070-38,"March 1, 2017","August 28, 2018","June 30, 2020","October 4, 2016",,"August 11, 2020","Sydney Local Health District, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|NHS Foundation Trust, Bristol, United Kingdom|NHS Trust, Leeds, United Kingdom|NHS Foundation Trust, Liverpool, United Kingdom|NHS Foundation Trust, Manchester, United Kingdom|NHS Foundation Trust, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02923375
589,15,NCT01659762,A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.,EPIC/MSC/IBD,Completed,No Results Available,Crohn's Disease,Biological: autologous mesenchymal stromal cell,Number of adverse events|Crohn's disease activity Index (CDAI),Emory University|Atlanta Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00051454|EPIC001,July 2012,July 2015,,"August 8, 2012",,"October 17, 2016","Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01659762
590,470,NCT02325843,the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn,,Completed,No Results Available,Chemical Burns,Other: human bone marrow MSC,Incidence of adverse events by subconjunctival injection of BMMSCs|Incidence of corneal perforation rate after subconjunctival injection of BMMSCs|Time of corneal epithelialization|Visual acuity,Sun Yat-sen University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014MEKY059,July 2015,December 2017,December 2017,"December 25, 2014",,"April 11, 2019",,,https://ClinicalTrials.gov/show/NCT02325843
591,84,NCT04318600,Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis,,Completed,No Results Available,Lupus Nephritis|Mesenchymal Stem Cells,Drug: human amniotic mesenchymal stem cell,Incidence of Adverse Events|Changes in 24h urine protein quantification before and after treatment；|Changes in eGFR before and after treatment;|Changes in SLEDAI score before and after treatment；,Yan'an Affiliated Hospital of Kunming Medical University|The First People's Hospital of Yunnan,All,"14 Years to 60 Years   (Child, Adult)",Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2014001,"January 1, 2014","March 1, 2017","January 1, 2019","March 24, 2020",,"March 24, 2020",,,https://ClinicalTrials.gov/show/NCT04318600
592,663,NCT05047276,Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma,PULSE-UM,Not yet recruiting,No Results Available,"Uveal Melanoma, Metastatic",Biological: AloCelyvir,Overall response rate|Progression Free Survival (PFS)|Overall Survival (OS)|Evaluate Safety,José María Piulats Rodríguez|Instituto de Salud Carlos III|Institut d'Investigació Biomèdica de Bellvitge,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PULSE-UM,"October 1, 2021","June 30, 2023","December 31, 2024","September 17, 2021",,"September 17, 2021","ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT05047276
593,162,NCT04785027,Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis,,Recruiting,No Results Available,Traditional Chinese Medicine|Drug Effect|Drug Safety|Psoriasis|Mesenchymal Stromal Cells,Drug: PSORI-CM01 formula|Drug: Gu Ben Hua Yu formula|Biological: adipose-derived multipotent mesenchymal stem cells,PASI score improvement rate|PASI (Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI (Dermatology Life Quality Index),Guangdong Provincial Hospital of Traditional Chinese Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2020-01-01,"March 17, 2021","September 30, 2022","September 30, 2022","March 5, 2021",,"May 25, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04785027
594,35,NCT02687646,Clinical Trial With MSC for Graft Versus Host Disease Treatment,,"Active, not recruiting",No Results Available,Acute Graft Versus Host Disease,Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.,Safety measured by incidence of serious adverse events|Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Andalusian Initiative for Advanced Therapies|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-EICH-2014|2014-005533-32,May 2016,June 2022,June 2022,"February 22, 2016",,"February 2, 2022","Clinica Universitaria de Navarra, Av Pio XII ,36, Pamplona, Navarra, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital clinico universitario de salamanca, Salamanca, Spain|Virgen del Rocio University Hospital, av. Manuel Siurot s/n, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT02687646
595,70,NCT04889963,Regeneration of Posterior Cruciate Ligament Injury Using Hypoxic Conditioned Allogenic Adipose Mesenchymal Stem Cell and Condition Medium,,Recruiting,No Results Available,Adypose Mesenchimal Stem Cell|Ligament Rupture|Ligament Derived Conditined Medium,Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium,tensile strength of posterior cruciate ligament|Thrombosite of Growth Factor - beta 1|basic fibroblast of growth factor,Gadjah Mada University,Male,2 Months to 12 Months   (Child),Early Phase 1,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STEMCELL-LIGAMENTREGENERATION,"January 1, 2021","June 30, 2021","June 30, 2021","May 17, 2021",,"May 17, 2021","Sholahuddin Rhatomy, Sleman, Yogyakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04889963
596,98,NCT04996966,Effect of Human Umbilical Cord-derived Mesenchymal Stem Cells on Non-cardiac Surgery-induced Lung Injury,,Recruiting,No Results Available,Ischemic Heart Disease|Lung Injury|Non-cardiac Surgery,Biological: human umbilical cord-derived mesenchymal stem cells|Other: saline,oxygenation index|The value of arterial blood cLAC|The content of IL-1β|The content of IL-6|The content of TGF-α|The content of HMGB1|The content of IL-10|The content of B-type natriuretic peptide (BNP)|electrocardiogram|The average length of stay in hospital|The visual analog scale（VAS）score|The hospital for special surgery (HSS) Knee Score|The New York Heart Association (NYHA) Functional Classification|The 36-Item Short Form Survey (SF-36)|The Hamilton Anxiety Scale|The incidence of allergic reaction|The body temperature|The pulse rate|The respiration rate|The blood pressure|The content of C-reactive protein (CRP),Shanghai East Hospital,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DFDA-001,August 2021,April 2022,June 2022,"August 9, 2021",,"August 9, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04996966
597,249,NCT05407766,Mesenchymal Stem Cells (MSCs) for Perianal Fistula,,Not yet recruiting,No Results Available,Rectal Fistula,Biological: OSSM-001|Other: Placebo,OSSM-001 (100M dose) related adverse events as assessed by CTCAE v5.0|OSSM-001 (300M dose) related adverse events as assessed by CTCAE v5.0|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (100M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (100M dose)|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (300M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (300M dose),"Ossium Health, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",OSSM-001-001-01,August 2022,April 2024,August 2024,"June 7, 2022",,"June 7, 2022",,,https://ClinicalTrials.gov/show/NCT05407766
598,107,NCT03477942,Impact of Mesenchymal Stem Cells in Knee Osteoarthritis,,Recruiting,No Results Available,Musculoskeletal Pain|Knee Osteoarthritis|Cartilage Injury|Cartilage Degeneration,Biological: Autologous Mesenchymal Stem Cells,"Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI.",University Hospitals Cleveland Medical Center|Case Western Reserve University,All,18 Years to 60 Years   (Adult),Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,JV 1.1,"October 1, 2018",June 2024,July 2024,"March 27, 2018",,"September 10, 2022","University Hospital Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03477942
599,1,NCT04104451,"PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS",,"Active, not recruiting",No Results Available,Diabetic Foot Ulcer,Drug: Corlicyte,SAE|Antibodies to HLA Class I - number and percent|Antibodies to HLA Class I - Time To Development|Increase Ulcer Size|Adverse Reaction|Suspected Adverse Reaction|Suspected Serious Adverse Reaction|Change in A1c,"University of Colorado, Denver",All,"18 Years and older   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-1113,"November 12, 2019","September 30, 2022","September 30, 2022","September 26, 2019",,"August 12, 2022","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04104451
600,4,NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,ACESO,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells,Number of Treatment Emergent Serious Adverse Events (TE-SAEs)|EPC-CFU Levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels|Tumor Necrosis Factor (TNF) Alpha Levels,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20160686|1R01HL134558-01,"October 20, 2017","August 26, 2019","September 3, 2020","September 1, 2016","May 11, 2022","May 11, 2022","University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02886884/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02886884
601,81,NCT02292628,"Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence",,Completed,No Results Available,Faecal Incontinence,Drug: Infusion of mesenchymal stem cells from adipose tissue|Other: Infusion of placebo,Number of Serious Adverse Events|Changes in the faecal incontinence diary|Anorectal manometry|Jorge-Wexner Score|Faecal Incontinence Quality of Life,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CMMAd/InFe/2011,October 2013,September 2017,September 2017,"November 17, 2014",,"April 17, 2018","H. Juan Ramón Jiménez, Huelva, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Regional U de Málaga, Málaga, Spain|Hospital U Virgen del Rocio, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT02292628
602,164,NCT03529877,Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa,,"Active, not recruiting",No Results Available,Recessive Dystrophic Epidermolysis Bullosa,Biological: allo-APZ2-EB,"Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24",RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Granzer Regulatory Consulting & Services|Ticeba GmbH,All,"0 Years to 55 Years   (Child, Adult)",Phase 1|Phase 2,16,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,allo-APZ2-EB-II-01,"January 16, 2019",December 2021,December 2021,"May 18, 2018",,"October 14, 2020","University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States|EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg, Austria|Hôpital Saint-Louis; Département de dermatologie, Paris, France|Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany|King's College London; St John's Institute of Dermatology;, London, United Kingdom|Great Ormond Street Hospital; Dermatology Department, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03529877
603,238,NCT04822922,Safety of UC-MSC Transfusion for ACLF Patients,,Not yet recruiting,No Results Available,Acute-On-Chronic Liver Failure,Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs),Safety of treatment|Short-time efficacy of treatment,Hai Li|Shanghai Jiao Tong University School of Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-ACLF-1,"September 30, 2021","July 31, 2022","July 21, 2024","March 30, 2021",,"July 21, 2021","Ren Ji Hospital, School of Medicine, Shanghai Jiao TongUniversity,, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04822922
604,74,NCT02685098,A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation,CHAMP,Recruiting,No Results Available,Ischemia|Peripheral Arterial Disease|Peripheral Vascular Disease|Vascular Disease|Arterial Occlusive Disease|Arteriosclerosis|Atherosclerosis|Cardiovascular Disease|Pathologic Processes|Orthopedic Procedures|Amputation,Biological: Allogeneic bone marrow derived mesenchymal stem cells,"Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation.",Indiana University,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1505714405,January 2017,September 2021,September 2025,"February 18, 2016",,"February 12, 2020","Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02685098
605,224,NCT01981330,Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring,,Completed,No Results Available,Improved Healing of Scarred Vocal Folds|Improved Vocal Fold Status|Improved Vocal Fold Function,Biological: aMSC|Biological: aMSC+hyaluronan gel,Improved healing of scarred vocal folds,Karolinska University Hospital|The Swedish Research Council|Laryngfonden|Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010/1650 and 2014-51432,January 2012,"February 24, 2020","February 24, 2020","November 11, 2013",,"February 25, 2020","Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01981330
606,223,NCT03643614,Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula,,Completed,No Results Available,Rectovaginal Fistula,Procedure: Injection of autologous regenerative cells of adipose tissue,Serious adverse events|Serious adverse reactions|Changes of fistula size|Changes in rectovaginal soft tissue density and flexibility|Quality of life monitoring - 1|Quality of life monitoring - 2,South Ural State Medical University,Female,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RU SUSMU 310855.210617.1,"August 1, 2017","November 15, 2019","January 22, 2020","August 23, 2018",,"January 27, 2020","South Ural State Medical University, Chelyabinsk, Chelyabinsk Oblast, Russian Federation",,https://ClinicalTrials.gov/show/NCT03643614
607,555,NCT03828344,Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis,,Not yet recruiting,No Results Available,Rheumatoid Arthritis,Biological: hUC-MSC suspension|Biological: Placebo,Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)|Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24|Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24|Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24|Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24|Change from Baseline of rheumatoid factor at Week 12 and Week 24|Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24,Baylx Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BXU001-RA,July 2023,December 2024,December 2024,"February 4, 2019",,"August 11, 2022",,,https://ClinicalTrials.gov/show/NCT03828344
608,73,NCT04711200,LYell SYndrome MEsenchymal Stromal Cells Treatment,LYSYME,Not yet recruiting,No Results Available,Epidermal Necrolysis|Lyell Syndrome|Toxic Epidermal Necrolysis|Overlap Syndrome|Mesenchymal Stromal Cells|Adipose Derived Stromal Cells,Drug: Adipose derived stromal cells intravenously injected,"Safety : Observation of at least one adverse effect|Efficacy : Rate of complete or almost complete reepithelialisation|Rate of observed and predicted death by the SCORTEN|Duration of hospitalisation according to our historical cohort related to BSA involved|Duration of hospitalisation according to our historical cohort related to onset of the disease|Duration of hospitalisation according to our historical cohort related to SCORTEN|Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)|Rate of sepsis|Rate of intensive care transfer|Rate of sequelae|Th1/Th2 immune response in the peripheral blood of the patients|Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood|Epidermal chimerism study on healed skin biopsy|Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed.",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P150941J,September 2022,September 2025,September 2025,"January 15, 2021",,"May 3, 2022",,,https://ClinicalTrials.gov/show/NCT04711200
609,168,NCT05008588,Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct,,Not yet recruiting,No Results Available,Ischemic Stroke,Biological: Conditioned Medium|Biological: Umbilical Cord Mesenchymal Stem Cells|Procedure: Neurologic and Neutrophic Drugs,"Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation|Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation|Change baseline Magnetic Resonance Imaging at 6 month after transplantation|The National Institute of Health Stroke Scale (NIHSS) Scoring|modified Rankin Scale (mRS)",PT. Prodia Stem Cell Indonesia,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/STROKE/PSI/2021,September 2021,December 2021,January 2022,"August 17, 2021",,"August 17, 2021","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|PT Prodia StemCell Indonesia, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT05008588
610,86,NCT01769872,Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury,,Completed,No Results Available,Spinal Cord Injury,Procedure: Autologous Adipose Tissue derived MSCs Transplantation,ASIA (American Spinal Injury Association) scale|Magnetic Resonance Imaging|MEP/SSEP|ADL (activities of daily living)|SF-36|ODI (Oswestry Disability Questionnaire)|Frequency of Adverse Events,R-Bio|Korea University Anam Hospital,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KSC-MSCs-SPI,January 2013,January 2016,,"January 17, 2013",,"August 2, 2016","Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01769872
611,36,NCT01624779,Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury,,Completed,No Results Available,Spinal Cord Injury,Drug: autologous adipose tissue derived mesenchymal stem cells,Significant MRI Change before and after intervention|Significant neurologic funtion Change before and after intervention|Significant Electrophysiological Change before and after intervention|Adverse event,Bukwang Pharmaceutical,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KOR-01,April 2012,May 2014,May 2014,"June 21, 2012",,"February 13, 2015","Korea University Anam Hospital, Seoul, Seongbukgu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01624779
612,41,NCT04388761,Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI),,Recruiting,No Results Available,Ischemia Reperfusion Injury,Drug: Allogeneic adipose derived mesenchymal stem cells,Serious Adverse Events (SAEs),Tambi Jarmi|Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-000264,"September 28, 2020","February 1, 2024","February 1, 2024","May 14, 2020",,"October 14, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04388761
613,36,NCT04876326,Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy,,Recruiting,No Results Available,"Multiple System Atrophy|Parkinsonism|Multiple System Atrophy, Parkinson Variant",Biological: Autologous Adipose Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation,"Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",Indonesia University,All,"Child, Adult, Older Adult",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,TGHISMMSCMSA,"October 5, 2020","October 5, 2021","October 5, 2021","May 6, 2021",,"May 6, 2021","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04876326
614,196,NCT04014166,Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia,,Recruiting,No Results Available,Thrombocytopenia|Mesenchymal Stem Cells,Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs),Changes of the platelet counts after hUC-MSCs infusion|Incidence of adverse events after hUC-MSCs infusion|Changes in virus safety indicators after hUC-MSCs infusion|Changes of concentration of hUC-MSCs in peripheral blood|Changes of antibody production of hUC-MSCs in peripheral blood|Changes of immune function in refractory ITP patients after hUC-MSCs infusion,Institute of Hematology & Blood Diseases Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC2019002-EC-1,"November 21, 2019","December 31, 2021","December 31, 2022","July 10, 2019",,"July 1, 2021","Yunfei Chen, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT04014166
615,35,NCT04400032,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,CIRCA-19,Completed,No Results Available,Acute Respiratory Distress Syndrome|Covid19,Biological: Mesenchymal Stromal Cells,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28,Ottawa Hospital Research Institute|Stem Cell Network|Ontario Research Fund,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20200243-01H,"May 15, 2020","April 22, 2021","April 22, 2021","May 22, 2020",,"April 26, 2021","The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04400032
616,134,NCT04385056,Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia,,Recruiting,No Results Available,Bradykinesia,Biological: MSCTC-0010,Incidence of Serious Adverse Events and Adverse Events,"IMAC Holdings, Inc.",All,"55 Years and older   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMAC-001,"December 15, 2020","July 1, 2022","July 1, 2022","May 12, 2020",,"January 6, 2021","IMAC Regeneration Center, Paducah, Kentucky, United States|Ozzie Smith IMAC Regeneration Center, Chesterfield, Missouri, United States|David Price IMAC Regeneration Center, Brentwood, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04385056
617,2,NCT00734396,Mesenchymal Stem Cells and Subclinical Rejection,Measure,Completed,No Results Available,Organ Transplantation,Procedure: Mesenchymal stem cell infusion,"Primary 1 Safety: rate of (serious) adverse events in the study population 2 Feasibility: determination of the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses|Secondary endpoints: 1 Presence of late acute rejection (in the 6 month biopsy compared with the 4 week biopsy). 2 Sirius red staining for renal cortical matrix accumulation. 3 Immunologic response before and after MSC infusion.",Leiden University Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P08.119|NL21298.000.08,February 2009,March 2012,December 2012,"August 14, 2008",,"January 7, 2013","Leiden Universitary Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT00734396
618,97,NCT02104440,Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro,,Completed,No Results Available,Cytopenia,"Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro""",Adverse effects at the time of infusion and infections after infusion of MSC|Mesenchymal cell efficiency in recovering cytopenia,"Red de Terapia Celular|University of Navarrra Hospital (Clinica Universitaria)|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Hospitales Universitarios Virgen del Rocío|Spanish National Health System",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,15,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/CIT|2013-000534-35,October 2013,March 2017,March 2017,"April 4, 2014",,"March 30, 2017","University Clinical Hospital of Salamanca, Salamanca, Salamanca/Castilla León, Spain",,https://ClinicalTrials.gov/show/NCT02104440
619,1,NCT01956903,Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.,CSM/EICH2010,Completed,No Results Available,Chronic Graft-Versus-Host Disease,Genetic: Allogenic Mesenchymal Stem Cell,Adverse effects|efficacy,Grupo Espanol de trasplantes hematopoyeticos y terapia celular,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/EICH2010|2010-020947-11,January 2010,September 2013,September 2013,"October 8, 2013",,"October 8, 2013","Grupo Espanol de trasplantes hematopoyeticos y terapia celular, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01956903
620,202,NCT04392206,AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses,,Recruiting,No Results Available,End Stage Renal Disease,Drug: Adipose Derived Mesenchymal Stem Cells,Number of participants with treatment-related adverse events,Albert Hakaim|Mayo Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-007203,"May 15, 2020",June 2025,June 2025,"May 18, 2020",,"July 28, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04392206
621,163,NCT02589119,Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP),,Completed,No Results Available,Perianal Fistula|Cryptoglandular Perianal Fistula,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-003200,January 2016,September 2019,September 2019,"October 28, 2015",,"December 6, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02589119
622,192,NCT02104713,Stem Cell Therapy to Improve Burn Wound Healing,,Completed,No Results Available,Skin Burn Degree Second,Biological: Allogeneic (MSC's) Application to the Burn Wounds,Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.,E.Badiavas|United States Department of Defense|University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20120925,"June 4, 2014","March 18, 2019","March 18, 2019","April 4, 2014",,"April 30, 2020","University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02104713
623,142,NCT04290182,A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring,,Recruiting,No Results Available,Hoarseness|Dysphonia|Aphonia|Vocal Fold; Scar,Biological: MSC-KI-PL-204,Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing,Karolinska University Hospital|Swedish Foundation for Strategic Research,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-06160 and 5.1-2019-92069,March 2020,June 2022,June 2023,"February 28, 2020",,"February 28, 2020","Karolinska Trial Alliance, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT04290182
624,113,NCT05018858,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus,,Recruiting,No Results Available,Lupus,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-20-ATG-4,February 2022,October 2025,October 2025,"August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05018858
625,4,NCT04125329,Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy,,Recruiting,No Results Available,Mesenchymal Stem Cells|Diabetic Nephropathy,Drug: Human umbilical cord mesenchymal stem cells,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient|Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment,Yan'an Affiliated Hospital of Kunming Medical University,All,18 Years to 60 Years   (Adult),Early Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,43136152-9,"April 1, 2020","September 1, 2024","September 1, 2024","October 14, 2019",,"April 21, 2021","Yan'an Hospital of Kunming City, Kunming, China",,https://ClinicalTrials.gov/show/NCT04125329
626,257,NCT04623606,Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones,BOOST2B,Recruiting,No Results Available,Osteogenesis Imperfecta,Biological: BOOST cells,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)|Number of fractures [ Time Frame: From baseline to 16 months follow-up ]|Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.|Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)|Growth (cm). [ Time Frame: From baseline to16 months follow up]|Weight (kg). [ Time Frame: From baseline to 16 months follow up]|Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]|Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)|Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.","Christian Medical College, Vellore, India|Ministry of Science and Technology, India|Vinnova|Karolinska Institutet",All,1 Year to 8 Years   (Child),Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMCB2B0X,"May 20, 2019",November 2021,December 2021,"November 10, 2020",,"November 10, 2020","Christian Medical College, Vellore, Tamil Nadu, India",,https://ClinicalTrials.gov/show/NCT04623606
627,140,NCT03555773,Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas,,Completed,No Results Available,Crohn Disease|Perianal Fistula,Procedure: Lipogems,Healing|Health-related quality of life assessed by a disease specific questionnaire|Health-related quality of life assessed by a generic questionnaire,IRCCS Azienda Ospedaliero-Universitaria di Bologna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Lipogems-crohn2,"May 11, 2016","June 28, 2017","June 28, 2017","June 14, 2018",,"June 14, 2018","S. Orsola-Malpighi Hospital, Bologna, BO, Italy",,https://ClinicalTrials.gov/show/NCT03555773
628,253,NCT00919958,Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia,,Completed,No Results Available,Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia,Biological: PLX-PAD IM injection,"Adverse events, Safety laboratory values and ECG findings|Immunological reaction|Tumorigenesis",Pluristem Ltd.,All,"40 Years to 81 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLX-PAD 1202-1,June 2009,June 2012,June 2012,"June 12, 2009",,"June 19, 2012","Franziskus-Krankenhaus, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00919958
629,20,NCT03973827,Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes,,"Active, not recruiting",No Results Available,Type1diabetes,Drug: ProTrans,"The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",NextCell Pharma Ab,Male,18 Years to 41 Years   (Adult),Phase 1|Phase 2,15,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ProTrans-Repeat|2018-004158-11,"May 17, 2019","December 10, 2020","October 30, 2024","June 4, 2019",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT03973827
630,91,NCT01513694,Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease,,Completed,No Results Available,Intervertebral Disc Disease,Procedure: Instrumented posterolateral arthrodesis,,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/Fusión/2009,January 2010,"May 4, 2017","May 4, 2017","January 20, 2012",,"June 2, 2017","Trauma Service. Hospital Universitario de Salamanca, Salamanca, Castilla-León, Spain",,https://ClinicalTrials.gov/show/NCT01513694
631,739,NCT00790413,Haploidentical Stem Cell Transplantation in Neuroblastoma,,"Active, not recruiting",No Results Available,Neuroblastoma,Drug: iodine I 131 metaiodobenzylguanidine|Drug: Fludarabine|Drug: Thiotepa|Procedure: T-cell depletion|Procedure: Haploidentical stem cell transplantation|Procedure: Donor Lymphocyte Infusion|Drug: Rituximab|Procedure: Co-transplantation of mesenchymal stem cells,Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease,Lund University Hospital,All,"6 Months to 21 Years   (Child, Adult)",Early Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,385/2005,August 2005,"December 31, 2022","December 31, 2022","November 13, 2008",,"February 21, 2021","Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT00790413
632,5,NCT02249676,Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders,,Completed,No Results Available,Devic's Syndrome|Devic's Neuromyelitis Optica|Devic Syndrome|Devic's Disease|Devic Disease,Biological: Autologous mesenchymal stem cells,EDSS|Annual relapse rate|Lesion load|Retinal nerve fiber layer (RNFL)|Cognition|Immunological assessments|cerebral volume,Tianjin Medical University General Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB2013-055-02,January 2013,"December 31, 2014","December 31, 2014","September 25, 2014",,"October 17, 2018","Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT02249676
633,10,NCT01157650,Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue,,Completed,No Results Available,Crohn Disease,Other: Autologous mesenchymal stem cells,Security and tolerance|therapeutic effect,"Clinica Universidad de Navarra, Universidad de Navarra",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/CROH|2009-009880-71,June 2010,September 2013,September 2013,"July 7, 2010",,"November 8, 2016","Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Provincial de Navarra, Pamplona, Spain|Hospital Virgen del Camino, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT01157650
634,115,NCT05003960,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism,,Recruiting,No Results Available,Autism,Biological: AlloRx,Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-8-ATG-8-02,February 2022,September 2025,September 2025,"August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003960
635,178,NCT05279157,Autologous Adipose-Derived Adult Stem Cell Implantation for Corneal Diseases (ADASCs-CT-CD),ADASCs-CT-CD,Recruiting,No Results Available,Ophthalmological Disorder|Corneal Dystrophy|Treatment|Therapy|Keratoconus,Procedure: Implantation|Procedure: Lipoaspiration,Improvement in best-corrected distance visual acuity (BCDVA).|Increase in corneal thickness.|Refractive changes|Improvement in anterior corneal surface regularity,"Vissum, Instituto Oftalmológico de Alicante|Universidad Miguel Hernandez de Elche|Instituto de Salud Carlos III",All,18 Years to 60 Years   (Adult),Phase 2,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EI17-00523|2018-000523-14,"April 19, 2022","June 30, 2022","June 30, 2022","March 15, 2022",,"April 28, 2022","Jorge L. Alio, Alicante, Spain",,https://ClinicalTrials.gov/show/NCT05279157
636,105,NCT04047810,Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD),,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease,Biological: Mesenchymal Stem Cells,Adverse Events,Mayo Clinic,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-007748,"January 6, 2020","June 30, 2023","June 30, 2023","August 7, 2019",,"May 3, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04047810
637,715,NCT01860495,Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane,MPM,Completed,No Results Available,Periodontal Pocket,Procedure: perforated membrane|Procedure: G2,gingival cervicular fluid BMP-2 level|intrabony components (defect bony filling),Al-Azhar University,All,31 Years to 51 Years   (Adult),,15,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ahmedgamal,March 2012,May 2012,December 2012,"May 22, 2013",,"May 22, 2013","Al azhar universty, Cairo Governorate, Egypt",,https://ClinicalTrials.gov/show/NCT01860495
638,60,NCT01643655,Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head,,Completed,No Results Available,Avascular Necrosis of the Femoral Head,Procedure: Autologous Adipose Tissue derived MSCs Transplantation,Magnetic Resonance Imaging|SPECT/CT|Hip X-ray|HHS (Harris Hip Score)|WOMAC (Western Ontario and McMaster Universities) Index|UCLA (University of California Los Angeles) hip questionnaire|Safety evaluation,R-Bio|SMG-SNU Boramae Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,15,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KSC-MSCs-AVN,May 2012,December 2014,March 2015,"July 18, 2012",,"August 31, 2017","SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01643655
639,206,NCT04314661,Comparative Effectiveness of Arthroscopy and Non-Arthroscopy Using Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium for Osteoartrithis,OA,Recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Mesenchymal Stem Cells with Arthoscopy|Biological: Mesenchymal Stem Cells without Arthoscopy|Biological: Conditioned Medium without Arthoscopy,Visual Analog Scale (VAS)|Western Ontario and McMaster Universities Osteoarthritis Index|Laboratory Asessment|Magnetic Resonance Imaging (MRI) T2 mapping,PT. Prodia Stem Cell Indonesia,All,"55 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/OA/01/2020,"August 3, 2020","July 8, 2024","December 8, 2024","March 19, 2020",,"June 14, 2022","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04314661
640,7,NCT03691909,Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis,HB-adMSCs,Completed,Has Results,Rheumatoid Arthritis,Biological: HB-adMSCs,Total Number of Adverse Events and Serious Adverse Events|The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA.,Hope Biosciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HBRA01,"September 25, 2018","August 17, 2020","September 28, 2020","October 2, 2018","March 22, 2022","March 31, 2022","Accurate Clinical Research, Pasadena, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03691909/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03691909/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03691909
641,111,NCT05158101,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke,,Recruiting,No Results Available,Stroke,Biological: AlloRx,Safety (adverse events),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATG-2-MSC-011,February 2022,February 2026,February 2026,"December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05158101
642,153,NCT01227694,Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis,,Completed,No Results Available,"Osteoarthritis, Knee|Knee Injuries|Joint Diseases|Rheumatic Diseases|Cartilage Diseases",Other: Autologous MSC knee implantation,Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Efficacy by imaging procedures.|Clinical outcomes.,"Banc de Sang i Teixits|Centro Medico Teknon|Institut de Terapia Regenerativa Tissular|Cetir Sant Jordi, S.a..",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XCEL-M-09-01,October 2010,July 2012,January 2013,"October 25, 2010",,"December 11, 2015","Centro Medico Teknon-ITRT, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT01227694
643,118,NCT05003388,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,,Recruiting,No Results Available,Multiple Sclerosis,Biological: AlloRx,Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-8-ATG-9-03,February 2022,October 2025,October 2025,"August 12, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003388
644,40,NCT01302015,Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease,,Completed,No Results Available,Buerger's Disease,Biological: RNL-Vascostem®,"Treadmill Walking Distance|VAS(Visual Analog Scale)|Toe-Brachial Pressure Index, TBPI|Transcutaneous oxygen pressure, TcPO2|Arterial Brachial Pressure Index, ABPI|Pain Free Walking Distance, PFWD|Angiography|Laser Doppler|dose and frequency in use of a analgesic medicine|Safety Evaluation",R-Bio,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Vascostem,December 2007,December 2013,December 2013,"February 23, 2011",,"June 5, 2019","Seoul St. Mary's Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01302015
645,116,NCT05018819,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP,,Recruiting,No Results Available,Cerebral Palsy,Biological: AlloRx,Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-11-ATG-11-02,February 2022,November 2025,November 2025,"August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05018819
646,698,NCT04138017,ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis,ViviGen,Enrolling by invitation,No Results Available,Ankle Deformity|Ankle Arthritis,Device: ViviGen,Fusion|Failure of hardware or obvious non-union|Foot and Ankle Ability Measure (FAAM)|Vitamin D levels|Visual Analog Pain Scale|American Orthopaedic Foot and Ankle Society(AOFAS) hindfoot score|VR-12 (Veterans RAND 12)|Patient-Reported Outcomes Measurement Information System Physical Function-Short Form 8b (PROMIS Item Bank v2.0-Physical Function -Short Form 8b),University of Virginia|DePuy Synthes,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,15,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20532,"October 23, 2018",May 2023,January 2024,"October 24, 2019",,"February 25, 2022","University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04138017
647,123,NCT05003947,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD,,Recruiting,No Results Available,Inflammatory Bowel Diseases,Biological: AlloRx,Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-8-ATG-11-04,February 2022,October 2025,October 2025,"August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003947
648,131,NCT05553132,A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects,,Recruiting,No Results Available,Cartilage Defect,Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier,Incidence of Adverse Events|Incidence of serious adverse events (SAEs)|Change in pain|Change in physical function|Change in hip function,Daniel B. F. Saris|Mayo Clinic,All,18 Years to 50 Years   (Adult),Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22-004639,October 2022,December 2023,December 2025,"September 23, 2022",,"September 23, 2022","Mayo Clinic Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT05553132
649,57,NCT03333681,Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients,,Completed,No Results Available,Rheumatoid Arthritis,Biological: Autologous mesenchymal stem cells,Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells,Mashhad University of Medical Sciences,Female,35 Years to 60 Years   (Adult),Phase 1,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,931523|122,"June 20, 2016","August 15, 2018","September 15, 2018","November 7, 2017",,"March 13, 2019",,,https://ClinicalTrials.gov/show/NCT03333681
650,32,NCT02866721,Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis,CEASE-CF,Completed,No Results Available,Cystic Fibrosis,Biological: Mesenchymal Stem Cells,"Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28",Erica Roesch|Case Western Reserve University|Cystic Fibrosis Foundation|University Hospitals Cleveland Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Protocol CF-MSC-01|DASENB15A0,August 2016,August 2020,August 2020,"August 15, 2016",,"December 22, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02866721
651,165,NCT01777646,"Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,"Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF",Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters,Brainstorm-Cell Therapeutics|Hadassah Medical Organization,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,14,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-NTF-002-HMO-CTIL,December 2012,September 2014,September 2015,"January 29, 2013",,"March 8, 2018","Hadassah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01777646
652,235,NCT04434768,Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke,,Recruiting,No Results Available,Acute Stroke,Biological: UMSC01,"SAE incidences over the study period|SUSAR incidences over the study period|TEAE incidences over the study period|Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.|Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits|Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits|Change and ratios of MRI image from baseline to subsequent scheduled visits|Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits","Ever Supreme Bio Technology Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,14,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ES-CMSC01-B1101,"May 5, 2020","December 31, 2023","December 31, 2023","June 17, 2020",,"March 23, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04434768
653,240,NCT04825730,Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy,,Not yet recruiting,No Results Available,Degenerative Arthritis|Knee Arthritis,Drug: JOINTSTEM,Adverse Events|Adverse Events (Special Attention Target),R-Bio,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,14,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BS-JS-IIT1-FU,"December 1, 2021","December 1, 2027","December 31, 2028","April 1, 2021",,"April 1, 2021",,,https://ClinicalTrials.gov/show/NCT04825730
654,345,NCT01531348,Intravitreal Injection of MSCs in Retinitis Pigmentosa,,Completed,No Results Available,Retinitis Pigmentosa,Other: BM-MSC,Change from baseline in laser flare and cell measurements|Change from baseline in visual function tests,"Mahidol University|Ministry of Health, Thailand",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RP-001,April 2012,July 2020,July 2020,"February 10, 2012",,"September 8, 2021","Siriraj Hospital Mahidol University, Bangkoknoi, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT01531348
655,695,NCT05322057,Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease,,Completed,No Results Available,Crohn Disease|Fistula Perianal,Drug: Darvadstrocel,Fistula Closure|Evaluation of perianal disease|Evaluation of Crohn's disease,Medical University of Vienna,All,"18 Years to 90 Years   (Adult, Older Adult)",,14,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,1682/2018,"October 1, 2018","December 1, 2021","December 1, 2021","April 11, 2022",,"April 11, 2022","Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT05322057
656,27,NCT02981576,Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.,,Completed,No Results Available,Spinal Cord Injuries,Biological: Autologous Mesenchymal Stem Cells,Comparing the number of side effects and the improvement on ASIA Impairment score between SCI patients receiving autologous AT-MSC vs BM-MSC.|Investigating the number of side effects in SCI patients receiving autologous BM-MSC.|Investigating the effectiveness of autologous BM-MSC in treating SCI patients.|Investigating the number of side effects in SCI patients receiving autologous AT-MSC.|Investigating the effectiveness of autologous AT-MSC in treating SCI patients.,University of Jordan,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCIUJCTC,November 2016,"May 5, 2018","January 20, 2019","December 5, 2016",,"September 24, 2019","Cell Therapy Center, University of Jordan, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02981576
657,123,NCT01325103,Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury,,Completed,No Results Available,Spinal Cord Injury,Procedure: Stem Cell Transplantation,Feasibility and safety of bone marrow stem cell transplantation in patients with spinal cord injury|Functional improvement in muscle strength|Improvement of sphincters control.,Hospital Sao Rafael|Oswaldo Cruz Foundation|Irep Sociedade de Ensino Superior Médio e Fundamental Limitada|Hospital Espanhol,All,18 Years to 50 Years   (Adult),Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCI-001,July 2010,December 2012,December 2012,"March 29, 2011",,"November 28, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,https://ClinicalTrials.gov/show/NCT01325103
658,55,NCT02118519,Mesenchymal Stem Cells in Knee Cartilage Injuries,,Completed,No Results Available,"Articular Cartilage Disorder of Knee|Osteoarthritis, Knee",Biological: Autologous Mesenchymal Stem Cells,Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.|Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.,University of Jordan,All,"40 Years to 68 Years   (Adult, Older Adult)",Phase 2,13,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KneeUJCTC,January 2014,August 2015,August 2015,"April 21, 2014",,"February 24, 2016","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02118519
659,61,NCT02751125,Reconstruction of Jaw Bone Using Mesenchymal Stem Cells,,Completed,No Results Available,Bone Atrophy,Drug: BCP with autologous mesenchymal stem cells (MSC).,Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],University of Bergen|University of Ulm|Haukeland University Hospital|Université de Nantes,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,13,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-003139-50,June 2014,"March 1, 2019","March 1, 2020","April 26, 2016",,"March 3, 2020","Institute of Clinical Dentistry, University of Bergen, Bergen, Hordaland, Norway",,https://ClinicalTrials.gov/show/NCT02751125
660,265,NCT02888704,Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis,,Completed,No Results Available,Atopic Dermatitis,Drug: ADSTEM Inj. (Adult human mesenchymal stem cells),The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03|The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value|The variation of SCORAD index as contrasted with baseline value|The variation of each index score of SCORAD index as contrasted with baseline value|The variation of the degrees of disease as contrasted with baseline value|The variation of investigator's global assessment (IGA) as contrasted with baseline value|The variation of eczema area and severity index (EASI) total score as contrasted with baseline value|The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value|The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value|The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value|The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value|The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value,"EHL Bio Co., Ltd.",All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AD-CP-15-1|30902,July 2016,December 2017,December 2017,"September 5, 2016",,"December 22, 2017","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02888704
661,74,NCT01895439,Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis,,Completed,No Results Available,Multiple Sclerosis,Biological: Autologous Mesenchymal Stem Cells,The number of patients with any relevant side effects observed|Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.,University of Jordan,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,13,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSUJCTC,October 2012,February 2016,February 2016,"July 10, 2013",,"May 2, 2017","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT01895439
662,60,NCT04357600,Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B,,Recruiting,No Results Available,Liver Cirrhoses,Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell,Child Pugh Score|Examination of liver function|MELD Score,PT. Prodia Stem Cell Indonesia,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/LC/01/2018,"May 17, 2018","June 20, 2023","December 20, 2023","April 22, 2020",,"June 15, 2022","Cipto Mangunkusumo hospital, Jakarta, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04357600
663,1,NCT04339504,Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial,,Recruiting,No Results Available,Knee Osteoarthritis,Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose),"Change of total score in WOMAC (Western Ontario and McMaster University)|Change of score in WOMAC three subscales (Pain, stiffness, physical function)|Change of score in 100 mm VAS (Visual Analogue Scale)|Change of score in IKDC(International Knee Documentation Committee)|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)|Change in K&L(Kellgren-Lawrence) grade|Change in joint space width|Change in mechanical axis, anatomical axis|Rate of surgery to treat application site after treatment of SMUP-IA-01|Changes in biomarker",Medipost Co Ltd.,All,"19 Years and older   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-SMUP-IA-P01-F/U,"April 14, 2020",December 2025,December 2025,"April 9, 2020",,"August 24, 2022","Seoul national University Hospital, Seoul, Jongno-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04339504
664,130,NCT02351011,Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA,,Completed,No Results Available,Osteoarthritis of Knee,Biological: 1 x 10^6 MSCs|Biological: 10 x 10^6 MSCs|Biological: 50 x 10^6 MSCs,"Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15","Jas Chahal|University Health Network, Toronto",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MSC-001,February 2015,December 2018,December 2018,"January 30, 2015",,"September 27, 2019","Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02351011
665,2,NCT04037345,Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis,,Completed,No Results Available,Knee Osteoarthritis,Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose),"Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment|Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment|Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline|Change of score in IKDC(International Knee Documentation Committee)compared to baseline|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment|Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment|Change in joint space width compared to the baseline at 3 months and 6 months after treatment|Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment",Medipost Co Ltd.,All,"19 Years and older   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-SMUP-IA-01-P01,"October 7, 2019","November 12, 2020","November 12, 2020","July 30, 2019",,"February 24, 2021","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04037345
666,121,NCT03130374,Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells,,Completed,No Results Available,Tracheal Stenosis|Laryngeal Stenosis|Mesenchymal Stem Cells,Biological: Olfactory mucosa-derived mesenchymal stem cells,Number of patients who didn't require the repeated surgical interventions|Tracheostomy decannulation,The Republican Research and Practical Center for Epidemiology and Microbiology|Belarusian Medical Academy of Post-Graduate Education|The Republican Center for Research and Practice in Otolaryngology,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RRPCEM_MSC1,"January 3, 2017","January 4, 2019","May 20, 2019","April 26, 2017",,"June 7, 2019","The Republican Center for Research and Practice in Otolaryngology, Minsk, Belarus|The Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT03130374
667,104,NCT04484077,hCT-MSC Infusion in Adults With Autism Spectrum Disorder,AIMs,Recruiting,No Results Available,Autism Spectrum Disorder|Autism,Biological: hCT-MSC,"Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,18 Years to 34 Years   (Adult),Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00104691,"January 24, 2022",March 2023,June 2023,"July 23, 2020",,"September 6, 2022","Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04484077
668,6,NCT01183728,Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells,KDD&MSV,Completed,Has Results,"Osteoarthritis, Knee|Knee Degenerative Disease|Knee Osteoarthritis",Other: Autologous bone marrow mesenchymal stem cells (MSV),Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee.|Indication of Efficacy,"Red de Terapia Celular|Fundacion Teknon, Centro Medico Teknon, Barcelona|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Institut de Terapia Regenerativa Tissular|EGARSAT Suma Intermutual, Barcelona, Spain|Cetir Sant Jordi, S.a..",All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TerCel001|Eudra-CT 2009-017405-11|Protocol Code,May 2010,August 2014,September 2014,"August 18, 2010","January 15, 2015","January 15, 2015","Teknon Medical Center, ITRT, Barcelona, Spain|Instituto de Biologia y Genetica Molecular (IBGM), University of Valladolid, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT01183728
669,262,NCT01733186,"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",,Completed,Has Results,Degeneration Articular Cartilage Knee,Biological: CARTISTEM®,IKDC Score|VAS|Lysholm Score|KOOS Score,Medipost Co Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-0201-01,"January 7, 2013","June 2, 2017","August 29, 2017","November 26, 2012","July 30, 2021","July 30, 2021","Cartilage Restoration Center; RUSH University Medical Center, Chicago, Illinois, United States|Cartilage Repair Center; Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01733186/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01733186
670,518,NCT05315661,The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia,FTD_ET-STEM,Not yet recruiting,No Results Available,Frontotemporal Dementia,Drug: ET-STEM,To determine DLT (Dose limiting toxicity)|adverse events as assessed by CTCAE v5.0|ADAS-Cog 13 response rate|The Clinical Dementia Rating Sum of Boxes|Alzheimer's Disease Cooperative Study- instrumental items of the Activities of Daily Living Inventory|Caregiver-administered Neuropsychiatric Inventory|preliminary efficacy|K-MMSE,Samsung Medical Center,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2022-02-089,"May 17, 2022","December 31, 2026","December 31, 2026","April 7, 2022",,"May 13, 2022",,,https://ClinicalTrials.gov/show/NCT05315661
671,119,NCT03099239,hCT-MSCs for Children With Autism Spectrum Disorder (ASD),hCT-MSCs,Completed,No Results Available,Autism|Autism Spectrum Disorder|ASD,Biological: hCT-MSC infusion,Incidence of Infusion reactions|Incidence of Infections,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,2 Years to 11 Years   (Child),Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00079421,"June 6, 2017","June 10, 2019","June 10, 2019","April 4, 2017",,"December 3, 2019","Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03099239
672,210,NCT03455335,Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia,,Completed,No Results Available,Critical Limb Ischemia,Drug: 20 million hMSCs|Drug: 40 million hMSCs|Drug: 80 million hMSCs,"The number of Serious Adverse Events that are attributable to the treatment|The severity of Serious Adverse Events that are attributable to the treatment|Amputation free survival|median time to amputation,|Change in Transcutaneous Pressure of Oxygen TcPO2|Change in Ankle Brachial Index|Collateral vessel formation|Change in Ischemic rest pain|Change in Ulcer size|Change in Quality of Life","National University of Ireland, Galway, Ireland|University Hospital of Limerick",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-001,"March 23, 2015","October 31, 2019","October 31, 2019","March 6, 2018",,"March 4, 2021","Galway University Hospital, Galway City, Galway, Ireland",,https://ClinicalTrials.gov/show/NCT03455335
673,754,NCT04007081,Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia,,Completed,No Results Available,Xerostomia|Head and Neck Cancer,Procedure: Bone Marrow Aspiration|Diagnostic Test: Ultrasound Imaging of Salivary Glands|Other: Salivary Assay|Other: Quality of Life Instruments,Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size,"University of Wisconsin, Madison",All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,UW19009|2019-0497|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|A533300|Protocol Version 7/24/2020,"October 18, 2019","March 10, 2021","March 10, 2021","July 5, 2019",,"March 24, 2021","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04007081
674,133,NCT01051882,"Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT),"Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death",Brainstorm-Cell Therapeutics|Hadassah Medical Organization,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-NTF-001-HMO-CTIL,June 2011,December 2012,March 2013,"January 20, 2010",,"January 10, 2019","Hadassah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01051882
675,177,NCT04758533,Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy,AloCELYVIR,Recruiting,No Results Available,"Diffuse Intrinsic Pontine Glioma|Medulloblastoma, Childhood, Recurrent",Biological: AloCELYVIR,Dose-Limiting Toxicities rate (DLTs)|Objective response rate|Feasibility of the combination/monotherapy|Incidence of treatment-Emergent Adverse Event|Progression-free survival (PFS)|Overall Survival (OS)|Antiadenoviral humoral immune response in patients|Antiadenoviral tumoral immune response in patients|Replication kinetics of Icovir-5,"Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.",All,"1 Year to 21 Years   (Child, Adult)",Phase 1|Phase 2,12,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FIBHNJ-2020-01,"April 19, 2021",October 2024,October 2024,"February 17, 2021",,"August 26, 2021","Hospital Infantil Universitario Niño Jesús, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04758533
676,165,NCT05333029,Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD,,Not yet recruiting,No Results Available,Graft Versus Host Disease,Biological: Allogeneic mesenchymal stromal cells (MSCs)|Biological: Extracorporeal photopheresis (ECP),Percent of participants with response to therapy|aGVHD severity per Blood and Marrow Transplant Clinical Trials Network Manual of Operations (BMT MOP).|aGVHD incidence|Safety as measured by number of adverse events attributed to MSC and ECP therapy|Safety as measured by severity of adverse events attributed to MSC and ECP therapy|Number of participants with non-relapse mortality (NRM)|Number of participants with relapse-related mortality|Average time to relapse|Chronic GVHD incidence|Overall Survival (OS)|Steroid dose decrease|Steroid discontinuation rate|Change in FACT-BMT (Functional Assesment of Cancer Therapy-Bone Marrow Transplant) survey score|Percent regulatory T cells (% Tregs)|CD4:CD8 ratio,Molly Gallogly|Case Comprehensive Cancer Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE1Z20,October 2022,June 2023,December 2023,"April 18, 2022",,"July 26, 2022","University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT05333029
677,226,NCT05549609,A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers,,Recruiting,No Results Available,Venous Leg Ulcer,Biological: XSTEM-VLU|Other: Vehicle,Safety and tolerability: Adverse events (AEs)|Safety and tolerability: Local tolerability|Safety and tolerability: Number of participants with abnormal 12-lead electrocardiogram (ECG)|Safety and tolerability: Number of participants with abnormal vital signs|Safety and tolerability: Number of participants with abnormal laboratory test results|Safety and tolerability: Number of participants with abnormal physical examination findings|Preliminary efficacy: Wound area reduction (absolute and percentage) compared to baseline|Preliminary efficacy: Proportion of patients with re-epithelialization of >=95% and >=50% of the wound area measured at baseline|Preliminary efficacy: Time to re-epithelialization of >=95% and >=50% of the wound area measured at baseline|Preliminary efficacy: Pain for target wound and the affected leg using Visual Analogue Scale (VAS)|Preliminary efficacy: Scar formation assessed by the Patient and Observer Scar Assessment Scale (POSAS),Xintela AB|Vinnova,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,XIN-XSTEM-201,September 2022,June 2023,June 2023,"September 22, 2022",,"September 23, 2022","Burn Centre, Linköping University Hospital, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT05549609
678,15,NCT01856140,Treatment of Tendon Injury Using Mesenchymal Stem Cells,ALLO-ASC,Completed,Has Results,Lateral Epicondylitis,Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection,Change From Baseline in Visual Analog Scale (VAS) at 6 and 12 Weeks|Modified Mayo Clinic Performance Index for the Elbow|Defect Area of Tendon by Ultrasonography in Long Axis|Defect Area of Tendon by Ultrasonography in Short Axis,"Seoul National University Hospital|Medical Research Collaborating Center, Seoul, Korea",All,"19 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNUH-RM-SGChung-ASC-01,May 2013,July 2016,April 2018,"May 17, 2013","February 18, 2022","March 18, 2022","Seoul National University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01856140
679,283,NCT02483364,A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure),Bonecure,Completed,No Results Available,Pseudoarthrosis,Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment),Safety of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones by recording of adverse events.|Effectiveness by mean of radiological methods on the appearance of signs of osseous setting formation.|Comparative statistical analysis,Salvat,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STEMQUIRI/12ES01,"November 10, 2015","May 18, 2020","October 20, 2020","June 26, 2015",,"March 17, 2021","Laboratorios Salvat, S.A., Esplugues de Llobregat, Barcelone, Spain",,https://ClinicalTrials.gov/show/NCT02483364
680,26,NCT05035862,Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma,,Recruiting,No Results Available,Asthma,Drug: Albuterol Sulfate|Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)|Drug: Prednisone,Change in number of adverse events and severe adverse events post-intervention|Number of grade ≥3 adverse reaction attributable to the γMSC product|Change in lung function test|In- vivo trafficking of MSCs after intravenous infusion|Upper airway inflammation of MSC treatment|Circulating inflammatory cells of MSC treatment|Biophysical characteristics of the cell products and correlation with clinical outcome,"Emory University|The Marcus Foundation|Ossium Health, Inc.",All,18 Years to 30 Years   (Adult),Phase 1,12,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STUDY00002655|2709,"March 16, 2022",July 2023,July 2023,"September 5, 2021",,"July 25, 2022","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT05035862
681,140,NCT03798353,Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue,PERISCOPE,"Active, not recruiting",No Results Available,Myocardial Infarction,Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|Procedure: Surgery by sternotomy,Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.|Death rate or rehospitalization due to cardiovascular causes|Rate of relevant arrhythmias in Holter of 24 hours|Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels|Changes in the necrotic myocardial mass ratio|Changes of regional contractility|Changes in ejection fraction of the left ventricle|changes in left and right ventricular geometric remodeling|Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).|Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used.,Fundació Institut Germans Trias i Pujol|Germans Trias i Pujol Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ICOR-2016-02|2018-001964-49,"May 13, 2019",September 2022,September 2022,"January 9, 2019",,"October 5, 2021","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03798353
682,446,NCT04972890,The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction,,Recruiting,No Results Available,Urologic Diseases|Erectile Dysfunction With Diabetes Mellitus,Biological: stem cells|Other: placebo,Changes in IIEF-5 Score after stem cells injection|Changes in Peak Systolic Velocity (PSV) after stem cells injection|Changes in End Diastolic Velocity after stem cells injection|Changes in Resistive Index after stem cells injection|Changes in Pulsatility Index after stem cells injection|Changes in E-selectin expression after stem cells injection|Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection|Changes in Bcl-2 expression after stem cells injection|Changes in microRNA 16 expression after stem cells injection|Changes in microRNA 126 expression after stem cells injection|Changes in Hba1c after stem cells injection|Changes in Fasting Blood Glucose after stem cells injection|Changes in total cholesterol after stem cells injection|Changes in low-density lipoprotein (LDL) after stem cells injection|Changes in high-density lipoprotein (HDL) after stem cells injection|Changes in Triglycerides (TG) level after stem cells injection|Number of participants with side effects after intracavernosal injection,Indonesia University,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",19-04-0516,"October 27, 2020","December 31, 2022","January 31, 2023","July 22, 2021",,"March 31, 2022","Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04972890
683,228,NCT05333406,Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A,,Recruiting,No Results Available,"Charcot-Marie-Tooth Disease, Type IA",Drug: EN001,"Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with 12-lead Electrocardiography (ECG) abnormalities|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Change from baseline in disease severity CMTNS-v2 score|Change from baseline in gait and balance functions|Change from baseline in the degree of muscle damage (%)|Change from baseline in nerve regeneration potential",ENCell,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ENCell_2020_02,"February 22, 2022","December 20, 2022","December 31, 2027","April 19, 2022",,"May 13, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05333406
684,270,NCT05443464,Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD),,Not yet recruiting,No Results Available,"GVHD,Acute",Biological: OSSM-001,Safety events|Maximum tolerated dose (MTD),"Ossium Health, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSSM-001-006-01,"June 5, 2023","June 10, 2024","October 14, 2024","July 5, 2022",,"July 5, 2022",,,https://ClinicalTrials.gov/show/NCT05443464
685,500,NCT04706312,Transplantation of hAMSCs for Woman With DOR,,Not yet recruiting,No Results Available,Diminished Ovarian Response,Other: stem cells,Safety and tolerability after hAMSCs injection.|The ratio of transplantable embryo in DOR patients after hAMSCs injection.|Ovarian function in DOR patients after hAMSCs injection.|Outcomes of IVF in DOR patients after hAMSCs injection.,The First Affiliated Hospital with Nanjing Medical University,Female,35 Years to 45 Years   (Adult),Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-SCR-03,April 2021,January 2022,April 2024,"January 12, 2021",,"February 9, 2021","Clinical Center of Reproductive Medicine at the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04706312
686,140,NCT03007576,Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem),,Completed,No Results Available,"Osteoarthritis,Knee",Biological: RegStem,"Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI",EMO Biomedicine Corporation|Far Eastern Memorial Hospital,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,12,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EMOCT01,"August 1, 2017","August 31, 2019","August 31, 2019","January 2, 2017",,"November 13, 2019","Far Eastern Memorial Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03007576
687,227,NCT05338099,Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD),,Recruiting,No Results Available,Duchenne Muscular Dystrophy,Drug: EN001,"Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with abnormalities of 12-lead Electrocardiography (ECG)|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Rate of change at the time of visit compared to baseline (percent [%]) in CK level|Change from baseline in Function tests",ENCell,Male,"2 Years to 18 Years   (Child, Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ENCell_2020_01,"January 18, 2022","January 31, 2023","August 19, 2028","April 20, 2022",,"May 13, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05338099
688,149,NCT04489732,MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer,,Recruiting,No Results Available,Xerostomia Following Radiotherapy,"Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells",Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size|Change in salivary gland stiffness measured by shear wave velocity|Participant Drop out Rate,"University of Wisconsin, Madison|University of Wisconsin Carbone Cancer Center (UWCCC)|National Institute of Dental and Craniofacial Research (NIDCR)",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,12,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-1290|A533300|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|UW20025|NCI-2021-00070|1UG3DE030431-01|Protocol Version 10/7/2021|Head & Neck SPORE,"February 18, 2022",June 2023,May 2024,"July 28, 2020",,"March 22, 2022","University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04489732
689,207,NCT05559801,Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI),,Not yet recruiting,No Results Available,Osteogenesis Imperfecta|Osteogenesis Imperfecta Type III,Drug: Bone marrow-derived mesenchymal stromal cells (MSCs),"Recruitment rate of participants|Number of participants with correctly collected data for the study outcomes|Total number of visits with protocol deviation|Visit attendance by participants|Patient retention rate|Patient Primary Clinical Outcome Retention Rate|Change in acceptability from baseline|Number of unexpected adverse events|Number of participants with change in vital signs from baseline|Number of participants with changes in laboratory panels from baseline (CBC, CMP)|Change in number of participants with changes in radiological parameters|Change in annualized linear growth velocity|Change in fracture rate from baseline|Change in bone mineral density from baseline|Change in bone age|Change in Vertebral Compression Fractures (VCFs)|Number of participants with changes in bone metabolism markers|Change in Limb Deformity Modified EOS Questionnaire (LD-EOSQ-22) from baseline|Change in BAMF (Brief Assessment of Motor Function) from baseline|Change in Pediatric Orthopedic Data Collection Instrument (PODCI) from baseline",Emory University,All,3 Years to 10 Years   (Child),Phase 1|Phase 2,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00003434,October 2022,October 2026,October 2026,"September 29, 2022",,"September 29, 2022",,,https://ClinicalTrials.gov/show/NCT05559801
690,68,NCT01909154,Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia,CME-LEM1,Completed,Has Results,Spinal Cord Injury,Biological: Mesenchymal stromal cell therapy,Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI),Puerta de Hierro University Hospital,All,18 Years to 60 Years   (Adult),Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CME-LEM1|2010-023285-46,March 2013,April 2014,March 2015,"July 26, 2013","March 29, 2019","March 29, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01909154
691,242,NCT00951210,Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI),,Completed,No Results Available,Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia,Biological: PLX-PAD,"Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence|Immunological reaction",Pluristem Ltd.,All,"40 Years to 81 Years   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1202-2,August 2009,January 2011,October 2011,"August 4, 2009",,"May 27, 2015","Cardiology PC, Birmingham, Alabama, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00951210
692,8,NCT02814864,"Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",PRISME,Recruiting,No Results Available,Pelvic Radiation Therapy|Radiation-induced Hemorrhagic Cystitis,Drug: Mesenchymal Stromal Cell (MSC) injections,"Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P130935|2014-001462-99,"April 14, 2021",April 2022,April 2022,"June 28, 2016",,"August 3, 2021","Hématologie et thérapie cellulaire, Hôpital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT02814864
693,99,NCT04294290,Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder,TACT,"Active, not recruiting",No Results Available,Autism Spectrum Disorder,Biological: hCT-MSC infusion,Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG,Duke University|The Marcus Foundation,All,18 Months to 48 Months   (Child),Phase 1,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00104460,"February 24, 2021","December 1, 2022","December 1, 2022","March 4, 2020",,"January 20, 2022","Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04294290
694,331,NCT02381366,Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study,,Completed,No Results Available,Bronchopulmonary Dysplasia,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,Number of participants with adverse reactions for 84 days after treatment|Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)|Hospital Re-admission between 84 days after treatment until 20 months of corrected age|Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age,Medipost America Inc.|Medipost Co Ltd.,All,3 Days to 14 Days   (Child),Phase 1|Phase 2,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MD-BPD-US001,March 2015,September 2016,May 2018,"March 6, 2015",,"August 16, 2018","Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02381366
695,728,NCT04750499,Treatment of Perianal Fistulas by Endorectal Advancement Flap Associated With Adipose Tissue Injection,Fistula_CM1,Recruiting,No Results Available,Anal Fistula,Procedure: Adipose tissue injection associated with endorectal advancement flap.,Healing rate|Incontinence rate|Treatment related adverse events,Hospital Plató,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Fistula_CM1,"September 1, 2020",September 2022,September 2022,"February 11, 2021",,"February 15, 2021","Hospital Plato, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04750499
696,245,NCT05456243,Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients,,Recruiting,No Results Available,Kidney Transplant,Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC),Worsening kidney allograft rejection|Adverse Events,Mayo Clinic,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-012522,October 2022,August 2025,August 2025,"July 13, 2022",,"September 9, 2022","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT05456243
697,139,NCT01753440,Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy,,Completed,No Results Available,Coronary Artery Disease|Ischemic Cardiomyopathy,Procedure: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).,iMP-related adverse events|Hypersensitivity|Scar reduction|LVEF|Change in quality of life,AHEPA University Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,11,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AHEPA_CTL_01,November 2012,September 2014,December 2014,"December 20, 2012",,"May 7, 2019","AHEPA University Hospital, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT01753440
698,77,NCT01389661,Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H),BIOMAX,Completed,No Results Available,Maxillary Cyst|Bone Loss of Substance,Biological: MSV treatment,To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts|Indication of efficacy,Red de Terapia Celular|Sanidad de Castilla y León|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Citospin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,11,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TerCel0002|2010-024246-30|EC10-255|BIOMAX-VA-2010,April 2011,"April 25, 2016","April 25, 2016","July 8, 2011",,"April 27, 2017","Río Hortega University Hospital, Valladolid, Valladid, Spain|Bionand, Parque Tecnológico de Andalucía, Universidad de Málaga, Malaga, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT01389661
699,232,NCT04340284,Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion,,Completed,No Results Available,Nonunion of Fracture,Biological: autologous adipose tissue derived stromal vascular fraction (SVF),Union|Short Form 12 survey,Dr. Himanshu Bansal Foundation,All,"25 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,11,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HimanshubansalFoundation,"November 10, 2019","February 14, 2020","February 14, 2020","April 9, 2020",,"August 2, 2022","Anupam Hospital, Rudrapur, Uttrakhand, India",,https://ClinicalTrials.gov/show/NCT04340284
700,684,NCT03252340,Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis,,"Active, not recruiting",No Results Available,Atopic Dermatitis,Drug: ADSTEM Inj.,Tumor formation|Adverse events,"EHL Bio Co., Ltd.",All,"19 Years to 70 Years   (Adult, Older Adult)",,11,Industry,Observational,Observational Model: Case-Only|Time Perspective: Other,AD-CP-17-1|30902,"September 19, 2017","August 16, 2022","August 16, 2022","August 17, 2017",,"January 12, 2022","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03252340
701,12,NCT00284986,Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients,,Completed,No Results Available,Graft Versus Host Disease,Drug: Prochymal®,Response by Day 28|Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at day 1|Best stage of each involved organ by Day 28|Time to improvement or resolution of GVHD in one or more organs|Adverse events|Infusional toxicity|Overall relapse of underlying disease|Overall survival|Formation of ectopic tissue foci|Incidence of infection,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"6 Months to 70 Years   (Child, Adult, Older Adult)",Phase 2,11,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Osiris 270-271,"November 18, 2005","April 25, 2006","February 8, 2007","February 1, 2006",,"January 31, 2022","Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00284986
702,78,NCT02359929,BMT Autologous MSCs for GvHD,,Completed,No Results Available,Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease,Biological: Autologous mesenchymal stromal cells (MSCs),Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival,Emory University|CURE Foundation,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1,11,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00076372,January 2015,"June 15, 2020","January 11, 2021","February 10, 2015",,"March 4, 2021","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02359929
703,248,NCT03509025,Follow-up Study for Participants Jointstem Clinical Trial,,Completed,No Results Available,Knee Osteoarthritis,Drug: Jointstem,Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray,R-Bio,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JM2b-FU,"February 8, 2017","December 9, 2020","December 9, 2020","April 26, 2018",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03509025
704,216,NCT04034316,Reduce Immunosuppression With Atmp in NS ChildrEn,RACE,Enrolling by invitation,No Results Available,Nephrotic Syndrome in Children|Steroid-Dependent Nephrotic Syndrome|Idiopathic Nephrotic Syndrome,Other: Cord-blood mesenchymal stromal cells,The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|Laboratorio Sperimentale di Immunologia e Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia",All,"3 Years to 18 Years   (Child, Adult)",Phase 2,11,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIFA-2016-02364896|2018-001162-42,"November 2, 2018","June 30, 2022",December 2022,"July 26, 2019",,"August 26, 2021","Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, MI, Italy",,https://ClinicalTrials.gov/show/NCT04034316
705,28,NCT04426643,Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells,,Completed,No Results Available,Urinary Incontinence,Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,Number of cured patients|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The state institution N. N. Alexandrov National Cancer Centre of Belarus,Male,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(UIM),"August 1, 2020","February 20, 2021","March 31, 2021","June 11, 2020",,"May 25, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04426643
706,219,NCT05176366,Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis,,Not yet recruiting,No Results Available,Ulcerative Colitis,Drug: ExoFlo,Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin,"Direct Biologics, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DB-EF-ULCERATIVE-0004,"December 1, 2022","January 1, 2024","March 1, 2024","January 4, 2022",,"September 10, 2022",,,https://ClinicalTrials.gov/show/NCT05176366
707,131,NCT05060107,Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1),ExoOA-1,Not yet recruiting,No Results Available,"Osteoarthritis, Knee",Biological: Exosomes (sEVs),Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders,"Francisco Espinoza|Universidad de los Andes, Chile",All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C4C060921,"October 5, 2021","April 5, 2023","October 5, 2023","September 28, 2021",,"September 28, 2021",,,https://ClinicalTrials.gov/show/NCT05060107
708,58,NCT03562065,Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord,MSC-SLE,Recruiting,No Results Available,Lupus Erythematosus|Stem Cell Transplant,Biological: mesenchymal stem cells,Toxicity of allogeneic MSC injection according to CTCAE|Toxicity of allogeneic MSC injection according to CTCAE Month 1|Toxicity of allogeneic MSC injection according to CTCAE Month 3|Toxicity of allogeneic MSC injection according to CTCAE Month 6|Toxicity of allogeneic MSC injection according to CTCAE Month 12|Proportion of subjects with Clinical Response Month 3|Proportion of subjects with Clinical Response Month 6|Proportion of subjects with Clinical Response Month 9|Proportion of subjects with Clinical Response Month 12|Disease activity measured by the BILAG index Month 3|Disease activity measured by SELENA-SLEDAI Month 3|Disease activity measured by SELENA-SLEDAI Month 6|Disease activity measured by the BILAG index Month 6|Disease activity measured by the BILAG index Month 9|Disease activity measured by SELENA-SLEDAI Month 9|Disease activity measured by the BILAG index Month 12|Disease activity measured by SELENA-SLEDAI Month 12|SRI Month 3|SRI Month 6|SRI Month 9|SRI Month 12|comorbidities Month 3|comorbidities Month 6|comorbidities Month 9|comorbidities Month 12|Quality of life Month SF-36 Month 3|Quality of life EQ-5D Month 3|Quality of life Month SF-36 Month 6|Quality of life EQ-5D Month 6|Quality of life Month SF-36 Month 9|Quality of life EQ-5D Month 9|Quality of life Month SF-36 Month 12|Quality of life EQ-5D Month 12|Steroids Month 3|Steroids Month 6|Steroids Month 9|Steroids Month 12,Assistance Publique - Hôpitaux de Paris,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P150302,"September 11, 2019","June 1, 2023","June 1, 2024","June 19, 2018",,"July 8, 2021","Saint-Louis Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03562065
709,738,NCT02859025,Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone in Alveolar Cleft Osteoplasty,,Completed,No Results Available,Cleft of Alveolar Ridge,Biological: anterior iliac crest graft|Biological: lateral ramus cortical bone+BFPSC+NBBM|Biological: anterior iliac crest graft+BFPSC+NBBM,change in bone volume,Shahid Beheshti University of Medical Sciences,All,"Child, Adult, Older Adult",Phase 1,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,sbmu9221,January 2015,January 2016,February 2016,"August 8, 2016",,"August 8, 2016","School of Dentristry at Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02859025
710,75,NCT04815213,The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans,,Recruiting,No Results Available,Premature Ovarian Failure,Biological: expanded autologous bone marrow derived MSC,"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness",University of Jordan,Female,18 Years to 38 Years   (Adult),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,POF.UJCTC,"January 1, 2020","January 31, 2022","January 31, 2022","March 24, 2021",,"March 24, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT04815213
711,423,NCT02442817,Linagliptin and Mesenchymal Stem Cells: A Pilot Study,,Completed,No Results Available,Schizophrenia,Drug: Linagliptin,SDF1-α (stromal cell-derived factor alpha) Concentration|DPP-4 (Dipeptidyl peptidase-4) Activity|Monocyte State|Absolute/Differential leukocyte count|CD271+ cells,"University of Nevada, Reno|Augusta University",All,18 Years to 45 Years   (Adult),Phase 4,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,LING-1,"March 2, 2015","March 2, 2018","March 2, 2018","May 13, 2015",,"November 9, 2020","University of Nevada School of Medicine, Reno, Nevada, United States",,https://ClinicalTrials.gov/show/NCT02442817
712,40,NCT02387151,Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients,Neptune,Completed,No Results Available,Rejection|Graft Loss,Drug: mesenchymal stromal cells,"biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses",Leiden University Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL4724400013|2013-005407-14,March 2015,November 2018,November 2018,"March 12, 2015",,"July 2, 2019","Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT02387151
713,263,NCT03003364,Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury,,Completed,No Results Available,"Spinal Cord Injury, Chronic",Drug: XCEL-UMC-BETA|Drug: Placebo,"Incidence of treatment-emergent adverse events|Extent and severity of a patient's spinal cord injury|Motor electrophysiology assessment|Somatosensory electrophysiology assessment|Electrical nerve stimulation on pain perception|Mictional dysfunction|Anal sphincter integrity|Neuropathic pain|Spasticity|Functionality|Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)|Urinary disorder|Size injury|Presence of allogeneic cells|Immunology","Banc de Sang i Teixits|Hospital de Neurorehabilitació Institut Guttmann|Recerca Clínica S.L.|Syntax for Science, S.L",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XCEL-SCI-01,"December 27, 2016","July 25, 2019","February 11, 2020","December 28, 2016",,"February 17, 2020","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03003364
714,218,NCT05078385,Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds,,Not yet recruiting,No Results Available,Burns,Drug: AGLE-102,Primary Objective|Secondary Objective,Aegle Therapeutics|Congressionally Directed Medical Research Programs,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Industry|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AGLE-102-102,July 2022,April 2024,July 2024,"October 14, 2021",,"October 14, 2021",,,https://ClinicalTrials.gov/show/NCT05078385
715,228,NCT05308836,Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment,,Recruiting,No Results Available,Type 1 Diabetes,Combination Product: adipose-derived messenchymal stem cell,Safety measure|HbA1c|Fasting blood glucose (FPG)|C-peptide levels|Blood insulin|Insulin dose,Vinmec Research Institute of Stem Cell and Gene Technology|Gwoxi Stem cell applied technology Company,All,"5 Years and older   (Child, Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISC20.01,"October 4, 2021","October 30, 2022","October 30, 2023","April 4, 2022",,"April 4, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT05308836
716,741,NCT05120700,Synovial Tissue and Fat Pad Stromal Vascular Fraction Bioengineering in Patients With Knee Articular Cartilage Injury,,Not yet recruiting,No Results Available,Cell- and Tissue-Based Therapy|Cartilage Injury|Knee Injuries,Biological: Synovial Tissue and Fat Pad Stromal Vascular Fraction,Cartilage Repair|Visual Analog Score for pain|International Knee Documentation Committee Questionnaire|Western Ontario and McMaster Universities Osteoarthritis Index|Perioperative and post-operative complications|Measurement of health resources expenses,University of Sao Paulo General Hospital,All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4.285.308,April 2022,April 2025,May 2025,"November 15, 2021",,"November 15, 2021",,,https://ClinicalTrials.gov/show/NCT05120700
717,59,NCT01378182,Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis,,Completed,No Results Available,Wilson's Disease,Genetic: allogeneic mesenchymal stem cell transplantation,differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies,Murat Kantarcioglu|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110S153,April 2011,March 2013,December 2014,"June 22, 2011",,"December 31, 2014","Department of Gastroenterology; Gulhane Military Medical Academy, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT01378182
718,27,NCT02966951,Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis,,Recruiting,No Results Available,Knee Osteoarthrosis,Biological: Adipose tissue derived mesenchymal stem cell,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of ATMSC,Hanan Jafar|University of Jordan,All,"42 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATKneeUJCTC,"January 17, 2017",September 2021,December 2021,"November 17, 2016",,"April 28, 2021","Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02966951
719,523,NCT01318330,Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD),Homeo-GH,Completed,No Results Available,Graft-vs-Host Disease,Drug: Homeo-GH,To evaluate number of paticipants with adverse events|GVHD clinical response,"HomeoTherapy Co., Ltd",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),Homeo-GH,November 2010,December 2011,June 2012,"March 18, 2011",,"July 19, 2012","Inha University Hospital, In Cheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01318330
720,599,NCT05523011,Safety and Tolerability Study of MSC Exosome Ointment,,Completed,No Results Available,Psoriasis,Drug: Exosome ointment,Treatment-emergent adverse events (TEAEs)|Change from baseline in the systolic blood pressure after 20 days of treatment|Change from baseline in the diastolic blood pressure after 20 days of treatment|Change from baseline in the heart rate after 20 days of treatment|Change from baseline in the respiratory rate after 20 days of treatment|Change from baseline in the body temperature after 20 days of treatment|Change from baseline in the basophils after 20 days of treatment|Change from baseline in the eosinophils after 20 days of treatment|Change from baseline in the hemoglobin after 20 days of treatment|Change from baseline in the lymphocytes after 20 days of treatment|Change from baseline in the monocytes after 20 days of treatment|Change from baseline in the red blood cell after 20 days of treatment|Change from baseline in the white blood cell after 20 days of treatment|Change from baseline in the bicarbonate after 20 days of treatment|Change from baseline in the blood urea nitrogen after 20 days of treatment|Change from baseline in the calcium after 20 days of treatment|Change from baseline in the chloride after 20 days of treatment|Change from baseline in the creatinine after 20 days of treatment|Change from baseline in the glucose after 20 days of treatment|Change from baseline in the potassium after 20 days of treatment|Change from baseline in the sodium after 20 days of treatment|Change from baseline in the alanine transaminase after 20 days of treatment|Change from baseline in the albumin after 20 days of treatment|Change from baseline in the alkaline phosphatase after 20 days of treatment|Change from baseline in the aspartate aminotransferase after 20 days of treatment|Change from baseline in the direct bilirubin after 20 days of treatment|Change from baseline in the total bilirubin after 20 days of treatment|Change from baseline in the c-reactive protein after 20 days of treatment|Change from baseline in the erythrocyte sedimentation rate after 20 days of treatment|Assessment of the dryness of the area of application|Assessment of the oozing/crusting of the area of application|Assessment of the redness of the area of application|Assessment of the scratch marks of the area of application|Assessment of the skin thickening of the area of application|Assessment of the swelling of the area of application,"Paracrine Therapeutics Dermatology Pte. Ltd.|National University Hospital, Singapore",All,"21 Years and older   (Adult, Older Adult)",Phase 1,10,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PTD2021P001,"March 8, 2022","April 5, 2022","April 5, 2022","August 31, 2022",,"August 31, 2022","National University Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT05523011
721,164,NCT01076920,Mesenchymal Stem Cells and Myocardial Ischemia,MESAMI,Completed,No Results Available,Chronic Myocardial Ischemia|Left Ventricular Dysfunction,Genetic: Mesenchymal stem cells,"Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction|Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function","University Hospital, Toulouse|French Blood Establishment|Nantes University Hospital|Ministry of Health, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0505008,October 2009,February 2014,September 2014,"February 26, 2010",,"September 19, 2014","University Hospital (Rangueil), Toulouse, France",,https://ClinicalTrials.gov/show/NCT01076920
722,151,NCT02277145,A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells,,Completed,No Results Available,Post-radiotherapy Pulmonary Fibrosis,Biological: clinical grade umbilical cord mesenchymal stem cells,"Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content|Safety Evaluation|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in pulmonary function analysis|Clinical Indicator 3: 6-minute walk test distance|Clinical Indicator 4: change in MRC chronic dyspnea scale|Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood|Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in serum 3: concent of immunoglobulin|Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in serum 6: expression levels of IL-12, IL-10|Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood|Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in lavage fluid 3: concent of immunoglobulin|Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10|Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)|Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in serum 2: content of hydroxyproline|Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)|Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in lavage fluid 2: content of hydroxyproline|Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)","Jianwu Dai|Southwest Hospital, China|Chinese Academy of Sciences",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAS-XDA001-SH/IGDB,October 2014,December 2018,December 2018,"October 28, 2014",,"July 24, 2019","First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital), Chongqing, Chongqing, China",,https://ClinicalTrials.gov/show/NCT02277145
723,37,NCT02387749,Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .,,Completed,Has Results,Diabetic Peripheral Neuropathy,Genetic: mesenchymal stem cells,"Measurement of b-FGF, v-EGF MEASURED BY ELISA|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.|Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %",Cairo University,All,18 Years to 45 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FACULTY OF MEDICINE,CAIRO U",May 2014,August 2016,December 2016,"March 13, 2015","October 11, 2017","July 3, 2018",,,https://ClinicalTrials.gov/show/NCT02387749
724,178,NCT04410731,Allogeneic BM-MSCs in Patients With Lumbar Facet Arthropathy,Cellkine,"Active, not recruiting",No Results Available,Facet-Mediated Low Back Pain,Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy,"Clinical assessment of nature, incidence, and severity of adverse events (AEs)|Self-reported assessment of nature, incidence, and severity of AEs|Study personnel assessment of nature, incidence, and severity of AEs|Global Health Scale (GHS)|Visual Analog Scale (VAS) - back and leg pain|Oswestry Disability Index (ODI)|Patient Health Questionnaire-4 (PHQ-4)|Narcotic Use Questionnaire|Work Status Questionnaire|PROMIS-CAT|Changes from Baseline evaluated by MRI|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide",Mayo Clinic,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-000330,"April 28, 2020",April 2024,April 2024,"June 1, 2020",,"May 12, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT04410731
725,68,NCT05490173,The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants,,Not yet recruiting,No Results Available,"Premature Birth|Extreme Prematurity|Preterm Intraventricular Hemorrhage|Hypoxia-Ischemia, Cerebral|Neurodevelopmental Disorders",Other: Exosomes derived from mesenchymal stromal cells (MSCs),Occurrence and rate of dose limiting toxicity|Rate of death|Occurrence of Other Severe Complications of Prematurity|Need for Ventilatory Support|Changes in Hemodynamics|Feasibility: Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Griffiths-II and Bayley Scales of Infant Development (2nd edition)|Long-term Safety Follow-Up,"Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare",All,1 Day to 3 Days   (Child),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,ncagp4382277,"September 5, 2022","May 22, 2026","December 28, 2026","August 5, 2022",,"August 5, 2022","Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT05490173
726,51,NCT01872624,Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema,,Completed,No Results Available,Pulmonary Emphysema,Procedure: Bronchoscopy,Absence of lung deficits during the procedure and/or in the 4 months follow-up|Quality of Life|Pulmonary function|Inflammation,"Hospital de Clinicas de Porto Alegre|Ministry of Health, Brazil|National Research Council, Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Universidade Federal do Rio de Janeiro|Pontifícia Universidade Católica do Paraná",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-0150,May 2013,December 2014,March 2015,"June 7, 2013",,"March 25, 2015","Pontificia Universidade Catolica do Parana, Curitiba, PR, Brazil|Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT01872624
727,50,NCT01175655,A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation,MSC in OB,Completed,No Results Available,Bronchiolitis Obliterans|Lung Transplantation,Other: MSC,To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.|To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC|To document survival post MSC infusion,The Prince Charles Hospital|Cell and Tissue Therapies Western Australia,All,"Child, Adult, Older Adult",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC 28105,February 2010,July 2015,July 2016,"August 5, 2010",,"April 26, 2022","TPCH, Brisbane, Queensland, Australia|RPH, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT01175655
728,299,NCT05093725,CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage,,Not yet recruiting,No Results Available,Umbilical Cord of Normal Labor,Device: flow cytomery,evaluation the best passage of MSC culture by CD49 surface marker,Sohag University,All,"1 Day and older   (Child, Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Soh-med-21-10-01,November 2021,June 2022,June 2022,"October 26, 2021",,"October 26, 2021","Sohag University Hospital, Sohag, Egypt",,https://ClinicalTrials.gov/show/NCT05093725
729,633,NCT04173650,MSC EVs in Dystrophic Epidermolysis Bullosa,,Not yet recruiting,No Results Available,Dystrophic Epidermolysis Bullosa,Drug: AGLE 102,Dose Limiting Toxicity|Wound size evaluation,Aegle Therapeutics,All,"6 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EB IND,October 2023,July 2024,January 2025,"November 22, 2019",,"April 8, 2022",,,https://ClinicalTrials.gov/show/NCT04173650
730,66,NCT05152160,Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease,,Recruiting,No Results Available,Graft Vs Host Disease,Biological: Umbilical Cord Mesenchymal Stem Cell Therapy,Disease-related clinical reactions|PFS,Shenzhen University General Hospital,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HEM-ONCO-014,"August 1, 2021",August 2024,August 2024,"December 9, 2021",,"December 9, 2021","Li Yu, Shenzhen, Guangdong, China",,https://ClinicalTrials.gov/show/NCT05152160
731,526,NCT03158896,Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease,,Recruiting,No Results Available,Acute Graft Versus Host Disease,Biological: MSCTC-0010 Dose Escalation,proportion of participants who have a TRSAE after infusion of MSCTC 0010|Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42|Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42|Occurrence of addition of escalated immunosuppressive therapy by day 90|Occurrence of Formation of ectopic tissue foci at day 90,University of Kansas Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIT-2016-aGvHD-MSCTC-0010,"July 9, 2018",August 2022,August 2023,"May 18, 2017",,"June 8, 2022","Kansas University Cancer Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03158896
732,71,NCT03386708,hUC Mesenchymal Stem Cells (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury,,Completed,No Results Available,Uterus; Injury,Procedure: intrauterine injection|Biological: human umbilical cord mesenchymal stem cell,Intrauterine adhesion patients efficacy evaluation|Incision lacuna and incision diverticulum patients efficacy evaluation|Ultrasound of uterus evaluation|Hysteroscopy evaluation|Pain score,"Sclnow Biotechnology Co., Ltd.",Female,18 Years to 40 Years   (Adult),Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCLnow-XY-01,"October 1, 2018","June 1, 2021","September 21, 2021","December 29, 2017",,"February 4, 2022","Xiangya Hospital Central South University, Changsha, Hunan, China",,https://ClinicalTrials.gov/show/NCT03386708
733,82,NCT02344849,Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction,,Completed,No Results Available,Erectile Dysfunction,Drug: mesenchymal stem cell,"Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)","Pharmicell Co., Ltd.",Male,"20 Years and older   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Cellgram-ED,July 2015,"January 31, 2018",April 2018,"January 26, 2015",,"January 9, 2019","Asan medical center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02344849
734,90,NCT03356821,Perinatal Arterial Stroke Treated With Stromal Cells Intranasally,PASSIoN,Completed,No Results Available,Perinatal Arterial Ischemic Stroke|Neonatal Stroke,Biological: Mesenchymal Stem Cells,Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting,UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development|M.D. Anderson Cancer Center|The University of Texas Health Science Center at San Antonio,All,up to 10 Days   (Child),Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL59265.000.16,"February 11, 2020","July 27, 2021","July 27, 2021","November 29, 2017",,"October 7, 2021","Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT03356821
735,90,NCT02443961,Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies,,"Active, not recruiting",No Results Available,Bronchopulmonary Dysplasia,Biological: Mesenchymal Stem Cell (MSC) therapy,"Feasibility and security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia (Number of participants with adverse events)|Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.|Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)|Incidence of BPD and PH in very low birth weight babies treated with MSC",Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Instituto de Salud Carlos III|Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar,All,1 Month to 28 Weeks   (Child),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,PULMESCEL-1,"April 2, 2019","April 2, 2020",April 2025,"May 14, 2015",,"February 3, 2021","Hospital Universitario A Coruña, A Coruña, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02443961
736,260,NCT03181087,Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars,,Recruiting,No Results Available,Uterine Scar,Other: Umbilical cord MSCs,"Safety evaluation through vital signs, the results of clinical lab tests and adverse events|Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence",Maternal and Child Health Hospital of Foshan,Female,21 Years to 35 Years   (Adult),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCHHFoshan-1701,"December 11, 2021","October 31, 2022","May 30, 2023","June 8, 2017",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03181087
737,508,NCT04657315,"Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients",MSC11FCD-GBM,Enrolling by invitation,No Results Available,"Glioblastoma|Adult Gliosarcoma|Neoplasms, Brain|Neoplasms, Germ Cell and Embryonal|Recurrent Glioblastoma",Drug: MSC11FCD,Maximum tolerated dose (MTD)|Number Of Adverse Events related to the treatment|Overall Survival improvement (OS)|Progression Free Survival (PFS)|Tumor assessment in regard to the investigational drug based on the RANO criteria|Clinical efficacy assessment,CHA University|Ajou University School of Medicine,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHAMC 2019-08-022,"June 24, 2020","December 31, 2022","December 31, 2022","December 8, 2020",,"January 11, 2022","Bundang CHA Medical Center, Seongnam, Kyunggido, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04657315
738,16,NCT04432467,Fertility Restoration Using Autologous Mesenchymal Stem Cells,,Completed,No Results Available,Chronic Endometritis|Uterus; Scar|Uterine Synechiae|Fallopian Tube Obstruction,Biological: Autologous mesenchymal stem cells|Other: standard treatment,Number of cured patients|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,Female,18 Years to 45 Years   (Adult),Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(Fertility),"October 1, 2020","September 30, 2021","September 30, 2021","June 16, 2020",,"December 10, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04432467
739,658,NCT00221130,Clinical Trials of Regeneration for Periodontal Tissue,,Completed,No Results Available,Adult Periodontitis,Procedure: surgical operation of cell transplantation,Alveolar bone defect|Tooth mobility,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|ArBlast Co.,Ltd.|Nagoya University",All,35 Years to 60 Years   (Adult),Phase 1|Phase 2,10,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRI PDT03-01,July 2004,,December 2005,"September 22, 2005",,"February 9, 2009","Ｉｎstitute of Biomedical Research and Innovation, Kobe, Hyogo Pref., Japan",,https://ClinicalTrials.gov/show/NCT00221130
740,45,NCT05286255,Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias,SAMPSON-1,Recruiting,No Results Available,COVID-19 Pneumonia|Viral Pneumonia,Biological: Allogeneic Mesenchymal Stromal Cells,Clinical deterioration|Serious Adverse Events|ICU transfer|Respiratory support|Hospital mortality and length of stay|Ventilator free days|28 day mortality,"Medical University of South Carolina|Pandorum International, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,115966,"May 4, 2022","May 4, 2023","May 4, 2023","March 18, 2022",,"May 10, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT05286255
741,2,NCT02824393,Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria,,Completed,No Results Available,Urticaria|Autoimmune Diseases|Immune System Diseases|Skin Diseases,Biological: Autologous mesenchymal stem cell,Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody,Celal Bayar University|The Scientific and Technological Research Council of Turkey|Acıbadem Labcell,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TUBITAK-1001-215S612,"March 3, 2017","May 15, 2018","July 15, 2018","July 6, 2016",,"July 18, 2018","Celal Bayar University, Medical School, Manisa, Turkey",,https://ClinicalTrials.gov/show/NCT02824393
742,51,NCT01895413,Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair,,Completed,No Results Available,Osteoarthritis,Procedure: Bone marrow aspiration,Change in WOMAC (Western Ontario and McMaster Universities)score|Change from baseline in cartilage thickness at 6 months by MRI|Knee pain relief (WOMAC and Lequesne scores)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray),"Alexandra Cristina Senegaglia|Pontifícia Universidade Católica do Paraná|Consultório Médico Dr. Alcy Vilas Boas Jr., Paraná, Brasil|Hospital Marcelino Champagnat, Paraná, Brasil|Fundação Araucária",All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTM_LESÃO ARTICULAR-461/2010,September 2012,July 2013,January 2016,"July 10, 2013",,"December 13, 2017","Centro de Tecnologia Celular, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,https://ClinicalTrials.gov/show/NCT01895413
743,233,NCT03525418,Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS),ELPIS,Completed,No Results Available,HLHS,Biological: Longeveron Mesenchymal Stem Cells,"Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.",Longeveron Inc.,All,1 Day to 1 Year   (Child),Phase 1|Phase 2,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-0000-05,"February 21, 2018","December 31, 2021","December 31, 2021","May 15, 2018",,"March 7, 2022","Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03525418
744,167,NCT01913886,Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy,,Completed,No Results Available,Ischemic Cardiomyopathy,Procedure: MSCs injection,Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.|Change in quality of life|Changes in exercise capacity|Changes in plasma inflammatory markers,"Alexandra Cristina Senegaglia|Santa Casa de Misericórdia de Curitiba, Brazil|Fundação Araucária|Pontifícia Universidade Católica do Paraná",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC_Isquemica,January 2010,September 2013,March 2016,"August 1, 2013",,"December 13, 2017","Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,https://ClinicalTrials.gov/show/NCT01913886
745,130,NCT05042206,Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease,,Recruiting,No Results Available,Chronic Kidney Disease Stage 3B|Chronic Kidney Disease stage4,Biological: Cellgram-CKD,"Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)|Changes in eGFR|Changes in BUN|Changes in Creatinine","Pharmicell Co., Ltd.",All,"19 Years to 79 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-P-12,October 2021,April 2023,April 2023,"September 13, 2021",,"October 21, 2021","Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05042206
746,58,NCT03308565,Adipose Stem Cells for Traumatic Spinal Cord Injury,CELLTOP,Completed,No Results Available,Spinal Cord Injuries|Paralysis,"Biological: Autologous, Adipose derived Mesenchymal Stem Cells",Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide,Mohamad Bydon|Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-004621,"December 5, 2017","October 22, 2019","October 11, 2021","October 12, 2017",,"August 30, 2022","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03308565
747,151,NCT03684122,Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).,,"Active, not recruiting",No Results Available,Parkinson Disease,Biological: Injection of Umbilical cord derived MSCs,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Drug Reduction Rate test|Tractography|Blood-based biomarkers|Cerebrospinal Fluid (CSF) based biomarkers,University of Jordan,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKUJCTC,"June 1, 2018","July 30, 2020","September 20, 2021","September 25, 2018",,"August 25, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT03684122
748,77,NCT04835883,Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients,,Recruiting,No Results Available,Systemic Lupus Erythematosus,Biological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell),Reduction of corticosteroid dose to ≤ 7.5 mg/day of prednisone or equivalent|Hematologic improvement without ongoing SLE treatment|Renal response improvement|Proportion of subjects who achieve a prednisone dose of ≤ 7.5mg/day or equivalent|Proportion of subjects achieving Low Level Disease Activity State|Proportion of subjects with ≥ 4 point reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 4 having SLE responder index 4 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 5 having SLE responder index 5 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 6 having SLE responder index 6 (SRI6)|Time to first severe modified SLE Flare Index (SFI) flare|Change from baseline of hematologic parameters|Time to first hematologic flare|Change in baseline of renal function parameters|Time to event for each of the individual components of treatment failure|Time to complete remission|Time to first renal flare,"Hanyang University Seoul Hospital|Corestem, Inc.|Ministry of Health & Welfare, Korea",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,10,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS20AT04-SLE101,"September 26, 2019","November 5, 2021","January 20, 2026","April 8, 2021",,"April 8, 2021","Hanyang University Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04835883
749,3,NCT02570932,Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries,,Completed,No Results Available,Spinal Cord Injury,Biological: Autologous Mesenchymal Bone Marrow Cell,Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.|Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment|Changes in PENN score are considerate for the motor and sensory functions evaluation|Changes in VAS score are considerate for quantification of pain|Changes in BDS score are considerate for the Assessment of the functional status|Changes in GEFFNER score are considerate for the Assessment of the functional status,Puerta de Hierro University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CME-LEM3|2014-005613-24,July 2015,"December 4, 2017","December 4, 2017","October 7, 2015",,"April 5, 2018","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02570932
750,213,NCT03838250,Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC,,Recruiting,No Results Available,Alcoholic Liver Cirrhosis,Biological: Cellgram™ (Bone marrow-derived MSCs),Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire,"Pharmicell Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-P-08,"June 20, 2019",March 2021,June 2021,"February 12, 2019",,"October 22, 2020","University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03838250
751,150,NCT03933995,Follow up Study(Phase 1) to Evaluate Safety of Autologous Bone Marrow Derived MSCs in Erectile Dysfunction,,Recruiting,No Results Available,Erectile Dysfunction,Other: no Intervention,"Safety Evaluation assessed by Tumor Marker Test.|Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer.|Safety Evaluation assessed by Vital Signs.","Pharmicell Co., Ltd.",Male,"20 Years and older   (Adult, Older Adult)",,10,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,PMC-P-09,"March 11, 2019","February 28, 2022","November 30, 2022","May 1, 2019",,"October 22, 2020","Asan medical center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03933995
752,42,NCT01306513,Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema,,Completed,No Results Available,Emphysema,Biological: autologous bone marrow derived mesenchymal stromal cells,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Leiden University Medical Center,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL28562.000.09,October 2010,June 2012,November 2012,"March 2, 2011",,"November 19, 2012","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT01306513
753,43,NCT03929120,Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD),,Completed,No Results Available,Interstitial Lung Disease|Connective Tissue Diseases,Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs),Adverse Events,Mayo Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-007216,"November 5, 2019","July 27, 2021","February 17, 2022","April 26, 2019",,"April 20, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03929120
754,148,NCT00395200,Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS),MSCIMS,Completed,No Results Available,Multiple Sclerosis,Procedure: MSC Treatment,Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score,University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Medical Research Council,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRCRG44871|REC Reference: 07/Q0108/104,July 2008,December 2010,December 2010,"November 2, 2006",,"October 25, 2011","University of Cambridge Dept of Clinical Neurosciences, Cambridge, Cambridgeshire, United Kingdom|University College London Institute of Neurology, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00395200
755,690,NCT03563495,Tissue Engineered Constructs for Alveolar Cleft Repair,,Completed,No Results Available,Cleft Lip and Palate,Other: tissue engineered group|Procedure: autogenous bone graft group,Assessment of changes in the bone volume at the grafted alveolar cleft site from the immediate postoperative to 6 months|Assessment of changes in the bone density at the grafted alveolar cleft site from the immediate postoperative to 6 months,Cairo University,All,8 Years to 14 Years   (Child),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,MSCs in alveolar cleft repair,February 2015,July 2017,September 2017,"June 20, 2018",,"June 20, 2018",,,https://ClinicalTrials.gov/show/NCT03563495
756,402,NCT03570333,Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites,,"Active, not recruiting",No Results Available,Gingival Recession|Lack of Keratinized Gingiva (Disorder),Diagnostic Test: progenitor potential of Gingival Mesenchymal cells,Osteogenic potential|Adipogenic potential|Genotype assay,University of Alabama at Birmingham,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GMC:18,"September 17, 2018","December 30, 2019","December 30, 2022","June 26, 2018",,"March 11, 2022","UAB School of Dentistry Department of Periodontology, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT03570333
757,23,NCT02824653,Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD,,Completed,No Results Available,Graft Versus Host Disease,Biological: Mesenchymal Stem Cells,Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]|Acute GVHD-restaging [Efficacy]|Chronic GVHD-restaging [Efficacy]|Survival analysis at six months after MSC infusion|Incidence free survival at six months after MSC infusion,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",All,"1 Year to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFBMTC-GVHD-2015,January 2015,July 2016,December 2016,"July 7, 2016",,"January 25, 2017","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT02824653
758,200,NCT04446897,Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction,,Completed,No Results Available,"Periodontitis, Chronic",Biological: mesenchymal stem cells|Other: standard treatment,number of patients cured,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,All,70 Years to 70 Years   (Older Adult),Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(periodontitis),"August 3, 2020","December 31, 2020","December 31, 2020","June 25, 2020",,"February 9, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04446897
759,26,NCT02963727,Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis,,Recruiting,No Results Available,Knee Osteoarthrosis,Biological: Wharton Jelly derived mesenchymal stem cell,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of WJMSC,Hanan Jafar|University of Jordan,All,"42 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AlloKneeUJCTC,"January 27, 2017",October 2021,December 2021,"November 15, 2016",,"April 28, 2021","Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02963727
760,4,NCT02165904,Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI,,Completed,Has Results,Spinal Cord Injury,Biological: Adult Autologous Mesenchymal Bone Marrow Cell,"Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples",Puerta de Hierro University Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CME-LEM2|2011-005684-24,May 2014,May 2016,May 2016,"June 18, 2014","July 19, 2019","July 19, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02165904
761,129,NCT04527224,Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia,,Not yet recruiting,No Results Available,Covid19 Pneumonia,Drug: AstroStem-V,"Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 / FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test",Nature Cell Co. Ltd.,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASVP1N2A-US,"December 1, 2021","October 1, 2022","April 1, 2023","August 26, 2020",,"April 1, 2021",,,https://ClinicalTrials.gov/show/NCT04527224
762,50,NCT03874572,Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth,MESRIX-SAFETY,"Active, not recruiting",No Results Available,Xerostomia Due to Radiotherapy|Hyposalivation|Xerostomia|Oropharynx Cancer|Salivary Gland Diseases|Dry Mouth|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Stem Cells,Biological: Allogeneic adipose derived stem/stromal cells,Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse,"Rigshospitalet, Denmark",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CVB2018-2|2018-003856-19,"March 18, 2019","June 22, 2020","December 1, 2025","March 14, 2019",,"January 29, 2021","Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03874572
763,172,NCT02801890,Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF),,Completed,No Results Available,Ultra Filtration Failure,Biological: Intravenous injection,Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):,Royan Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-kidney-006,August 2015,February 2017,March 2017,"June 16, 2016",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02801890
764,1,NCT00294112,Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease,,Completed,No Results Available,Crohn's Disease,Drug: Prochymal™ adult human mesenchymal stem cells|Drug: adult human mesenchymal stem cells,Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points|Number of Participants with Reduction in CDAI of at Least 70 points|Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)|Time to Improvement in IBDQ|Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression|Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150|Time to Reduction in CDAI of at Least 100 Points|Time to Reduction in CDAI of at Least 70 Points|Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.|Number of Participants with Adverse Events,"Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSIRIS-601-602,"March 13, 2006","July 21, 2006","July 21, 2006","February 20, 2006",,"April 2, 2020","Osiris Clinical Site, Baton Rouge, Louisiana, United States|Osiris Clinical Site, Charlotte, North Carolina, United States|Osiris Clinical Site, Pittsburgh, Pennsylvania, United States|Osiris Clinical Site, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00294112
765,188,NCT02566655,Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis,CSM/OP/2011,Completed,No Results Available,Osteoporosis|Spinal Fractures,Biological: Fucosylated MSC for Osteoporosis,"Rate of serious and non-serious adverse events related to the procedure.|Number of new fractures|Pain, measured by Visual Analog Scale|Functionality, measured by Oswestry Disability Questionnaire|Quality of Life, measured by EuroQoL-5D test|Bone resorption, measured by biochemical index|Bone formation, measured by biochemical index|Bone metabolism, measured by biochemical index|Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)|Bone structure, measured by histomorphometric evaluation|Trabecular bone density measured by quantitative computed tomography of the radius","Red de Terapia Celular|Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital Universitario Virgen de la Arrixaca|Spanish National Health System|Public Health Service, Murcia|BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn|Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia",Female,"50 Years to 70 Years   (Adult, Older Adult)",Phase 1,10,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/OP/2011|2012-005814-20,September 2015,December 2016,May 2018,"October 2, 2015",,"October 8, 2020","Hospital Clínico Virgen de la Arrixaca, El Palmar, Murcia, Spain",,https://ClinicalTrials.gov/show/NCT02566655
766,186,NCT05130983,"A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,Not yet recruiting,No Results Available,Crohn Disease|IBD - Irritable Bowel Disease,Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate,"• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.","Direct Biologics, LLC",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DB-EF-CROHNS-0004,"September 1, 2022","January 1, 2024","March 1, 2024","November 23, 2021",,"September 10, 2022",,,https://ClinicalTrials.gov/show/NCT05130983
767,81,NCT04056819,Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction,,Completed,No Results Available,Acute Myocardial Infarction,Biological: Allogeneic umbilical cord mesenchymal stem cells,Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system|Incidence of Serious adverse event (SAE) as presented by MedDRA coding system|Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system|New York Heart Association (NYHA) Classification|Incidence of major adverse cardiovascular events (MACE)|Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)|Pulmonary function test|Echocardiogram|Cardiac MRI (cMRI) for baseline and efficacy evaluation,"Ever Supreme Bio Technology Co., Ltd.",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,10,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ES-CMSC01-A1101,"May 27, 2019","August 2, 2021","December 17, 2021","August 14, 2019",,"September 8, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,https://ClinicalTrials.gov/show/NCT04056819
768,22,NCT04446884,Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells,,Completed,No Results Available,Stress Urinary Incontinence,Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,Number of cured patients|Number of patients with treatment-related adverse events,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC(UIW),"March 1, 2018","December 31, 2019","December 31, 2019","June 25, 2020",,"June 25, 2020","Hrodna City Clinical Hospital, Hrodna, Belarus",,https://ClinicalTrials.gov/show/NCT04446884
769,75,NCT04791878,Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease,,Recruiting,No Results Available,Perianal Fistula Due to Crohn's Disease (Disorder),Drug: Mesenchymal stem cells,Treatment related adverse events|Complete clinical healing|Partial clinical healing|Lack of response|Worsening of disease,Amy Lightner|The Cleveland Clinic,All,13 Years to 17 Years   (Child),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-134,"April 1, 2021","April 1, 2023","April 1, 2023","March 10, 2021",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04791878
770,174,NCT01824069,Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy,HULPVAS,Completed,No Results Available,Nonrevascularizable Critical Ischemia of the Lower Limbs,Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived,Safety of inject mesenchymal stem cells in MMII|Quality of life of patients after treatment,Instituto de Investigación Hospital Universitario La Paz|Hospital Universitario La Paz,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HULPVAS-2011-01|2012-000290-23,April 2013,April 2014,September 2015,"April 4, 2013",,"June 15, 2016","Hospital Universitario La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01824069
771,15,NCT00823316,Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation,,Completed,No Results Available,Acute Leukemia,Biological: Human umbilical cord blood-derived mesenchymal stem cells,- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate|- AGVHD grade,Medipost Co Ltd.,All,"2 Years to 19 Years   (Child, Adult)",Phase 1|Phase 2,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-CR-MSC003,August 2008,February 2010,February 2010,"January 15, 2009",,"April 23, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00823316
772,27,NCT01775774,Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome,START,Completed,Has Results,Acute Respiratory Distress Syndrome,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells,Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge,"Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,9,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARDS MSC 001|1U01HL108713-01,July 2013,February 2014,February 2015,"January 25, 2013","August 14, 2017","August 14, 2017","University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01775774
773,71,NCT05094011,"Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease",,Not yet recruiting,No Results Available,Idiopathic Parkinson's Disease,Biological: Aadipose-Derived Mesenchymal Stem Cells,Grading of Adverse Events|Routine physical examinations|Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]|Changes in vital signs: blood pressure [Safety of Mitocell]|Changes in vital signs: pulse rate [Safety of Mitocell]|Changes in vital signs: body temperature [Safety of Mitocell]|Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]|Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]|Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]|Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]|Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]|Electrocardiogram (ECG)|Magnetic Resonance Imaging (MRI)|MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)|Modified Hoehn & Yahr staging|18F-DOPA PET|levodopa equivalent daily dose (LEDD)|PDQ-39 (Parkinson's Disease Questionnaire)|Beck Depression Inventory (BDI-II) scores|Hamilton Depression Rating Scale (HAM-D-17) scores|Mini Mental State Examination (MMSE) Scores,"Taiwan Mitochondrion Applied Technology Co., Ltd.",All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MITOCELL-01,"May 1, 2022","September 30, 2023","July 31, 2024","October 26, 2021",,"January 21, 2022",,,https://ClinicalTrials.gov/show/NCT05094011
774,30,NCT02035514,Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,,Completed,No Results Available,Relapsing Remitting Multiple Sclerosis (RRMS),Biological: Bone marrow autologous mesenchymal stem cells transplantation,Change from baseline in safety|Change from baseline in effectiveness by MRI|Feasibility|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect,"Germans Trias i Pujol Hospital|Ministerio de Sanidad, Servicios Sociales e Igualdad",All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CELLTRiMS|2010-024081-21,December 2013,July 2016,July 2016,"January 14, 2014",,"December 15, 2016","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02035514
775,3,NCT02580617,A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease,,Recruiting,No Results Available,Crohn's Disease,Biological: ALLO-ASC,Safety (Clinically measured abnormality of laboratory tests and adverse events)|CDAI value|The ratio of patients applicable to CDAI <150,"Anterogen Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALLO-ASC-CD-101,April 2015,December 2022,June 2023,"October 20, 2015",,"July 21, 2021","Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02580617
776,75,NCT04456361,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,,"Active, not recruiting",No Results Available,"ARDS, Human|Covid-19",Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords,Oxygen saturation|Oxygen pressure in inspiration|ground-glass opacity|Pneumonia infiltration|Lactate dehydrogenase|C-reactive protein|D-dimer|Ferritine,Instituto de Medicina Regenerativa,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-ARDS-001,"April 16, 2020","October 15, 2022","December 15, 2022","July 2, 2020",,"August 4, 2022","Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico",,https://ClinicalTrials.gov/show/NCT04456361
777,688,NCT02274428,Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage,,Completed,No Results Available,Mesenchymal Stromal Cells,Drug: pneumostem,unsuspected death or anaphylactic shock|Death or hydrocephalus required shunt operation,Samsung Medical Center,All,23 Weeks to 34 Weeks   (Child),Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-06-103,October 2014,February 2016,December 2016,"October 24, 2014",,"April 19, 2017","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02274428
778,351,NCT04342325,The Clinical Trial of ADR-001 for IgA Nephropathy,,"Active, not recruiting",No Results Available,"Glomerulonephritis , IGA",Biological: infusion of ADR-001 (Mesenchymal stem cell),"Incidence of adverse events|Clinical remission (proteinuria, hematuria)|Proteinuria|Hematuria|Estimated glomerular filtration rate (eGFR)","Nagoya University|Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,9,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMCR013|jRCT2043200002,"June 15, 2020","January 31, 2022","March 31, 2023","April 13, 2020",,"November 12, 2021","Kasugai Municipal Hospital, Kasugai, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan",,https://ClinicalTrials.gov/show/NCT04342325
779,47,NCT02421484,Cellular Immunotherapy for Septic Shock: A Phase I Trial,CISS,Completed,No Results Available,Septic Shock,Biological: Allogeneic mesenchymal stromal cells,Number of adverse events as a measure of safety and tolerability,Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014809,May 2015,June 2016,"October 30, 2018","April 20, 2015",,"October 31, 2018","The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02421484
780,292,NCT04971980,Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis,,Recruiting,No Results Available,Rheumatoid Arthritis,Drug: hUC-MSC infusion (BC-U001),Number and frequency of adverse events (AEs)|Changes of vital signs from 1 hour after infusion to day 28±3|Changes of complete blood count (CBC) from day 1 to day 28±3|Changes of blood biochemical from day 1 to day 28±3|Changes of coagulation function from day 1 to day 28±3|Routine urine analysis|Urine pregnancy test (female only)|Cardiac rate measured by twelve-lead electrocardiogram|Percentage of participants achieving ACR20|Percentage of participants achieving ACR50|Percentage of participants achieving ACR70|Change from baseline of the disease activity score based on DAS28-CRP|Change from baseline of the disease activity score based on DAS28-ESR|EULAR response|Change from baseline of the health assessment questionnaire(HAQ) score|Change from baseline of the simplified disease activity index (SDAI) score|Change from baseline of the clinical disease activity index (CDAI) score|Change from baseline of TNF-α level|Change from baseline of IL-6 level,"Beijing Baylx Biotech Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BC-U001-RA2019,"April 12, 2021",December 2022,January 2023,"July 22, 2021",,"July 20, 2022","Peking Union Medical College Hospital (Dongdan campus), Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04971980
781,60,NCT05227846,Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1),,Recruiting,No Results Available,Decompensated Cirrhosis,Biological: Human Umbilical Cord-derived Mesenchymal Stem Cells,"Incidence of Adverse Events Incidence of Adverse Events|Change in Model for End-Stage Liver Disease (MELD) score from baseline to 28th day|Change in Model for End-Stage Liver Disease (MELD) score from baseline to 3 days, 7days, 14 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, and 24 months|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|plasma prealbumin (PALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin time (PT)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|Incidence of liver cancer|ChronicLiver Disease Questionnaire (CLDQ)","Beijing 302 Hospital|VCANBIO Cell & Gene Engineering Corporation, Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-DLC-1,"March 22, 2022","December 30, 2022","March 1, 2025","February 7, 2022",,"July 29, 2022","Beijing 302 Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT05227846
782,11,NCT02482194,Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study,,Completed,No Results Available,Spinal Cord Injury,Biological: mesenchymal stem cells,Number of adverse events|Sensory and motor strength|Functional Independence|Muscle strength assessment,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan|Armed Forces Institute of Regenerative Medicine",All,18 Years to 50 Years   (Adult),Phase 1,9,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFBMTC-SCI-2013,June 2013,January 2016,March 2016,"June 26, 2015",,"June 29, 2016","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan",,https://ClinicalTrials.gov/show/NCT02482194
783,236,NCT00705120,Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation,,Completed,No Results Available,Osteogenesis Imperfecta,"Other: Bone Marrow Cell Transplantation|Radiation: Irradiation, Total Body|Drug: Cyclophosphamide|Drug: Cyclosporin|Procedure: Mesenchymal Stem Cell Transplantation|Drug: Busulfan",To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI),St. Jude Children's Research Hospital,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOIT,November 1995,July 2000,October 2007,"June 25, 2008",,"June 25, 2008","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00705120
784,173,NCT05491681,AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial,ACE_CARD,Not yet recruiting,No Results Available,"ARDS, Human",Biological: intravenous delivery of allogeneic bone marrow-derived MSCs,Number of product related adverse events through the duration of the study.|Secondary Endpoint,"BioCardia, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05539-A,"September 15, 2022","December 31, 2023","March 31, 2024","August 8, 2022",,"August 9, 2022",,,https://ClinicalTrials.gov/show/NCT05491681
785,267,NCT03631420,Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants,,"Active, not recruiting",No Results Available,Bronchopulmonary Dysplasia,Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells,"The incidence and frequency of adverse events related to administration of UMC119-01.|The percentage of subjects who died from any cause during the study.|Changes of the oxygen saturation.|Changes of chest x-ray findings in participants before and after administration.|Changes of inflammatory markers (pg/ml) before and after administration.|Comparison of the incidence and severity of preterm children's complications in participants before and after administration.|The number of days of intubation, or where ventilator or oxygen therapy.|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).","Meridigen Biotech Co., Ltd.",All,3 Days to 51 Days   (Child),Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UMC119-01-001,"October 26, 2018","December 31, 2022","July 31, 2025","August 15, 2018",,"April 26, 2021","National Chen-Kung University Hospital, Tainan City, Taiwan",,https://ClinicalTrials.gov/show/NCT03631420
786,235,NCT03265444,Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy,,Completed,No Results Available,Multiple System Atrophy,Biological: CS10BR05,"Dose-Limiting Toxicity and Maximum Tolerated Dose of CS10BR05 Inj.|Adverse events, frequency and rate of vitals sign, laboratory test, physical examination, ECG, etc.|Unified Multiple System Atrophy Rating Scale(UMSARS)","Corestem, Inc.",All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS10BR05-MSA101,"April 13, 2018","December 5, 2019","December 5, 2019","August 29, 2017",,"August 7, 2020","Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03265444
787,694,NCT05162326,BC-101 in Treatment of Nasolabial Fold Wrinkles,,Not yet recruiting,No Results Available,Moderate to Severe Nasolabial Fold Wrinkles,Biological: BC-101,Safety and tolerability of BC-101 injection|Changes in wrinkle severity assessment from baseline,"Bright Cell, Inc.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BC101-C01,"July 1, 2022","June 30, 2023","June 30, 2023","December 17, 2021",,"December 17, 2021",,,https://ClinicalTrials.gov/show/NCT05162326
788,135,NCT04535856,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,DW-MSC,Completed,No Results Available,Covid19|Corona Virus Infection|SAR,Drug: allogeneic mesenchymal stem cell|Other: Placebo,Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change,"Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.",All,"19 Years and older   (Adult, Older Adult)",Phase 1,9,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DW_DWP710101|U1111-1263-1723,"November 14, 2020","January 14, 2021","January 14, 2021","September 2, 2020",,"January 27, 2021","Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia",,https://ClinicalTrials.gov/show/NCT04535856
789,80,NCT04255147,Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia,,Not yet recruiting,No Results Available,Bronchopulmonary Dysplasia,Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells,Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video,Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Ontario Institute of Regenerative Medicine (OIRM)|Stem Cell Network,All,7 Days to 21 Days   (Child),Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HULC-1,June 2022,June 2023,December 2035,"February 5, 2020",,"April 21, 2022","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04255147
790,230,NCT01297972,Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia,,Completed,No Results Available,Aplastic Anemia,Biological: Intravenous bone marrow mesenchymal stem cells infusion,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.|Level of cytopenias|Transfusional requirements|Incidence of infections and febrile neutropenia,University of Sao Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CONEP 16119,February 2011,November 2013,November 2013,"February 17, 2011",,"February 4, 2014","Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01297972
791,746,NCT04466098,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),,"Active, not recruiting",No Results Available,Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia,Biological: Mesenchymal stromal cells|Other: Placebo,Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2020LS075|MT2020-12,"July 30, 2020","August 21, 2021",December 2022,"July 10, 2020",,"February 28, 2022","University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04466098
792,506,NCT04097652,Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke,,Recruiting,No Results Available,Acute Ischemic Stroke,Biological: UMC119-06,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Modified Rankin Score (mRS)|Changes in National Institute of Health Stroke Scale (NIHSS)|Changes in Barthel Index (BI)|Changes in Brain MRI,"Meridigen Biotech Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMC119-06-01,"December 5, 2019",December 2022,December 2023,"September 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04097652
793,221,NCT02945449,Safety of Wharton Jelly in Erectile Dysfunction,,Completed,No Results Available,Erectile Dysfunction Associated With Type 2 Diabetes Mellitus,Biological: Wharton Jelly Mesenchymal stem cells,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire,Sophia Al-Adwan|University of Jordan,Male,"25 Years to 70 Years   (Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WJ.EDUJCTC,"January 4, 2017","October 15, 2018",November 2018,"October 26, 2016",,"November 15, 2018","Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT02945449
794,255,NCT04896853,Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®,,Recruiting,No Results Available,COVID-19 Acute Respiratory Distress Syndrome,Biological: ProTrans®,"Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion",NextCell Pharma Ab|Karolinska Trial Alliance,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO TRANS 19+|2020-002078-29,"May 18, 2021","September 30, 2024","December 31, 2024","May 21, 2021",,"May 21, 2021","Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT04896853
795,231,NCT03371329,Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage,,Completed,No Results Available,Hemorrhagic Stroke|Intracerebral Hemorrhage,Biological: MSC,Occurrence of adverse events|Changes in neurological function test,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-003524,"December 12, 2017","October 9, 2020","October 9, 2020","December 13, 2017",,"December 21, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03371329
796,207,NCT03751735,Efficacy of Wharton Jelly in Erectile Dysfunction,,Completed,No Results Available,Erectile Dysfunction Associated With Type 2 Diabetes Mellitus,Biological: Wharton Jelly Mesenchymal stem cells,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,Sophia Al-Adwan|University of Jordan,Male,"25 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WJEF.EDUJCTC,"January 27, 2017","January 13, 2019","February 26, 2019","November 23, 2018",,"April 10, 2019","Cell Therapy Center, Amman, Jordan",,https://ClinicalTrials.gov/show/NCT03751735
797,362,NCT04954534,Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM®,,Not yet recruiting,No Results Available,Alzheimer's Disease,Biological: human umbilical cord blood derived mesenchymal stem cells,Change from the baseline in ADAS-Cog|Change in CDR-SOB|Change from the baseline in K-MMSE(korean version)|Change from the baseline in CGA-NPI|Change from the baseline in SIB|ADAS-Cog Response Rate|Change in CIBIC-plus|Change from the baseline in CSF biomarkers,Samsung Medical Center|Medipost Co Ltd.,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,9,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SARC-CR-01,"July 12, 2021","January 31, 2022","June 30, 2022","July 8, 2021",,"July 14, 2021","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04954534
798,535,NCT01632475,Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia,,"Active, not recruiting",No Results Available,Bronchopulmonary Dysplasia,Biological: Pneumostem®,"Number of subjects with Adverse Drug Reaction|Neurological development test outcome from the subjects who were treated with Pneumostem®, compared with the patients who suffered from the same conditions but not treated with Pneumostem®|Growth",Samsung Medical Center|Medipost Co Ltd.,All,4 Months to 2 Years   (Child),,9,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,MP-CR-006-F/U,September 2011,September 2025,September 2026,"July 3, 2012",,"April 9, 2019","Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01632475
799,509,NCT04206007,Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease,,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease Moderate,Biological: UMC119-06,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Forced Vital Capacity (FVC).|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).|Changes in exercise performance using 6-min walk test (6MWT).|Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).|Changes in modified medical research council (mMRC) -dyspnea scale.,"Meridigen Biotech Co., Ltd.",All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMC119-06-COPD-01,"June 11, 2020","March 31, 2022","December 31, 2023","December 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04206007
800,395,NCT01297205,Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia,,Completed,No Results Available,Bronchopulmonary Dysplasia,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,Number of participant with adverse reaction|Incidence of BPD at 36 Week's postmenstrual age,Medipost Co Ltd.,All,5 Days to 14 Days   (Child),Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-CR-006,December 2010,September 2011,December 2011,"February 16, 2011",,"April 7, 2014","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01297205
801,702,NCT04261335,The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy,SHIELD,"Active, not recruiting",No Results Available,"Hypoxia-Ischemia, Brain",Biological: CL2020 cells,"Incidence of adverse events|Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)|Mortality|Overall survival|Duration of continuous respiratory support|Duration of continuous use of vasopressors or pulmonary vasodilators|The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition|The developmental quotient in Kyoto Scale of Psychological Development 2001|Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words|Presence of spasticity|Presence of epilepsy|MRI score|Gross Motor Function Classification System (GMFCS) score","Nagoya University|Life Science Institute, Inc.",All,4 Days to 14 Days   (Child),Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMCR-014|jRCT2043190112,"March 4, 2020",December 2021,September 2023,"February 7, 2020",,"September 5, 2021","Nagoya University Hospital, Nagoya, Aich, Japan",,https://ClinicalTrials.gov/show/NCT04261335
802,320,NCT01297218,The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease,,Completed,No Results Available,Dementia of the Alzheimer's Type,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose,Medipost Co Ltd.,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-CR-007,February 2011,September 2011,December 2011,"February 16, 2011",,"April 23, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01297218
803,696,NCT03855631,Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders,Epi-KAB,Completed,No Results Available,Kabuki Syndrome 1,Genetic: Intervention on primary cultured cells,success rate of fibroblasts culture|success rate of turning fibroblasts into mesenchymal stem cells|success rate of CRISPR/Case9 gene therapy treatment on patients' cells,"University Hospital, Montpellier|Association Française contre les Myopathies Telethon",All,"6 Years and older   (Child, Adult, Older Adult)",,8,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL18_0242,"September 28, 2020","November 27, 2020","November 27, 2020","February 27, 2019",,"December 1, 2020","Arnaud de villeneuve Hospital, Montpellier, Herault, France",,https://ClinicalTrials.gov/show/NCT03855631
804,4,NCT01385644,A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis,MSC in IPF,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Other: Placental MSC,Number of Participants Who Demonstrated Acute Adverse Events Following Infusion|Percentage Change in Lung Function as Assessed by FVC Compared to Baseline|Percentage Change in 6 Minute Walk Distance Compared to Baseline|Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline,The Prince Charles Hospital|Mater Medical Research Institute,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,8,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HREC/09/QPCH/105,October 2010,May 2013,May 2013,"June 30, 2011","December 29, 2015","December 29, 2015","The Prince Charles Hospital, Brisbane, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT01385644
805,494,NCT04275024,Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients,,Enrolling by invitation,No Results Available,Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity,Drug: Calcipotriol ointment|Drug: PSORI-CM01 Granule|Biological: adipose-derived multipotent mesenchymal stem cells,PASI score improvement rate|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI(Dermatology Life Quality Index),Guangdong Provincial Hospital of Traditional Chinese Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2016-05-02,"April 1, 2020","July 24, 2020","December 24, 2021","February 19, 2020",,"March 4, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04275024
806,184,NCT01771640,Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: intrathecal injection,Fever|Unconscious|Vomiting|ALS-FRS|FVC,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-006,August 2013,October 2014,December 2014,"January 18, 2013",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01771640
807,100,NCT02495766,Autologous Mesenchymal Stromal Cells for Multiple Sclerosis,EMMES,Completed,No Results Available,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Drug: XCEL-MC-ALPHA|Drug: Placebo,Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence,Banc de Sang i Teixits|Vall d'Hebron Research Institute (VHIR),All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XCEL-MS-02,"May 11, 2015","November 27, 2017","November 15, 2018","July 13, 2015",,"January 21, 2020","Hospital Vall Hebron, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02495766
808,153,NCT00186914,Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation,,Completed,No Results Available,Osteodysplasia,Biological: Marrow stromal cell infusion,To evaluate the safety of the stromal cell infusion,St. Jude Children's Research Hospital|Drexel University|Wayne State University,All,"Child, Adult, Older Adult",Phase 1,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STOD,July 1999,November 2001,January 2008,"September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00186914
809,512,NCT02023788,Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study,,Completed,No Results Available,Bronchopulmonary Dysplasia|Respiratory Tract Infections|Premature Birth of Newborn,Biological: PNEUMOSTEM,Number of subjects with adverse drug reactions|Respiratory outcomes|Survival|Z-score|Potential neurological development test outcomes,Medipost Co Ltd.,All,45 Months to 63 Months   (Child),,8,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,MP-CR-006-F/U-5y,April 2014,October 2016,October 2016,"December 30, 2013",,"September 4, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02023788
810,48,NCT01274975,Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.,MSC,Completed,No Results Available,Spinal Cord Injury,Other: Autologous Adipose Derived Mesenchymal Stem Cells,safety evaluation,R-Bio,Male,19 Years to 60 Years   (Adult),Phase 1,8,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Astrostem,July 2009,November 2009,February 2010,"January 12, 2011",,"March 26, 2014",,,https://ClinicalTrials.gov/show/NCT01274975
811,211,NCT03392311,Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis,,Enrolling by invitation,No Results Available,Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity,Drug: Calcipotriol ointment|Biological: adipose-derived multipotent mesenchymal stem cells,Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）,Guangdong Provincial Hospital of Traditional Chinese Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2016-04-02,"August 17, 2019","December 15, 2019","April 30, 2021","January 5, 2018",,"March 4, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03392311
812,1,NCT02398370,Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED,PMD-MSC-ED-01,Completed,No Results Available,Erectile Dysfunction,Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs),Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s),Melissa Marchand|Z Urology,Male,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMD-MSC-ED-01,July 2013,December 2014,March 2015,"March 25, 2015",,"April 27, 2015","Z Urology, Coral Springs, Florida, United States",,https://ClinicalTrials.gov/show/NCT02398370
813,747,NCT04495582,Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101),,"Active, not recruiting",No Results Available,Multiple System Atrophy,,Safety assessment(evaluation)|Efficacy assessment(evaluation),"Corestem, Inc.",All,"Child, Adult, Older Adult",,8,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,CS10BR05-MSA101-E,"August 28, 2018",November 2024,November 2024,"August 3, 2020",,"March 9, 2022","Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04495582
814,156,NCT03967275,Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn,SYMBOLpreclini,Completed,No Results Available,Bone Marrow Donor,Other: bone marrow harvest,The number of donors needed to obtain 3 BM harvest.,Fondation Ophtalmologique Adolphe de Rothschild,All,"18 Years and older   (Adult, Older Adult)",,7,Other,Observational,Observational Model: Other|Time Perspective: Prospective,EGN_2018_11,"September 9, 2020","June 1, 2022","June 1, 2022","May 30, 2019",,"July 5, 2022","Saint Louis Hospital, APHP, Paris, France",,https://ClinicalTrials.gov/show/NCT03967275
815,187,NCT04592640,Stem Cells for Uremic Calciphylaxis Patients,,"Active, not recruiting",No Results Available,Chronic Kidney Diseases|Calciphylaxis|Calcific Uremic Arteriolopathy|Treatment,Other: Human amniotic mesenchymal stem cells,Wound Healing|Wound Pain|Measured Quality of Life|Systemic Infection|Survival State,Ningning Wang|The First Affiliated Hospital with Nanjing Medical University,All,18 Years to 60 Years   (Adult),Not Applicable,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Stem cell,"September 17, 2018","September 17, 2022","September 17, 2022","October 19, 2020",,"August 9, 2022","The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT04592640
816,190,NCT02975960,ADMSCs for the Treatment of Systemic Sclerosis,,Completed,No Results Available,Systemic Sclerosis,Biological: injection of autologous stromal vascular fraction,Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks,The Catholic University of Korea|Seoul St. Mary's Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KC16TISI0343,"October 25, 2016","October 30, 2017","January 20, 2018","November 29, 2016",,"January 25, 2018","Seoul St. Mary's hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02975960
817,92,NCT03878628,Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease,MESADDE,"Active, not recruiting",No Results Available,Dry Eye|Kerato Conjunctivitis Sicca|Aqueous Tear Deficiency,Drug: Adipose tissue-derived mesenchymal stem cells,Pain at injection site: grade|Infection at injection site|Bleeding at injection site|Eyelid function disorder|Periorbital edema|Ocular discomfort|Flu-like symptoms|Fever|OSDI questionnaire|Schirmer's I test|Tear osmolarity|Ocular SICCA Grading Score|HLA anti-bodies,"Rigshospitalet, Denmark",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001-2018,"October 16, 2019","June 30, 2020","June 30, 2022","March 18, 2019",,"February 15, 2022","Rigshospitalet, Copenhagen, DK, Denmark",,https://ClinicalTrials.gov/show/NCT03878628
818,161,NCT03209700,Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas,MSC-AFP,Completed,No Results Available,Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,"William A. Faubion, M.D.|Mayo Clinic",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-004503,"July 20, 2017","December 10, 2019","December 10, 2019","July 6, 2017",,"January 3, 2020","Mayo Clinic in Minnesota, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03209700
819,104,NCT03265613,Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis,ADMSP,"Active, not recruiting",No Results Available,Mesenchymal Stromal Cells|Psoriasis|Drug Toxicity|Drug Effect,Biological: adipose-derived multipotent mesenchymal stem cells,Incidence of adverse events (AEs) related to intervention|Incidence of serious adverse events (SAEs) related to intervention|Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）,Guangdong Provincial Hospital of Traditional Chinese Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2017-01,"September 24, 2017","August 20, 2019","December 28, 2021","August 29, 2017",,"March 1, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03265613
820,97,NCT02195323,Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD),,Completed,No Results Available,Chronic Kidney Disease,Biological: Intravenous injection,mass formation|Creatinin|GFR,Royan Institute,All,25 Years to 60 Years   (Adult),Phase 1,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Kidney-004,April 2014,December 2015,January 2016,"July 21, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02195323
821,682,NCT04522505,Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis,,"Active, not recruiting",No Results Available,Lupus Nephritis,,Incidence of adverse events|Incidence of abnormal results of Physical examination|Percentage of abnormal Vital signs|Percentage of abnormal results of Laboratory tests|SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)|BILAG 2004 (British Isles Lupus Assessment Group 2004)|SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index|Disease activity assessed by PGA (Physician Global Assessment),"Corestem, Inc.|Hanyang University",All,"17 Years to 70 Years   (Child, Adult, Older Adult)",,7,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CS20AT04-LN101-E,"November 29, 2017","January 24, 2024","January 24, 2024","August 21, 2020",,"March 9, 2022","Hanyang university hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04522505
822,69,NCT03174587,Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis,,Completed,No Results Available,Lupus Nephritis,Biological: allogenic bone marrow derived mesenchymal stem cells,Safety assessment(evaluation),"Corestem, Inc.|Hanyang University",All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,7,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS20AT04-LN101,"May 30, 2017","March 12, 2019","August 19, 2019","June 2, 2017",,"November 20, 2019","Hanyang university hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03174587
823,169,NCT02408432,Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines,,Completed,No Results Available,Cardiomyopathy|Heart Failure,Other: Laboratory Biomarker Analysis|Other: Standard of Care|Drug: Mesenchymal Stem Cell Transplantation,Incidence of adverse events of intravenous injection of human mesenchymal stem cells (hMSCs) in patients with recent onset left ventricular systolic dysfunction from anthracyclines|Change in improvement in left ventricular systolic function by 7 points|Development of acute heart failure decompensation|Emergency center visits for heart failure|Need for new pacemaker/automatic implantable cardioverter defibrillator|New onset arrhythmias|Sudden cardiac death|Acute pulmonary edema|Asymptomatic decrease in left ventricular ejection fraction (LVEF) of > 10%|Heart failure admission|Progression free survival,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,7,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-0519|NCI-2015-00969,"January 11, 2016","December 8, 2021","December 8, 2021","April 3, 2015",,"May 17, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02408432
824,66,NCT05039411,Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease,,Recruiting,No Results Available,Perianal Fistula Due to Crohn's Disease|Fistula in Ano,Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs),Incidence of any treatment-emergent adverse events (TE-AEs)|Clinical healing,CryoCord Sdn Bhd|University of Malaya,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCSB-CT-PF-01-2021 (Ver_01),"March 1, 2022","December 31, 2024","December 31, 2024","September 9, 2021",,"March 22, 2022","University of Malaya Medical Centre, Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT05039411
825,53,NCT04447833,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,ARDS-MSC-205,"Active, not recruiting",No Results Available,"ARDS, Human|COVID",Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test,Uppsala University|Uppsala University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-02238,"June 17, 2020","January 30, 2021","June 30, 2025","June 25, 2020",,"March 4, 2021","Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT04447833
826,10,NCT04184258,Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells,,Completed,No Results Available,Systemic Lupus Erythematosus,Biological: Pooled mesenchymal stem cell|Other: Standard treatment according to the Clinical protocols,Efficacy evaluation|Safety eveluation,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,7,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCE_MSC1(SLE),"July 1, 2019","December 31, 2020","December 31, 2020","December 3, 2019",,"January 22, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,https://ClinicalTrials.gov/show/NCT04184258
827,54,NCT01649687,Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells,,Completed,No Results Available,Cerebellar Ataxia,Biological: Allogeneic adult adipose-derived mesenchymal stem cells,Safety evaluation|Alterations in SARA score|Positron emission tomography|Magnetic resonance spectroscopy|Assessment of language and swallowing functions|Evaluation of syncope|Balance test,National Yang Ming University,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-VGH-201001,May 2012,January 2014,January 2014,"July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01649687
828,32,NCT03778333,Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden,,Completed,No Results Available,Autologous Mesenchymal Stem Cells|Multiple Sclerosis,Biological: Autologous mesenchymal stem cells,To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.|To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.,Karolinska Institutet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-progressive MS,"December 1, 2012",December 2016,"December 31, 2016","December 19, 2018",,"December 19, 2018","Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03778333
829,550,NCT02728115,Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease,SAVE-DH,"Active, not recruiting",No Results Available,Huntington Disease,Biological: Cellavita HD Lower Dose|Biological: Cellavita HD Higher dose,"Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms|Preliminary efficacy of Cellavita HD by UHDRS improvement and global clinical response (CIBIS)|Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers|Immunological Response of Cellavita HD|Preliminary efficacy of Cellavita HD by comparison of the CNS assessment|Risk of suicidal ideation by Hamilton Depression Rating Scale (HDRS)",Azidus Brasil|Cellavita Pesquisa Científica Ltda|Azidus Brasil Scientific Research and Development Ltda,Male,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,SAVE-DH|51005115.9.0000.5412,"October 16, 2017",October 2022,December 2023,"April 5, 2016",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02728115
830,12,NCT03504241,Tolerance by Engaging Antigen During Cellular Homeostasis,TEACH,Recruiting,No Results Available,Kidney Transplantation|Renal Transplantation|Renal Transplant Recipient,Biological: Donor-derived Mesenchymal Stromal Cells|Drug: alemtuzumab|Drug: belatacept|Drug: sirolimus|Drug: mycophenolate mofetil|Drug: mycophenolate acid|Drug: prednisone,Proportion of Participants who Achieve Operational Tolerance|Proportion of Participants who Remain Off Immunosuppression|Proportion of Participants who Return to Immunosuppression|Proportion of Participants who Achieve Belatacept Monotherapy|Proportion of Participants who Die|Time from Transplant to the First Episode of Rejection|Incidence of Participants who Develop Donor Specific Antibody (DSA)|Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration|Frequency of Select Adverse Events (AEs)|Incidence of Post-Transplant Diabetes|Frequency of Antibody-Mediated Acute Cellular Rejection|Frequency of Antibody-Mediated Chronic Rejection,"National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.",All,"19 Years and older   (Adult, Older Adult)",Phase 1,6,NIH|Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAIT ITN062ST|UM1AI109565|NIAID CRMS ID#: 20676,"July 30, 2018",December 2027,December 2029,"April 20, 2018",,"May 13, 2022","Duke University Health System, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03504241
831,10,NCT05157958,Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa,,Not yet recruiting,No Results Available,Dystrophic Epidermolysis Bullosa,Biological: ALLO-ASC-SHEET|Other: Vehicle Control,Incidence of Treatment-Emergent Adverse Events|Proportion of complete wound closure,"Anterogen Co., Ltd.",All,"4 Years to 60 Years   (Child, Adult)",Phase 2,6,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALLO-ASC-DEB-201,"March 1, 2022","April 1, 2023","February 29, 2024","December 15, 2021",,"March 3, 2022",,,https://ClinicalTrials.gov/show/NCT05157958
832,171,NCT01759797,Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: intra venous injection of stem cell,Fever|Unconsciousness|vomiting|ALS-FRS|FVC|EMG-NCV,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-005,January 2013,January 2014,March 2014,"January 3, 2013",,"July 6, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01759797
833,448,NCT01207661,Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint,,Completed,No Results Available,Osteoarthritis,Biological: Mesenchymal Injection,Pain relief,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-002,August 2009,July 2010,November 2010,"September 23, 2010",,"January 5, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01207661
834,95,NCT01436058,Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis,,Completed,No Results Available,Osteoarthritis,Biological: mesenchymal stem cell,safety|pain|physical function|defect,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-007,September 2010,September 2011,September 2011,"September 19, 2011",,"September 19, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01436058
835,205,NCT04040348,Alzheimer's Disease Stem Cells Multiple Infusions,,"Active, not recruiting",No Results Available,Alzheimer Disease,Biological: Approximately 100 million cells allogeneic hMSC,Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume,Bernard (Barry) Baumel|University of Miami,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20190438,"October 8, 2019","May 1, 2023","May 1, 2023","July 31, 2019",,"August 16, 2022","University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04040348
836,192,NCT01210950,Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation,,Completed,No Results Available,Leg Length Inequality,Biological: cell and RPR injection,effect of mesenchymal cell transplantation to decrease limb inequal|improve life quality,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-006,September 2009,December 2013,December 2013,"September 29, 2010",,"April 28, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01210950
837,193,NCT01206179,Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell,,Completed,No Results Available,Nonunion Fractures,Biological: cell injection,Radiological progression of bone fusion|Reduction of pain using VAS|Cost analysis based on length of hospital stay,Royan Institute,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-004,March 2009,March 2011,May 2011,"September 21, 2010",,"December 14, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01206179
838,502,NCT04914403,Mesenchymal Stem Cells for The Treatment of Frailty Syndrome,,Recruiting,No Results Available,Frailty Syndrome,Biological: UMC119-06-05,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes in exercise performance using 6-min walk test (6MWT).|Changes in grip strength.|Changes in quality of life measured by change in SF12 (12-Item Short Form).|Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in Clinical Frailty Scale.,"Meridigen Biotech Co., Ltd.",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMC119-06-05-FS-01,"September 1, 2021",December 2022,July 2023,"June 4, 2021",,"April 7, 2022","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04914403
839,49,NCT01840540,MSC for Occlusive Disease of the Kidney,,Completed,No Results Available,Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension,Drug: Arterial infusion of autologous mesenchymal stem cells,Renal blood flow and function in the treated kidneys.|Level of kidney function.,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-009298,April 2013,March 2014,April 2017,"April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01840540
840,671,NCT02181478,Intra-Osseous Co-Transplant of UCB and hMSC,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia,Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation,Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery,Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,6,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE1Z14|NCI-2014-01316|P30CA043703,"July 22, 2015","December 19, 2019","February 7, 2020","July 4, 2014",,"December 4, 2020","Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02181478
841,66,NCT02166489,Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease,,Completed,No Results Available,Chronic Renal Failure|Polycystic Kidney Disease,Biological: Intravenous injection autologous mesenchymal stem cells,Mass formation|Glomerular Filtration Rate (GFR),Royan Institute,All,18 Years to 60 Years   (Adult),Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Kidney-003,March 2014,December 2015,January 2016,"June 18, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02166489
842,626,NCT01207193,Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation,,Completed,No Results Available,Bone Cyst,Biological: cell injection,fulfill bone cyst defect|effect of mesenchymal cell transplantation,Royan Institute,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-005,October 2009,October 2011,December 2011,"September 22, 2010",,"December 14, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01207193
843,180,NCT04522986,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,COVID-19,Completed,No Results Available,Severe Acute Respiratory Syndrome Coronavirus 2,Biological: Mesenchymal stem cell,Safety: Adverse Event,"Rohto Pharmaceutical Co., Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADR-001-1919,"August 21, 2020","February 2, 2021","February 2, 2021","August 21, 2020",,"March 18, 2021","Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT04522986
844,61,NCT02625246,Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis,CELEB,Completed,No Results Available,Bronchiectasis,Biological: hMSCs,Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause,Marilyn Glassberg|University of Miami,All,"30 Years to 87 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20150627,"February 4, 2016","May 15, 2019","May 15, 2019","December 9, 2015",,"August 28, 2019","University of Miami Hospitals & Clinics, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02625246
845,258,NCT01499056,Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint,,Completed,No Results Available,Hip Osteoarthritis,Biological: stem cell injection,swelling of hip joint|deterioration of joint function|skin allergic reaction|Respiratory reaction|Quantitative changes in pain intensity|physical function improvement|subchondral bone edema|cartilage thickness,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Bone-008,June 2010,February 2011,March 2011,"December 26, 2011",,"December 26, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01499056
846,116,NCT02012153,Mesenchymal Stromal Cells in Kidney Transplant Recipients,,Recruiting,No Results Available,Kidney Transplant Rejection,Biological: Mesenchymal Stromal Cells,Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.,Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII,All,"18 Years and older   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-Tx tolerance|2013-003221-29,December 2013,December 2022,March 2023,"December 16, 2013",,"November 26, 2021","U.O. Nefrologia e Dialisi, Bergamo, Italy",,https://ClinicalTrials.gov/show/NCT02012153
847,745,NCT04695522,ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery,,Recruiting,No Results Available,D017202,Biological: ADR-002K administration,Number of participants with Adverse event|Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery|Number of complication associated with drug administration method,"Osaka University|Rohto Pharmaceutical Co., Ltd.",All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,6,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CVSR0006,"November 27, 2019","April 30, 2021","October 31, 2021","January 5, 2021",,"January 5, 2021","Osaka University Hospital, Suita, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT04695522
848,664,NCT03678467,Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction,EB-CMF,Recruiting,No Results Available,Mandible Tumor|Mandibular Injuries|Mandible; Deformity,Combination Product: EB-CMF,Number of participants with treatment-related adverse events|Bone regeneration as assessed by high-resolution CT scans|Quality of life as measured by the Glasgow Benefit Inventory|Quality of life as measured by SF-12,"Epibone, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EB-CMF-02,"March 31, 2021",August 2023,November 2023,"September 19, 2018",,"May 27, 2022","VA Healthcare System, San Francisco, San Francisco, California, United States|Cleveland Clinic, Cleveland, Ohio, United States|UT Health San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03678467
849,190,NCT03171194,Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus,,Completed,No Results Available,System; Lupus Erythematosus,Drug: Low Dose Mesenchymal Stem Cells (MSCs),Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum,Medical University of South Carolina,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00061632,"April 27, 2017","April 30, 2018","October 25, 2018","May 31, 2017",,"May 2, 2019","Emory University, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT03171194
850,284,NCT03635450,Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE,,Completed,No Results Available,Moderate to Severe Hypoxic-ischemic Encephalopathy,Biological: Infusion of hCT-MSC,Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments,"Joanne Kurtzberg, MD|Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA)|Duke University",All,0 Hours to 48 Hours   (Child),Phase 1,6,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00100253,"December 27, 2018","July 28, 2019","December 28, 2020","August 17, 2018",,"March 22, 2021","Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03635450
851,514,NCT04893174,Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).,,Not yet recruiting,No Results Available,"Osteoarthritis, Knee",Biological: UMC119-06-05|Device: Hyaluronic acid,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.|Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).|Whole Organ Magnetic Resonance Imaging Score (WORMS).|Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.|Amount of rescue medications required.,"Meridigen Biotech Co., Ltd.",All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMC119-06-05-KOA-01,January 2022,September 2022,June 2023,"May 19, 2021",,"May 28, 2021","Taipei Medical University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT04893174
852,90,NCT00850187,Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage,,Completed,No Results Available,Knee Osteoarthritis,Biological: Bone marrow derived mesenchymal stem cells,Knee cartilage defects|pain,Royan Institute|Tehran University of Medical Sciences,All,45 Years to 60 Years   (Adult),Phase 1,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan - Bone - 001,August 2008,July 2010,December 2010,"February 24, 2009",,"January 5, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00850187
853,686,NCT05494723,Safety and Efficacy of YB-1113 in Treatment of POI,,Not yet recruiting,No Results Available,POI,Drug: YB-1113,Incidence of treatment-emergent adverse events (AE)|Blood anti-Müllerian hormone (AMH) level|Day 3 follicle stimulating hormone (FSH) and estradiol (E2) levels|Antral follicle counts (AFC),"YB Life Science, LLC",Female,18 Years to 40 Years   (Adult),Phase 1|Phase 2,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YB1113-POI,"January 9, 2023","July 9, 2024","August 30, 2024","August 10, 2022",,"August 10, 2022",,,https://ClinicalTrials.gov/show/NCT05494723
854,32,NCT03106662,Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies,,Completed,No Results Available,Hematopoietic Stem Cell Transplantation,Biological: mesenchymal stem cells|Drug: cyclophosphamide administration,Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft versus host disease incidence in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft failure incidence in haploidentical stem cell transplantation,Ankara University|The Scientific and Technological Research Council of Turkey,All,"18 Years and older   (Adult, Older Adult)",Phase 3,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,213S196,October 2014,July 2017,October 2017,"April 10, 2017",,"January 10, 2018","Ankara University School of Medicine Department of Hematology, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03106662
855,31,NCT00957931,"Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs",,Completed,Has Results,Sickle Cell Disease|Thalassemia|Diamond-Blackfan Anemia,Procedure: Bone marrow transplantation|Biological: Mesenchymal Stromal Cells,Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT,Stanford University|University of Minnesota|University of Alabama at Birmingham,All,"1 Year to 25 Years   (Child, Adult)",Phase 2,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC01,March 2009,August 2013,August 2013,"August 13, 2009","August 6, 2018","August 6, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00957931
856,7,NCT03384433,Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke,,Recruiting,No Results Available,Cerebrovascular Disorders,Biological: exosome,Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale,Isfahan University of Medical Sciences|Tarbiat Modarres University,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,med shahid beheshti university,"April 17, 2019","June 17, 2021","December 17, 2021","December 27, 2017",,"January 25, 2021","Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03384433
857,11,NCT02394873,A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound,,Completed,No Results Available,Burn,Biological: ALLO-ASC-DFU,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Time to reach re-epithelialization of wound|Vancouver Burn Scar Scale,"Anterogen Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,5,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALLO-ASC-BI-101,March 2015,August 2015,October 2015,"March 20, 2015",,"December 30, 2015","Hallym university Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02394873
858,122,NCT03651791,In Vivo Tracking of USPIO Labeled MSC in the Heart,USPIO-MSC,Completed,No Results Available,Ischemic Heart Disease,Combination Product: USPIO labeled MSC injection,MSC identification using MRI in-vivo on day 0|MSC identification using MRI in-vivo on day 1|MSC identification using MRI in-vivo on day 7|MSC identification using MRI in-vivo after 2 weeks|MSC identification using MRI in-vivo after 4 weeks|MSC identification using MRI in-vivo after 8 weeks|MSC identification using MRI in-vivo after 12 weeks|MSC identification using MRI in-vivo after 26 weeks|Cardiac pump function changes|CCS class|Seattle Angina Questionnaire|Weekly number of angina attacks|Weekly nitroglycerin consumption|Adverse events,"Rigshospitalet, Denmark",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USPIO-MSC1,May 2013,June 2014,October 2017,"August 29, 2018",,"August 29, 2018",,,https://ClinicalTrials.gov/show/NCT03651791
859,14,NCT01061099,Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta,STOD3,Completed,No Results Available,Osteogenesis Imperfecta Type II|Osteogenesis Imperfecta Type III,Biological: Mesenchymal Stromal Cells,"To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.|To determine if MSCs elicit an immune response after repeated infusions.|To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy.",Nationwide Children's Hospital,All,"up to 19 Years   (Child, Adult)",Phase 1,5,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-4-5947,February 2010,March 2013,February 2014,"February 2, 2010",,"April 24, 2015","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01061099
860,112,NCT03745417,Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis,UCMSCs,Not yet recruiting,No Results Available,Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity,Biological: Umbilical cord mesenchymal stem cells,PASI score improvement rate|Psoriasis Area and Severity Index(PASI)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|the Body Surface Area (BSA%)|the Dermatology Life Quality Index（DLQI）,Guangdong Provincial Hospital of Traditional Chinese Medicine|Peking Union Medical College Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S2018-11,"August 31, 2021","August 28, 2022","December 31, 2022","November 19, 2018",,"February 9, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03745417
861,102,NCT02290041,Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response,,Completed,No Results Available,Discordant Immunological Response in HIV Infected Subjects,Drug: Infusion of MSC|Drug: Infusion of placebo,Incidence of adverse reactions|Incidence of opportunist diseases|Changes in CD4+ cell count and CD4+/CD8+ ratio|T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CeTMAd-VIH-2014,"February 8, 2017","July 30, 2019","July 30, 2019","November 13, 2014",,"March 4, 2020","Virgen del Rocío University Hospital, Seville, Spain",,https://ClinicalTrials.gov/show/NCT02290041
862,158,NCT02530047,Mesenchymal Stem Cells (MSC) for Ovarian Cancer,,Completed,No Results Available,Ovarian Cancer,Genetic: MSC-INFβ|Behavioral: Questionnaires,Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)|Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment,M.D. Anderson Cancer Center,Female,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-0032|CA 136411|NCI-2015-01504,"May 16, 2016","June 13, 2019","June 13, 2019","August 20, 2015",,"July 18, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02530047
863,19,NCT03173638,Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy,NEUROSTEM,"Active, not recruiting",No Results Available,Non Arteritic Ischemic Optic Neuropathy,Procedure: intravitreal injection of MSV,Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale|Adverse events procedure-related (intravitreal injection),Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IOBA01-2016|2016-003029-40,"March 23, 2018",April 2022,December 2022,"June 2, 2017",,"April 6, 2021","IOBA - Applied Ophthalmobiology Institute, Valladolid, Spain",,https://ClinicalTrials.gov/show/NCT03173638
864,121,NCT01932164,Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients,,Completed,Has Results,Cleft Lip and Palate,Procedure: maxillary alveolar graft by tissue engineering|Procedure: Bone tissue engineering using mesenchymal stem cells,Amount of New Bone Mass Formed|Quality of Bone Regeneration,"Hospital Sirio-Libanes|Hospital Infantil Universitario Niño Jesús, Madrid, Spain",All,7 Years to 12 Years   (Child),Not Applicable,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSL 2013-04,May 2013,"December 16, 2015","December 16, 2015","August 30, 2013","March 30, 2015","May 28, 2020","Hospital Sírio Libanês, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01932164
865,146,NCT04243681,Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis,,Completed,No Results Available,"Cirrhosis, Liver",Combination Product: CD 34 and MSC infusion|Drug: Standard of care for Cirrhosis management,To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.|Change in MELD (Model for End stage Liver disease) score.|Change in Child Pugh score.|Change in the percentage of CD 34 cells in liver.,"Asian Institute of Gastroenterology, India",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,5,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECR/346/Inst/AP/2013,"July 1, 2019","August 1, 2020","September 1, 2020","January 28, 2020",,"October 22, 2020","Asian Institute Of Gastroenterology, Hyderabad, Telangana, India",,https://ClinicalTrials.gov/show/NCT04243681
866,199,NCT01309061,The Effect of Human Adipose Tissue-derived MSCs in Romberg's Disease,,Completed,No Results Available,Progressive Hemifacial Atrophy|Romberg's Disease,Procedure: Autologous Adipose Tissue derived MSCs Transplantation,The volume change of fatty layer|Clinical lab tests|Fat absorption rate,R-Bio|Asan Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,5,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KSC-Facial-Stem,March 2008,December 2009,February 2010,"March 4, 2011",,"June 5, 2019","ASAN Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01309061
867,194,NCT03449069,Pediatric MSC-AFP Sub-study for Crohn's Fistula,,Recruiting,No Results Available,Fistula in Ano|Crohn Disease,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.,Mayo Clinic,All,12 Years to 17 Years   (Child),Phase 1,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-010539,"July 23, 2018","February 28, 2023","February 28, 2023","February 28, 2018",,"March 31, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03449069
868,98,NCT04520022,Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB,,Completed,No Results Available,Recessive Dystrophic Epidermolysis Bullosa,Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells,Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell|Change in type VII collagen and anchoring fibril expression at dermoepidermal junction|Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)|Change in Global severity score|Change in total body surface area affected by RDEB|Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire|Change in blister count|Change in pruritus visual analogue scale (VAS)|Change in pain visual analogue scale (VAS),Gangnam Severance Hospital|Daewoong Pharmaceutical Co. LTD.,All,"10 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,5,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3-2015-0285,"October 13, 2016","January 10, 2020","January 10, 2020","August 20, 2020",,"August 20, 2020","GangnamSeverance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04520022
869,2,NCT03183622,A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial,,Completed,No Results Available,Burn,Biological: ALLO-ASC-DFU,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale,"Anterogen Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",,5,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALLO-ASC-BI-102,November 2015,July 2017,December 2017,"June 12, 2017",,"January 10, 2018","Hallym university Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03183622
870,162,NCT03220243,Stem Cell Coated Fistula Plug in Patients With Crohn's RVF,,Completed,No Results Available,Fistula Vagina|Crohn Disease,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,Mayo Clinic,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-002892,"October 19, 2017","September 20, 2020","September 20, 2020","July 18, 2017",,"October 30, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03220243
871,5,NCT02394886,Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers,,Completed,No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement,"Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,5,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALLO-ASC-DFU-101,November 2014,May 2015,July 2015,"March 20, 2015",,"October 16, 2015","Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02394886
872,2,NCT02395029,Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD,PMD-MSC-PD-01,Completed,No Results Available,Peyronie's Disease,Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs),Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s),Melissa Marchand|Z Urology,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMD-MSC-PD-01,August 2013,December 2014,March 2015,"March 20, 2015",,"March 20, 2015","Z Urology, Coral Springs, Florida, United States",,https://ClinicalTrials.gov/show/NCT02395029
873,164,NCT02152657,Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study,,Completed,No Results Available,Spinal Cord Injury,Other: Mesenchymal stem cell transplantation,Magnetic resonance imaging|Sensitivity and motor strength on the inferior limbs|Improvement in urological function|Improvements in sensorial mapping and neuropathic pain,Hospital Sao Rafael,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCI-002,January 2015,December 2015,December 2016,"June 2, 2014",,"April 26, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,https://ClinicalTrials.gov/show/NCT02152657
874,160,NCT04545307,Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis,MSC,Completed,No Results Available,Pulp Necroses|Apical Periodontitis,Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis,Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal,Universidad Central de Venezuela|Instituto Venezolano de Investigaciones Cientificas,All,6 Years to 16 Years   (Child),Phase 2|Phase 3,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSCYPPNAP001,"November 27, 2019","December 27, 2019","January 27, 2020","September 11, 2020",,"September 16, 2020","Unidad de Terapia Celular del Instituto de Investigaciones Científicas, San Antonio de los Altos, Miranda, Venezuela",,https://ClinicalTrials.gov/show/NCT04545307
875,208,NCT04435249,ENgineered Tissue Repair of BronchopleUral fiSTula,ENTRUST,Not yet recruiting,No Results Available,Bronchopleural Fistula,Other: BPF-001,"Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months",Videregen Limited|Cell Therapy Catapult|Papworth Hospital NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust,All,18 Years to 64 Years   (Adult),Phase 1|Phase 2,5,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UK-2019-004939-24,October 2022,March 2024,November 2026,"June 17, 2020",,"April 5, 2022",,,https://ClinicalTrials.gov/show/NCT04435249
876,1,NCT03183726,A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial,,Completed,No Results Available,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement,"Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",,4,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALLO-ASC-DFU-102,"January 11, 2016","June 30, 2017","July 31, 2017","June 12, 2017",,"January 10, 2018",,,https://ClinicalTrials.gov/show/NCT03183726
877,171,NCT04340609,Stem Cell in Acute Myocardial Infarction,AMI,Completed,No Results Available,Acute Myocardial Infarction,Biological: Mesenchymal Stem Cells,Major adverse cardiac events (MACE) endpoints of mortality|Re-infarction|Target vessel revascularization (TVR)|Heart failure hospitalization|Cardiac MRI|Echocardiography|Electrocardiography (ECG)|Wellness Parameter|Laboratory Assessment,PT. Prodia Stem Cell Indonesia,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/AMI/01/2019,"March 11, 2019","April 8, 2021","April 8, 2022","April 9, 2020",,"June 14, 2022","PT Prodia StemCell Indonesia, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT04340609
878,41,NCT05011474,Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration,MANT3_ASC,Enrolling by invitation,No Results Available,Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc,Biological: administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3,1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection|Confirmation of the degree of pain improvement in VAS|Confirmation of the degree of improvement in disability (ODI)|Confirmation of increase in water content in the nucleus using MRI,Inbo Han|CHA University,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-10-013,"April 23, 2021","January 20, 2022","December 31, 2022","August 18, 2021",,"August 25, 2021","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT05011474
879,17,NCT02945462,Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED),,Completed,No Results Available,Erectile Dysfunction,Biological: autologous mesenchymal stem cells,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire|Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.,University of Jordan,Male,"25 Years to 65 Years   (Adult, Older Adult)",Phase 1,4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EDUJCTC,September 2013,November 2015,October 2016,"October 26, 2016",,"November 16, 2016",,,https://ClinicalTrials.gov/show/NCT02945462
880,26,NCT02384018,Mesenchymal Stem Cell and Islet Co-transplantation,,Completed,No Results Available,Chronic Pancreatitis|Diabetes,Biological: autologous mesenchymal stromal cell,"C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes",Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,3,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCT-BMMSC15-001|5R21DK099696,December 2014,"June 1, 2016","November 21, 2017","March 10, 2015",,"April 4, 2022","GI Surgery, Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02384018
881,114,NCT01700920,"PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells",CSM/ON/2011,Completed,No Results Available,Osteonecrosis of the Femoral Head,Procedure: bone marrow aspirate,,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,3,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSM/ON/2011,July 2012,December 2015,December 2015,"October 4, 2012",,"March 30, 2017","University Hospital of Salamanca, Salamanca, Castilla y León, Spain",,https://ClinicalTrials.gov/show/NCT01700920
882,481,NCT01323894,Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling,,Completed,No Results Available,Primary Disease,,Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration,China Medical University Hospital,All,"10 Years to 80 Years   (Child, Adult, Older Adult)",,3,Other,Observational,,DMR-99-IRB-122,August 2011,August 2012,July 2013,"March 28, 2011",,"June 17, 2016","China Medical Universty Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT01323894
883,458,NCT04610359,Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis,,Recruiting,No Results Available,Interstitial Cystitis|Stem Cell Transplant|Mesenchymal Stem Cell,Drug: MR-MC-01,Incidence of Treatment-Emergent Adverse Events (TEAEs)|Incidence of Treatment-Emergent Adverse Events|Changes of pain after stem cell injection|Changes of PUF (Pelvic Pain and Urgency/Frequency) scores after stem cell injection|Changes of ICQ (O'Leary-Sant interstitial cystitis symptom index/problem index) scores after stem cell injection|Changes of voiding profiles after stem cell injection|Changes of Hunner lesion after stem cell injection,Asan Medical Center|MIRAE CELL BIO,Female,"20 Years and older   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-1451,"October 20, 2020",October 2022,December 2022,"October 30, 2020",,"October 30, 2020","Department of Urology, Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04610359
884,19,NCT02987413,Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients,,Completed,No Results Available,Motor Neuron Disease,Biological: Autologous Mesenchymal stem cells (MSCs),Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R),Hospital e Maternidade Dr. Christóvão da Gama|IEP São Lucas - Instituto de Ensino e Pesquisa|Clinica Jordy Sinapse|TECHLIFE - Centro de Tecnologia Celular,All,"18 Years and older   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HospitalMCG|IEPSaoLucas,"April 28, 2015",March 2016,"April 5, 2017","December 9, 2016",,"August 7, 2017","Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil|Instituto de Ensino e Pesquisas - IEP-São Lucas, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT02987413
885,622,NCT04713436,The Effects of Antibiotic Combinations on Stem Cells,,Completed,No Results Available,Stem Cells|Anti-Bacterial Agents,Drug: Differentiation Markers,Measurment of Cell Viability and Apoptosis|Measurment of cell differantiation,Eskisehir Osmangazi University|TC Erciyes University,All,"16 Years to 22 Years   (Child, Adult)",,3,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2015-68,"January 1, 2014","January 1, 2016","February 1, 2017","January 19, 2021",,"January 19, 2021","Eskişehir Osmangazi University, Eskişehir, Turkey",,https://ClinicalTrials.gov/show/NCT04713436
886,173,NCT01454336,Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone,,Completed,No Results Available,Liver Fibrosis,Biological: Cell injection,ALT|AST|Serum Albumin|Liver Fibrosis|Progression of fibrosis,Royan Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-liver-003,June 2010,July 2013,July 2013,"October 19, 2011",,"May 13, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01454336
887,67,NCT02330978,Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.,,Completed,Has Results,Retinal Degeneration|Primary Open-angle Glaucoma,Procedure: Intravitreal transplantation of mesenchymal stem cell|Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells,Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR)|Changes in Visual Acuity|Changes in Visual Field|Changes in Optical Coherence Tomography Parameters Related to Glaucoma|Changes in Retinal Ganglion Cells Function by ERG,University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 1,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCRP 14151/2010,January 2014,September 2016,September 2016,"January 5, 2015","July 8, 2019","July 8, 2019","Ribeirão Preto Medical School, Ribeirao Preto, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02330978
888,160,NCT02807389,Stem Cell Fistula Plug in Post Surgical Leak Fistulas,,Completed,No Results Available,Surgical Leak Fistula,Drug: MSC Fistula Plug,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure,Mayo Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-004326,"March 14, 2017","April 2, 2019","April 2, 2019","June 21, 2016",,"April 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02807389
889,3,NCT02172885,Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta,TERCELOI,Completed,No Results Available,Osteogenesis Imperfecta,Biological: Mesenchymal Stem Cells,Adverse Events as a Measure of Safety|bone mineral density|fracture rate|growth velocity|change from baseline in degree of functionality|change from baseline in well-being,"Hospital de Cruces|Hospital Universitario Getafe|Hospital Infantil Universitario Niño Jesús, Madrid, Spain",All,6 Months to 12 Years   (Child),Phase 1,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT Number:2012-002553-38|Health Department of Spain,April 2014,December 2018,December 2018,"June 24, 2014",,"March 26, 2019","Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Getafe, Getafe, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02172885
890,194,NCT00515307,Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia,,Completed,No Results Available,"Hypercholesterolemia, Familial",Procedure: Cellular transplantation,Serum cholesterol and LDL levels|Tracking the infused cells,University of Tehran,Female,"Child, Adult, Older Adult",Phase 1,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DDRC 85-15,June 2007,May 2008,June 2008,"August 13, 2007",,"August 29, 2008","Digestive Disease Research Center, Shariati Hospital, North Kargar Ave., Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00515307
891,9,NCT01649700,Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells,,Completed,No Results Available,The Sequelae Caused by Severe Brain Injury,Biological: autologous adipose-derived mesenchymal stem cells,Safety evaluation|Positron emission tomography|Magnetic Resonance Imaging|Electroencephalogram|Neuropsychological assessment|Electrodiagnostic Testing|Assessment of language and swallowing functions|Measure of the severity of disability|Assessment of spasticity and strength|Assessment of brain motor control,National Yang Ming University,All,20 Years to 40 Years   (Adult),Phase 1|Phase 2,1,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-VGH-201101,October 2011,May 2013,May 2013,"July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01649700
892,69,NCT01142856,Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Safety|Neurologic disability score,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,1,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-001995,June 2010,April 2011,April 2011,"June 11, 2010",,"May 3, 2012","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01142856
893,21,NCT03979898,Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP,CP,Completed,No Results Available,Cerebral Palsy,Biological: ASTROSTEM,Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan,R-Bio|Kyung Hee University Hospital at Gangdong,All,36 Months to 12 Years   (Child),Early Phase 1,1,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,biostar-CP,"June 15, 2017","April 23, 2019","May 13, 2019","June 7, 2019",,"June 7, 2019","KyungHee University Gandong Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03979898
894,42,NCT02150551,Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease,,Completed,No Results Available,Inflammatory Bowel Diseases,Biological: Allogeneic bone marrow-derived mesenchymal stromal cells,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment.",Catherine Bollard|Children's National Research Institute,All,"12 Years to 22 Years   (Child, Adult)",Phase 1,1,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STOMP,September 2015,"September 27, 2019","September 27, 2019","May 30, 2014",,"July 14, 2020","Children's National Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02150551
895,20,NCT02414295,Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection,,Completed,No Results Available,Klinefelter Syndrome|Azoospermia,Drug: Mesenchymal stem cell injection,Sperm detection|Hormonal profile,"Man Clinic for Andrology, Male Infertility and Sexual Dysfunction",Male,20 Years to 50 Years   (Adult),Not Applicable,1,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,6714,August 2013,August 2014,August 2014,"April 10, 2015",,"April 10, 2015","Man Clinic for Andrology and male infertility, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT02414295
896,65,NCT05240430,When to Apply to Which Patient in MSC?,MSC,Recruiting,No Results Available,COVID-19 Acute Respiratory Distress Syndrome,"Drug: Mesenchymal Stem Cell Antigen-1, Human","Change in acute phase reactants (C-reactive protein (CRP) after MSC administration in group I, II, III|Change in acute phase reactants (procalcitonin) after MSC administration in group I, II, III|Change in acute phase reactants ( white blood cell count) after MSC administration in group I, II, III|Changes in respiratory support after MSC administration in Groups I, II, III|Changes in arterial blood gas analysis (partial oxygen/fractionated oxygen (Pa/Fi) ratio) after MSC administration in Groups I, II, III|Effect on mortality after MSC administration in Groups I, II, III",Trabzon Kanuni Education and Research Hospital,All,"18 Years and older   (Adult, Older Adult)",,1,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,Trabzon Kanuni TRH,"January 1, 2022","February 28, 2022","March 31, 2022","February 15, 2022",,"February 15, 2022","Trabzon Kanuni Training and Research Hospital, University of Healthy Sciences, Trabzon, Yomra, Turkey",,https://ClinicalTrials.gov/show/NCT05240430
897,87,NCT02235844,Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD),,Completed,No Results Available,Duchenne's Muscular Dystrophy,Biological: Umbilical Cord Mesenchymal Stem Cells,Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %,"Allergy and Asthma Consultants, Wichita, Kansas|Aidan Foundation|Neil H. Riordan PhD",Male,28 Years to 31 Years   (Adult),Phase 1,1,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND 16026 DMD Single Patient,September 2014,"September 30, 2017","September 30, 2017","September 10, 2014",,"September 16, 2019","Asthma and Allergy Consultants, Wichita, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02235844
